SAMPLE_ID,SAMPLE_NAME,PUBCHEM_SID,PRIMARY_MOA,ASSAY_NAME,LIBRARY,CAS,ALIAS,AC50(uM),label,LOG_AC50,AUC,CURVE_CLASS2,DATA_POINTS,DRUG_NAME,EFFICACY,MAX_RESPONSE,P_HILL,R2,GENE_ID,GENE_SYMBOL,SMILES,SUPPLIER,SUPPLIER_ID,DATA0,DATA1,DATA2,DATA3,DATA4,DATA5,DATA6,DATA7,DATA8,DATA9,DATA10,DATA11,DATA12,DATA13,DATA14,CONC0(M),CONC1(M),CONC2(M),CONC3(M),CONC4(M),CONC5(M),CONC6(M),CONC7(M),CONC8(M),CONC9(M),CONC10(M),CONC11(M),CONC12(M),CONC13(M),CONC14(M)
NCGC00182030-01,Sulbenicillin disodium,144206509,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),28002-18-8,"Sulbenicillin; Lilacillin; I.M., Kedacilli; Sulbenicilina; Kedacillin I.M.; ",39.81071706,0,-4.4,-8.476347955,-2.4,4,"Hormona Brand of Sulbenicillin Sodium Salt;Disodium alpha-Sulfobenzylpenicillin;CIPLUS_711187;Sulbenicillin;alpha-Sulfobenzylpenicillin, Disodiu;Sulbenicillin sodium;Sulbenicillinum;SULBENICILLIN SODIUM;Sulbenicilina;4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylsulfoacetyl)amino)-, (2S-(2alpha,5alpha,6beta(S*)))-;sulbenicillinum;I.M., Kedacilli;CIPLUS_180114;Disodium alpha Sulfobenzylpenicilli;SULBENICILLIN;Sulbenicilline;LS-174908;Sulbenicillin Sodium;Kedacillin I.M.;Lilacillin;sulbenicilline;",-30.07292606,-24.22743838,0.013277916,0.999891478,,,[Na+].[Na+].O=C([O-])[C@@H]2N3C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)S([O-])(=O)=O)[C@H]3SC2(C)C,ACC,SULBENICILLIN DISODIUM,0,0,0,-24.22743838,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182081-04,Zotepine,170465934,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),26615-21-4,,19.95262315,0,-4.7,-101.3770729,-2.3,4,,-85.99148435,-80.29657905,0.310920617,0.935200296,3269,HRH1,CN(C)CCOC1=Cc3ccccc3Sc2ccc(Cl)cc12,Prestwick,Prestw-1368,-18.36037587,0,-25.80412365,-80.29657905,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00168463-06,Bretylium tosylate,405558464,norepinephrine secretion Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61-75-6,,7.079457844,1,-5.15,-13.03278093,-3,4,,-37.43778764,-6.04581251,1,0.990726498,,,CC[N+](C)(C)CC1=C(Br)C=CC=C1,Prestwick,Prestw-942,-1.02813547,2.60686963,-33.73869226,-6.04581251,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00161605-02,L-Ascorbyl 6-palmitate,405558500,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),137-66-6,,31.6227766,0,-4.5,-11.87468128,-3,4,,-47.20171982,-43.50143318,0.026455588,0.999568318,,,CCCCCCCCCCCCCCCC(=O)OCC(O)C\1OC(=O)\C(=C1O)O,APExBIO,B2105,1.11133321,0,0,-43.50143318,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389662-01,Luteinizing hormone releasing hormone human acetate salt (LHRH),405558523,Putative gonadotropin-releasing hormone II receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),71447-49-9,,39.81071706,0,-4.4,-34.52102435,-3,4,,-32.76897191,-31.05747659,0.287075407,0.945533309,,GNRHR2,CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC2=C[NH]C3=CC=CC=C23)NC(=O)C(CC4=CN=C[NH]4)NC(=O)C5CCC(=O)N5)C(=O)NC(CCCN=C(N)N)C(=O)N6CCCC6C(=O)NCC(N)=O,APExBIO,A1147,-7.60704342,-1.08637185,0,-31.05747659,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166270-02,"1,3,5-Trihydroxybenzene dihydrate",225144277,Voltage-gated calcium channel Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6099-90-7,,39.81071706,0,-4.4,-31.68772779,-3,4,,-50.55512791,-44.88502215,0.547447507,0.753076388,,,OC1=CC(=CC(=C1)O)O,SIGMA,P38005,0,-21.42400447,-1.45970117,-44.88502215,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00168748-02,Rotigotine,170465204,Dopamine D4 receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),99755-59-6,,39.81071706,0,-4.4,-42.1691856,-3,4,,-53.40256116,-47.41880097,0.223581811,0.967858763,,,Oc2cccc1C[C@H](CCc12)N(CCC)CCc3cccs3,Tocris,3896,-8.49834955,0,0,-47.41880097,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344546-01,Fenipentol,225144389,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),583-03-9,,39.81071706,0,-4.4,-13.18161084,-3,4,,-45.21145183,-37.67620986,0.006832298,0.999971231,,,CCCCC(O)C1=CC=CC=C1,Prestwick,Prestw-1501,0,0,0,-37.67620986,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016511-08,Chlorotrianisene,170465394,Estrogen receptor Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),569-57-3,,11.22018454,0,-4.95,-23.11792456,-2.2,4,,-32.5950167,-32.57918058,0.015646505,0.999849162,,,COc1ccc(cc1)C(\Cl)=C(/c2ccc(OC)cc2)c3ccc(OC)cc3,Prestwick,Prestw-757,0,0,-16.7806183,-32.57918058,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167507-04,Lapatinib,170465125,EGFR Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),231277-92-2,;Lapatinib; Lapatinib;GW-572016F?; Lapatinib base;LAPATINIB DITOSYLATE; Tykerb;Tykerb,0.707945784,1,-6.15,-133.7916285,-1.4,4,,-31.52249749,-35.23551692,0.507408319,0.797796662,1956,EGFR,Fc1cccc(c1)COc2ccc(cc2Cl)Nc3ncnc4ccc(cc34)c5ccc(CNCCS(C)(=O)=O)o5,Sequoia,231277-92-2,-17.04517892,-49.98413774,-50.4673649,-35.23551692,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018100-08,Fasudil hydrochloride,170466011,ROCK Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),105628-07-7,;HA-1077; Fasudil; Fasudil (HA 1077); HA 1077 hydrochloride; Eril-S;Fasudil; HA-1077 dihydrochloride,39.81071706,0,-4.4,-20.29449137,-3,4,,-34.125246,-33.437705,0.450077095,0.849844477,6093,ROCK1,Cl.O=S(=O)(c2cccc1cnccc12)N3CCCNCC3,Enzo,EI233,0,-12.79200303,0.48590161,-33.437705,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015500-19,Haloperidol,170464841,Dopamine D2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52-86-8,; ;Haloperidol; Haloperidol hydrochloride; Haloperidol Lact;Haloperidol..HCl; Vesadol;HALOPERIDOL;Haloperidol?HCl;Haloperidol hydrochloride; Haloperidol metabolite II; Haloperidol Dec; Haldol,39.81071706,0,-4.4,-15.12642998,-3,4,,-51.8819641,-43.23497008,0.006832298,0.999971225,1813,DRD2,Fc1ccc(cc1)C(=O)CCCN2CCC(O)(CC2)c3ccc(Cl)cc3,Enzo,AC250,0,0,0,-43.23497008,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178840-05,Cloxacillin sodium,170465404,beta-lactam antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),642-78-4,"; Viccillin S (combination);CLOXACILLIN SODIUM; Tegopen; Dicloxacillin Sodium; Sodium syntarpen; Cloxacilina; Sodium, Cloxacilli; Syntarpen;Cloxacillin sodium salt; Orbenin D.C.; 4   Cloxacillin Sodium;Cloxacillin sodium; Sodium cloxacillin; Cloxapen; Cloxacillin, Sodiu; Oxacillin; Ampiclox; Cloxacillin sodium salt",25.11886432,0,-4.6,-33.41862915,-2.4,4,,-55.52596588,-46.07270159,0.782541275,0.999946253,,,[Na+].O=C([O-])[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(C)onc2c1ccccc1Cl)[C@H]4SC3(C)C,Microsource,1500201,-31.79862807,-2.32500018,-12.42469825,-46.07270159,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00184708-02,NCGC00184708-02,124896555,smooth muscle contraction Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),26538-44-3,,31.6227766,0,-4.5,-91.69319564,-2.4,4,Zearalanol`,-74.82400344,-76.52000287,0.278627565,0.948842758,,,CC1CCCC(O)CCCCCC2=CC(=CC(=C2C(=O)O1)O)O,SIGMA,NTP_SID_1403,-14.85840914,3.5120464,-26.18784547,-76.52000287,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00181104-04,Dithiazanine chloride,124893646,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,10,0,-5,-138.9564392,-2.3,4,,-82.62818971,-97.65073105,0.597876093,0.999987405,,,CCN1C(/SC2=C1C=CC=C2)=C/C=C/C=C/C3=[N+](CC)C4=C(S3)C=CC=C4,NCI,NSC-221154,-49.01780992,-15.18153567,-69.43446319,-97.65073105,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249908-01,Mefenorex,170465601,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),17243-57-1,,3.981071706,1,-5.4,-10.83565101,-3,4,,-33.30699352,0.11928504,1,0.999996275,,,CC(NCCCCl)Cc1ccccc1,GVK,FFS-11-286-NCI-140,-24.63114768,0,-31.08916127,0.11928504,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167465-02,Calcipotriene,170464710,Vitamin D receptor Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),112965-21-6,,39.81071706,0,-4.4,-63.77147773,-3,4,,-65.59145402,-58.82621168,0.301583832,0.939356713,,,C=C1C(/C[C@@H](O)C[C@@H]1O)=C\C=C2/CCC[C@]3(C)[C@H](CC[C@@H]23)[C@H](C)/C=C/[C@@H](O)C4CC4,"Prestwick Chemical, Inc.",Prestw-1257,-14.34949828,0,0,-58.82621168,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183879-01,Bisbentiamine,144206468,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2667-89-2,,39.81071706,0,-4.4,-22.41327775,-3,4,BISBENTIAMINE;Bisbentiamina;Beston;CIPLUS_213921;bisbentiaminum;Bisbentiamine;bisbentiamine;Bisbentiaminum;,-76.87503746,-64.06253122,0.006832298,0.999971213,,,Nc4nc(C)ncc4CN(C=O)C(/C)=C(/CCOC(=O)c1ccccc1)SSC(/CCOC(=O)c2ccccc2)=C(/C)N(C=O)Cc3cnc(C)nc3N,ACC,Bisbentiamine,0,0,0,-64.06253122,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389762-01,D-(+)-MALTOSE,405558630,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),69-79-4,,39.81071706,0,-4.4,-65.79126529,-3,4,,-36.51146662,-35.121042,0.537745375,0.764724184,,,OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O,Microsource,1301024,-17.25248058,-1.72790672,-0.52815315,-35.121042,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00186054-01,Tannic acid,124896727,Beta-secretase 1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-59.30030536,-3,4,,-66.19659938,-59.33049948,0.267346136,0.953163922,,,OC1=CC(=CC(=C1O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@H]3O[C@@H](OC(=O)C4=CC(=C(O)C(=C4)OC(=O)C5=CC(=C(O)C(=C5)O)O)O)[C@H](OC(=O)C6=CC(=C(O)C(=C6)OC(=O)C7=CC(=C(O)C(=C7)O)O)O)[C@@H](OC(=O)C8=CC(=C(O)C(=C8)OC(=O)C9=CC(=C(O)C(=C9)O)O)O)[C@@H]3OC(=O)C%10=CC(=C(O)C(=C%10)OC(=O)C%11=CC(=C(O)C(=C%11)O)O)O,SIGMA,16201,-12.80537966,0,0,-59.33049948,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179590-04,Syrosingopine,405558663,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),84-36-6,,31.6227766,0,-4.5,-57.57713664,-2.4,4,,-94.43203279,-74.56972181,0.517411358,0.787150838,,,CCOC(=O)OC1=C(OC)C=C(C=C1OC)C(=O)O[C@@H]2C[C@@H]3CN4CCC5=C([NH]C6=C5C=CC(=C6)OC)[C@H]4C[C@@H]3[C@@H]([C@H]2OC)C(=O)OC,Glixx,GLXC-06136,0,-30.25694749,-14.82451788,-74.56972181,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263480-01,Medroxyprogesterone acetate,170464622,Progesterone Receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),71-58-9,,10,0,-5,-41.20867239,-2.2,4,,-52.4615914,-52.59788719,0.008777258,0.999952498,,PGR,CC(=O)[C@@]3(OC(C)=O)CC[C@H]2[C@@H]4C[C@H](C)C1=CC(=O)CC[C@]1(C)[C@H]4CC[C@@]23C,Vitas,STK801943,0,0,-32.65531116,-52.59788719,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188440-01,Zinc dibutyldithiocarbamate,144206589,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),136-23-2,,39.81071706,0,-4.4,-29.4279769,-3,4,ZINC DIBUTYLDITHIOCARBAMATE,-46.99962863,-43.33302386,0.523921527,0.780216624,,,[Zn+2].[S-]C(=S)N(CCCC)CCCC.CCCCN(CCCC)C([S-])=S,APAC,878050,-0.16786888,-19.70234586,0,-43.33302386,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00186014-02,Paliperidone,170464996,Serotonin 2a (5-HT2a) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),144598-75-4,,6.309573445,1,-5.2,-33.80319595,-2.4,4,,-38.95580049,-35.19378825,0.07590778,0.996433057,,,CC=5N=C1[C@H](O)CCCN1C(=O)C=5CCN2CCC(CC2)c4noc3cc(F)ccc34,Tocris,4493,-0.42021243,0,-16.88346787,-35.19378825,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00178860-06,Ethopropazine hydrochloride,170465065,Butyrylcholinesterase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1094-08-2,,10,0,-5,-50.41168176,-2.4,4,,-65.22318055,-46.38119739,0.581635139,0.708288712,,,Cl.CCN(CC)C(C)CN1c3ccccc3Sc2ccccc12,Microsource,1500293,0,-29.38691045,-19.55598321,-46.38119739,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015099-11,Alprenolol,170465812,Beta-adrenergic receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13655-52-2,,31.6227766,0,-4.5,-19.51335076,-3,4,,-46.93349279,-38.58597939,0.452635884,0.847737725,,,CC(C)NCC(O)COc1ccccc1CC=C,Enzo,AC812,3.2839974,-13.68747262,-9.07394398,-38.58597939,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179291-04,Fursultiamine Hydrochloride,405558735,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2105-43-3,,39.81071706,0,-4.4,-62.13847357,-3,4,,-39.76735892,-37.30613243,0.501749214,0.803450011,,,CC1=NC(=C(CN(C=O)C(/C)=C(\CCO)SSCC2CCCO2)C=N1)N,Prestwick,Prestw-1007,-16.30842689,0,0,-37.30613243,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00248803-03,DL-Cysteine,170464842,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3374-22-9,,19.95262315,0,-4.7,-19.19737246,-3,4,,-41.40546573,-36.67080737,0.022948034,0.999675378,,,O=C(O)C(N)CS,Bosche,C2088,0,0,-9.11728886,-36.67080737,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00319175-03,Rilpivirine,405558769,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),500287-72-9,,22.38721139,0,-4.65,-49.40789163,-2.1,4,,-115.4636886,-100.4067444,0.023536163,0.999658189,,,CC1=C(NC2=CC=NC(=N2)NC3=CC=C(C=C3)C#N)C(=CC(=C1)\C=C\C#N)C,APExBIO,A3765,0,1.21034743,-21.65583756,-100.4067444,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263884-02,Zolmitriptan,170464875,5-HT1B Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),139264-17-8,ZOLMITRIPTAN;Zolmitriptan (Zomig),39.81071706,0,-4.4,-62.03818209,-3,4,,-40.83084088,-38.1923674,0.50078053,0.804397993,3351,HTR1B,CN(C)CCc2cnc1ccc(cc12)C[C@@H]3NC(=O)OC3,Microsource,1505281,-16.44358638,1.16989916,0,-38.1923674,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249888-01,Vitamin B12,170464872,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),68-19-9,,35.48133892,0,-4.45,-183.2535146,5,4,,-8.195066876,-46.6532613,0.594746438,0.694240877,,,NC(=O)CC[C@@H]8C=2N=C(C(C)=C1[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@](C)(N1[Co+]C#N)[C@@H]7N=C(C(C)=C3N=C(C=2)C(C)(C)[C@@H]3CCC(N)=O)[C@](C)(CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@@H]6[C@@H](CO)O[C@H](n5cnc4cc(C)c(C)cc45)[C@@H]6O)[C@H]7CC(N)=O)[C@@]8(C)CC(N)=O,GVK,FFS-11-286-NCI-25,-36.49070557,-42.43539904,-39.31522212,-46.6532613,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183046-03,Mequitazine,170465794,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),29216-28-2,,10,0,-5,-47.46681857,-2.4,4,,-71.93428721,-69.67919931,0.621361818,0.999973596,,,c3ccc4Sc5ccccc5N(CC2CN1CCC2CC1)c4c3,Vitas,STK324459,-28.68792897,1.84296088,-42.84483026,-69.67919931,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016401-09,Hydroflumethiazide,170465082,Thiazide-sensitive sodium-chloride cotransporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),135-09-1,,0.707945784,1,-6.15,-49.34058552,-1.4,4,,-34.59528703,-46.70985138,0.746915628,0.33672427,,,FC(F)(F)c1cc2NCNS(=O)(=O)c2cc1S(N)(=O)=O,Microsource,1500341,0,-46.91703465,-0.32521682,-46.70985138,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159453-05,Zileuton,170465222,5-Lipoxygenase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),111406-87-2,;Zileuton; Zileuton; Zyflo;A-64077/ABT-077,6.309573445,1,-5.2,-18.63245659,-3,4,,-38.16813422,-10.42527575,1,0.999716997,240,ALOX5,NC(=O)N(O)C(C)c1cc2ccccc2s1,"Prestwick Chemical, Inc.",Prestw-1365,-1.56958576,-1.31643173,-37.2665299,-10.42527575,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167442-03,Tamsulosin hydrochloride,170464826,alpha1-Adrenoceptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),106463-17-6,,1.258925412,1,-5.9,-57.26712741,-1.4,4,,-38.81694233,-45.35215814,0.424870892,0.869076185,,ADRA1A,Cl.O=S(N)(=O)c1cc(ccc1OC)C[C@@H](C)NCCOc2ccccc2OCC,Sequoia,106463-17-6,0,-30.7890047,-28.48512616,-45.35215814,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159403-03,Nandrolone decanoate,26754490,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,Nandrolone decanoate; Deca-durabolin; Retabolyl; Decadurobolin; Decadurabolin; Retabolil; Deca-Durabol; ,39.81071706,0,-4.4,-17.0994013,-3,4,CIPLUS_152890;Decadurabolin;Nandrolone Decanoate;Decadurobolin;Retabolil;Retabolyl;17 beta-hydroxyestr-4-en-3-one 17-decanoate;Deca-durabolin;LS-64854;NCGC00159403-03;Nandrolone decanoate;NANDROLONE DECANOATE;nandrolone decanoate;19-nor-4-androstene-17 beta-ol-3-one 17-decanoate;19-nortestosterone decanoate;Deca-Durabol;,-58.6490352,-48.874196,0.006832298,0.99997122,,,[H]C1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCCCCCCCC,Labotest,LT01138619,0,0,0,-48.874196,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346610-02,NCGC00346610-02,384568857,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),79-83-4,,25.11886432,0,-4.6,-87.47509788,-2.4,4,,-51.77562367,-49.45123005,0.540133967,0.761793454,,,CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O,Selleck,S2498,-21.4794562,2.48425642,-10.39311521,-49.45123005,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179652-04,Nalbuphine hydrochloride,405558847,Kappa opioid receptor Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),23277-43-2,,25.11886432,0,-4.6,-9.969743637,-3,4,,-34.07290432,-32.14408693,0.058363842,0.997895503,,,O[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@@]25CCN3CC6CCC6,Axon Medchem,1577,0,1.82731268,0,-32.14408693,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181109-03,Decoquinate,170466244,Antiprotozoal agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),18507-89-6,,0.354813389,1,-6.45,-96.18055543,-2.4,4,,-31.84780311,1.82206432,1,0.999989422,,,O=C(OCC)c1cnc2cc(OCC)c(cc2c1O)OCCCCCCCCCC,Microsource,1505356,-54.31211333,-10.08120189,-34.60109244,1.82206432,,,,,,,,,,,,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,,,,
NCGC00249915-01,Bupranolol,170465802,Beta-3 adrenergic receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),14556-46-8,,31.6227766,0,-4.5,-80.18697932,-2.4,4,,-55.84573918,-53.21110878,0.16034761,0.98381227,,,Clc1ccc(C)cc1OCC(O)CNC(C)(C)C,GVK,FFS-11-286-NCI-172,-11.16077034,-17.69390459,-22.36341543,-53.21110878,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016344-07,5-Aminosalicylic acid,170464840,reactive oxygen species biosynthetic process Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),89-57-6,,31.6227766,0,-4.5,-164.1986062,-2.4,4,,-32.15201748,-41.78594446,0.931335846,0.999998068,16534,,OC(=O)c1cc(N)ccc1O,Vitas,STK301678,-35.32763073,-48.17437061,-13.74259656,-41.78594446,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094516-08,Coumaphos,170466302,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),56-72-4,,3.548133892,1,-5.45,-39.96010703,-3,4,,-33.30140973,0.47998327,1,0.999987933,,,CCOP(=S)(OCC)Oc1ccc2c(c1)OC(=O)C(Cl)=C2C,Microsource,330012,-28.75529923,-7.34474437,-36.50447629,0.47998327,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015862-07,Pyridostigmine bromide,170464878,Acetylcholinesterase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),101-26-8,,1.412537545,1,-5.85,-61.12639014,-1.2,4,,-39.47202406,-37.58258688,0.043803519,0.998815746,,,[Br-].O=C(Oc1ccc[n+](C)c1)N(C)C,Specs,AQ-776/42801589,0,-29.82932423,-38.86298524,-37.58258688,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182055-03,Bazedoxifene,170466793,Selective Estrogen Receptor Modulators (SERM),SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),198481-33-3,TSE-424/WAY-140424;Bazedoxifene; Bazedoxifene,39.81071706,0,-4.4,-52.80607768,-2.4,4,,-87.75071602,-79.37559668,0.562636159,0.733870239,2099,ESR1,CC(=O)O.Oc1ccc(cc1)c5c(C)c2cc(O)ccc2n5Cc3ccc(cc3)OCCN4CCCCCC4,APAC,872287,0,-37.43787734,1.59630545,-79.37559668,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00162068-06,Opipramol dihydrochloride,170465942,Serotonin 2 (5-HT2) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),909-39-7,,39.81071706,0,-4.4,-11.62012482,-3,4,,-39.8557293,-33.21310775,0.006832298,0.999971239,,,Cl.Cl.OCCN1CCN(CC1)CCCN3c4ccccc4C=Cc2ccccc23,"Prestwick Chemical, Inc.",Prestw-1456,0,0,0,-33.21310775,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015829-12,Promazine hydrochloride,170464766,Serotonin 2a (5-HT2a) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),53-60-1,,28.18382931,0,-4.55,-58.87673831,-2.3,4,,-102.0737276,-80.35888457,0.371855463,0.903672559,,,Cl.CN(C)CCCN1c3ccccc3Sc2ccccc12,Microsource,1500509,0,-23.7792452,-20.26382084,-80.35888457,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164624-02,Adefovir dipivoxil,170464742,DNA Polymerase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),142340-99-6," ;Hepsera;Adefovir Dipivoxil (Preveon, Hepsera);Adefovir dipivoxil; Preveon; Adefovir dipivoxil; Adefovir pivoxil; Adefovir Pivoxil",0.354813389,1,-6.45,-473.3550143,5,4,,-3.54168468,-99.97478307,0.761374825,0.531044811,,,CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)COCCn2cnc1c(N)ncnc12,Sequoia,SRP02645a,-99.19836456,-100.8997685,-99.26197916,-99.97478307,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253603-01,Mibolerone,170466095,Progesterone receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3704/9/4,,35.48133892,0,-4.45,-20.50236964,-3,4,,-73.65837998,-65.13198332,0.01292111,0.999897032,,,C[C@@H]3CC1=CC(=O)CC[C@@H]1[C@H]4CC[C@@]2(C)[C@@H](CC[C@]2(C)O)[C@H]34,GVK,FFS-11-286-NCI-098,0.75919166,0,0,-65.13198332,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179341-04,Ondansetron,170464701,5-HT3 Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),99614-02-5,"; ; Ondansetron, (R)-Isomer; Zofran;Ondansetron hydrochloride; Methoxamine HCl;Ondansetron Hydrochloride; Zofran ODT; Ondansetron, (S)-Isomer; Ondansetron; Ondansetron, (+,-)-Isomer",39.81071706,0,-4.4,-36.62229775,-3,4,,-63.83722352,-57.36435293,0.495916335,0.809077267,3359,HTR3A,O=C1C(CCc3c1c2ccccc2n3C)Cn4ccnc4C,Prestwick,Prestw-1058,0,-23.69737556,0,-57.36435293,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015146-17,Brompheniramine (maleate),405559063,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),980-71-2,,3.16227766,1,-5.5,-46.2745209,-2.4,4,,-45.56848137,-39.87822349,0.208424938,0.972240234,,,CN(C)CCC(C1=CC=C(Br)C=C1)C2=CC=CC=N2,MedChem Express,HY-B0480,0,-18.20195476,-28.07636064,-39.87822349,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016059-13,Thioridazine,170465080,Serotonin 2c (5-HT2c) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),50-52-2,,11.22018454,0,-4.95,-83.36112272,-2.3,4,,-117.1888788,-90.696217,0.249566141,0.959506805,,,CN4CCCCC4CCN1c3ccccc3Sc2ccc(SC)cc12,Enzo,NS835,1.04797055,-30.9162293,-47.52157703,-90.696217,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017358-15,Rotenone,170466816,NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),83-79-4,;ROTENONE;Rotenone,11.22018454,0,-4.95,-386.6226774,5,4,,8.470638964,-96.063804,1,0.889011724,51103,NDUFAF1,C=C(C)[C@@H]2Oc3ccc1C(=O)[C@H]4c5cc(OC)c(OC)cc5OC[C@H]4Oc1c3C2,Microsource,200013,-95.29169657,-96.99607389,-91.97160636,-96.063804,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164283-07,Hexadecyltrimethylammonium bromide,170465714,Cell membrane Interacts,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57-09-0,,14.12537545,0,-4.85,-72.31633975,-2.3,4,,-98.18795688,-97.73329106,0.056106494,0.99805347,,,[Br-].C[N+](C)(C)CCCCCCCCCCCCCCCC,Microsource,1503200,-4.16596279,0,-36.63198487,-97.73329106,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164397-05,NCGC00164397-05,225144254,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1952/1/7,,39.81071706,0,-4.4,-23.84166211,-3,4,,-42.65658679,-40.54715566,0.472579993,0.83079292,,,CC(=O)S[C@@H]1CC/2=C/C(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13,Prestwick,Prestw-128,0,-15.9404036,2.11723194,-40.54715566,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016421-07,Cyclizine hydrochloride,170465270,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),303-25-3,,31.6227766,0,-4.5,-36.97491766,-2.4,4,,-53.13447468,-43.55917132,0.114017841,0.99190205,,,Cl.Cl.CN1CCN(CC1)C(c2ccccc2)c3ccccc3,Microsource,1500211,-2.80302622,-7.28728108,-11.75282323,-43.55917132,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00093644-07,Amsacrine,404904675,DNA Topoisomerase II Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54301-15-4,,0.794328235,1,-6.1,-199.3620741,-1.1,4,,-92.92998737,-97.20214878,0.008241373,0.999958108,,TOP2A,COC1=C(NC2=C3C=CC=CC3=NC4=C2C=CC=C4)C=CC(=C1)N[S+](C)([O-])=O,Glixx,GLXC-03289,-9.97213809,-96.78255416,-96.98939068,-97.20214878,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183832-01,Ro 22-9194,144206801,Thromboxane A2 receptor Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),106134-33-2,,31.6227766,0,-4.5,-6.746835099,-3,4,"(-)-(R)-2-AMINO-N-(3-(3-PYRIDYL)PROPYL)-2',6'-PROPIONOXYLIDIDE;Milacainide Tartrate;CIPLUS_3853846;milacainide;MILACAINIDE TARTRATE;CIPLUS_705772;Ro 22-9194;MILACAINIDE;Ro-22-9194;Milacainide tartrate;Milacainide;milacainidum;2-amino-N-(2,6-dimethylphenyl)-N-(3-(3-pyridyl)propyl)propionamide;",-84.69904619,-67.57503499,0.029911938,0.999447832,,,Cl.Cl.CC(N)C(=O)N(CCCc1cccnc1)c2c(C)cccc2C,Pharmaron,PH-NIH-100499-100,4.92870484,2.94999871,0,-67.57503499,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164385-05,Clomifene citrate,170464951,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),911-45-5,"; Zuclomifeno; Clomifeno; Clomiphene citrate (Z,E);CLOMIPHENE CITRATE; Clomifene Citrate; ; Clomiphene Hydrochloride; Clomid; Clomiphene citrate salt; (E)-isomer, HCl; Clomifen; cis-Clomiphene citrate; Clomifene citrate; Enclomifeno; (Z)-isomer, citrate; Clomiphene citrate",0.794328235,1,-6.1,-62.73281178,-1.4,4,,-42.21694199,-50.79660221,0.505752899,0.799346585,2099,ESR1,CCN(CCOc1ccc(cc1)C(c2ccccc2)=C(Cl)c3ccccc3)CC,Microsource,1500196,0.57405912,-40.36328118,-26.48216229,-50.79660221,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00024494-02,D-Alanine,170465038,Alanine aminotransferase 1 Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),338-69-2,,39.81071706,0,-4.4,-21.4989829,-3,4,,-37.43812661,-35.36510551,0.434478026,0.861993495,,,C[C@@H](N)C(=O)O,Tocris,205,0,-13.06517132,0,-35.36510551,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016951-05,Clebopride maleate,170465853,Dopamine D2 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),84370-95-6,,31.6227766,0,-4.5,-12.49983825,-3,4,,-58.65967313,-52.50767709,0.038170454,0.999100605,,,O=C(O)/C=C\C(=O)O.Clc1cc(c(OC)cc1N)C(=O)NC3CCN(Cc2ccccc2)CC3,Prestwick,Prestw-380,1.95051009,0,0,-52.50767709,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015897-08,Ranolazine,170465435,Sodium channel Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),95635-55-5, ;RANOLAZINE;Ranolazine dihydrochloride; Ranolazine dihydrochloride; Ranexa;Ranolazine,39.81071706,0,-4.4,-8.402266838,-3,4,,-43.52336214,-36.26946845,0.042447932,0.998887971,6335,SCN9A,OC(CN1CCN(CC1)CC(=O)Nc2c(C)cccc2C)COc3ccccc3OC,Microsource,1505366,1.12865349,0,1.27443623,-36.26946845,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159417-05,Triclosan,170464936,Bacterial enoyl-[acyl-carrier-protein] reductase Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3380-34-5,,10,0,-5,-21.50123123,-2.4,4,,-46.08977801,-42.1840158,0.889375421,0.999960564,,,Clc2cc(Cl)ccc2Oc1ccc(Cl)cc1O,Labotest,LT02056532,-46.96231249,2.64984124,-23.72433965,-42.1840158,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159393-03,N-Acetyl-L-tyrosine,170465742,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),537-55-3,,31.6227766,0,-4.5,-16.85701581,-3,4,,-48.33031132,-36.99266009,0.01687567,0.999824473,,,Oc1ccc(C[C@H](NC(C)=O)C(=O)O)cc1,Labotest,LT03380081,0,0,-5.60503119,-36.99266009,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016003-10,Trihexyphenidyl hydrochloride,170464756,Muscarinic acetylcholine receptor M5 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52-49-3,,5.011872336,1,-5.3,-35.91347438,-1.4,4,,-32.99910736,-34.25843274,0.05626281,0.998044196,,,Cl.OC(CCN1CCCCC1)(c2ccccc2)C3CCCCC3,Microsource,1500592,0,-2.57953578,-31.68073491,-34.25843274,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015563-13,Imipramine,170464777,Serum paraoxonase/arylesterase 1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),50-49-7,,31.6227766,0,-4.5,-41.08326055,-2.4,4,,-98.97847658,-78.01399741,0.070101106,0.996957164,5444,PON1,CN(C)CCCN2c3ccccc3CCc1ccccc12,Enzo,AC813,0,-5.36770248,-14.37504309,-78.01399741,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015748-17,Nifedipine,170465006,Voltage-gated L-type calcium channel alpha-1C subunit Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),21829-25-4,,39.81071706,0,-4.4,-13.15165959,-3,4,,-74.09525968,-62.1627164,0.042607183,0.998878882,,,CC=1NC(C)=C(C(C=1C(=O)OC)c2ccccc2[N+]([O-])=O)C(=O)OC,Specs,AN-153/I100964,2.42411895,0,1.86231472,-62.1627164,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163778-09,Imazalil sulfate,170466809,O75469|||Q9UJ26 REC20 - 20% relative effective concentration; the concentration of the test compound showing 20% of the agonistic activity of 1 _ 10_5 M rifampicin via hPXR,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58594-72-2,,39.81071706,0,-4.4,-8.643080948,-3,4,,-49.5166966,-41.26391383,0.045806654,0.998704421,,,O=S(=O)(O)O.Clc2ccc(C(OCC=C)Cn1ccnc1)c(Cl)c2,"Prestwick Chemical, Inc.",Prestw-963,1.57069515,0,1.52655546,-41.26391383,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016740-18,Prazosin,170465415,alpha1-Adrenoceptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),19216-56-9,Prazosin hydrochloride;PRAZOSIN HYDROCHLORIDE;PRAZOSIN; Polypress;; ; Pratsiol;Terazosin hydrochloride; Prazosina; Justac; Minipress;Prazosin; Prazosin hydrochloride; Furazosin hydrochloride,0.316227766,1,-6.5,-142.9445924,-1.4,4,,-22.60978742,-45.41063385,0.857882238,0.704681855,148,ADRA1A,O=C(N1CCN(CC1)c3nc2cc(OC)c(OC)cc2c(N)n3)c4ccco4,Vitas,STK301545,-28.51920077,-55.55502953,0,-45.41063385,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00095165-07,Carmofur,170465833,Pyrimidine Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61422-45-5, Mifurol;CARMOFUR; CARMOFUR; Carmofur; ,4.466835922,1,-5.35,-86.38741953,-2.4,4,,-85.82040952,-75.75963844,0.463858546,0.838275601,,TYMS,O=C1NC(=O)C(F)=CN1C(=O)NCCCCCC,Microsource,1505317,0,-43.60984821,-42.12554598,-75.75963844,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025349-05,Apomorphine,170465297,D2-like dopamine receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58-00-4,,1.995262315,1,-5.7,-58.34360884,-1.4,4,,-42.85315628,-37.97721171,0.144035532,0.986992211,,,Oc3ccc2C[C@@H]1c4c(CCN1C)cccc4c2c3O,Specs,AE-562/J258166,0,-22.53464258,-41.97645288,-37.97721171,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00161414-03,Tropisetron,170466432,5-HT3 Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),89565-68-4, ;Tropisetron hydrochloride; Tropisetron hydrochloride;Navoban,39.81071706,0,-4.4,-55.42481243,-3,4,,-67.26142431,-60.21785359,0.299690071,0.940174165,3359,HTR3A,CN4[C@H]1CC[C@@H]4CC(C1)OC(=O)c3cnc2ccccc23,Bosche,T0234,-12.48134837,0,4.59715384,-60.21785359,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015578-12,Ketoprofen,170465449,non-steroidal antiinflammatory,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),22071-15-4, Alrheumat; Orudis; Alrheumum; ; Ketoprofen;Ketoprofen; Ketoprofeno; (S)-(+)-Ketoprofen; (S)-Ketoprofen; Profenid;KETOPROFEN,35.48133892,0,-4.45,-56.08999617,-2.4,4,,-48.65755063,-44.74626255,0.784362733,0.999943388,,PTGS1,CC(C(=O)O)c1cccc(c1)C(=O)c2ccccc2,Microsource,1501215,-36.37146628,-8.67292995,-11.84475731,-44.74626255,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00531790-01,JTT-501,405558852,Peroxisome proliferator-activated receptor gamma Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),170861-63-9,,2.238721139,1,-5.65,-44.03167725,-2.4,4,,-35.03817069,-31.42015012,0.260981548,0.955576885,5468,PPARG,CC1=C(CCOC2=CC=C(CC3C(=O)NOC3=O)C=C2)N=C(O1)C4=CC=CC=C4,Glixx,GLXC-08947,-1.80500788,-17.17482248,-22.3503351,-31.42015012,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016618-04,Dimethisoquin hydrochloride,170465516,Neuronal acetylcholine receptor; alpha4/beta4 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2773-92-4,,17.7827941,0,-4.75,-88.71795865,-2.4,4,,-87.54222112,-73.6039644,0.507289152,0.797732445,,,Cl.CN(C)CCOc2nc(cc1ccccc12)CCCC,"Prestwick Chemical, Inc.",Prestw-630,-5.99897835,-36.05124898,-28.2483959,-73.6039644,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00177979-05,Azelastine hydrochloride,170465172,Histamine H1 Receptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),79307-93-0,; Astelin; Azelastina;AZELASTINE HYDROCHLORIDE; Azelastine Hydrchloride,39.81071706,0,-4.4,-49.77393743,-3,4,,-95.86779206,-83.22316005,0.781591243,0.985920975,9704,HRH1,Cl.Clc1ccc(cc1)CC3=NN(C(=O)c2ccccc23)C4CCCN(C)CC4,Microsource,1505340,-68.87055481,-6.45569586,4.70087947,-83.22316005,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181782-03,Sertindole,170465613,Serotonin 2c (5-HT2c) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),106516-24-9,,14.12537545,0,-4.85,-74.85628641,-2.3,4,,-97.33743306,-95.70080256,0.070654033,0.996908519,,,Fc1ccc(cc1)n5cc(C3CCN(CCN2CCNC2=O)CC3)c4cc(Cl)ccc45,Prestwick,Prestw-1341,-4.772132,0,-38.67458198,-95.70080256,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166037-04,beta-Glycerol phosphate disodium salt pentahydrate,405558431,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13408-09-8,,5.623413252,1,-5.25,-35.51840744,-1.4,4,,-38.0520637,-34.1389089,0.158290613,0.984229882,,,OCC(CO)OP([O-])([O-])=O,SIGMA,50020,-0.69043319,4.91641396,-35.69635528,-34.1389089,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253572-01,Embutramide,170465662,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),15687-14-6,,3.16227766,1,-5.5,-56.18118641,-1.4,4,,-32.76377864,-28.9599402,0.852591011,0.938334761,,,COc1cc(ccc1)C(CC)(CC)CNC(=O)CCCO,GVK,FFS-11-286-NCI-121,-25.47206368,-5.43984554,-37.05058165,-28.9599402,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00165979-06,CINNAMIC ACID,405558448,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),621-82-9,,70.79457844,0,-4.15,-85.94635649,-3,4,,-60.80687928,-60.0063697,0.403477859,0.883908248,,,OC(=O)\C=C\C1=CC=CC=C1,Microsource,270092,-19.64458751,0,0,-60.0063697,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00181122-01,2-Dodecylisoquinolinium tosylate,144206285,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5412-37-3,CIPLUS_189611; ,2.818382931,1,-5.55,-124.4442948,-1.1,4,CIPLUS_160386;CIPLUS_150169;Lauryl isoquinolinium bromide;CIPLUS_164262;CIPLUS_189611;LAURYL ISOQUINOLINIUM BROMIDE;LAURYL ISOQUINOLINIUM SACCHARINATE;,-97.82181293,-95.71361248,0.036897058,0.999159405,,,[O-]S(=O)(=O)c1ccc(C)cc1.CCCCCCCCCCCC[n+]1cc2ccccc2cc1,NCI,NSC-4486,0,-33.60367746,-96.62855582,-95.71361248,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091687-01,Benzene sulfonic acid,17389167,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-69.17344868,-3,4,"CIPLUS_668287;CIPLUS_746452;CIPLUS_158198;Benzene sulfonic acid;Sodium benzenesulfonate;SODIUM BENZENESULFONATE;CIPLUS_188702;AB08082695-01;CIPLUS_750422;Benzenesulfonic acid monohydrate;CIPLUS_3730420;Benzenesulfonic Acid Sodium Salt;CIPLUS_750425;CIPLUS_740728;CIPLUS_153872;CIPLUS_213852;4-Formyl-1-methylpyridinium benzenesulfonate;CIPLUS_213853;CIPLUS_750569;Benzenesulfonic acid;Benzene Sulfonic Acid;p-Toluenesulfonic acid, polymer-bound;benzenesulfonic acid;CIPLUS_664858;ALUMINUM PHENOLSULFONATE;SODIUM DECYLBENZENESULFONATE;CIPLUS_198271;CIPLUS_3741824;CIPLUS_753058;CIPLUS_203733;CIPLUS_752981;CIPLUS_198836;CIPLUS_763507;CIPLUS_210324;CIPLUS_750514;CIPLUS_750536;CIPLUS_198267;CIPLUS_198368;Benzenesulfonic acid sodium salt;CIPLUS_3729342;CIPLUS_198511;CIPLUS_150435;CIPLUS_204905;CIPLUS_198364;CIPLUS_670392;CIPLUS_3825062;CIPLUS_3745729;",-55.29566237,-50.24638531,0.814822945,0.913864581,,,O[S+]([O-])(=O)C1=CC=CC=C1,NIEHS,AB08082695,-43.49316565,-13.91284127,0,-50.24638531,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179419-05,Guanadrel sulfate,405558962,Norepinephrine transporter Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),22195-34-2,,3.981071706,1,-5.4,-12.51816588,-3,4,,-39.28988162,0,1,0.999998308,,,NC(=N)NCC1COC2(CCCCC2)O1,Prestwick,Prestw-767,-49.44892548,0,-35.91655706,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015821-10,Piracetam,170465901,"Glutamate receptor ionotropic, AMPA 3 Positive Allosteric Modulator",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7491-74-9,,39.81071706,0,-4.4,-100.7343941,-2.4,4,,-33.9678472,-49.95806752,0.292435392,0.943317629,,,O=C1CCCN1CC(=O)N,Specs,AE-641/30117005,-17.07029148,-25.63755139,-20.00090935,-49.95806752,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164625-04,Cerivastatin sodium,170465109,HMG-CoA reductase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),143201-11-0,,100,0,-4,-393.5495176,5,4,,87.94941085,-76.14909351,0.678710692,0.53461677,,,[Na+].CC(C)c1nc(c(/C=C/[C@@H](O)C[C@@H](O)CC([O-])=O)c(c1COC)c2ccc(F)cc2)C(C)C,Sequoia,143201-11-0,-79.84686378,-90.77458447,-90.4536947,-76.14909351,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164533-02,Buformin,170465982,"AMP-activated protein kinase, AMPK Activator",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),692-13-7,,7.943282347,1,-5.1,-439.9007428,5,4,,9.028531608,-85.50796315,0.171897647,0.981563457,,,NC(=N)NC(=N)NCCCC,Labotest,LT02684528,-93.8921501,-95.53173949,-86.84468236,-85.50796315,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00080392-05,Phosmet,170466810,Acetylcholinesterase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),732-11-6,,39.81071706,0,-4.4,-13.13036624,-3,4,,-45.03568856,-37.52974047,0.006832298,0.999971231,,,COP(=S)(OC)SCN2C(=O)c1ccccc1C2=O,Vitas,STK097158,0,0,0,-37.52974047,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188864-02,Iloperidone,170465198,Dopamine D2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),133454-47-4,Iloperidone,22.38721139,0,-4.65,-43.35599341,-2.1,4,,-100.4147321,-90.95537329,0.007177598,0.999968225,1813,DRD2,CC(=O)c4ccc(OCCCN1CCC(CC1)c3noc2cc(F)ccc23)c(OC)c4,Bosche,I2337,0,0,-16.51464692,-90.95537329,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183877-01,Unoprostone isopropyl ester,144207178,Prostanoid FP receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),120373-24-2,,39.81071706,0,-4.4,-9.406591414,-2.4,4,"Ciba Vision brand of isopropyl unoprostone;Unoprostone;isopropyl 20-ethyl-9alpha,11alpha-dihydroxy-15-keto-cis-delta-5-prostanoate;ISOPROPYL UNOPROSTONE;UNOPROSTONE ISOPROPYL;unoprostone isopropyl;UF-021;Isopropyl unoprostone;Unoprostone isopropyl;Novartis brand of isopropyl unoprostone;CIPLUS_3762607;Eescula;LS-176760;ISOPROPYL Z-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-(3-OXODECYL)CYCLOPENTYL)HEPT-5-ENOATE, D-;isopropyl unoprostone;UF 021;Rescula;CIPLUS_729221;",-31.10667138,-25.92222615,0.028502008,0.999499563,,,O[C@@H]1C[C@H](O)[C@H](C/C=C\CCCC(=O)OC(C)C)[C@H]1CCC(=O)CCCCCCC,Toronto Research,U800050,0,-0.48288935,0,-25.92222615,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378877-01,Methylnaltrexone Bromide,405558536,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),73232-52-7,,39.81071706,0,-4.4,-20.35709085,-3,4,,-42.64196624,-36.3683052,0.089522186,0.995028836,4988,OPRM1,[H][C@]12OC3=C4C(C[C@@H]5[C@](O)(CCC1=O)[C@]24CC[N+]5(C)CC6CC6)=CC=C3O,MedChem Express,HY-75766,-2.53600856,0,0,-36.3683052,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346688-03,Alectinib (CH5424802),405559044,ALK Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1256580-46-7,,12.58925412,0,-4.9,-18.19678721,-3,4,,-37.15133922,-34.34328002,0.090113446,0.994962545,,ALK,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C)(C)C5=C(C2=O)C6=CC=C(C=C6[NH]5)C#N,Axon Medchem,1884,0,3.07923585,0,-34.34328002,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00507798-01,Drostanolone propionate,405559055,Androgen Receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),521-12-0,,39.81071706,0,-4.4,-35.48052335,-3,4,,-41.42410004,-37.02008337,0.250955829,0.95906427,,,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)[C@H](C)C[C@]4(C)[C@H]3CC[C@]12C,Carbosynth,FD22623,-7.48484981,0,0,-37.02008337,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164626-02,Tiagabine hydrochloride,170465153,GAT-1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),145821-59-6,,3.981071706,1,-5.4,-23.56476591,-1.4,4,,-37.55456592,-24.90248595,0.901906543,0.890610626,,SLC6A1,Cl.Cc3ccsc3C(=C\CCN1CCC[C@H](C1)C(=O)O)\c2sccc2C,Sequoia,SRP023505t,-43.73588303,3.33033456,-38.94951769,-24.90248595,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378571-03,NCGC00378571-03,405559085,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,35.48133892,0,-4.45,-37.60586423,-3,4,,-122.2782009,-97.51052705,0.010145792,0.999936507,,PARP1,NC(=O)C1=CC=CC2=C[N](N=C12)C3=CC=C(C=C3)C4CCCNC4,Bio Vision,May-62,0,0,-4.99753843,-97.51052705,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263164-17,Cabozantinib,405558578,VEGFR-2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),849217-68-1,,8.912509381,1,-5.05,-72.04400502,-2.3,4,,-85.77855878,-85.63490786,0.521843635,0.999023337,,KDR,COC1=C(OC)C=C2C(=CC=NC2=C1)OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3,MedChem Express,HY-13016,-29.02245602,0,-60.25669431,-85.63490786,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183846-01,Toborinone,144206841,Phosphodiesterase 3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),143343-83-3,,31.6227766,0,-4.5,-54.44158942,-3,4,"toborinone;OPC 18790;6-(3-(3,4-DIMETHOXYBENZYLAMINO)-2-HYDROXYPROPOXY)-2(1H)-QUINOLINONE,DL-;torborinone;CIPLUS_208056;Toborinone;LS-141868;OPC-18790;TOBORINONE;2(1H)-Quinolinone, 6-(3-(((3,4-dimethoxyphenyl)methyl)amino)-2-hydroxypropoxy)-, (+-)-;6-(3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy)-2(1H)-quinolinone;toborinonum;taborinone;CIPLUS_197035;CIPLUS_698797;",-66.54593297,-61.01964619,0.174304881,0.980785603,,,COc1ccc(cc1OC)CNCC(O)COc2ccc3NC(=O)C=Cc3c2,Pharmaron,PH-NIH-152870,-9.41185484,0,-6.82187273,-61.01964619,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016397-04,Benzydamine hydrochloride,170465576,prostaglandin production involved in inflammatory response Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132-69-4,,12.58925412,0,-4.9,-117.6511111,-2.3,4,,-90.60299053,-93.29683484,0.267136462,0.953231889,,,Cl.CN(C)CCCOc3nn(Cc1ccccc1)c2ccccc23,Vitas,STK711092,-18.34719987,0,-42.65026976,-93.29683484,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346555-05,Apixaban,405558566,Coagulation Factor Xa Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),503612-47-3,,39.81071706,0,-4.4,-11.38278402,-3,4,,-38.0416769,-32.53473075,0.004175958,0.999989256,,F10,COC1=CC=C(C=C1)[N]2N=C(C(N)=O)C3=C2C(=O)N(CC3)C4=CC=C(C=C4)N5CCCCC5=O,APExBIO,A4341,0,0,0,-32.53473075,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00014648-04,Spiclomazine hydrochloride,405558575,Adrenergic receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,35.48133892,0,-4.45,-33.57609108,-3,4,,-109.2112342,-83.87959615,0.574296415,0.999979595,,,ClC1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCC5(CC4)NC(=O)CS5)C=C1,NCI,NSC-290956,-35.1966713,0,-6.05598735,-83.87959615,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00085849-02,MEBHYDROLIN,405558588,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),524-81-2,,35.48133892,0,-4.45,-188.7174852,-2.3,4,,-75.40064805,-85.31407223,0.216597847,0.969914227,,,CN1CCC2=C(C1)C3=CC=CC=C3[N]2CC4=CC=CC=C4,Microsource,1501116,-31.81522833,-42.92481837,-47.43181512,-85.31407223,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183030-02,Terodiline hydrochloride,405558600,HERG Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7082-21-5,,8.912509381,1,-5.05,-46.6487826,-1.4,4,,-53.23248537,-53.27410997,0.694215277,0.99998512,,,CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C,SIGMA,T4577,-27.97496995,0,-40.10594228,-53.27410997,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183108-01,Propamidine,144206602,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),104-32-5,Propamidine; DAPP-Br; Propamidina; ,11.22018454,0,-4.95,-68.43732346,-2.3,4,"Propamidine;Propamidinum;propamidinum;Propamidina;LS-171900;1,3-di-(p-amidinophenoxymethyl)-propane;propamidine;4,4'-(trimethylenedioxy)dibenzamidine dihydrochloride;CIPLUS_209523;DAPP-H;4,4'-(TRIMETHYLEDEDIOXY)DIBENZAMIDINE;CIPLUS_657475;CIPLUS_206886;propamidine diisethionate;1,3-bis(p-amidinophenoxy)propane;1,3-di-(4-amidinophenoxy)propane;PROPAMIDINE;propamidine isethionate;LS-27580;propamidine dihydrochloride;DAPP-Br;4,4'-(trimethylenedioxy)dibenzamidine;",-84.46160283,-85.80482212,0.054519749,0.998162354,,,N=C(N)c1ccc(cc1)OCCCOc2ccc(cc2)C(=N)N,Beta Pharma,86-41342,-2.83066012,0,-42.80815655,-85.80482212,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016741-09,Tinidazole,170465196,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),19387-91-8,,3.981071706,1,-5.4,-5.240157564,-3,4,,-41.62182065,-6.7662362,1,0.999919466,,,O=S(=O)(CCn1c(cnc1C)[N+]([O-])=O)CC,Vitas,STK801761,2.77529145,0,-39.00168579,-6.7662362,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00242480-03,Ivacaftor,405559089,CFTR Channel Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),873054-44-5,,39.81071706,0,-4.4,-26.04068869,-3,4,,-74.68860023,-63.90716686,0.10419762,0.993244701,,CFTR,CC(C)(C)C1=CC(=C(NC(=O)C/2=C/NC3=C(C=CC=C3)C2=O)C=C1O)C(C)(C)C,APExBIO,A5047,0,-5.27100573,0,-63.90716686,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178526-03,APRAMYCIN SULFATE,405559094,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),65710-07-8,,28.18382931,0,-4.55,-13.54555552,-3,4,,-37.25150457,-31.87625381,0.821142872,0.999990474,,,CN[C@H]1[C@@H](O)[C@H]2O[C@@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]4O[C@H](CO)[C@@H](N)[C@H](O)[C@H]4O,Microsource,1505249,-29.29120339,0,-3.42661637,-31.87625381,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182974-01,Improsulfan tosylate,144206762,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),32784-82-0,NSC-140117; Improsulfano; ,39.81071706,0,-4.4,-11.27719561,-3,4,"Improsulfano;improsan hydrochloride;LS-1222;NSC-102627;3,3'-IMINO BIS(DIMETHANESULFONATE)1-PROPANOL HYDROCHLORIDE;IMPROSULFAN TOSILATE;improsan tosylate;Improsulfan;iminodipropyl dimethanesulfonate 4-toluenesulphonate;alkylating agent 864;yoshi 864;dimesyloxydipropylamine tosylate;improsulfan;CIPLUS_161918;Improsulfanum;bis(3-mesyloxypropyl)amine;3,3'-iminobis-1-propanol dimethanesulfonate;864 T;improsan;LS-122362;LS-122363;CIPLUS_168735;improsulfanum;IMPROSULFAN;3,3'-iminodi-1- propanol dimethanesulfonate;NSC-140117;Improsulfan Tosilate;Improsulfan tosilate;CIPLUS_731133;",-37.67952046,-32.23293372,0.762903986,0.999988977,,,Cc1ccc(cc1)S(O)(=O)=O.CS(=O)(=O)OCCCNCCCOS(C)(=O)=O,NCI,NSC_140117,-24.60433188,0,0,-32.23293372,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386237-08,Brintellix,405558626,5-HT1D Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),508233-74-7,,39.81071706,0,-4.4,-106.1323092,-2.4,4,,-72.41886889,-76.0682475,0.58624098,0.9936043,,HTR1D,CC1=CC=C(SC2=CC=CC=C2N3CCNCC3)C(=C1)C,MedChem Express,HY-15414,-42.50441896,-18.87496506,-13.63585676,-76.0682475,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00485328-01,"(6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride",363681287,Phenylalanine-4-hydroxylase Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),69056-38-8,,31.6227766,0,-4.5,-11.74102061,-3,4,,-45.98578804,-42.4881567,0.025405513,0.999601938,,,C[C@H](O)[C@H](O)[C@H]1CNC\2=C(N1)\C(=O)N\C(=N2)N,SIGMA,T4425,1.03795811,0,0,-42.4881567,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00521078-02,Cephaloglycin,405558643,Bacterial penicillin-binding protein Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3577/1/3,,4.466835922,1,-5.35,-13.58605214,-3,4,,-41.59892719,-8.31610654,1,0.999996994,,,CC(=O)OCC/1=C(/N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C2=O)C(O)=O,Toronto Research,C258000,-42.93219482,0,-38.98048814,-8.31610654,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160580-02,2-Hydroxy-N-(4-hydroxyphenyl)-benzamide,405558623,Ribonucleoside-diphosphate reductase M2 chain Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),526-18-1,,28.18382931,0,-4.55,-28.60878225,-3,4,,-77.85892928,-62.39312824,0.015175036,0.999857977,,,OC1=CC=C(NC(=O)C2=CC=CC=C2O)C=C1,DC Chemicals,DC8981,0,0,-9.7072855,-62.39312824,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167506-04,Pimecrolimus,405558652,Macrolide Antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),137071-32-0,,39.81071706,0,-4.4,-21.03431201,-3,4,,-78.17058878,-65.55882398,0.728180653,0.998604675,,,CC[C@@H]1/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)/C(C)=C/[C@@H]4CC[C@H](Cl)[C@@H](C4)OC,Selleck,S5004,-43.4661534,0,2.72403535,-65.55882398,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183001-01,Tolvaptan,124894207,Vasopressin (AVP) V2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),150683-30-0, ; Tolvaptan;Tolvaptan,22.38721139,0,-4.65,-29.24882823,-3,4,"OPC 41061;OPC-41061;7-chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine;tolvaptan;TOLVAPTAN;Tolvaptan;7-CHLORO-5-HYDROXY-1-(2-METHYL-4-(2-METHYLBENZOYLAMINO)BENZOYL)-2,3,4,5-TETRAHYDRO-1H-BENZAPINE, DL-;CIPLUS_789421;tolvaptanum;",-35.50480842,-32.92067368,0.539244585,0.763089423,554,AVPR2,Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N4CCCC(O)c3cc(Cl)ccc34,Pharmaron,PH-NIH-116369,0,-15.49187394,-9.89408206,-32.92067368,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182074-03,Nicomolol,170465790,Cholesterol biosynthesis Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),27959-26-8,,28.18382931,0,-4.55,-8.240691799,-3,4,,-46.30072582,-33.9399438,0.847455346,0.999937874,311849,,O=C(OCC4(COC(=O)c1cccnc1)CCCC(COC(=O)c2cccnc2)(COC(=O)c3cccnc3)C4O)c5cccnc5,Kemprotec,27959-26-8,-33.28263215,1.90073967,-4.88962885,-33.9399438,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160383-02,Lenperone Hydrochloride,405558683,Serotonin 2 (5-HT2) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),24677-86-9,,31.6227766,0,-4.5,-26.48427601,-3,4,,-56.95930559,-46.18129211,0.145482713,0.986722709,,,FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)C(=O)C3=CC=C(F)C=C3,Glixx,GLXC-06484,0,-6.11492287,-8.67094442,-46.18129211,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167470-05,Mezlocillin Sodium,405558684,Bacterial penicillin-binding protein Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),42057-22-7,,39.81071706,0,-4.4,-95.57039782,-2.4,4,,-40.42677562,-42.16238514,0.878551218,0.534821558,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)[S+](C)([O-])=O)C4=CC=CC=C4)C(=O)N2[C@H]1C(O)=O,APExBIO,B4959,-43.69718184,-25.51364835,-2.74390318,-42.16238514,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182042-04,Propylhexedrine (hydrochloride),405558687,Trace amine-associated receptor 1 Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1007-33-6,,56.23413252,0,-4.25,-50.1434862,-3,4,,-45.05224098,-43.90547454,0.268889557,0.952605504,,,CNC(C)CC1CCCCC1,Cayman,12058,-10.34058522,0,-2.62401446,-43.90547454,,,,,,,,,,,,6.86E-07,0.00000343,0.0000171,0.0000857,,,,,,,,,,,
NCGC00167490-03,Lumefantrine,170465388,antimalarial agents,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),82186-77-4,";benflumetol, (+-)-isomer;Lumefantrine; Lumefantrine",39.81071706,0,-4.4,-22.77626736,-3,4,,-46.56568962,-42.97140802,0.345214988,0.918495889,,,CCCCN(CCCC)CC(O)c4cc(Cl)cc3c4c1ccc(Cl)cc1\C3=C\c2ccc(Cl)cc2,SIGMA,L5420,0.23849364,-12.11160151,0,-42.97140802,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095836-05,Guaiazulene,170465862,lipid oxidation Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),489-84-9,,1.584893193,1,-5.8,-33.48224994,-2.4,4,,-40.01232666,-15.17685741,1,0.999958656,,,CC(C)c1ccc(C)c2ccc(C)c2c1,Microsource,1502249,0,-28.60561736,-38.73757516,-15.17685741,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091023-06,Cetylpyridinium bromide,170465500,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),140-72-7,,3.16227766,1,-5.5,-186.4283111,-1.1,4,,-82.27379037,-99.68550641,0.011393026,0.999919939,,,[Br-].CCCCCCCCCCCCCCCC[n+]1ccccc1,Vitas,STK177346,-18.00923921,-40.97382863,-98.40519348,-99.68550641,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016000-18,Disulfiram,170464767,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),97-77-8, ;Tetraethylthiuram disulfide; Disulfiram; Tetraethylthiuram disulfide; Disulfiramo; Teturam; Antabuse;Disulfiram;DISULFIRAM,0.794328235,1,-6.1,-115.460146,-1.3,4,,-97.44670275,0,1,0.999867466,217,ALDH2,CCN(CC)C(=S)SSC(=S)N(CC)CC,Microsource,1500262,-4.9619,-96.20856562,-95.61259577,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00024928-23,Tamoxifen,170465425,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54965-24-1,"Soltamox; ""Tamoxifen; ; Novaldex; Tamoxifen; Tomaxithen; Tamoxifen citrate salt; Tamoxifen, citrate salt; Nolvadex; Tamoxifeno;ICI-46474;ICI-46474?;Tamoxifen citrate;Tamoxifen; Zitazonium; Citrate, Tamoxife",25.11886432,0,-4.6,-79.33286815,-2.4,4,,-53.92525013,-46.55452888,0.696642801,0.488654524,2099,ESR1,O=C(O)C(O)(CC(=O)O)CC(=O)O.CN(C)CCOc1ccc(cc1)/C(c2ccccc2)=C(/CC)c3ccccc3,Microsource,1500557,-9.60560666,-33.62288084,-15.24621846,-46.55452888,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094981-07,Benzyl benzoate,170465382,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),120-51-4,,0.630957345,1,-6.2,-61.44899163,-1.4,4,,-31.94422187,-39.622803,0.710842821,0.450446466,,,O=C(OCc1ccccc1)c2ccccc2,Microsource,1503002,-3.76285065,-42.2138603,-9.6999951,-39.622803,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164543-02,Lomerizine dihydrochloride,170466010,Ca channel blocker - benzhydryl class,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),101477-54-7, ; Terranas; Lomerizine HCl; LOMERIZINE DiHCl;Lomerizine; Lomerizine,39.81071706,0,-4.4,-16.14313186,-3,4,,-55.36913792,-46.14094827,0.006832298,0.999971222,,,Cl.Cl.Fc1ccc(cc1)C(c2ccc(F)cc2)N3CCN(CC3)Cc4ccc(OC)c(OC)c4OC,Sequoia,SRP01568l,0,0,0,-46.14094827,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263951-01,CEPHRADINE,405558705,Cephalosporin antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-19.91751099,-3,4,,-32.35761715,-31.54801429,0.531926443,0.771429208,,,CC/1=C(/N2[C@@H](SC1)[C@H](NC(=O)[C@H](N)/C3=C/C/C=C\C3)C2=O)C(O)=O,Microsource,MS-01500168,0,-14.65791619,1.94519693,-31.54801429,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00371144-02,AWD 131-138,405558706,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),188116-07-6,,31.6227766,0,-4.5,-9.902618333,-3,4,,-65.27141402,-56.5646143,0.059462666,0.997813447,,,ClC1=CC=C(C=C1)N2CC(=N/C2=O)\N3CCOCC3,MedChem Express,HY-14953,3.28498467,0,0,-56.5646143,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00165846-04,Nefazodone hydrochloride,170465078,Serotonin transporter Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),82752-99-6,,39.81071706,0,-4.4,-39.95080825,-3,4,,-101.4337204,-85.36143368,0.050677172,0.998412764,,,Cl.Clc1cccc(c1)N4CCN(CCCN3N=C(CC)N(CCOc2ccccc2)C3=O)CC4,Prestwick,Prestw-1152,-3.35089457,0,0,-85.36143368,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159351-05,Cholesterol,225144221,Transient receptor potential cation channel subfamily V member 1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57-88-5,,0.891250938,1,-6.05,-78.54760707,-1.4,4,,-43.24626343,0,1,0.999989185,7442,TRPV1,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C\C=C/4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,SIGMA,362794,0,-32.54087321,-43.19847669,0,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00253581-01,Indomethacin farnesil,170466014,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),85801-02-1,,0.794328235,1,-6.1,-57.91466539,-1.2,4,,-36.7115775,-33.51892763,0.014855833,0.999864003,,,Clc1ccc(cc1)C(=O)n3c2ccc(cc2c(CC(=O)OC\C=C(/C)CC\C=C(/C)CC\C=C(/C)C)c3C)OC,GVK,FFS-11-286-NCI-252,0,-32.83254294,-33.2963765,-33.51892763,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091288-05,NCGC00091288-05,170465063,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),83-88-5,,0.354813389,1,-6.45,-58.24382221,-1.4,4,,-35.26068254,0,1,0.848282893,,,OC[C@@H](O)[C@@H](O)[C@@H](O)CN2C3=NC(=O)NC(=O)C3=Nc1cc(C)c(C)cc12,Selleck,S2540 ,0,-39.17853616,-23.89841484,0,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00016961-06,Atovaquone,170464681,"Synergistic with proguanil, mitochondrial sensitizer (cytochrome bc1 complex)",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),95233-18-4, ; Atovaquone;Atovaquone; Mepron,0.891250938,1,-6.05,-188.6192508,-1.1,4,,-99.07861818,-99.78993552,0.040330904,0.998995457,,PFF0160c,Clc1ccc(cc1)[C@H]2CC[C@@H](CC2)C=4C(=O)c3ccccc3C(=O)C=4O,Bosche,A2953,-6.01118165,-97.49093294,-96.67293551,-99.78993552,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178854-03,Minocycline hydrochloride,170465049,Tetracycline Antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13614-98-7,,39.81071706,0,-4.4,-13.04580797,-3,4,,-42.51375304,-35.42812753,0.011299401,0.999921318,,PARP1,Cl.CN(C)c2ccc(O)c1C(=O)C3=C(O)[C@]4(O)C(=O)C(=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc12)C(N)=O,Microsource,1500414,-0.21619625,0,0,-35.42812753,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166299-03,BISMUTH SUBSALICYLATE,225144280,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),14882-18-9,,0.390750408,1,-6.40810056,-97.96353749,-3,4,,-44.9899589,-39.99163242,0.759135799,0.992209681,,,O[Bi]1OC(=O)C2=CC=CC=C2O1,Microsource,1505412,-30.69200973,-3.68464446,0,-39.99163242,,,,,,,,,,,,4.57E-09,2.29E-08,1.14E-07,5.71E-07,,,,,,,,,,,
NCGC00179240-04,Levocabastine hydrochloride,170465061,Neurotensin receptor type 2 Inverse Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),79547-78-7,,39.81071706,0,-4.4,-61.86626213,-3,4,,-37.89875579,-35.74896316,0.519926772,0.784634251,23620,NTSR2,Cl.Fc1ccc(cc1)[C@@]2(CC[C@H](CC2)N3CC[C@@]([C@H](C)C3)(c4ccccc4)C(=O)O)C#N,"Prestwick Chemical, Inc.",Prestw-1039,-16.39899161,0,0,-35.74896316,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00483924-02,Brigatinib,384569265,IGF-1R Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1197953-54-0,,14.12537545,0,-4.85,-114.0088712,-2.4,4,,-69.61945719,-75.81710254,0.322165174,0.929981731,,IGFR1,COC1=C(NC2=NC=C(Cl)C(=N2)NC3=CC=CC=C3[P](C)(C)=O)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5,MedChem Express,HY-12857,-20.78430814,-3.13584463,-32.55227114,-75.81710254,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159492-03,Perazine,29215457,Cytochrome P450 1A2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,"Perazine; Perazine Maleate (1:1); Perazine Maleate (1:2); Maleate, Perazin; Taxilan; Dihydrochloride, Perazin; Perazine Dihydrochloride; Perazine Fendizoate; ",28.18382931,0,-4.55,-48.87293836,-2.1,4,"CIPLUS_744600;Perazine Fendizoate;LS-172810;CIPLUS_776815;PERAZINE DIMALONATE;Maleate, Perazin;10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-;Perazine Dihydrochloride;Dihydrochloride, Perazin;CIPLUS_666528;10-(3-(4-Methyl-1-piperazinyl)propyl)phenothiazine dihydrochloride;Perazine Dimalonate;CIPLUS_660985;Perazine Maleate (1:1);Perazine Maleate;10h-phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, (z)-2-butenedioate;CIPLUS_777988;PERAZINE MALEATE;LS-105591;LS-105593;pernazine;LS-173237;Perazine maleate;Pernazine;Perazine Maleate (1:2);Perazine;LS-105589;Perazine dimalonate;CIPLUS_149789;Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (2:1) (salt), mixt. with 5,5-diphenyl-2,4-imidazolidinedione and 10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine (Z)-2-butenedioate (1:2);Taxilan;CIPLUS_769544;phenrytmat;",-111.8474478,-98.84663704,0.007020363,0.999969601,,,CN1CCN(CCCN2C3=CC=CC=C3SC4=CC=CC=C24)CC1,AKos,AKJ-93711,4.3866917,0,-41.43669734,-98.84663704,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00389470-01,Dirithromycin,405558768,Bacterial 70S ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),62013-04-1,,39.81071706,0,-4.4,-36.24683716,-3,4,,-69.83164239,-59.85970199,0.107153508,0.99285263,,,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC3OC(C)CC(C3O)N(C)C)C(C)(O)CC(C)C4NC(COCCOC)OC(C4C)C1(C)O,APExBIO,B1731,-5.0845901,0,0,-59.85970199,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090762-11,Rifabutin,405558775,Cytochrome P450 3a4 Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),72559-06-9,,22.38721139,0,-4.65,-43.17349179,-2.4,4,,-70.71806305,-65.69550231,0.069274256,0.99702911,,PRKDC,[H][C@]1(C)\C=C\C=C(C)\C(=O)NC2=C3NC4(CCN(CC(C)C)CC4)N=C3C5=C(C2=O)C(O)=C(C)C6=C5C(=O)[C@](C)(O6)O\C=C\[C@]([H])(OC)[C@@]([H])(C)[C@@]([H])(OC(C)=O)[C@]([H])(C)[C@]([H])(O)[C@]([H])(C)[C@@]1([H])O,MedChem Express,HY-17025,-3.73505793,0,-12.81046528,-65.69550231,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389455-01,Penicillin G Sodium,405558782,Bacterial penicillin-binding protein Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),69-57-8,,39.81071706,0,-4.4,-53.23836414,-3,4,,-54.24811641,-49.37343034,0.815307057,0.963342478,,,CC1(C)SC2C(NC(=O)CC3=CC=CC=C3)C(=O)N2C1C([O-])=O,APExBIO,B1678,-46.84523894,-9.69814131,0,-49.37343034,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166005-02,L-Cysteine methyl ester hydrochloride,225144264,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),18598-63-5,,3.16227766,1,-5.5,-71.80976249,-2.4,4,,-31.40726549,-25.86323,1,0.999945064,,,COC(=O)[C@@H](N)CS,SIGMA,410209,-13.52046768,-23.90783808,-41.35985559,-25.86323,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390731-01,Tafamidis,405558810,Transthyretin Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),594839-88-0,,39.81071706,0,-4.4,-58.78220469,-3,4,,-106.5534988,-91.75334909,0.121503367,0.990782906,,,OC(=O)C1=CC=C2N=C(OC2=C1)C3=CC(=CC(=C3)Cl)Cl,MedChem Express,HY-14852,-8.86443925,0,0,-91.75334909,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183024-01,Proglumetacin,144206876,Cyclooxygenase-2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57132-53-3,Proglumetacin; Miridacin; Proglumetacina; ,39.81071706,0,-4.4,-44.408621,-3,4,"LS-82118;proglumetacine;Proglumetacinum;proxil;Proglumetacina;Proglumetacin Maleate;Proglumetacin;Proglumetacine;CIPLUS_182770;proglumetacin;Proglumetacin maleate;METACINE-P;LS-175816;Miridacin;PROGLUMETACIN MALEATE;PROTACINE;3'-(4-(2-(1-p-chlorobenzoyl-5-methoxy-2-methylindol-3-ylacetoxy)ethyl)piperazin-1-yl)propyl-4-benzamido-N,N-dipropylglutaramate (+-) dimaleate;PROGLUMETACIN;proglumetacinum;CIPLUS_685564;3-(4-(2-HYDROXYETHYL)-1-PIPERAZINYL)PROPYL DL-4-BENZAMIDO-N,N-DIPROPYLGLUTARAMATE 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETATE;",-76.77736266,-68.14780222,0.369374307,0.905123825,,,CCCN(CCC)C(=O)C(NC(=O)c1ccccc1)CCC(=O)OCCCN5CCN(CCOC(=O)Cc4c2cc(OC)ccc2n(C(=O)c3ccc(Cl)cc3)c4C)CC5,Pharmaron,PH-NIH-183347,-2.13608086,-20.2388318,0,-68.14780222,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181103-02,Propiverine hydrochloride,170466036,Muscarinic acetylcholine receptor Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54556-98-8,,39.81071706,0,-4.4,-24.70755615,-3,4,,-78.48086846,-65.81739038,0.048006827,0.998576121,,,Cl.CN3CCC(OC(=O)C(OCCC)(c1ccccc1)c2ccccc2)CC3,Sequoia,54556-98-8,0,-2.40562226,0,-65.81739038,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167576-02,Aprindine hydrochloride,170465842,Calmodulin Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),33237-74-0,,17.7827941,0,-4.75,-50.04524595,-2.1,4,,-100.7001867,-92.31498772,0.033510797,0.999306773,,,Cl.CCN(CC)CCCN(c1ccccc1)C2Cc3ccccc3C2,Key Organics,KS-1222,-0.29762592,1.28321068,-25.41222096,-92.31498772,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179358-04,Methacycline hydrochloride,170465224,Tetracycline Antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3963-95-9,,11.22018454,0,-4.95,-32.33110514,-2.4,4,,-52.24598632,-46.98702437,0.754164004,0.999310508,,,Cl.NC(=O)C=3C(=O)[C@@]4(O)C(O)=C2C(=O)c1c(O)cccc1C(=C)[C@H]2[C@H](O)[C@H]4[C@@H](C=3O)N(C)C,"Prestwick Chemical, Inc.",Prestw-964,-24.7447956,0,-22.75480127,-46.98702437,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274083-01,Loxiglumide,170465971,Cholecystokinin A receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),107097-80-3,,39.81071706,0,-4.4,-16.87392927,-3,4,,-34.63946889,-32.19955741,0.305386338,0.937750948,,,Clc1ccc(cc1Cl)C(=O)NC(CCC(=O)O)C(=O)N(CCCCC)CCCOC,SIGMA,SML0130,0,-8.02928624,0,-32.19955741,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378902-03,Toceranib,405558487,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),[356068-94-5],,17.7827941,0,-4.75,-53.48724389,-3,4,,-98.58419068,-90.27856289,0.006976366,0.999969982,,FLT1,CC1=C(C(=C([NH]1)\C=C2/C(=O)NC3=C2C=C(F)C=C3)C)C(=O)NCCN4CCCC4,Tocris,3909,0,0,0,-90.27856289,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00166309-02,Altrenogest,170465646,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),850-52-2,,39.81071706,0,-4.4,-84.58355663,-3,4,,-88.84703074,-78.20585895,0.307416875,0.936774216,,,O=C3C=C4CC[C@@H]2C(C=C[C@@]1(C)[C@H]2CC[C@@]1(O)CC=C)=C4CC3,SIGMA,33994,-19.01142029,0,0,-78.20585895,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167562-01,Buquinolate,144206110,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5486/3/3,Buquinolate; Buquinolato; Bonaid; ,7.079457844,1,-5.15,-80.77119477,-3,4,"buquinolatum;BUQUINOLATE;Buquinolatum;CIPLUS_164381;buquinolate;Buquinolato;ethyl 4-hydroxy-6,7-diisobutoxy-3-quinolinecarboxylate;Buquinolate;Bonaid;",-77.67422931,-39.7946652,1,0.994736944,,,CC(C)COc1cc2ncc(c(O)c2cc1OCC(C)C)C(=O)OCC,SigmaAldrich,R239542,-15.04769136,-9.59027926,-82.57644854,-39.7946652,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00014810-01,Pirbuterol hydrochloride,144203612,Beta-2 adrenergic receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),38029-10-6,Pirbuterol hydrochloride; Maxair; ,39.81071706,0,-4.4,-91.66064714,-2.4,4,"6-(2-(tert-butylamino)-1-hydroxyethyl)-3-hydroxy-2-pyridinemethanol dihydrochloride;CIPLUS_3865153;CIPLUS_749202;pirbuterol sulfate;PIRBUTEROL HYDROCHLORIDE;Maxair;CIPLUS_210786;CP-24315-1;LS-176467;Pirbuterolum;pirbuterol acetate;Pirbuterol Hydrochloride;LS-66540;PIRBUTEROL;cp-24,314-14;CP 24315-1;pirbuterol acetate salt;LS-176523;CP-24,314-1;Pirbuterol Acetate;2-HYDROXYMETHYL-3-HYDROXY-6-(1-HYDROXY-2-TERT-BUTYLAMINOETHYL)-PYRIDINE, ACETATE;pirbuterolum;pyrbuterol;pirbuterol;PIRBUTEROL ACETATE;CIPLUS_179342;Pirbuterol acetate;LS-131417;Pirbuterol hydrochloride;pirbuterol dihydrochloride;Pirbuterol;2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride;",-31.56546555,-42.33067694,0.800640328,0.94999548,,,Cl.Oc1ccc(nc1CO)C(O)CNC(C)(C)C,NCI,,-39.94955093,-18.57477409,-11.40958847,-42.33067694,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181134-04,Haloprogin,405558522,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),777-11-7,,39.81071706,0,-4.4,-104.3440142,-3,4,,-102.388547,-89.10263567,0.337408208,0.922475972,,,[Cl]C1=CC(=C([O][CH2][C]#[C][I])C=C1[Cl])[Cl],Prestwick,Prestw-1269,-23.43445575,-3.77277564,0,-89.10263567,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178891-03,NCGC00178891-03,404904688,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),"316-42-7, 483-18-1 [emetine]",,5.623413252,1,-5.25,-102.7837886,-1.1,4,,-98.8377841,-98.64050309,0.007358746,0.999966599,,,CC[C@H]1CN2CCC3=C(C=C(OC)C(=C3)OC)C2C[C@@H]1CC4NCCC5=C4C=C(OC)C(=C5)OC,Microsource,1500272,0,-1.62944032,-96.12640615,-98.64050309,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181116-02,Carbomycin A,124893648,Bacterial 70S ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,22.38721139,0,-4.65,-38.28494133,-2.4,4,,-54.07372756,-50.81342997,0.098554495,0.993963971,,,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C[C@@H]2OC2\C=C/C(=O)[C@H](C)C[C@H](CC=O)[C@@H]1OC3OC(C)C(OC4CC(C)(O)C(OC(=O)CC(C)C)C(C)O4)C(C3O)N(C)C)OC(C)=O,NCI,NSC-51001,-4.15978877,0,-11.43559195,-50.81342997,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00348375-01,TILMICOSIN,405558560,Bacterial 70S ribosome Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),108050-54-0,,6.309573445,1,-5.2,-11.21303089,-3,4,,-42.5085019,-5.78754364,1,0.99526727,,,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN3C[C@H](C)C[C@H](C)C3)C[C@@H](C)C(=O)/C=C/C(=C/[C@@H]1CO[C@@H]4O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]4OC)C,FLUKA,33864,0.08189318,3.00267455,-38.89676102,-5.78754364,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181149-01,3-Anilinopropan-1-ol,144206306,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),31121-11-6,PHENYLPROPANOLAMINE MALEATE; ,39.81071706,0,-4.4,-42.60071191,-3,4,PHENYLPROPANOLAMINE MALEATE;,-34.49076628,-32.49230523,0.409123092,0.880214553,,,OCCCNc1ccccc1,NCI,NSC-29092,-10.6998973,0,1.39259855,-32.49230523,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164578-02,Etoricoxib,170465621,Cyclooxygenase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),202409-33-4,,0.707945784,1,-6.15,-52.54959883,-1.4,4,,-40.57123734,-31.70353853,0.529739562,0.773748435,5743,PTGS2,CS(=O)(=O)c1ccc(cc1)c3cc(Cl)cnc3c2cnc(C)cc2,Sequoia,SRP02700e,3.02692138,-48.29909207,-24.10027011,-31.70353853,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00319019-01,Nemorubicin,170465590,DNA Topoisomerase II Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),108852-90-0,,5.623413252,1,-5.25,-441.7079754,5,4,,-1.78464094,-94.37892255,0.092438199,0.995952823,,TOP2A,COC1CN(CCO1)C6CC(OC5C[C@@](O)(Cc4c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c4O)C(=O)CO)OC(C)C6O,GVK,FFS-11-286-NCI-135,-92.4750551,-92.48194069,-94.14584743,-94.37892255,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253608-01,Chlorexolone,170466039,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2127/1/7,,35.48133892,0,-4.45,-48.35456821,-3,4,,-39.8496824,-35.11339576,0.351140097,0.915399804,,,NS(=O)(=O)c1cc2C(=O)N(Cc2cc1Cl)C3CCCCC3,GVK,FFS-11-286-NCI-259,-10.67626928,0,-5.63480984,-35.11339576,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015340-14,Desipramine hydrochloride,170465424,Serotonin transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58-28-6,,39.81071706,0,-4.4,-27.04489866,-3,4,,-80.33774544,-68.1981212,0.084718016,0.995547807,,,Cl.CNCCCN2c3ccccc3CCc1ccccc12,Microsource,1500227,0,-4.5594073,0,-68.1981212,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183869-01,Gusperimus trihydrochloride,144206777,Heat shock protein HSP90 Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),85468-01-5,,25.11886432,0,-4.6,-56.32186,-2.4,4,"CIPLUS_667980;15-DEOXYSPERGUALIN TRIHYDROCHLORIDE;LS-171915;Gusperimus;Heptanamide, 7-((aminoiminomethyl)amino)-N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-, trihydrochloride, (-)-;gusperimus trihydrochloride;gusperimus;Heptanamide, 7-((aminoiminomethyl)amino)-N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-;Gusperimus Hydrochloride;deoxyspergualin;LS-74249;CIPLUS_667979;LS-74248;NKT-01;CIPLUS_756341;NSC-356894;1-amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione;(-)-15-Deoxyspergualin;BMY-42215-1;gusperimusum;Gusperimus trihydrochloride;Gusperimus hydrochloride;GUSPERIMUS TRIHYDROCHLORIDE;15-deoxyspergualin;3HCl of gusperimus;GUSPERIMUS;gusperimus, (+-)-isomer;Spanidin;DEOXYSPERGUALIN;CIPLUS_192812;",-48.28447485,-46.04884458,0.284069018,0.946709057,3303,,Cl.Cl.Cl.O=C(NCCCCNCCCN)C(O)NC(=O)CCCCCCNC(=N)N,NCI,NSC_356894,-10.85912226,0,-10.77654486,-46.04884458,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00509862-02,Fluralaner,405558651,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),864731-61-3,,39.81071706,0,-4.4,-14.39768668,-3,4,,-49.38245605,-41.15204671,0.819622248,0.999967633,,,CC1=C(C=CC(=C1)\C2=N\OC(C2)(C3=CC(=CC(=C3)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F,MedChem Express,HY-16973,-41.49475005,0,0,-41.15204671,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188435-01,2-Hydroxyethyl octadecanoate,144206587,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),111-60-4,,35.48133892,0,-4.45,-5.897080481,-3,4,Polyoxyl?40?Stearate,-45.89757234,-36.28603965,0.064661054,0.99741452,,,O=C(CCCCCCCCCCCCCCCCC)OCCO,APAC,878043,2.25861728,0,0,-36.28603965,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160543-01,Pregnandiol,144205439,G-protein coupled bile acid receptor 1 Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),80-92-2,Pregnandiol; Diol; Pregnantriol; ,70.79457844,0,-4.15,-85.65144016,-3,4,"ALLOPREGNANDIOL;CIPLUS_3727430;CIPLUS_149642;CIPLUS_679210;5BETA-PREGNANE-3ALPHA,20ALPHA-DIOL;CIPLUS_742702;CIPLUS_678965;allopregnane-3,20-diol;PREGNANDIOL;CIPLUS_696772;(3 alpha,5 alpha,20S)-pregnane-3,20-diol;Pregnantriol;Diol;Pregnanediol;Pregnandiol;PREGNANEDIOL;CIPLUS_742124;",-47.0448923,-47.26378917,0.550228783,0.749693062,,,CC(O)[C@H]4CC[C@@H]3[C@]4(C)CC[C@H]1[C@H]3CC[C@@H]2C[C@@H](O)CC[C@]12C,SigmaAldrich,R195952,-18.46832666,-12.61765113,1.12399328,-47.26378917,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00163415-04,NCGC00163415-04,405559133,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),20554-84-1,PARTHENOLIDE;Parthenolide,39.81071706,0,-4.4,-34.55594669,-3,4,,-118.5230347,-98.7691956,0.006832298,0.999971208,4790,NFKB1,CC/1=C\CC[C@@]2(C)O[C@@H]2[C@H]3OC(=O)C(=C)[C@@H]3CC1,SIGMA,P0667,0,0,0,-98.7691956,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018102-12,Flunarizine,170466037,Calcium Channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52468-60-7,"Sibelium; ; Flu Narizine;Flunarizine dihydrochloride; Hydrochloride, Flunarizin;Flunarizine; Flunarizin; Flunarizina; Flunarizine",39.81071706,0,-4.4,-20.071512,-3,4,,-68.84304271,-57.36920226,0.006832298,0.999971216,,,Fc1ccc(cc1)C(c2ccc(F)cc2)N3CCN(CC3)C/C=C/c4ccccc4,Enzo,CA225,0,0,0,-57.36920226,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095978-06,Lufenuron,170465736,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),103055-07-8,,39.81071706,0,-4.4,-38.86725653,-3,4,,-59.15431381,-48.60175289,0.641899868,0.60931166,,,Clc2cc(NC(=O)NC(=O)c1c(F)cccc1F)c(Cl)cc2OC(F)(F)C(F)C(F)(F)F,Microsource,1505355,0,-28.44781098,-2.8530044,-48.60175289,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016393-07,"2,2'-Dihydroxy-4-methoxybenzophenone",170465540,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),131-53-3,,1.584893193,1,-5.8,-46.85684191,-1.4,4,,-38.09707943,-35.49756619,0.210132006,0.971773398,,,O=C(c1ccc(cc1O)OC)c2ccccc2O,Microsource,1500255,0,-21.0448415,-28.26138659,-35.49756619,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090708-11,OXYQUINOLINE HEMISULFATE,405558695,Trichophyton interdigitale Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),134-31-6,,2.818382931,1,-5.55,-221.5956439,-1.3,4,,-96.07723546,-100.4687961,0.053101729,0.998257173,,,OC1=CC=CC2=CC=CN=C12,Microsource,1500456,-29.43854295,-57.35625245,-82.72574944,-100.4687961,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263442-05,NCGC00263442-05,405558710,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),154-42-7,,10,0,-5,-75.99229157,-2.3,4,,-92.83142039,-92.59069483,0.524951481,0.999609084,,,NC1=NC2=C(N=C[NH]2)C(=N1)S,Cayman,15774,-32.80102823,0,-62.42550172,-92.59069483,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00507775-01,Midecamycin Acetate,405558744,Ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55881-07-7,,39.81071706,0,-4.4,-12.90879967,-3,4,,-44.27574001,-36.89645001,0.006832298,0.999971232,,,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@](C)(OC(C)=O)[C@H](OC(=O)CC)[C@@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC,AvaChem,2845,0,0,0,-36.89645001,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018271-07,Homochlorcyclizine,170465786,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),848-53-3,,11.22018454,0,-4.95,-110.3873569,-2.3,4,,-73.50137035,-84.45815771,0.099264316,0.993873914,,,Clc1ccc(cc1)C(c2ccccc2)N3CCCN(C)CC3,Enzo,AC927,-14.08330816,-8.84912894,-46.20312236,-84.45815771,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016636-05,Flavoxate hydrochloride,170466285,Muscarinic acetylcholine receptors; M1 & M2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3717-88-2,,12.58925412,0,-4.9,-22.7794417,-2.4,4,,-40.69988696,-38.14804348,0.115373336,0.991705743,,,Cl.O=C(OCCN1CCCCC1)c4cccc2c4OC(=C(C)C2=O)c3ccccc3,Prestwick,Prestw-242,0,3.5271359,-17.03383674,-38.14804348,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159478-04,Benzoxiquine,170465534,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),86-75-9,,7.943282347,1,-5.1,-213.1273617,-1.3,4,,-71.45908165,-97.97707385,0.176837451,0.980204266,,,O=C(Oc1cccc2cccnc12)c3ccccc3,Specs,AE-848/01460057,-33.79566339,-20.66817399,-89.76398922,-97.97707385,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262537-04,Thiethylperazine dimalate ,405558764,Dopamine receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52239-63-1,,11.22018454,0,-4.95,-161.9917284,-2.3,4,,-75.50596563,-94.90458959,0.088808119,0.995104518,,,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(C)CC4)C=C1,Prestwick,Prestw-1068,-24.17135002,-19.83059646,-60.40024913,-94.90458959,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00381723-02,Taltirelin,405558765,Thyrotropin-Releasing Hormone (TRH) Analogs,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),103300-74-9,,39.81071706,0,-4.4,-35.83434686,-3,4,,-35.01969672,-33.34974727,0.267536289,0.95314466,,TRHR,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=C[NH]C=N2)C(=O)N3CCC[C@H]3C(N)=O,MedChem Express,HY-B0596,-6.45740192,-6.77233639,0,-33.34974727,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179306-04,Zuclopenthixol (-)-10-Camphorsulfonic Acid Salt,405558792,Serotonin 2 (5-HT2) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),53772-83-1,,19.95262315,0,-4.7,-65.60253672,-2.3,4,,-105.1640448,-98.67775763,0.059723814,0.997793612,,,OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1,Toronto Research,Z701495,-4.58088525,0,-24.75755647,-98.67775763,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166115-02,Dibutyltin dilaurate,170466843,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),77-58-7,,39.81071706,0,-4.4,-22.62276876,-3,4,,-77.59356824,-64.66130687,0.634624402,0.999967616,,,O=C(O[Sn](CCCC)(OC(=O)CCCCCCCCCCC)CCCC)CCCCCCCCCCC,SIGMA,291234,-32.99757921,0,0,-64.66130687,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182044-02,Toltrazuril (sulfone),405558806,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),69004-04-2,,19.95262315,0,-4.7,-102.6189861,-2.3,4,,-99.80585472,-95.06030652,0.235353963,0.96420166,,,CN1C(=O)NC(=O)N(C1=O)C2=CC=C(OC3=CC=C(C=C3)[S+]([O-])(=O)C(F)(F)F)C(=C2)C,MedChem Express,HY-17008,-16.82706215,0,-26.79449603,-95.06030652,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181290-01,Furazabol,144206325,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1239-29-8,Furazabol; Miotolan; ,39.81071706,0,-4.4,-26.47978656,-3,4,"androfurazanol;Miotolan;CIPLUS_157956;17 alpha-methyl-5 alpha-androstano(2,3-c)furazan-17 beta-ol;furazabol;FURAZABOL;LS-19413;Furazabol;17-METHYL-5.ALPHA.-ANDROSTANO(2,3-C)FURAZAN-17.BETA.-OL;Furazabolum;furazabolum;17-methyl-5 alpha-androstano(2,3-c)(1,2,5)oxadiazol-17 beta-ol;5-alpha-Androstano(2,3-c)(1,2,5)oxadiazol-17-beta-ol, 17-methyl-;",-91.62970868,-78.02475723,0.020852562,0.999731738,,,C[C@]5(O)CC[C@@H]4[C@]5(C)CC[C@H]1[C@H]4CC[C@H]2Cc3nonc3C[C@]12C,ACC,furazabol,0,0,1.17181242,-78.02475723,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017360-04,Aconitine,405558809,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),302-27-2,,39.81071706,0,-4.4,-24.9607174,-3,4,,-53.06490282,-43.98856274,0.265322839,0.953932441,,,CCN1C[C@]2(COC)[C@H](O)C[C@H](OC)[C@@]34C5C[C@]6(O)[C@@H](OC)[C@H](O)[C@](OC(C)=O)(C([C@H](OC)C23)[C@@H]14)C5[C@H]6OC(=O)C7=CC=CC=C7,Prestwick,Prestw-NAT-0127,0,-10.14856869,-3.55371205,-43.98856274,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167435-07,Nilvadipine,405558817,Voltage-gated L-type calcium channel alpha-1C subunit Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),75530-68-6,,11.22018454,0,-4.95,-42.48662662,-2.4,4,,-60.51174106,-44.85058814,0.468656055,0.834250569,,,COC(=O)C\1=C(\N\C(=C(/C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C)C)C#N,MedChem Express,HY-14284,0,-20.48782207,-17.8755933,-44.85058814,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00021666-04,Nalmefene,170465281,Kappa opioid receptor Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55096-26-9,,0.891250938,1,-6.05,-69.61762333,-2.4,4,,-30.62254316,0,1,0.999839824,,,C=C1CC[C@@]6(O)[C@H]3Cc5ccc(O)c4O[C@@H]1[C@]6(CCN3CC2CC2)c45,"Prestwick Chemical, Inc.",Prestw-1490,-14.12314536,-23.8115683,-30.05859799,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389453-01,Chlortetracycline HCl,405558866,translation Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),64-72-2 ,,25.11886432,0,-4.6,-42.66050505,-2.4,4,,-43.17453879,-44.41775385,0.802421901,0.999880295,,,CN(C)C1C2CC3\C(=C(O)/C4=C(O)C=CC(=C4C3(C)O)Cl)C(=O)C2(O)\C(=C(C(N)=O)/C1=O)O,APExBIO,B1699,-37.54477281,-5.38074691,-10.26124736,-44.41775385,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016777-08,Probucol,170464772,Serine Protease Hepsin Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),23288-49-5, Bisbid; Aventis Brand of Probucol; Panavir; Lorelco; Biphenabid;PROBUCOL; Probucol; Superlipid;Probucol; Lurselle; Hoechst Brand of Probucol; ,7.079457844,1,-5.15,-89.88755971,-1.4,4,,-36.94864535,-41.1561531,0.449793136,0.850008091,,ABCA1,CC(C)(C)c2cc(SC(C)(C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)cc(c2O)C(C)(C)C,Microsource,1501109,-16.30410611,0.12363314,-37.94594276,-41.1561531,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378604-01,ABT-333,405558941,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1132935-63-7,,5.011872336,1,-5.3,-79.47204571,-1.4,4,,-32.76495416,-33.85991118,0.36132667,0.909764406,,,COC1=C(C=C(C=C1C2=CC3=CC=C(N[S+](C)([O-])=O)C=C3C=C2)N4\C=C/C(=O)NC4=O)C(C)(C)C,MedChem Express,HY-13998,-10.58644584,-5.04231565,-46.16222181,-33.85991118,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00168251-01,Ethylmorphine,144206163,Opioid receptors; mu/kappa/delta Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),76-58-4,Ethylmorphine hydrochloride; Veralgin; Dionin; Morphine 3-ethyl ether; ,39.81071706,0,-4.4,-29.86580157,-3,4,"Dionin;LS-91899;CIPLUS_781610;Veralgin;Morphine 3-ethyl ether;Ethylmorphine;LS-91901;LS-91902;LS-91903;CIPLUS_173377;CIPLUS_165781;O-Ethylmorphine hydrochloride;CIPLUS_730767;CIPLUS_149399;ETHYLMORPHINE HYDROCHLORIDE;Ethylmorphine hydrochloride;Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-ethoxy-17-methyl-, hydrochloride,dihydrate;ethyl-alpha-isomorphine;CIPLUS_3884309;Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-ethoxy-17-methyl-, (5alpha,6alpha)-;Ethylmorphine Hydrochloride;ETHYLMORPHINE;",-46.96082691,-39.55068909,0.27050552,0.951998587,,,CCOc1ccc2C[C@H]4N(C)CC[C@@]35[C@@H](Oc1c23)[C@@H](O)C=C[C@@H]45,SigmaAldrich,E8512,-6.31860805,4.28042252,0,-39.55068909,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00532508-01,DROMETRIZOLE TRISILOXANE,405558978,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,3.548133892,1,-5.45,-43.23988588,-2.2,4,,-40.51817304,-40.29460467,0.007069326,0.9999692,,,CC(CC1=CC(=CC(=C1O)[N]2N=C3C=CC=CC3=N2)C)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C,SIGMA,68790,0,0,-10.3696439,-40.29460467,,,,,,,,,,,,1.14E-07,5.71E-07,2.86E-06,0.0000143,,,,,,,,,,,
NCGC00015199-20,Chlorambucil,170464770,DNA Alkylating Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),305-03-3,; ;CHLORAMBUCIL; Chlorambucil;Chlorambucil; Leukeran; Clorambucilo,22.38721139,0,-4.65,-44.63412443,-2.3,4,,-102.2685768,-90.22036953,0.688046428,0.999979622,,H2AFX,O=C(O)CCCc1ccc(cc1)N(CCCl)CCCl,Microsource,1500171,-47.12952789,0,-18.71293283,-90.22036953,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179460-03,Medrysone,170465194,Glucocorticoid receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2668-66-8,,39.81071706,0,-4.4,-20.47758985,-3,4,,-70.23584435,-58.52987029,0.006832298,0.999971215,,,CC(=O)[C@H]4CC[C@@H]2[C@]4(C)C[C@H](O)[C@@H]1[C@@]3(C)CCC(=O)C=C3[C@@H](C)C[C@H]12,"Prestwick Chemical, Inc.",Prestw-743,0,0,0,-58.52987029,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253737-01,Istradefylline,174007485,Adenosine A2A Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),155270-99-8,Istradefylline,0.707945784,1,-6.15,-73.33593341,-1.4,4,,-49.82699062,-64.67498883,0.647360889,0.598693237,135,ADORA2A,COc1ccc(cc1OC)/C=C/c3nc2c(C(=O)N(CC)C(=O)N2CC)n3C,GVK,FFS-12-73-NCI-1738,0,-52.28724027,-20.31218616,-64.67498883,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164789-04,Fulvestrant,170464917,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),129453-61-8,; Faslodex;Fulvestrant;Fulvestrant (Faslodex),39.81071706,0,-4.4,-17.93440496,-3,4,,-61.51300442,-51.26083702,0.006832298,0.999971219,2099,ESR1,FC(F)(F)C(F)(F)CCCS(=O)CCCCCCCCC[C@@H]2Cc1cc(O)ccc1[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@H]23,Prestwick,Prestw-1424,0,0,0,-51.26083702,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00484844-01,Cilastatin,405559021,Renal dipeptidase  Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),81129-83-1,,0.707945784,1,-6.15,-37.26363109,-1.4,4,,-38.44201264,-6.94462236,1,0.974703699,,,CC1(C)C[C@H]1C(=O)N\C(=C/CCCCSC[C@@H](N)C(O)=O)C(O)=O,Enzo,PI153,0,-37.68824769,-31.38454916,-6.94462236,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263557-01,NCGC00263557-01,170465337,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),124937-51-5,,8.912509381,1,-5.05,-52.43513939,-2.4,4,,-61.86624444,-62.16337232,0.577363552,0.999245366,,CHRM3,Oc1ccc(C)cc1[C@H](CCN(C(C)C)C(C)C)c2ccccc2,Bosche,T0008,-24.18510171,0,-43.93799873,-62.16337232,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179250-03,Halofantrine,170465140,antimalarial agents,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),36167-63-2,; Halfan;HALOFANTRINE HYDROCHLORIDE; Halofantrina;Halofantrine hydrochloride;Halofantrine,39.81071706,0,-4.4,-38.77589859,-3,4,,-79.99408334,-67.91173612,0.101504354,0.993592082,,,Cl.CCCCN(CCCC)CCC(O)c2cc1c(Cl)cc(Cl)cc1c3cc(ccc23)C(F)(F)F,"Prestwick Chemical, Inc.",Prestw-1031,-5.14627626,0.67822488,0,-67.91173612,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016256-17,Pyrimethamine,170464930,Dihydrofolate Reductase (DHFR) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58-14-0,Pirimetamina; ; Daraprim; Tindurine; Fansimef; Chloridin;Pyrimethamine; Suldox; Maloprim; Pyrimethamine; A.E.S. mixture; Folaprim; Malocide,39.81071706,0,-4.4,-45.50275512,-2.4,4,,-45.10598766,-42.41332327,0.793427261,0.516823417,1719,DHFR,CCc1nc(N)nc(N)c1c2ccc(Cl)cc2,Microsource,1500520,0,-45.44257888,1.54294371,-42.41332327,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181045-01,Pyridoxamine phosphate,144206246,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),529-96-4,Pyridoxamine phosphate; pyridoxamine-P; Pyridoxamine-5'-phosphate; ,39.81071706,0,-4.4,-15.42010154,-3,4,4-Aminomethyl-5-hydroxy-6-methyl-3-pyridylmethyl phosphate;CIPLUS_3727741;Pyridoxamine Phosphate;CIPLUS_154034;pyridoxamine phosphate hydrochloride;PYRIDOXAMINE PHOSPHATE;pyridoxamine phosphate;Pyridoxamine Phosphate Anhydride;Pyridoxamine-5'-phosphate;Pyridoxamine phosphate;CIPLUS_3861203;pyridoxamine-P;,-52.88922474,-44.07435395,0.006832298,0.999971224,,,Oc1c(CN)c(cnc1C)COP(=O)(O)O,SigmaAldrich,82890,0,0,0,-44.07435395,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017337-17,(E)-Capsaicin,405559082,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),[404-86-4],,44.66835922,0,-4.35,-145.5287374,-2.4,4,,-30.23443443,-49.69085783,0.396946403,0.888398815,,NFKB1,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1,Tocris,462,-31.65177964,-25.4751262,-21.59428625,-49.69085783,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346551-03,Pomalidomide,405559099,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),19171-19-8,,39.81071706,0,-4.4,-11.71036301,-3,4,,-40.16523623,-33.47103019,0.794894148,0.999967648,,TNF,NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1,APExBIO,A4212,-29.40023466,0,0,-33.47103019,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181096-01,Chlophedianol,144206265,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),791-35-5,CHLOPHEDIANOL HYDROCHLORIDE; Coldrin; Baltix; ,39.81071706,0,-4.4,-46.83187018,-2.4,4,"sl 501;BENZENEMETHANOL, 2-CHLORO-.ALPHA.-(2-(DIMETHYLAMINO)ETHYL)- .ALPHA.-PHENYL;CHLOPHEDIANOL;Clofedanol hydrochloride;2-chloro-alpha-(2-dimethylaminoethyl)benzhydrol;clofedanol;Clofedanolum;clofedanol hydrochloride;Baltix;1-(2-CHLOROPHENYL)-3-(DIMETHYLAMINO)-1-PHENYLPROPAN-1-OL;2-CHLORO-.ALPHA.-(2-(DIMETHYLAMINO)ETHYL)BENZHYDROL HYDROCHLORIDE;CIPLUS_660723;chlophedianol;CLOFEDANOL;CHLOPHEDIANOL HYDROCHLORIDE;BENZENEMETHANOL, 2-CHLORO-.ALPHA.-(2-(DIMETHYLAMINO)ETHYL)-.ALPHA.-PHENYL-, HYDROCHLORIDE;Coldrin;1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol;Benzhydrol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-, hydrochloride;Chlophedianol;Clofedanol Hydrochloride;chlophendianol hydrochloride;clofedanolum;Clofedanol;Benzhydrol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-;CIPLUS_156451;Chlophedianol hydrochloride;1-(2-CHLOROPHENYL)-3-(DIMETHYLAMINO)-1-PHENYLPROPAN-1-OL HYDROCHLORIDE;LS-32307;LS-32306;",-71.46201036,-65.38500863,0.610532042,0.664294421,,,OC(CCN(C)C)(c1ccccc1Cl)c2ccccc2,NCI,NSC-113595,0,-35.25975444,0.96339498,-65.38500863,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378736-01,Cinepazide Maleate,405558463,Voltage-gated calcium channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),26328-04-1,,39.81071706,0,-4.4,-75.44995647,-2.4,4,,-53.96608209,-51.74867171,0.791620692,0.771381635,,,COC1=C(OC)C(=CC(=C1)\C=C/C(=O)N2CCN(CC2)CC(=O)N3CCCC3)OC,MedChem Express,HY-66010,-40.62957213,-20.77579869,4.57456791,-51.74867171,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164253-04,LITHIUM CITRATE,405558476,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),"6080-58-6, 919-16-4 [anhydrous]",,14.12537545,0,-4.85,-108.716152,-2.4,4,,-76.02459277,-63.17418084,0.882184983,0.999473911,,,OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,Microsource,1504269,-50.39268449,-16.31239591,-37.40157998,-63.17418084,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181130-02,Eletriptan,170465317,5-hydroxytryptamine receptor 1F Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),143322-58-1,,39.81071706,0,-4.4,-40.64510344,-3,4,,-84.53782041,-74.61485034,0.35214876,0.914761043,3355,HTR1F,CN4CCC[C@@H]4Cc2cnc3ccc(CCS(=O)(=O)c1ccccc1)cc23,Sequoia,143322-58-1,0,-20.81610602,0,-74.61485034,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00509864-02,ORNIPRESSIN,405558494,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,31.6227766,0,-4.5,4.226004372,-3,4,,-55.70489292,-39.5491613,0.857003581,0.999882125,,,NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)NCC(N)=O,MedChem Express,HY-P0083_cm1,-48.69346642,4.87084507,0,-39.5491613,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263155-09,Belinostat,404904701,HDAC Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),414864-00-9,,10,0,-5,-78.52265097,-2.1,4,,-95.4123604,-95.15115119,0.029440543,0.999465044,,HDAC1,ONC(=O)/C=C/C1=CC(=CC=C1)[S+]([O-])(=O)NC2=CC=CC=C2,MedChem Express,HY-10225,0,0,-64.76591265,-95.15115119,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178783-03,HYOSCYAMINE,405558529,M1 Muscarinic acetylcholine receptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),101-31-5,,39.81071706,0,-4.4,-11.78241394,-3,4,,-52.80805392,-43.59004493,0.13340602,0.988865724,,CHRM1,CN1C2CC[C@@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3,Microsource,1500346,0,0,4.96598364,-43.59004493,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181156-01,Oxabolone cipioncate,144206313,Androgen Receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1254-35-9,Oxabolone cipionate; Cipionato de oxabolona; ,3.16227766,1,-5.5,-83.77095943,-2.4,4,"LS-172626;oxaboloni cipionas;OXABOLONE CIPIONATE;cipionate d'oxabolone;Oxabolone cipionate;4,17beta-dihydroxy-estr-4-en-3-one 17-cyclopentylpropionate;CIPLUS_211114;Cipionato de oxabolona;Oxabolone Cipionate;oxabolone cypionate;Oxaboloni cipionas;Cipionate d'oxabolone;",-48.9462959,-36.67374542,1,0.999946456,,,OC=5C(=O)CC[C@H]4C=5CC[C@@H]2[C@@H]4CC[C@]3(C)[C@@H](OC(=O)CCC1CCCC1)CC[C@@H]23,NCI,NSC-522767,-14.25932647,-27.38404008,-62.33112953,-36.67374542,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178638-02,Valaciclovir,170465373,DNA Polymerase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),124832-27-5,"Valaciclovir HCl; Valaciclovir Hcl;;Valacyclovir hydrochloride; valacyclovir, (DL)-isomer; valacyclovir, (D)-isomer; Valtrex;VALACYCLOVIR HYDROCHLORIDE",39.81071706,0,-4.4,-53.01135434,-3,4,,-66.7301032,-59.775086,0.184565742,0.97838958,,,Cl.CC(C)[C@H](N)C(=O)OCCOCn2cnc1c2N=C(N)NC1=O,Vitas,STK802272,-9.65565271,-4.34619206,0,-59.775086,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00521952-01,ROMURTIDE,405558571,TNF-alpha Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),78113-36-7,,17.7827941,0,-4.75,-19.87585131,-2.2,4,,-36.90871404,-33.64296518,0.032959596,0.999330188,3557,,CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)C(O)=O,Carbosynth,FA110464,-0.21914304,0,-10.66113614,-33.64296518,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344529-02,Cefamandole (nafate),405558584,Bacterial Penicillin-binding Protein Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),42540-40-9,,39.81071706,0,-4.4,-95.77070824,-3,4,,-43.50530789,-40.45937081,0.801710735,0.781777723,,,C[N]1N=NN=C1SCC/2=C(/N3[C@H](SC2)[C@H](NC(=O)[C@H](OC=O)C4=CC=CC=C4)C3=O)C([O-])=O,MedChem Express,HY-B1166,-27.48040015,-18.69466257,0,-40.45937081,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00241108-04,Axitinib,170466656,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),319460-85-0,AG-013736;Inlyta;Axitinib; Axitinib;AG-13736,19.95262315,0,-4.7,-45.68586023,-2.4,4,,-96.77030637,-79.37144422,0.715696034,0.999929551,2321,FLT1,CNC(=O)c4ccccc4Sc1ccc3c(c1)nnc3/C=C/c2ccccn2,Sequoia,319460-85-0,-40.88584474,0,-25.65365405,-79.37144422,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178220-05,Dipyrone,170465672,Prostaglandin G/H synthase 1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),68-89-3,,39.81071706,0,-4.4,-48.97921284,-3,4,,-35.65417563,-33.87847969,0.385069175,0.89584453,5742,PTGS1,[Na+].[O-]S(=O)(=O)CN(C)C=2C(=O)N(c1ccccc1)N(C)C=2C,Vitas,STK177347,-11.04260913,-5.56828405,0,-33.87847969,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00186637-01,Chromomycin A<SUB>3</SUB> from Streptomyces griseus,124897824,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7059-24-7,,0.125892541,1,-6.9,-415.5463303,5,4,CHROMOMYCIN A3,-97.36979391,-96.91692238,0.193372925,0.976394298,,,CO[C@H]1[C@@H](O)CC(O[C@H]1C)O[C@H]2CC(O[C@@H](C)[C@H]2OC(C)=O)OC3=CC4=CC5=C(C(=C4C(=C3C)O)O)C(=O)[C@@H](OC6C[C@@H](OC7C[C@H](OC8C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O8)[C@@H](O)[C@H](C)O7)[C@H](O)[C@@H](C)O6)[C@@H](C5)[C@@H](OC)C(=O)[C@@H](O)[C@H](C)O,BIOMOL,GR302,-82.85876079,-94.83850055,-94.50123711,-96.91692238,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263120-06,Enzalutamide,384568604,Androgen Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),915087-33-1,,8.912509381,1,-5.05,-65.16928365,-2.2,4,,-76.83863555,-77.49003118,0.034525867,0.99926413,,AR,CNC(=O)C1=CC=C(C=C1F)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F,MedChem Express,HY-70002,0,0,-54.49336789,-77.49003118,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00532514-01,FLUPENTIXOL DECANOATE,405558676,Serotonin 2 (5-HT2) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,14.12537545,0,-4.85,-32.90318709,-2.2,4,,-55.59082293,-54.50080679,0.012131446,0.999909252,,,CCCCCCCCCC(=O)OCCN1CCN(CC\C=C2/C3=CC=CC=C3SC4=CC=C(C=C24)C(F)(F)F)CC1,SynInnova,SL-1062,0,0,-19.8098824,-54.50080679,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00023282-21,AMPICILLIN SODIUM,405558724,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),"69-52-3, 69-53-4 [ampicillin]",,17.7827941,0,-4.75,-18.07895063,-2.4,4,,-35.89158459,-30.74298716,0.845722913,0.999952469,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O,Microsource,1500123,-25.83589418,0,-10.48544219,-30.74298716,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00093350-05,Amikacin,174006656,30S ribosomal protein S12 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),37517-28-5,,0.08747812,1,-7.05810056,-179.251342,-2.4,4,,-45.1624727,-18.0299047,1,0.96402517,,,NCC[C@H](O)C(=O)N[C@@H]3C[C@H](N)[C@@H](O[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H]3O[C@H]2O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O,Vitas,STK039706,-19.31749368,-11.4999448,-50.7290958,-18.0299047,,,,,,,,,,,,4.57E-09,2.29E-08,1.14E-07,5.71E-07,,,,,,,,,,,
NCGC00179665-04,Danazol,170464884,Androgen Receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),17230-88-5,,39.81071706,0,-4.4,-13.15130762,-3,4,,-45.10751519,-37.58959599,0.006832298,0.999971231,,,C#C[C@]3(O)CC[C@H]2[C@@H]4CCC1=Cc5oncc5C[C@]1(C)[C@H]4CC[C@@]23C,Prestwick,Prestw-105,0,0,0,-37.58959599,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00023509-13,Lovastatin,170464913,HMG-CoA Reductase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),75330-75-5,; ; Lovastatin (Mevinolin); Monacolin K; Mevacor;LOVASTATIN; Mevinolin (lovastatin); 6-Methylcompactin; 6 Methylcompacti; Lovastatin;Lovastatin; 6-alpha-Methylcompactin; 6alpha-Methylcompactin,0.891250938,1,-6.05,-170.313138,-1.3,4,,-79.00327097,-86.66506979,0.075379513,0.996479383,3156,HMGCR,C[C@@H](CC)C(=O)O[C@H]2C[C@@H](C)C=C3C=C[C@H](C)[C@H](CC[C@@H]1C[C@@H](O)CC(=O)O1)[C@@H]23,Vitas,STK801953,-8.51265537,-82.521093,-81.22770973,-86.66506979,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00162445-05,Misoprostol,225144248,Prostanoid EP3 receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),59122-46-2,,0.707945784,1,-6.15,-58.45172562,-1.4,4,,-37.93980721,-35.13258131,0.450662499,0.849324381,,,CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,Prestwick,Prestw-1443,0,-41.60396584,-24.48439469,-35.13258131,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164507-02,Nifuroxime,124893124,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,28.18382931,0,-4.55,-11.91537562,-2.4,4,,-32.80028041,-28.16690034,0.005545148,0.999981066,,,[O-][N+](=O)C1=CC=C(CN=O)O1,Enamine,T1302-8796 ,0,0,-2.95066496,-28.16690034,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00345812-02,Ingenol mebutate,405558836,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),75567-37-2,,17.7827941,0,-4.75,-463.9040227,5,4,,-3.71387964,-99.35515564,0.724460853,0.441843479,,PRKCA,C\C=C(C)/C(=O)O[C@H]1C(=C/C23[C@H](C)C[C@@H]4[C@H](C(\C=C(CO)/[C@@H](O)[C@]12O)C3=O)C4(C)C)\C,MedChem Express,HY-B0719,-98.28491837,-93.76025594,-97.11716809,-99.35515564,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181341-02,Emedastine difumarate,170465197,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),87233-62-3,,22.38721139,0,-4.65,-21.89885233,-3,4,,-55.28388195,-48.69991057,0.049750604,0.998471017,3269,HRH1,CN1CCCN(CC1)c3nc2ccccc2n3CCOCC.O=C(O)\C=C\C(=O)O.O=C(O)\C=C\C(=O)O,Prestwick,Prestw-1274,0.00697407,1.78597183,-8.77564009,-48.69991057,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00482976-01,Vorapaxar Sulfate,405558904,Proteinase-activated receptor 1 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),705260-08-8,,31.6227766,0,-4.5,-165.2110698,-3,4,,-59.12902159,-74.56725385,0.00585045,0.999978902,2149,F2R,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3C([C@@H](C)OC3=O)[C@H]2\C=C\C4=NC=C(C=C4)C5=CC(=CC=C5)F,DC Chemicals,DC8229,-30.24979458,-30.8569536,-37.97394879,-74.56725385,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00482904-01,Capromorelin,405558917,Ghrelin receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),193273-66-4,,39.81071706,0,-4.4,-14.13825276,-3,4,,-59.28577052,-49.40480877,0.106288306,0.992969506,,,CN1\N=C2\CCN(C[C@]2(CC3=CC=CC=C3)C1=O)C(=O)[C@H](COCC4=CC=CC=C4)NC(=O)C(C)(C)N,DC Chemicals,DC7615,0,0.05745439,4.44825136,-49.40480877,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182998-01,Bisoxatin acetate,144206872,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),14008-48-1,Bisoxatin acetate; ,11.22018454,0,-4.95,-79.00275156,-2.3,4,"LS-41817;2H-1,4-Benzoxazin-3-(4H)-one, 2,2-bis(p-hydroxyphenyl)-, diacetate;BISOXATIN ACETATE;bisoxatin diacetate;Bisoxatin Acetate;bisoxatin acetate;CIPLUS_169129;laxonalin;Bisoxatin acetate;",-95.03739885,-95.84570744,0.076363164,0.996386201,,,CC(=O)Oc1ccc(cc1)C2(Oc3ccccc3NC2=O)c4ccc(OC(C)=O)cc4,Pharmaron,PH-NIH-183223,-4.1721653,0,-47.12474027,-95.84570744,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249901-01,Thiocyanoacetic acid sodium salt,170465517,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),63906-52-5,,19.95262315,0,-4.7,-43.64627431,-2.4,4,,-53.1604934,-47.6337445,0.640055224,0.612855475,,,[Na+].[O-]C(=O)CSC#N,GVK,FFS-11-286-NCI-92,0,-27.27819361,-11.35051168,-47.6337445,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015273-19,Chlorpromazine,170465371,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),50-53-3,,28.18382931,0,-4.55,-41.44524297,-3,4,,-101.3858686,-91.74360989,0.01937386,0.999768435,,,CN(C)CCCN1c3ccccc3Sc2ccc(Cl)cc12,Vitas,STK182870,-1.43998878,0,-7.17800337,-91.74360989,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017324-07,Simvastatin,170464984,HMG-CoA Reductase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),79902-63-9,; Zocor;Simvastatin;SIMVASTATIN,1.258925412,1,-5.9,-141.094844,-1.4,4,,-75.99850113,-80.1650761,0.063542112,0.997501719,3156,HMGCR,CC(C)(CC)C(=O)O[C@H]2C[C@@H](C)C=C3C=C[C@H](C)[C@H](CC[C@@H]1C[C@@H](O)CC(=O)O1)[C@@H]23,Vitas,STK801938,-2.98315088,-73.32566068,-75.6748911,-80.1650761,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00271749-08,NCGC00271749-08,405558966,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),186826-86-8,,39.81071706,0,-4.4,-67.52173976,-3,4,,-56.20602747,-54.1267336,0.68787056,0.965639304,,TOP2B,COC1=C(N2C[C@@H]3CCCN[C@@H]3C2)C(=CC4=C1N(\C=C(C(O)=O)/C4=O)C5CC5)F,MedChem Express,HY-66011,-34.13012932,-12.59190706,-2.70504404,-54.1267336,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182704-02,Luliconazole,144206804,Lanosterol 14-alpha demethylase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),187164-19-8,Luliconazole; Lulicon; ,35.48133892,0,-4.45,-5.428629103,-3,4,Lulicon;Luliconazole;LULICONAZOLE;CIPLUS_787907;,-59.13729497,-44.04340528,0.184091096,0.978509183,3641571,ERG11,N#C/C(=C1/SC[C@H](S1)c2ccc(Cl)cc2Cl)n3ccnc3,Pharmaron,PH-NIH-102266,4.68566178,-3.30011237,-2.60238409,-44.04340528,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164563-04,Entecavir (monohydrate),405558991,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),209216-23-9,,39.81071706,0,-4.4,-21.68094319,-3,4,,-74.36321179,-61.96934316,0.006832298,0.999971214,,SLC22A3,NC/1=N/C2=C(N=C[N]2[C@H]3C[C@H](O)[C@@H](CO)C3=C)C(=O)N1,MedChem Express,HY-13623A,0,0,0,-61.96934316,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167558-02,Fleroxacin,170466056,Quinoline Antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),79660-72-3, Ro 23-6240; ; Ro 23624; Quinodis; Megalocin; Fleroxacin;Fleroxacin; fleroxacin N-oxide; Megalone; Ro 23 624,0.707945784,1,-6.15,-77.76348319,-1.4,4,,-37.21179203,-15.69417782,1,0.791725341,,,CN1CCN(CC1)c2c(F)c3c(cc2F)C(=O)C(=CN3CCF)C(=O)O,Prestwick,Prestw-1414,-9.69092887,-52.95927779,-33.29148001,-15.69417782,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390666-01,Opicapone,405559022,Catechol O-methyltransferase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),923287-50-7,,31.6227766,0,-4.5,-4.2529415,-3,4,,-40.16505524,-31.8042127,0.838551509,0.999962855,,,CC1=C(Cl)C(=[N+]([O-])C(=C1C2=NOC(=N2)C3=CC(=C(O)C(=C3)O)[N+]([O-])=O)Cl)C,MedChem Express,HY-14896,-34.45388345,1.85371445,0,-31.8042127,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263655-01,Huperzine A,170466837,Acetylcholinesterase Inhibitors,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),102518-79-6,,39.81071706,0,-4.4,-11.04286162,-3,4,,-36.87578107,-31.56315089,0.003659403,0.999991751,,ACHE,CC2=C[C@H]\3CC=1NC(=O)C=CC=1[C@@](N)(C2)C/3=C\C,Enzo,C117,0,0,0,-31.56315089,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389480-01,NCGC00389480-01,405559014,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),66852-54-8,,6.309573445,1,-5.2,-11.55825631,-3,4,,-34.79491335,0,1,0.999906429,,,CCC(=O)OC1(C(C)CC2C3CC(F)\C4=C\C(=O)\C=C/C4(C)C3(F)C(O)CC12C)C(=O)CCl,APExBIO,B1767,0,0,-33.16242779,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015603-08,Lomefloxacin hydrochloride,170465262,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),98079-52-8, ; Maxaquin;LOMEFLOXACIN HYDROCHLORIDE; Lomefloxacin hydrochloride;Lomefloxacin hydrochloride; Lemofloxacin,39.81071706,0,-4.4,-450.0213433,5,4,,39.73340286,-67.9989132,0.017790972,0.999805024,,,Cl.O=C(O)C2=CN(CC)c1c(F)c(c(F)cc1C2=O)N3CC(C)NCC3,Microsource,1502037,-96.89849733,-96.79321106,-95.88899759,-67.9989132,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094048-01,Iofetamine hydrochloride,144204790,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),82691-32-5,Iofetamine hydrochloride; Iofetamine; Spectamine; iofetaminum (123I); ,15.84893192,0,-4.8,-29.31734618,-2.4,4,"(123I)(+/-)-N-ISOPROPYL-P-IODOAMPHETAMINE;Spectamine;NCGC00162226-01;BENZENEETHANAMINE, 4-(IODO-(SUP 123) I)-.ALPHA.-METHYL-N-(1-METHYLETHYL)-, HYDROCHLORIDE;IOFETAMINE HYDROCHLORIDE I-123;IOFETAMINE (123 I);CIPLUS_733786;NCGC00015533-01;N-Isopropyl-p-Iodoamphetamine(123I) Hydrochloride;Benzeneethanamine, 4-iodo-alpha-methyl-N-(1-methylethyl)-;CIPLUS_192774;Iofetamine hydrochloride;M123 I-123;(+/-)-2-(N-Isopropyl)amino-4'-iodophenylpropane;NCGC_SIGMA_I120;N-ISOPROPYL-1-(4-IODOPHENYL)-2-PROPYLAMINE HYDROCHLORIDE, I-123, DL-;N-Isopropyl-p-iodoamphetamine(123I) hydrochloride;IOFETAMINE HYDROCHLORIDE I 123;IPRIOFENAMINE HYDROCHLORIDE, I-123;iofetaminum (123I);WHO NO. 5526;Iofetamine hydrochloride I 123;CIPLUS_210740;(+/-)-P-IODO-123I-N-ISOPROPYL-.ALPHA.-METHYLPHENETHYLAMINE;Iofetamine;iofetamine (123 I);N-Isopropyl-p-iodoamphetamine hydrochloride;RO-22-6303/001, I-123;NCGC00094048-01;IOFETAMINE I-123;BENZENEETHANAMINE, 4-(IODO-123I)-.ALPHA.-METHYL-N-(1-METHYLETHYL)-, (+/-)-;",-47.10287483,-45.00266188,0.063499855,0.997506415,,,Cl.Ic1ccc(CC(C)NC(C)C)cc1,SigmaAldrich,Lopac-I-120,0,-3.1730514,-16.26016339,-45.00266188,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183003-01,Depolipon,144206803,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),16488-48-5,p-Butylaminobenzoyldiethylaminoethyl hydrochloride; Calvital liquid; T cain; ,6.309573445,1,-5.2,-49.9343924,-2.4,4,P-BUTYLAMINOBENZOYLDIETHYLAMINOETHYL HYDROCHLORIDE;Calvital liquid;T cain;CIPLUS_170427;p-Butylaminobenzoyldiethylaminoethyl Hydrochloride;p-Butylaminobenzoyldiethylaminoethyl hydrochloride;CIPLUS_162500;,-58.40583803,-44.62563487,0.512782161,0.79217608,,,[Cl-].CC[NH+](CC)CCOC(=O)c1ccc(NCCCC)cc1,Pharmaron,PH-NIH-101688,0,-26.78747017,-22.35182374,-44.62563487,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164617-04,Adapalene,170464674,topical retinoid,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),106685-40-9, ; Differin; Alcon brand of adapalene; Differine; Adapalene;Adapalene; Adapalene (Differin); Adaferin; Adapaleno,1.77827941,1,-5.75,-38.50250313,-2.4,4,,-55.80411694,0,1,0.994490062,,RARB,O=C(O)c1ccc2cc(ccc2c1)c3cc(c(OC)cc3)C46CC5CC(CC(C4)C5)C6,Tocris,2852,0,-31.19222722,-47.95766435,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160445-02,Bromisovalum,170465828,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),496-67-3,,3.548133892,1,-5.45,-15.29152262,-3,4,,-34.03691603,-2.76358009,1,0.999953938,,,CC(C)C(Br)C(=O)NC(N)=O,Labotest,LT00134620,0,-5.02444639,-33.80431231,-2.76358009,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095048-06,Pipobroman,170465158,DNA Crosslinking Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54-91-1,,0.794328235,1,-6.1,-36.41943591,-1.4,4,,-42.51733611,0,1,0.998259423,,,O=C(CCBr)N1CCN(CC1)C(=O)CCBr,Microsource,1503393,1.3992439,-39.36790381,-37.67983356,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182995-01,Etomidoline,144206828,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),21590-92-1,Etomidoline; Smedolin; Etomidolina; ,39.81071706,0,-4.4,-11.39471805,-3,4,"Etomidolina;2-ethyl-3-(p-(beta-piperidinoethoxy)phenylamino)-isoindoline-1-one;Etomidolinum;K-2680;2-ETHYL-3-(.BETA.-PIPERIDINO-P-PHENETIDINO)PHTHALIMIDINE;K 2680;Phthalimidine, 2-ethyl-3-(beta-piperidino-p-phenetidino)-;etomidolinum;Etomidoline;LS-109527;CIPLUS_213965;Smedolin;ETOMIDOLINE;amidoline;1h-isoindol-1-one, 2-ethyl-2,3-dihydro-3-((4-(2-(1-piperidinyl)ethoxy)phenyl)amino)- (9ci);etomidoline;",-38.08260928,-32.56884107,0.004198366,0.999989141,,,O=C4c1ccccc1C(Nc3ccc(OCCN2CCCCC2)cc3)N4CC,Pharmaron,PH-NIH-150630,0,0,0,-32.56884107,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00532506-01,SODIUM LAURYL SULFOACETATE,405559116,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,10,0,-5,-25.4197633,-2.4,4,,-38.36221638,-34.52825998,0.82947859,0.999913857,,,CCCCCCCCCCCCOC(=O)C[S]([O-])(=O)=O,SIGMA,MFCD00214054,-23.46539706,0,-19.10009442,-34.52825998,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159476-09,Tribromsalan,170465542,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1987/10/5,,19.95262315,0,-4.7,-50.6491541,-2.4,4,,-69.61056906,-64.57067461,0.331721956,0.925347561,,,Oc1c(cc(Br)cc1Br)C(=O)Nc2ccc(Br)cc2,SIGMA,R416568,0,-18.12172314,-22.05063969,-64.57067461,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181776-02,Dicyclopentamethylenethiuram disulfide,170465709,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),94-37-1,,0.794328235,1,-6.1,-182.5644496,-1.3,4,,-73.16860855,-32.44959199,1,0.995477538,,,S=C(SSC(=S)N1CCCCC1)N2CCCCC2,Labotest,LT00159442,-27.16292054,-97.91831615,-92.99517246,-32.44959199,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095152-09,Alfuzosin hydrochloride,170465022,alpha1-Adrenoceptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),81403-68-1,; Uroxatral ER; ; ALFLUZOCIN;ALFUZOSIN HYDROCHLORIDE; Uroxatral; Alfuzosin Hcl (Uroxatral);Alfuzosin hydrochloride; Afluzosin;ALFLUZOSIN,39.81071706,0,-4.4,-19.93802843,-3,4,,-68.38520898,-56.98767415,0.006832298,0.999971216,148,ADRA1A,Cl.O=C(NCCCN(C)c2nc1cc(OC)c(OC)cc1c(N)n2)C3CCCO3,Microsource,1505263,0,0,0,-56.98767415,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018153-10,Dienestrol,170465362,Estrogen Receptor (ER) Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),84-17-3," (E,E)-Dienestrol; Ortho Dienestrol; Dienestrol, (Z,E)-Isomer; Dienoestrol; Ortho Brand of Dienestrol; Dienestrol, (E,E)-Isomer; Dienestrol, (Z,Z)-Isomer; Oestrasid;DIENESTROL; Synestrol;Dienestrol;",3.548133892,1,-5.45,-23.5207697,-3,4,,-44.90641068,-2.46867414,1,0.999957435,2099,ESR1,Oc1ccc(cc1)C(=C\C)/C(=C/C)c2ccc(O)cc2,Microsource,1500241,-1.1029358,-5.94472967,-46.04623485,-2.46867414,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00096056-02,Ethacridine lactate hydrate,170465798,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6402-23-9,,7.079457844,1,-5.15,-45.59538975,-3,4,,-32.12078339,0,1,0.879474749,,,O.O=C(O)C(C)O.CCOc1ccc2nc3cc(N)ccc3c(N)c2c1,Labotest,LT00244813,-11.27574353,0,-33.44516981,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091010-03,Domiphen bromide,170465494,HERG Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),538-71-6,,39.81071706,0,-4.4,-32.58183476,-3,4,,-106.83885,-89.4490417,0.028046631,0.999514545,,,[Br-].CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Labotest,LT00847867,0,-1.84209023,0,-89.4490417,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016395-06,Diphenylpyraline hydrochloride,170464816,Histamine H1 receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132-18-3,,39.81071706,0,-4.4,-48.92343988,-3,4,,-59.32542074,-54.85451728,0.594920901,0.688767529,,,Cl.CN3CCC(OC(c1ccccc1)c2ccccc2)CC3,Microsource,1500258,-3.68953003,-28.3600924,1.69338584,-54.85451728,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00161599-09,Troglitazone,170465091,CCL2 Expression Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),97322-87-7,; Rezulin;GR-92132X;Troglitazone; Troglitazone; Prelay;CS-045;CI-991,17.7827941,0,-4.75,-75.96599088,-2.4,4,,-75.51710897,-73.20508888,0.617957088,0.999995673,6347,CCL2,Cc1c(O)c(C)c(C)c2OC(C)(CCc12)COc4ccc(CC3SC(=O)NC3=O)cc4,"Prestwick Chemical, Inc.",Prestw-1467,-33.97649403,-8.01134029,-29.56045515,-73.20508888,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167421-02,Sevoflurane,225144283,GABA-B receptor Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-33.99339557,-3,4,,-48.63426854,-44.69522378,0.631037465,0.629400581,2890,,FCOC(C(F)(F)F)C(F)(F)F,Alfa Aesar,L16891,0,-26.27948766,0,-44.69522378,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00521080-01,Digitoxin 3'''-Acetate,405558469,Sodium/potassium-transporting ATPase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1111-39-3,,0.316227766,1,-6.5,-450.6752407,5,4,,-12.49949586,-96.19533601,0.32736361,0.935324238,,,CC1OC(CC(OC(C)=O)C1O)OC2C(O)CC(OC2C)OC3C(O)CC(OC3C)OC4CCC5(C)C(CCC6C5CCC7(C)C(CCC67O)\C8=C\C(=O)OC8)C4,Toronto Research,D445385,-93.53714651,-96.69301363,-97.28672639,-96.19533601,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017048-03,Levopropoxyphene napsylate,405558477,Kappa Opioid Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5714-90-9,,28.18382931,0,-4.55,-49.09175167,-3,4,,-63.2430614,-60.29288885,0.05484377,0.998140858,,,O[S+]([O-])(=O)C1=CC=C2C=CC=CC2=C1.CCC(=O)O[C@](CC3=CC=CC=C3)([C@@H](C)CN(C)C)C4=CC=CC=C4,Prestwick,Prestw-1054,-6.34689725,-3.61962657,-9.11465929,-60.29288885,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00532517-01,OZENOXACIN,405558514,Topoisomerase IV Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,11.22018454,0,-4.95,-72.87396856,-3,4,,-58.04746487,-48.52080672,0.267268244,0.953204557,,,CNC1=C(C)C=C(C=N1)C2=CC=C3C(=O)\C(=C/N(C4CC4)C3=C2C)C(O)=O,NanjingKaimubo Pharm,KB-80783,-11.31341925,0,-3.30351373,-48.52080672,,,,,,,,,,,,1.14E-07,5.71E-07,2.86E-06,0.0000143,,,,,,,,,,,
NCGC00496843-01,Ripasudil,405558535,ROCK1/ROCK2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),887375-67-9,,35.48133892,0,-4.45,-44.54132083,-3,4,,-97.34633795,-79.05025602,0.244956589,0.96106747,,ROCK1,C[C@H]1CNCCCN1[S+]([O-])(=O)C2=CC=CC3=CN=CC(=C23)F,Selleck,S7995,0,-15.73146297,-8.4421722,-79.05025602,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386382-03,Lurasidone (Hydrochloride),405558555,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),367514-88-3,,31.6227766,0,-4.5,-77.6072285,-2.4,4,,-82.31406304,-72.88668626,0.195341959,0.975707075,,,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)C6=NSC7=C6C=CC=C7,MedChem Express,HY-B0032,-7.41363569,-19.15147899,-23.50422751,-72.88668626,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179611-05,DIHYDROSTREPTOMYCIN [5mM],405558590,Large-conductance mechanosensitive channel Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),128-46-1,,22.38721139,0,-4.65,-17.59602707,-3,4,,-40.48770248,-36.35432006,0.019374554,0.999768636,947787,mscL,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]2[C@@H](O[C@@H](C)[C@]2(O)CO)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]3NC(N)=N,Microsource,1500249,0,0,-6.98295798,-36.35432006,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00370833-02,NS-304,405558607,platelet aggregation Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),475086-01-2,,39.81071706,0,-4.4,-45.63190366,-3,4,,-60.27869804,-54.39891503,0.175455026,0.980526661,,,CC(C)N(CCCCOCC(=O)N[S+](C)([O-])=O)C1=NC(=C(N=C1)C2=CC=CC=C2)C3=CC=CC=C3,MedChem Express,HY-14870,-7.24085549,-6.87982261,0,-54.39891503,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386162-01,NCGC00386162-01,405558619,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1407-03-0,,39.81071706,0,-4.4,-17.19873993,-3,4,,-58.98975559,-49.15812966,0.006832298,0.99997122,,HSD11B2,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2C(=O)\C=C4\[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(O)=O)O[C@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)C(O)=O)C(O)=O,Selleck,S2376,0,0,0,-49.15812966,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016505-06,PROPOXYCAINE HYDROCHLORIDE,405558691,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),550-83-4,,39.81071706,0,-4.4,-26.27161684,-3,4,,-65.41261283,-54.92717736,0.055618881,0.998087798,,,CCCOC1=C(C=CC(=C1)N)C(=O)OCCN(CC)CC,Microsource,1505572,-2.34377954,0,0,-54.92717736,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091595-07,Sodium 2-phenylphenate tetrahydrate,170465724,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6152-33-6,,1.995262315,1,-5.7,-77.79062161,-2.4,4,,-35.53301444,-13.1790333,1,0.999921978,,,[Na+].O.O.O.O.[O-]c2ccccc2c1ccccc1,Vitas,STK177354,-14.44234725,-28.58526578,-41.18472056,-13.1790333,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015508-16,Hydrochlorothiazide,170465005,Hypertension treatment,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58-93-5,; Moduretic; Dyazide;HYDROCHLOROTHIAZIDE; ; Tenesor; Capozide; Slimin; Hydrochlorothiazide; Esidrix; HydroDIURIL; Tolerzide; Oretic; Sectrazide; Triampur compositum; Spiridazide; Esidrex; Triampur (combination); Hypothiazide; Dihydrochlorothiazide; Hydrochlorothiazid;Hydrochlorothiazide; Dichlothiazide; Maxzide; Triampur; Hidroclorotiazida; Moducren,6.309573445,1,-5.2,-11.62371464,-3,4,,-35.01825691,0,1,0.999914238,,SLC12A3,NS(=O)(=O)c2cc1c(NCNS1(=O)=O)cc2Cl,Specs,AN-153/I107325,0,0,-33.35023788,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090770-09,5-Bromo-2'-deoxyuridine,170465870,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),59-14-3,,28.18382931,0,-4.55,-31.06341102,-2.4,4,,-56.99647767,-45.45187702,0.166330197,0.982550922,,,BrC1=CN(C(=O)NC1=O)[C@H]2C[C@H](O)[C@@H](CO)O2,Bosche,B0691,0,-7.5741622,-14.13351627,-45.45187702,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00387301-01,Timiperone,405558737,serotonin receptor signaling pathway Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-21.94278458,-3,4,,-75.38424474,-62.82020395,0.008016815,0.999960367,,,FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=S)NC4=C3C=CC=C4,Toronto Research,T443110,0,0,0.05132523,-62.82020395,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181097-01,Dimefline hydrochloride,144206266,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2740/4/7,Dimefline hydrochloride; Dimeflina; Remeflin; Reanimil; ,7.943282347,1,-5.1,-37.68247327,-1.4,4,"Flavone, 8-(dimethylaminomethyl)-7-methoxy-3-methyl-;4H-1-BENZOPYRAN-4-ONE, 8-((DIMETHYLAMINO)METHYL)-7-METHOXY-3-METHYL-2-PHENYL-;dimeflinum;LS-68986;Dimeflina;Dimefline hydrochloride;dimefline;4h-1-benzopyran-4-one, 8-((dimethylamino)methyl)-7-methoxy-3-methyl-2-phenyl-, hydrochloride;3-methyl-7-methoxy-8-dimethylamino-methylflavone;Flavone, 8-((dimethylamino)methyl)-7-methoxy-3-methyl-, hydrochloride;Reanimil;dimefline hydrochloride;CIPLUS_157700;Remeflin;8-((DIMETHYLAMINO)METHYL)-7-METHOXY-3-METHYLFLAVONE;LS-68987;DIMEFLINE HYDROCHLORIDE;DIMEFLINE;CIPLUS_160797;Dimeflinum;",-39.89871466,-39.91559555,0.814132389,0.999934331,,,Cl.CN(C)Cc3c(ccc1c3OC(=C(C)C1=O)c2ccccc2)OC,NCI,NSC-114650,-30.4688394,0,-33.95957578,-39.91559555,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00247988-03,Cochineal,170466801,Solute carrier organic anion transporter family member 1B1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1343-78-8,,1.995262315,1,-5.7,-82.04391945,-2.4,4,,-54.36761429,-51.63044436,0.422538996,0.870764665,,,O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]1CO)c4c(O)c3C(=O)c2c(C)c(C(=O)O)c(O)cc2C(=O)c3c(O)c4O,SIGMA,229253,-5.90743245,-32.9964367,-33.14966953,-51.63044436,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346829-03,Fotemustine,405558771,DNA Alkylating Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),92118-27-9,,39.81071706,0,-4.4,-10.65509568,-3,4,,-35.54578724,-30.4548227,0.743095297,0.99999148,,H2AFX,CCO[P](=O)(OCC)C(C)NC(=O)N(CCCl)N=O,SIGMA,F7307,-21.5815134,0,0,-30.4548227,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386567-02,FLIBANSERIN,405558804,Serotonin 2a (5-HT2a) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),167933-07-5,,39.81071706,0,-4.4,-28.1467769,-3,4,,-69.18823826,-60.57353188,0.205352493,0.973061135,,,FC(F)(F)C1=CC(=CC=C1)N2CCN(CC2)CCN3C(=O)NC4=CC=CC=C34,SIGMA,SML0797,0,-9.9559579,0,-60.57353188,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163953-03,Allethrin,144214035,Testis-specific androgen-binding protein Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),584-79-2,,63.09573445,0,-4.2,-34.03739537,-3,4,Allethrin,-105.3712645,-99.30990959,0.00980714,0.999940675,,,O=C2CC(OC(=O)C1C(/C=C(\C)C)C1(C)C)C(C)=C2CC=C,LightBiologicals,MOP-20453,0,0.82287089,0,-99.30990959,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00253588-01,Gimatecan,170465615,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),292618-32-7,,39.81071706,0,-4.4,-464.4379495,5,4,,2.114909248,-96.46305161,0.340097227,0.953847766,,,CC(C)(C)O\N=C\c1c3CN4C(=O)C=5COC(=O)[C@](O)(CC)C=5C=C4c3nc2ccccc12,GVK,FFS-11-286-NCI-141,-97.75449594,-98.03396057,-97.34214205,-96.46305161,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018258-10,Econazole nitrate,170465422,Antifungal Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),24169-02-6,; Pevisone; Spectazole;Econazole nitrate;ECONAZOLE NITRATE; Econazole nitrate salt,39.81071706,0,-4.4,-122.0252056,-2.4,4,,-57.0934337,-71.75342094,0.139621056,0.987785633,,,[O-][N+](=O)O.Clc3ccc(C(OCc1ccc(Cl)cc1)Cn2ccnc2)c(Cl)c3,Microsource,1501185,-21.25289513,-26.59146376,-20.58788848,-71.75342094,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091517-06,L-Ascorbic acid,170464728,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),50-81-7,,1.77827941,1,-5.75,-51.10966152,-2.4,4,,-33.28064278,-23.73510392,0.482405858,0.821995434,,,OC=1C(=O)O[C@H]([C@@H](O)CO)C=1O,Microsource,1502230,0,-20.47782684,-40.81028902,-23.73510392,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091325-09,Dichlorophen,170465475,"Indoleamine 2,3-dioxygenase Inhibitor",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),97-23-4,,19.95262315,0,-4.7,-85.83246765,-2.3,4,,-99.57666427,-97.05203189,0.437784148,0.999961102,,,Oc2ccc(Cl)cc2Cc1cc(Cl)ccc1O,Microsource,1500626,-31.91988587,-8.32205562,-30.09167427,-97.05203189,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015207-12,Cilostazol,170465347,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),73963-72-1,Cilostazol;CILOSTAZOL;; ; Pletal; Pletaal; Cilostazole; Cilostazol,39.81071706,0,-4.4,-16.59128824,-3,4,,-57.78627878,-48.98856565,0.164467215,0.982943442,5139,PDE3A,O=C1CCc2cc(ccc2N1)OCCCCc4nnnn4C3CCCCC3,Microsource,1505230,0,-3.5053695,4.29067359,-48.98856565,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160518-03,Orbifloxacin,170465644,DNA gyrase Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),113617-63-3,,3.981071706,1,-5.4,-37.91857268,-2.2,4,,-35.08312453,-34.79918938,0.038621483,0.999079747,,,C[C@@H]1CN(C[C@H](C)N1)c2c(F)c(F)c3c(c2F)N(C=C(C3=O)C(=O)O)C4CC4,SIGMA,34041,0,0,-24.72542187,-34.79918938,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00249416-01,Oberadilol,144206753,Adrenergic receptor beta Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),114856-44-9,,39.81071706,0,-4.4,-67.26864775,-3,4,,-69.47180231,-62.05983526,0.273747572,0.950743067,,,Clc3cc(OCC(O)CNC(C)(C)CNc1ccc(cc1)C2=NNC(=O)CC2C)c(C#N)cc3,NCGCChem,DJM10-028,-14.10295008,-4.44945024,0,-62.05983526,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00522040-01,Carpipramine Dihydrochloride,405558850,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7075/3/8,,22.38721139,0,-4.65,-22.90859176,-2.4,4,,-79.75429984,-70.26840897,0.510102885,0.999981668,,,NC(=O)C1(CCN(CCCN2C3=CC=CC=C3CCC4=C2C=CC=C4)CC1)N5CCCCC5,Toronto Research,C184320,-22.42036665,2.36671685,-10.16716734,-70.26840897,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00522306-02,Valbenazine,405558870,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1025504-45-3,,25.11886432,0,-4.6,-129.5635945,-2.3,4,,-70.17465249,-83.8909958,0.091877067,0.994758332,,,COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1,MedChem Express,HY-16771,-22.74520127,-17.43968581,-28.0229902,-83.8909958,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181786-02,Naratriptan hydrochloride,170465423,5-HT1B Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),143388-64-1,Naratriptan hydrochloride; Naratriptan hydrochloride; Amerge; ,39.81071706,0,-4.4,-43.8071261,-3,4,,-44.67913205,-36.49934246,0.391974302,0.891472493,3351,HTR1B,Cl.CN1CCC(CC1)c2cnc3ccc(CCS(=O)(=O)NC)cc23,SIGMA,N1415,-10.33027145,3.79278837,-3.71372599,-36.49934246,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182065-02,Dimemorfan phosphate,144206689,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),36304-84-4,dimemorfan; Astomin; Dimemorfano; Dimemorfane; Dastosin; ,39.81071706,0,-4.4,-22.14856662,-3,4,"LS-174594;Dimemorfano;DIMEMORFAN;CIPLUS_789081;Dimemorfane;3,17-dimethylmorphinan;Astomin;CIPLUS_775315;Dastosin;LS-174593;dimemorfanum;CIPLUS_739426;CIPLUS_207834;dimemorfan, (9alpha,13alpha,14alpha)-isomer;Yamanouchi brand of dimemorfan phosphate;Dimemorfan Phosphate;at-17;dinemorphan;Dimemorfan;(+)-3,17-DIMETHYLMORPHINAN;dimemorfan phosphate;dimemorfan phosphate (1:1) salt;dimemorfan;d-3-methyl-N-methylmorphinan;LS-174853;DIMEMORFAN PHOSPHATE;Dimemorfan phosphate;AT 17;LS-91711;Dimemorfanum;",-75.96710789,-63.30592324,0.006832298,0.999971214,,,O=P(O)(O)O.Cc3ccc4C[C@@H]1N(C)CC[C@]2(CCCC[C@H]12)c4c3,Kemprotec,36304-84-4,0,0,0,-63.30592324,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181111-02,Tamibarotene,170465883,Retinoid RAR Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),94497-51-5, ; Am80; Am 80;AM 80; Tamibarotene;tamibarotene; Amnoid,39.81071706,0,-4.4,-69.83874749,-3,4,,-51.21138954,-46.84282462,0.428846267,0.86614191,5915,RARB,O=C(O)c1ccc(cc1)C(=O)Nc2ccc3c(c2)C(C)(C)CCC3(C)C,Tocris,3507,-16.44947996,-5.63950306,0,-46.84282462,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015678-10,Moxisylyte hydrochloride,170465759,Adrenergic receptor alpha-1 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),964-52-3,,22.38721139,0,-4.65,-35.05853418,-3,4,,-33.65941637,-33.04951364,0.206481736,0.972785267,,,Cl.CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,"Prestwick Chemical, Inc.",Prestw-42,-5.65738695,0,-9.26061014,-33.04951364,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016101-10,Xylometazoline hydrochloride,170465470,alpha2A/B/C-Adrenoceptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1218-35-5,; Otrivine-Antistin; ;XYLOMETAZOLINE HYDROCHLORIDE;Xylometazoline hydrochloride; Xylometazoline hydrochloride; Neo-Synephrine II; Xilometazolina; Otrivin hydrochloride,3.981071706,1,-5.4,-68.16613722,-2.4,4,,-64.4438012,-57.52957963,0.110037664,0.992459865,150,ADRA2A,Cl.CC(C)(C)c2cc(C)c(CC1=NCCN1)c(C)c2,Microsource,1500614,-0.573454,-22.61757256,-43.69162311,-57.52957963,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164034-05,Triclocarban,170465481,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),101-20-2,,35.48133892,0,-4.45,-38.12957743,-3,4,,-123.1413243,-94.57859008,0.010864001,0.9999272,,,Clc2ccc(NC(=O)Nc1ccc(Cl)cc1)cc2Cl,Specs,AN-153/I101902,0,0,-7.216176,-94.57859008,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179276-04,Etilefrine hydrochloride,225144301,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),534-87-2,,12.58925412,0,-4.9,-111.8200653,-2.4,4,,-36.99141775,-54.08172259,0.146004209,0.986630247,,,CCNCC(O)C1=CC(=CC=C1)O,Prestwick,Prestw-1017,-19.74762697,-15.34736887,-32.56123114,-54.08172259,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00379061-01,Umeclidinium bromide,405558946,Muscarinic acetylcholine receptor M3 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),869113-09-7,,22.38721139,0,-4.65,-30.46452545,-2.2,4,,-69.47548604,-61.34506518,0.012867438,0.999897894,1131,CHRM3,OC(C1=CC=CC=C1)(C2=CC=CC=C2)C34CC[N+](CCOCC5=CC=CC=C5)(CC3)CC4,MedChem Express,HY-12100,0,0,-12.88944965,-61.34506518,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188863-02,Dronedarone hydrochloride,170465064,"alpha,beta-Adrenoceptor Antagonist",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),141626-36-0,Dronedarone; Dronedarone,22.38721139,0,-4.65,-45.65876586,-2.1,4,,-105.2199501,-95.30792582,0.008720055,0.9999531,148,ADRA1A,CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c2c3cc(ccc3oc2CCCC)NS(C)(=O)=O,SIGMA,D9696,0,0,-17.63143324,-95.30792582,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346540-03,FESOTERODINE FUMARATE,405558955,Muscarinic Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),286930-03-8,,39.81071706,0,-4.4,-30.66406233,-3,4,,-108.2766179,-91.68941701,0.029997481,0.999444604,,CHRM1,CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(OC(=O)C(C)C)C=CC(=C2)CO)C(C)C,Microsource,1504374,0,0,2.02593434,-91.68941701,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095175-08,Cefditoren (Pivoxil),405558969,Cephalosporin Antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),117467-28-4,,39.81071706,0,-4.4,-54.99492873,-3,4,,-43.93765799,-40.78138166,0.834832003,0.925792985,,,[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C(=O)OCOC(=O)C(C)(C)C,MedChem Express,HY-17452A,-41.7593719,-10.98243249,0,-40.78138166,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344330-02,Elaidic Acid,405558971,SiHa Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),112-79-8,,35.48133892,0,-4.45,-13.53818075,-3,4,,-42.82181518,-38.18484598,0.001517434,0.999998581,,,CCCCCCCC/C=C/CCCCCCCC(O)=O,Cayman,90250,0,0,-0.25574962,-38.18484598,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181760-01,Lobenzarit sodium,144206494,response to oxidative stress Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),64808-48-6,lobenzarit; Carfenil; CCA lobenzarit; ,10,0,-5,-40.63568245,-3,4,"U-69951F;2-((2-carboxyphenyl)amino)-4-chlorobenzoic acid;LOBENZARIT;CIPLUS_685410;Benzoic acid, 2-((2-carboxyphenyl)amino)-4-chloro-, disodium salt;LS-36386;LOBENZARIT SODIUM;lobenzarit, disodium salt;Carfenil;4-chloro-2,2'-iminodibenzoic acid;CCA lobenzarit;CIPLUS_186740;lobenzarit disodium;lobenzarit;Lobenzarit Disodium;DISODIUM 4-CHLORO-2,2'-IMINODIBENZOATE;disodium 4-chloro-2,2'-iminodibenzoate;Lobenzaritum;N-(2-carboxyphenyl)-4-chloroanthranilic acid;Lobenzarit sodium;Lobenzarit;Lobenzarit disodium;lobenzaritum;lobenzart;LS-176311;",-51.53837159,-51.34944876,0.044995864,0.998749726,2936,,[Na+].[Na+].O=C([O-])c2ccc(Cl)cc2Nc1ccccc1C([O-])=O,ACC,LOBENZARIT DISODIUM,-2.02356156,0,-6.76285359,-51.34944876,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00016747-07,Dilazep,170465831,Equilibrative nucleoside transporter 2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),35898-87-4,,11.22018454,0,-4.95,-51.52134823,-2.2,4,,-72.17228734,-70.32656784,0.046727045,0.998651124,,,COc1cc(cc(OC)c1OC)C(=O)OCCCN3CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC3,Enzo,AC640,0,0,-38.54021666,-70.32656784,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094819-07,Hexetidine,170465729,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),141-94-6,,6.309573445,1,-5.2,-12.95224763,-3,4,,-39.13496523,0,1,0.999928649,,,CCC(CCCC)CN1CC(C)(N)CN(CC(CCCC)CC)C1,Microsource,1500633,0,0,-37.16200484,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167982-04,Pirarubicin,405559004,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),72496-41-4,,7.943282347,1,-5.1,-88.20828719,-1.1,4,,-96.77213087,-97.24457664,0.019305977,0.999770046,,,[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(OC)C=CC=C5C4=O)C(O)=C23)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@@]6([H])CCCCO6,SIGMA,P8624,0,0,-77.58552118,-97.24457664,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181168-01,Trifluomeprazine 2-butenedioate,144206322,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),71609-19-3,Trifluomeprazine; Trifluomeprazina; ,35.48133892,0,-4.45,-33.67450434,-3,4,Trifluomeprazinum;Trifluomeprazine;CIPLUS_214394;trifluomeprazine;TRIFLUOMEPRAZINE;trifluomeprazinum;Trifluomeprazina;TRIFLUOMEPRAZINE MALEATE;,-109.562282,-87.37024079,0.009666626,0.999942365,,,O=C(O)C=CC(=O)O.FC(F)(F)c1cc2N(CC(C)CN(C)C)c3ccccc3Sc2cc1,NCI,NSC-170991,0,0,-4.44825136,-87.37024079,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00510028-01,Amezinium methylsulfate,405559018,Amine oxidase [flavin-containing] B Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),30578-37-1,,11.22018454,0,-4.95,-36.38655521,-2.4,4,,-58.04306602,-52.81765372,0.79144445,0.999363848,403451,MAOB,COC1=CC(=CN=[N+]1C2=CC=CC=C2)N,Ark Pharm,AK396807,-31.8806471,0,-25.640701,-52.81765372,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00379044-01,Paricalcitol-D6 (ABT-358),405559020,Vitamin D Receptor (VDR) Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,6.309573445,1,-5.2,-11.56585982,-3,4,,-34.82109214,-5.63131168,1,0.999907503,,VDR,C[C@H](\C=C\[C@H](C)C(C([2H])([2H])[2H])(C([2H])([2H])[2H])O)[C@H]1CC[C@H]2C(/CCC[C@]12C)=C/[CH]=[C]3C[C@@H](O)[CH2][C@H](O)C3,MedChem Express,HY-76585,0,0,-33.18424345,-5.63131168,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178707-05,NCGC00178707-05,405559039,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),196597-26-9,,39.81071706,0,-4.4,-52.31178999,-3,4,,-41.96215667,-39.13513056,0.412307581,0.877980053,,MTNR1A,CCC(=O)NCC[C@@H]1CCC2=C1C3=C(OCC3)C=C2,Microsource,1505817,-13.13610787,1.3146861,0,-39.13513056,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181021-02,Bufogenin,124893634,Sodium/potassium-transporting ATPase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,3.16227766,1,-5.5,-95.23992561,-1.3,4,"CIPLUS_153297;resibufogenin;Bufogeninum;Bufogenine;Bufogenina;BUFOGENIN;14,15 beta-epoxy-3 beta-hydroxy-5 beta-bufa-20,22-dienolide;Bufogenin;bufogenine;bufogeninum;RESIBUFOGENIN;bufogenin;Resibufogenin;LS-45295;",-94.01280533,-97.95758153,0.157234698,0.984434864,,,C[C@]12CC[C@H](O)C[C@H]1CCC3C2CC[C@]4(C)[C@H](C[C@H]5O[C@@]345)C/6=C/OC(=O)/C=C6,Sequoia,RESIBUFOGENIN,2.38189138,-14.99503205,-82.56466419,-97.95758153,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183026-01,Dicethiamine hydrochloride,144206821,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),616-96-6,"Cetotiamine; Cetotiamine Hydrochloride; O,S-dicarbethoxythiamine; Cetotiamina; ",10,0,-5,-41.33071011,-2.4,4,"Cetotiamine Hydrochloride;Cetotiamine;O,S-dicarbethoxythiamine;CETOTIAMINE;CIPLUS_210876;Cetotiaminum;Cetotiamina;CIPLUS_697013;O,S-bis(ethoxycarbonyl)thiamine;cetotiamine;cetotiaminum;",-40.99112697,-41.65888331,0.065202669,0.997370434,,,Cl.Nc1nc(C)ncc1CN(C=O)C(/C)=C(/CCOC(=O)OCC)SC(=O)OCC,Pharmaron,PH-NIH-149305,-2.22836197,0,-28.70646746,-41.65888331,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018125-05,Tripelennamine citrate,170465118,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6138-56-3,,11.22018454,0,-4.95,-68.73507493,-2.4,4,,-53.65699003,-57.08980558,0.275636533,0.950018608,,,O=C(O)C(O)(CC(=O)O)CC(=O)O.CN(C)CCN(Cc1ccccc1)c2ccccn2,Microsource,1500597,-10.23110116,3.70485853,-29.4312478,-57.08980558,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274270-01,NCGC00274270-01,405559068,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,0.707945784,1,-6.15,-57.10342885,-1.4,4,,-38.17110174,-40.80323098,0.508681574,0.796407499,,,COC1[C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/C(O)[C@H](C)C[C@H](CC=O)C1OC2OCC(OC3CC(C)(O)C(O)C(C)O3)C(C2O)N(C)C,GVK,FFS-11-286-NCI-160,0,-39.38335796,-21.93402331,-40.80323098,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00024714-11,Triprolidine,170464931,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),486-12-4,,39.81071706,0,-4.4,-14.25369765,-3,4,,-51.24398499,-43.53665416,0.757302365,0.999020214,,,Cc1ccc(cc1)C(=C\CN2CCCC2)/c3ccccn3,SigmaAldrich,T6764,-32.61033014,0,1.40074567,-43.53665416,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249912-01,Floctafenine,170465681,Prostaglandin G/H synthase 2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),23779-99-9,,19.95262315,0,-4.7,-20.03221892,-2.4,4,,-48.91704263,-42.36139593,0.08459111,0.995563334,5743,PTGS2,OCC(O)COC(=O)c3ccccc3Nc1ccnc2c(cccc12)C(F)(F)F,GVK,FFS-11-286-NCI-159,0,2.82495191,-10.28727402,-42.36139593,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016018-11,Tetrahydrozoline HCl,405559075,Adrenergic receptor alpha Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),522-48-5,,39.81071706,0,-4.4,-9.972515731,-3,4,,-36.12236471,-30.51863726,0.166901954,0.982437406,,,C1CC(\C2=N\CCN2)C3=C(C1)C=CC=C3,Selleck,S4043,0,-1.95997924,2.96955888,-30.51863726,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016889-06,Tenoxicam,170465677,non-steroidal antiinflammatory,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),59804-37-4, Tilcotil; Tenoxicam; ;TENOXICAM;Tenoxicam; Mobiflex,6.309573445,1,-5.2,-12.78613713,-3,4,,-45.89705631,-5.70540194,1,0.996495082,,PTGS2,OC=2c1sccc1S(=O)(=O)N(C)C=2C(=O)Nc3ccccn3,Microsource,1503142,0,2.66899567,-42.0343114,-5.70540194,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160481-02,Tioxidazole,124892286,microtubule polymerization Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-12.65979523,-3,4,,-43.42168261,-36.18473551,0.006832298,0.999971233,,,CCCOC1=CC=C2N=C(NC(=O)OC)SC2=C1,Chembridge,5175278,0,0,0,-36.18473551,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185750-01,Astromicin,144206938,Bacterial 70S ribosome Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55779-06-1,,39.81071706,0,-4.4,-26.65060384,-3,4,,-58.18126978,-49.31772482,0.080280543,0.996005503,,,NCC(=O)N(C)[C@H]2[C@@H](O)[C@H](O[C@H]1O[C@@H](CC[C@H]1N)[C@H](C)N)[C@@H](N)[C@H](O)[C@@H]2OC,Sequoia,ASTROMICIN SULPHATE,-3.12173244,0,0,-49.31772482,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00261970-01,BEMOTRIZINOL,225144355,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,Tinosorb s;Bemotrizinol;Bis-ethylhexyloxyphenol methoxyphenyl,3.981071706,1,-5.4,-76.48761094,-3,4,,-56.86440288,-49.8870024,0.228067152,0.966494111,,,CCCCC(CC)COC1=CC(=C(C=C1)C2=NC(=NC(=N2)C3=C(O)C=C(OCC(CC)CCCC)C=C3)C4=CC=C(OC)C=C4)O,GVK,FFS-11-286-NCI-081,-7.21934392,0,3.56004248,-49.8870024,,,,,,,,,,,,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,,,,
NCGC00183121-01,Zinc pyrithione,144206950,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13463-41-7,,281.8382931,0,-3.55,-461.3759165,5,4,"pyrithionum zincicum;LS-784;Pyrithione zincique;PYRITHIONE ZINC;pyrithione zinc;Zinc Pyrithione;Zinc pyrithione;NCGC00094659-02;ZINC OMADINE;NCGC00094659-01;CIPLUS_168786;ZINC DI(2-PYRIDINETHIOL-1-OXIDE);Piritionato cincico;zinc pyrithione;ZINC PYRION;AB07944716-01;Finecide ZPT;Pyrithione zinc;VANCIDE ZP;Pyrithionum zincicum;Sebulon shampoo;2-Mercaptopyridine N-oxide zinc salt Pyrithione zinc;(T-4)-bis(1-hydroxy-2(1H)- pyridinethionato-O,S)zinc;2-Mercaptopyridine N-oxide zinc salt;",-15.28257719,-99.28170426,0.332992672,0.936349605,,,[O-][n+]2ccccc2S[Zn]Sc1cccc[n+]1[O-],SIGMA,H6377,-96.87900426,-96.1295566,-97.22351942,-99.28170426,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181148-01,Metharbital,144206305,GABA-A receptor; anion channel Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1950/11/3,Metharbital; Metarbital; ,39.81071706,0,-4.4,-122.2847504,-2.4,4,"metharbitone;Metharbital;metharbital;endiemal;metharbitalum;CIPLUS_148525;Metarbital;2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-1-methyl-;LS-24178;Metharbitalum;METHARBITAL;Barbituric acid, 5,5-diethyl-1-methyl-;methobarbitone;5,5-DIETHYL-1-METHYLBARBITURIC ACID;2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5,5-DIETHYL-1-METHYL-;CIPLUS_178471;",-15.22267614,-40.05603459,0.772502374,0.51952074,,,O=C1NC(=O)N(C)C(=O)C1(CC)CC,NCI,NSC-27156,-21.2940048,-42.8172382,-20.43328426,-40.05603459,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00531794-01,Cimicoxib,405559129,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),265114-23-6,,8.912509381,1,-5.05,-34.77286695,-2.4,4,,-39.93464766,-39.85495409,0.774195203,0.999937315,,,COC1=CC=C(C=C1F)C2=C(Cl)N=C[N]2C3=CC=C(C=C3)[S+](N)([O-])=O,Toronto Research,C441690,-25.80387238,0,-29.82385318,-39.85495409,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00021145-11,Loxapine succinate,170465094,Muscarinic acetylcholine receptor M1 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),27833-64-3,,28.18382931,0,-4.55,-35.60988837,-3,4,,-68.3840544,-61.65458667,0.059501177,0.997810576,1128,CHRM1,O=C(O)CCC(=O)O.CN1CCN(CC1)C3=Nc4ccccc4Oc2ccc(Cl)cc23,Microsource,2300242,-3.23730214,0,-6.15004042,-61.65458667,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00022697-03,NCGC00022697-03,170464623,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),155-41-9,,12.58925412,0,-4.9,-27.39501119,-2.4,4,,-38.59580595,-31.74650496,0.060795012,0.997717025,,,[Br-].OC[C@H](c1ccccc1)C(=O)O[C@@H]2C[C@@H]3[C@H]4O[C@H]4[C@H](C2)[N+]3(C)C,SIGMA,S8502,0,-5.86604415,-17.45503474,-31.74650496,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018158-09,Doxazosin mesylate,170465395,alpha1-Adrenoceptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),77883-43-3,; Doxazosin Mesilate; Doxazosin mesylate salt;Doxazosin mesylate; Doxazosin mesilate; Doxazosin hydrochloride;DOXAZOSIN MESYLATE,39.81071706,0,-4.4,-52.48208142,-3,4,,-31.69447594,-30.99539662,0.545271936,0.755853404,148,ADRA1A,CS(=O)(=O)O.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4COc5ccccc5O4,Microsource,1505976,-14.55600934,0,3.11271818,-30.99539662,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181124-02,Sparteine,170465740,sodium ion transport Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),90-39-1,,14.12537545,0,-4.85,-12.78173125,-2.4,4,,-30.62501853,-28.43751544,0.03939732,0.999043007,,,C3CCCN4C[C@@H]2C[C@@H](CN1CCCC[C@H]12)[C@@H]34,Vitas,STK801664,1.52662209,0,-10.63482483,-28.43751544,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185741-02,Nepafenac,170465203,Cyclooxygenase-2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),78281-72-8,Nepafenac,35.48133892,0,-4.45,-36.43000229,-3,4,,-51.89914836,-42.34783967,0.71938357,0.4258831,5743,PTGS2,Nc1c(cccc1CC(N)=O)C(=O)c2ccccc2,Selleck,S1255,0,-28.74405165,-2.19987269,-42.34783967,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00022043-06,Deoxycorticosterone acetate,170465334,Mineralocorticoid receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),56-47-3,,12.58925412,0,-4.9,-86.00571351,-2.4,4,,-38.03929105,-49.00981909,0.143665157,0.98706178,,,CC(=O)OCC(=O)[C@H]2CC[C@H]3[C@@H]4CCC1=CC(=O)CC[C@]1(C)[C@H]4CC[C@]23C,SIGMA,D7000,-13.89713228,-9.49276131,-29.20900714,-49.00981909,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166312-02,Closantel,170466628,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57808-65-8,,19.95262315,0,-4.7,-138.7825821,-2.3,4,,-88.55627368,-96.31838584,0.213013463,0.970928994,,,Clc3cc(NC(=O)c1cc(I)cc(I)c1O)c(C)cc3C(C#N)c2ccc(Cl)cc2,Vitas,STK378904,-24.61071742,-9.55631919,-34.84226809,-96.31838584,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015826-13,Perphenazine,170464834,Muscarinic acetylcholine receptor M1 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58-39-9,,14.12537545,0,-4.85,-62.21961303,-2.1,4,,-93.01727388,-87.05303137,0.048655989,0.998537126,1128,CHRM1,OCCN1CCN(CC1)CCCN2c4ccccc4Sc3ccc(Cl)cc23,Microsource,1503934,0,-7.01607176,-38.46227255,-87.05303137,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178213-05,Nafronyl oxalate,170465616,Serotonin 2 (5-HT2) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3200/6/4,,35.48133892,0,-4.45,-55.73893873,-2.4,4,,-86.40943101,-68.49199319,0.629652797,0.631751157,,,O=C(O)C(=O)O.CCN(CC)CCOC(=O)C(Cc1cccc2ccccc12)CC3CCCO3,Microsource,1503419,0,-36.30123606,-9.19205929,-68.49199319,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182988-01,Acreozast,144206850,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),123548-56-1,Acreozast; Acreozst; Adeozast; ,25.11886432,0,-4.6,-33.98022275,-3,4,"LS-172573;Acetamide, N,N'-(2-chloro-5-cyano-1,3-phenylene)bis(2-(acetyloxy))-;Acreozst;CIPLUS_706509;TYB-2285;TYB 2285;Acreozast;acreozast;Adeozast;ACREOZAST;acreozastum;3,5-bis(acetoxyacetylamino)-4-chlorobenzonitrile;",-40.89286539,-37.41072116,0.679798749,0.529837459,,,Clc1c(cc(cc1NC(=O)COC(C)=O)C#N)NC(=O)COC(C)=O,Pharmaron,PH-NIH-154940,0,-23.2665377,-6.64368648,-37.41072116,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015252-12,Cyproheptadine hydrochloride,170465127,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),129-03-3,; ; Cyproheptadine hydrochloride;Cyproheptadine hydrochloride; Dihexazin; 1   Cyprohetadine;Cyproheptadine;CYPROHEPTADINE HYDROCHLORIDE; Viternum; 9   Cyproheptadine; Ciproheptadina; Periactin; Peritol; Antergan,31.6227766,0,-4.5,-29.2336966,-3,4,,-99.66055441,-89.39941203,0.036519182,0.999176568,9704,HRH1,CN1CC\C(CC1)=C2\c4ccccc4C=Cc3ccccc23,Vitas,STK802098,0,3.16396355,-0.23757966,-89.39941203,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025355-12,Paroxetine,170465075,5-HT Reuptake Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61869-08-7,;Paroxetine;Paroxetine hydrochloride hemihydrate (MW = 374.83); Paroxetine hydrochloride hemihydrate (MW = 374.83); Paroxetina; ; Paroxetine Base;PAROXETINE HYDROCHLORIDE; Paxil; Paroxetine maleate;Paroxetine?HCl;Paroxetine Hydrochloride,39.81071706,0,-4.4,-60.23009596,-3,4,,-66.23739872,-59.36449893,0.249763459,0.959448719,3350,HTR1A,Fc1ccc(cc1)[C@@H]4CCNC[C@H]4COc2ccc3OCOc3c2,Microsource,1504085,-11.20151523,-8.22530398,0,-59.36449893,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160408-06,Benziodarone,405558418,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-131.010286,-2.4,4,,-40.23737961,-54.26811282,0.464034695,0.838223244,,,CCC1=C(C(=O)C2=CC(=C(O)C(=C2)I)I)C3=CC=CC=C3O1,Bionet,KS-1133_CM2,-30.37817646,-16.45473999,-13.0235575,-54.26811282,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167437-02,Ramosetron hydrochloride,170465928,Serotonin 3a (5-HT3a) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132907-72-3,,22.38721139,0,-4.65,-35.19921753,-2.4,4,,-80.03473663,-64.7990429,0.647086461,0.999980542,,,Cl.O=C(c2cn(C)c1ccccc12)[C@H]3Cc4ncnc4CC3,Bosche,R2999,-28.5747402,0,-17.93850809,-64.7990429,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00522534-01,Quinagolide (hydrochloride),405558466,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),94424-50-7,,39.81071706,0,-4.4,-13.96090099,-3,4,,-47.88432994,-39.90360828,0.006832298,0.999971228,,,CCCN1C[C@H](C[C@@H]2CC3=C(O)C=CC=C3C[C@@H]12)N[S+]([O-])(=O)N(CC)CC,MedChem Express,HY-13736A,0,0,0,-39.90360828,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00177980-03,Oxiconazole nitrate,170465226,Steroid biosynthesis Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),64211-46-7,,39.81071706,0,-4.4,-32.41869707,-3,4,,-93.94119542,-82.45099618,0.263716123,0.954495,,,[O-][N+](=O)O.Clc3ccc(C(=N\OCc1ccc(Cl)cc1Cl)\Cn2ccnc2)c(Cl)c3,Microsource,1505330,2.61900985,-16.39930566,0,-82.45099618,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389674-01,Apremilast (CC-10004),405558478,Phosphodiesterase 4 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),608141-41-9,,10,0,-5,-143.8680217,-2.4,4,,-26.6853328,-47.6941555,0.523319761,0.94684441,,,CCOC1=C(OC)C=CC(=C1)C(C[S+](C)([O-])=O)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(C)=O,APExBIO,A4317,-30.06434319,-17.23833706,-35.29588215,-47.6941555,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167503-02,Aclarubicin,174007366,DNA Topoisomerase II Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57576-44-0,; Aclacin;Aclarubicin; Aclaplastin; Aclacinon; Aclarubicino;Aclacinomycin A,10,0,-5,-22.01123195,-2.4,4,,-49.59986038,-32.99988365,0.366331615,0.906988461,7153,TOP2A,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C5=C(O)C6=C(C=C5[C@H]1C(=O)OC)C(=O)C7=CC=CC(=C7C6=O)O,Carbosynth,OA08264,3.10807897,-13.07587691,-15.30241711,-32.99988365,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00345885-04,Etravirine,405558520,P-glycoprotein 1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),269055-15-4,,35.48133892,0,-4.45,-38.14577581,-3,4,,-108.1027606,-91.88050812,0.017317166,0.999815001,,,CC1=C(OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C(=CC(=C1)C#N)C,MedChem Express,HY-90005,-1.43842704,0,-2.39183354,-91.88050812,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274062-01,Zosuquidar trihydrochloride,174006281,P-Glycoprotein (MDR-1) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),167465-36-3,LY335979,39.81071706,0,-4.4,-60.42201596,-3,4,,-66.43493441,-59.52911201,0.292313519,0.94330723,,ABCBA,Cl.Cl.Cl.FC3(F)[C@@H]2c7ccccc7[C@H](c1ccccc1[C@@H]23)N4CCN(CC4)C[C@@H](O)COc6cccc5ncccc56,Selleck,S1481,-13.50661776,1.5152832,0,-59.52911201,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159506-06,Cyclandelate,405558545,Voltage-gated calcium channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),456-59-7,,2.238721139,1,-5.65,-35.48969575,-2.4,4,,-42.54780509,-38.4701899,0.261963219,0.955172829,,,CC1CC(CC(C)(C)C1)OC(=O)C(O)C2=CC=CC=C2,APExBIO,B1718,3.27751947,-18.56772736,-27.09874652,-38.4701899,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00538144-01,NCGC00538144-01,405558557,Taenia pisiformis Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,10,0,-5,-109.9326323,-2.4,4,,-53.05679848,-57.94456007,0.515655715,0.789052095,,,CC1CCCC(C)N1C(=S)NC2=CC(=CC=C2)C(F)(F)F,Pharmaron,PH-NIH-2017-009-L1-6-0,-22.67074568,4.33388376,-35.00984383,-57.94456007,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095161-05,Rebamipide,170465891,Free Radical Scavenger,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),90098-04-7, ; Rebamipida;REBAMIPIDE; REBAMIPIDE; Rebamipide; Mucosta,6.309573445,1,-5.2,-13.57633946,-3,4,,-41.06883065,2.7238304,1,0.999927243,,CAT,Clc1ccc(cc1)C(=O)NC(CC3=CC(=O)Nc2ccccc23)C(=O)O,Microsource,1505310,0,0,-38.95262097,2.7238304,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160451-02,Ibufenac,170465922,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1553-60-2,,22.38721139,0,-4.65,-14.51819821,-2.4,4,,-32.29385936,-27.7448828,0.022060567,0.999700257,,,CC(C)Cc1ccc(cc1)CC(=O)O,Enamine,Z104507406,0,0,-6.88891065,-27.7448828,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182981-01,Proxazole citrate,144206776,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132-35-4,Proxazole; Proxazol; ,19.95262315,0,-4.7,-15.57670237,-3,4,"CIPLUS_151746;proxazole, (+)-isomer;Proxazole;LS-99108;PROXAZOLE;pirecin;Proxazole citrate;LS-175790;3 alpha-phenylpropyl-5 beta- diethylaminoethyl-1,2,4-oxadiazole;proxazole, (+-)-isomer;3-(alpha-ethylbenzyl)-5-(2-diethylaminoethyl)- 1,2,4-oxadiazole;toness;CIPLUS_210763;Proxazol;Proxazole Citrate;N,N-Diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazole-5-ethanamine citrate;Proxazolum;CIPLUS_177396;CIPLUS_177395;CIPLUS_177394;proxazolum;propazoline;proxazole, (-)-isomer;Toness;PROXAZOLE CITRATE;1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate;proxazole;",-37.80568995,-33.94370451,0.069613055,0.997002434,,,CCC(c1nc(CCN(CC)CC)on1)c2ccccc2.O=C(O)C(O)(CC(=O)O)CC(=O)O,NCI,NSC_303872,0,1.9304769,-7.22994238,-33.94370451,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095086-04,PERICIAZINE,405558569,Dopamine D2 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2622-26-6,,39.81071706,0,-4.4,-55.19058368,-3,4,,-75.15007939,-65.95839949,0.201954807,0.973974429,,,OC1CCN(CCCN2C3=CC=CC=C3SC4=CC=C(C=C24)C#N)CC1,Microsource,MS-01503936,-10.66954535,0,0,-65.95839949,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179247-04,Nomegestrol acetate,405558605,Androgen Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58652-20-3,,28.18382931,0,-4.55,-23.07183235,-3,4,,-53.18545651,-43.70110342,0.05733185,0.997968593,,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3\C=C(C)/C4=C/C(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,SIGMA,SML0133,0,-2.57802499,-8.56469048,-43.70110342,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344562-01,Celiprolol hydrochloride,170465958,Beta-2 adrenergic receptor Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57470-78-7,,7.079457844,1,-5.15,-51.11643472,-2.2,4,,-60.3144154,-55.01144079,0.021655062,0.999710771,,,Cl.CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(C)=O,Prestwick,Prestw-1132,0,-8.58203223,-37.04941295,-55.01144079,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00387813-02,NCGC00387813-02,405558642,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),439081-18-2,,10,0,-5,-219.7664689,-2.2,4,,-62.97863113,-97.3769043,0.02008706,0.999751122,,EGFR,CN(C)C\C=C\C(=O)NC1=C(OC2CCOC2)C=C3N=CN=C(NC4=CC(=C(F)C=C4)Cl)C3=C1,APExBIO,A8247,-36.35328688,-38.15925154,-71.05486005,-97.3769043,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015747-09,Nicardipine,170465173,Ca channel blocker - DHP class,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55985-32-5, ;Nicardipine hydrochloride; YC-93 hydrochloride; Dagan;Nicardipine?HCl;Nicardipine; Nicardipine; Cardene/SR; Nicardipino,39.81071706,0,-4.4,-15.04576846,-3,4,,-62.17129819,-51.80941516,0.101497049,0.993594078,,,CC=2NC(C)=C(C(C=2C(=O)OCCN(C)Cc1ccccc1)c3cccc(c3)[N+]([O-])=O)C(=O)OC,Enzo,AC108,0,0,4.41088739,-51.80941516,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179248-03,Articaine hydrochloride,170464825,Sodium channel alpha subunit Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),23964-57-0,,3.981071706,1,-5.4,-14.58727048,-3,4,,-36.70715447,-15.02452188,1,0.999989161,,,Cl.O=C(Nc1c(scc1C)C(=O)OC)C(C)NCCC,"Prestwick Chemical, Inc.",Prestw-1032,0,-2.7694476,-36.30292081,-15.02452188,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00483049-02,Gamithromycin,405558723,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),145435-72-9,,11.22018454,0,-4.95,-124.7022991,-2.3,4,,-81.72791211,-85.04753186,0.354421847,0.913524525,,,CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)C(C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@H]1C,Ark Pharm,AK105038,-21.54222285,3.61615018,-46.72611758,-85.04753186,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182054-03,Aranidipine,170465977,Voltage-gated calcium channel Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),86780-90-7,,39.81071706,0,-4.4,-154.1368983,-3,4,,-45.77544512,-66.16300565,0.044752369,0.998763768,,,CC=1NC(C)=C(C(C=1C(=O)OCC(C)=O)c2ccccc2[N+]([O-])=O)C(=O)OC,APAC,826079,-30.02426683,-29.30657766,-28.85013472,-66.16300565,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016267-06,Isocarboxazid,405558734,Monoamine oxidase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),59-63-2,,63.09573445,0,-4.2,-14.74383764,-3,4,,-44.68654242,-42.30235409,0.681268238,0.999915952,,,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,Prestwick,Prestw-795,-24.59048196,0,0,-42.30235409,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00532494-01,PHENINDAMINE,405558785,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,5.623413252,1,-5.25,-13.98628884,-3,4,,-41.83913558,0,1,0.999999358,,,CN1CC\C2=C(/C1)C(C3=CC=CC=C3)C4=CC=CC=C24,SIGMA,A001025678,-26.29431667,0,-40.12882924,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095123-10,Candesartan cilexetil (Atacand),405558788,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),145040-37-5,,39.81071706,0,-4.4,-74.64684471,-3,4,,-74.72043112,-68.10035927,0.349313447,0.916286084,,,CCOC1=NC2=CC=CC(=C2[N]1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=N[NH]5)C(=O)OC(C)OC(=O)OC6CCCCC6,Adooq,A10176,-17.95420981,1.57175104,3.03724585,-68.10035927,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00092321-03,Tetrabenazine Mesylate,405558756,Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),804-53-5,,17.7827941,0,-4.75,-112.9009954,-2.4,4,,-67.24756677,-56.07795483,0.864851288,0.992082409,,SLC18A2,COC1=C(OC)C=C2[C@@H]3CC(=O)[C@@H](CC(C)C)CN3CCC2=C1,Glixx,GLXC-06104,-41.75446058,-18.97944467,-32.78698423,-56.07795483,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163128-08,Pioglitazone hydrochloride,170465116,PPARgamma Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),112529-15-4,Pioglitazona; Pioglitazone HCl;AA-10090;Pioglitazone HCl;PIOGLITAZONE HYDROCHLORIDE; ;Zactos;Actos;U-72107A;Glustin,0.794328235,1,-6.1,-105.8631269,-1.4,4,,-44.62386192,-64.51438169,0.581248745,0.708747979,5468,PPARG,Cl.CCc1ccc(nc1)CCOc3ccc(CC2SC(=O)NC2=O)cc3,Microsource,1504401,-8.69923467,-48.7037294,-33.05964623,-64.51438169,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015889-11,Raloxifene hydrochloride,170465341,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),82640-04-8, ; Keoxifene;Evista; Raloxifene Lilly Bran; Evista;RALOXIFENE HYDROCHLORIDE; Lilly Brand of Raloxifene; Raloxifene hydrochloride;Raloxifene hydrochloride,19.95262315,0,-4.7,-45.29578828,-2.1,4,,-107.3097998,-96.97034972,0.047332573,0.998615684,2099,ESR1,Cl.Oc1ccc(cc1)c3sc2cc(O)ccc2c3C(=O)c5ccc(OCCN4CCCCC4)cc5,Microsource,1505622,0,3.64576276,-19.92516366,-96.97034972,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015608-11,Loperamide hydrochloride,170464852,mu-Opioid Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),53179-11-6," ;LOPERAMIDE; Hydrochloride, Loperamid;Loperamide; Loperamide Hcl;Loperamide hydrochloride; Loperamide hydrochloride; Loperamida",14.12537545,0,-4.85,-72.19362796,-2.3,4,,-99.35207601,-83.21006334,0.154584742,0.984967428,4988,OPRM1,CN(C)C(=O)C(CCN1CCC(O)(CC1)c2ccc(Cl)cc2)(c3ccccc3)c4ccccc4,Enzo,ALX-550-253,0,-19.59585241,-42.0871735,-83.21006334,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015708-15,Maprotiline hydrochloride,170464778,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),10262-69-8, ; Ciba 34276 Ba;MAPROTILINE HYDROCHLORIDE; Maprotilene Hydrochloride; Maprotiline hydrochloride;Maprotiline hydrochloride; Maprotilline HCl; Ludiomil; Maprotilina;Maprotiline,0.794328235,1,-6.1,-100.6073473,-1.4,4,,-65.63855812,-80.70950902,0.535082615,0.767570123,,SLC6A2,CNCCCC24CCC(c1ccccc12)c3ccccc34,Vitas,STK711156,0,-64.01954622,-39.59416099,-80.70950902,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091034-10,Captan,225144202,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),133-06-2,,11.22018454,0,-4.95,-115.551192,-2.3,4,,-95.17281758,-96.65966626,0.198463759,0.974892477,,,ClC(Cl)(Cl)SN1C(=O)C2C\C=C/CC2C1=O,SIGMA,32054,-14.35715994,0,-55.15465499,-96.65966626,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185743-02,Cloflucarban,170465550,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),369-77-7,,6.309573445,1,-5.2,-93.25920032,-2.3,4,,-105.2229602,-93.66755083,0.085085595,0.995508245,,,FC(F)(F)c1cc(ccc1Cl)NC(=O)Nc2ccc(Cl)cc2,Enamine,Z124030490,0,-13.72530413,-72.88240825,-93.66755083,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167471-02,Anethole trithione,170465669,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),532-11-6,,10,0,-5,-81.054177,-2.4,4,,-31.04862157,-34.69177331,0.586080681,0.702117461,,,COc1ccc(cc1)C2=CC(=S)SS2,Prestwick,Prestw-1223,-17.28732859,0.46536558,-24.64068263,-34.69177331,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249933-01,Nitrogen mustard N-oxide,170465894,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),126-85-2,,39.81071706,0,-4.4,-17.84505261,-3,4,,-40.48724276,-36.23936897,0.25326957,0.958265341,,,[O-][N+](C)(CCCl)CCCl,GVK,FFS-11-286-NCI-237,0,-7.39611307,0,-36.23936897,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183854-01,Oxendolone,144206842,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),33765-68-3,,39.81071706,0,-4.4,-14.01997495,-3,4,"16 ethyl-17-hydroxy-4-estren-3-one;oxendolone;16-beta-Ethyl-19-nortestosterone;NE-19595;Oxendolonum;oxendolonum;(16 beta,17 beta)-16-ethyl-17-hydroxyestr-4-en-3-one;16 beta-ethyl-19-nortestosterone;CIPLUS_178076;Oxendolona;16 beta-ethyl-17 beta-hydroxyestr-4-en-3-one;TSAA291;LS-64849;Oxendolone;OXENDOLONE;EHOO;Prostetin;TSAA-291;TSAA 291;PROSTETIN;16B-ETHYL-17B-HYDROXYESTR-4-EN-3-ONE;",-50.14193053,-42.61827544,0.038873239,0.99906737,,,CC[C@H]2C[C@H]3[C@@H]4CCC1=CC(=O)CC[C@@H]1[C@H]4CC[C@]3(C)[C@H]2O,Pharmaron,PH-NIH-152939,0,0,1.27533558,-42.61827544,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015856-10,Prochlorperazine dimaleate,170464761,Dopamine D2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1984/2/6,"; ;Prochloperazine dimaleate; Proclorperazina; Prochlorperazine dimaleate; Compazine syrup;Prochlorperazine; Compro; Compazine;Prochlorperazine dimaleate; Maleate, Prochlorperazin",22.38721139,0,-4.65,-40.40000741,-2.1,4,,-95.88246625,-86.39716146,0.021777693,0.99970739,1813,DRD2,O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.CN1CCN(CC1)CCCN2c4ccccc4Sc3ccc(Cl)cc23,"Prestwick Chemical, Inc.",Prestw-399,0,1.14164755,-15.7073878,-86.39716146,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179680-05,Clonidine,170464900,alpha1-Adrenoceptor Agonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),4205-90-7,,3.548133892,1,-5.45,-13.15005197,-3,4,,-31.23324377,-0.66615199,1,0.999944462,,ADRA1A,Clc2cccc(Cl)c2\N=C1/NCCN1,Enzo,AC152,0,-3.34408049,-31.02770314,-0.66615199,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181914-01,Alloclamide,144206889,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5486-77-1,Alloclamide; Aloclamida; Hexacol; ,39.81071706,0,-4.4,-40.37385591,-2.4,4,"ALLOCLAMIDE HYDROCHLORIDE;Hexacol;Alloclamide;Alloclamidum;alloclamidum;alloclamide hydrochloride;alloclamide;ALLOCLAMIDE;2-allyloxy-4-chloro-N-(2-diethylaminoethyl)benzamide;264 CE;Aloclamida;LS-25294;CIPLUS_774246;CIPLUS_214111;Alloclamide hydrochloride;Benzamide, 2-(allyloxy)-4-chloro-N-(2-(diethylamino)ethyl)-;",-44.22121967,-41.1101997,0.765453685,0.637312201,,,O=C(NCCN(CC)CC)c1ccc(Cl)cc1OCC=C,Pharmaron,PH-NIH-93,0,-37.20976549,0,-41.1101997,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00189076-01,Dibromopropamidine dihydrochloride,144207153,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),50357-61-4,,31.6227766,0,-4.5,-11.97634674,-3,4,Dibromopropamidine dihydrochloride,-45.40673261,-42.00561051,0.022952342,0.999675138,,,Cl.Cl.Brc2cc(ccc2OCCCOc1ccc(cc1Br)C(=N)N)C(=N)N,Toronto Research,D425800,0.90368265,0,0,-42.00561051,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185778-04,Nitisinone,405558957,4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),104206-65-7,,39.81071706,0,-4.4,-131.7900216,-2.4,4,,-59.67118835,-69.96649442,0.192706689,0.976382674,,HPD,[O-][N+](=O)C1=CC(=CC=C1C(=O)C2C(=O)CCCC2=O)C(F)(F)F,MedChem Express,HY-B0607,-26.4515771,-17.32383746,-22.3290064,-69.96649442,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016528-05,Proguanil hydrochloride,170464800,DHFR inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),637-32-1,Proguanil hydrochloride; Chlorguanide; ; Proguanil hydrochloride;Proguanil hydrochloride; Chlorguanide; ;Proguanil hydrochloride;CHLOROGUANIDE HYDROCHLORIDE,39.81071706,0,-4.4,-40.33609806,-3,4,,-71.46151633,-61.63459694,0.12711738,0.989901791,,,Cl.Clc1ccc(NC(=N)NC(=N)NC(C)C)cc1,"Prestwick Chemical, Inc.",Prestw-999,-6.23689217,0,0,-61.63459694,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00388506-02,Pinaverium bromide,405559006,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),53251-94-8,,0.891250938,1,-6.05,-106.3664968,-1.4,4,,-32.14107485,-45.54914015,0.273233608,0.950992492,,,COC1=C(OC)C=C(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)C(=C1)Br,Prestwick,Prestw-1601,-11.93254009,-40.64759507,-37.40381998,-45.54914015,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00532500-01,GABAPENTIN ENACARBIL,405559030,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,35.48133892,0,-4.45,-13.25492482,-3,4,,-41.82125107,-38.18437589,0.682589854,0.999907575,,,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(O)=O,AdvChemBlocks,G-5813,-22.33991925,0,0.14959307,-38.18437589,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181040-02,dl-Coniine,170465693,Nicotinic acetylcholine receptor alpha1/beta1/gamma/delta Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3238-60-6,,6.309573445,1,-5.2,-16.42246888,-3,4,,-30.98917726,0,1,0.996002191,,,CCCC1CCCCN1,Specs,AE-562/J259451,-1.93507948,0,-30.40764772,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179867-02,NCGC00179867-02,405559098,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,35.48133892,0,-4.45,-29.67599639,-3,4,,-96.42722378,-74.56607862,0.006263603,0.999975805,,,O[C@@H]1[C@@H](COC(=O)C2=CC(=C(O)C(=C2)O)O)O[C@@H](OC(=O)C3=CC(=C(O)C(=C3)O)O)[C@H](O)[C@H]1OC(=O)C4=CC(=C(O)C(=C4)O)O,Analyticon,NP-005114,0,0,-5.13729499,-74.56607862,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015452-20,Flutamide,170464921,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13311-84-7,Flutamide; ; Eulexin; 2-Methyl-N-(4-nitro-3-;FLUTAMIDE; Flutamide; Flutamida,14.12537545,0,-4.85,-80.73313565,-2.3,4,,-89.60658662,-90.3418014,0.184946673,0.97829251,374,AR,O=C(Nc1cc(c(cc1)[N+]([O-])=O)C(F)(F)F)C(C)C,Microsource,1500995,-9.81447462,4.37373993,-32.41740672,-90.3418014,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182060-03,l-Oxyfedrine hydrochloride,170465929,Adrenergic receptor beta Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),16777-42-7,,7.079457844,1,-5.15,-63.36827708,-2.2,4,,-44.02700465,-47.05105538,0.019231642,0.999771977,,,Cl.COc1cc(ccc1)C(=O)CCN[C@@H](C)[C@H](O)c2ccccc2,APAC,555781,-5.21443761,-10.18460626,-34.50461019,-47.05105538,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016507-05,Thonzonium bromide,170465335,osteoclast development Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),553-08-2,,39.81071706,0,-4.4,-160.4450985,-2.3,4,,-93.1803134,-94.62546255,0.565091499,0.730670901,,,[Br-].COc1ccc(cc1)CN(CC[N+](C)(C)CCCCCCCCCCCCCCCC)c2ncccn2,"Prestwick Chemical, Inc.",Prestw-925,-29.06431489,-46.26241025,-10.80310417,-94.62546255,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178214-04,BENZALKONIUM CHLORIDE,405559118,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),8001-54-5,,11.22018454,0,-4.95,-95.17643788,-2.3,4,,-95.9730612,-98.09966588,0.104544905,0.993197953,,,CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,Microsource,1503610,-7.85447566,0,-53.2842546,-98.09966588,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00388392-01,NCGC00388392-01,405559126,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),477-90-7,,8.912509381,1,-5.05,-77.09454074,-3,4,,-41.18091403,-6.40801595,1,0.826901935,,PTP4A1,COC1=C(O)C=C2C(=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]3C2=C1O,Prestwick,Prestw-NAT-0201,-19.62671031,-4.95869438,-41.76617219,-6.40801595,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00024778-02,Bifemelane,170465900,Monoamine oxidase B Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),90293-01-9,,39.81071706,0,-4.4,-79.66464071,-2.4,4,,-82.31785385,-72.77588411,0.451344376,0.848681142,,,CNCCCCOc2ccccc2Cc1ccccc1,Tocris,767,-7.28859431,-31.75380028,-14.44049616,-72.77588411,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091585-05,Octocrylene,170464719,photosensitizer,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6197-30-4,"2-Ethylhexyl-2-cyano-3,3-diphenylacrylate; ; 2-Ethylhexyl-2-cyano-3,3-diphenylacrylate; ""2-Ethylhexyl-2-cyano-3; Octocrileno;OCTOCRYLENE",39.81071706,0,-4.4,-22.34463153,-3,4,,-76.63958862,-63.86632385,0.006832298,0.999971214,,CAT,CCC(CCCC)COC(=O)C(\C#N)=C(\c1ccccc1)c2ccccc2,Labotest,LT00159303,0,0,0,-63.86632385,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017134-08,Meclocycline sulfosalicylate,405559138,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),73816-42-9,,15.84893192,0,-4.8,-60.40464306,-2.4,4,,-84.83573268,-67.32994657,0.320748339,0.930659337,,,CN(C)[C@H]\1[C@@H]2[C@@H](O)[C@@H]\3C(=C)C4=C(Cl)C=CC(=C4C(=O)C3=C(\O)[C@@]2(O)C(=O)\C(=C1O)C(N)=O)O.OC(=O)C5=C(O)C=CC(=C5)[S+](O)([O-])=O,SIGMA,M1388,0,-23.00675575,-29.75101852,-67.32994657,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160484-02,Etafenone,170466000,vascular smooth muscle contraction Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),90-54-0,,39.81071706,0,-4.4,-29.42731463,-3,4,,-75.08245246,-65.48537705,0.178191218,0.979894171,,,CCN(CCOc2ccccc2C(=O)CCc1ccccc1)CC,Vitas,STK321191,0,-9.32896917,0,-65.48537705,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018261-06,Perhexiline,170466435,mitochondrial carnitine palmitoyltransferase-1 inhbitior,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6724-53-4,Perhexiline;rac Perhexiline Maleate; Perhexiline,25.11886432,0,-4.6,-43.29642123,-2.1,4,,-108.8518306,-93.56807479,0.008356381,0.999956931,,CPT1A,O=C(O)\C=C/C(=O)O.C(C(C1CCCCC1)C2CCCCC2)C3CCCCN3,Microsource,1503227,0,0,-15.1205086,-93.56807479,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00021141-05,Phenyltoloxamine citrate,170465477,Histamine H1 receptor Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1176-08-5,,12.58925412,0,-4.9,-47.77280111,-2.4,4,,-55.59464346,-48.24193776,0.801067529,0.999922192,,,O=C(O)C(O)(CC(=O)O)CC(=O)O.CN(C)CCOc2ccccc2Cc1ccccc1,SIGMA,P8404,-29.52148461,-3.66763799,-24.76179579,-48.24193776,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018269-05,Trimebutine maleate,170465734,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),34140-59-5,,7.943282347,1,-5.1,-145.8928508,-2.4,4,,-69.26948713,-58.61833058,0.491608589,0.813444812,,,COc1c(cc(cc1OC)C(=O)OCC(CC)(c2ccccc2)N(C)C)OC.O=C(O)/C=C\C(=O)O,Microsource,1505011,-23.4222577,-41.12575808,-37.45719319,-58.61833058,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178069-05,Cloperastine hydrochloride,170465832,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),14984-68-0,,3.16227766,1,-5.5,-69.05738427,-1.4,4,,-63.77783579,-57.62757526,0.142489974,0.987266486,,,Cl.Clc1ccc(cc1)C(OCCN2CCCCC2)c3ccccc3,"Prestwick Chemical, Inc.",Prestw-793,1.25582997,-8.48269163,-66.9390547,-57.62757526,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164155-02,Benzylparaben,170465711,Estrogen receptor alpha Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),94-18-8,,2.511886432,1,-5.6,-23.52642941,-2.4,4,,-41.81626874,-2.47120158,1,0.999939359,,,Oc1ccc(cc1)C(=O)OCc2ccccc2,SIGMA,380709,0,-16.32969562,-34.77481646,-2.47120158,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016892-04,Iopamidol,170464646,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),60166-93-0,,39.81071706,0,-4.4,-34.14044453,-3,4,,-33.50280718,-32.91900598,0.308355627,0.936437171,,,O=C(Nc1c(I)c(c(I)c(c1I)C(=O)NC(CO)CO)C(=O)NC(CO)CO)[C@H](C)O,Prestwick,Prestw-871,-5.71921026,-8.20070795,0.45682246,-32.91900598,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015254-20,Clozapine,170464853,Dopamine D4 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5786-21-0,;Clozapine; ; clozapine N-glucuronide;CLOZAPINE; Leponex; Clozaril; Clozapine; Clozapina; Clo-Glu,17.7827941,0,-4.75,-71.17127792,-2.4,4,,-79.47404183,-73.54135289,0.119051249,0.991157189,1815,DRD4,CN1CCN(CC1)C2=Nc4cc(Cl)ccc4Nc3ccccc23,Enzo,D107,-5.30258372,-12.36168135,-29.8496478,-73.54135289,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274082-01,Sodium dodecyl sulfate,170465474,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),151-21-3,,6.309573445,1,-5.2,-17.96055006,-3,4,,-55.65412835,-0.12128292,1,0.999995969,,,[Na+].[O-]S(=O)(=O)OCCCCCCCCCCCC,SIGMA,61749,-26.4858581,0,-51.53160032,-0.12128292,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179351-03,Quinethazone,170465167,Thiazide-sensitive sodium-chloride cotransporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),73-49-4,,11.22018454,0,-4.95,-27.58788185,-2.2,4,,-38.60722844,-37.81335828,0.04162939,0.998930537,,,NS(=O)(=O)c1cc2C(=O)NC(Nc2cc1Cl)CC,Prestwick,Prestw-1050,0,0,-20.55882168,-37.81335828,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00165752-04,Eslicarbazepine (acetate),405558796,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),236395-14-5,,39.81071706,0,-4.4,-11.23764107,-3,4,,-37.54385282,-32.11987735,0.003923603,0.999990516,,,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C3=C1C=CC=C3,MedChem Express,HY-B0703,0,0,0,-32.11987735,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015496-08,"N,N,N,N',N',N'-Hexamethylhexane-1,6-diaminium",170465837,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),60-26-4,,4.466835922,1,-5.35,2.723869778,-3,4,,-39.70659288,0,1,0.999984704,,,C[N+](C)(C)CCCCCC[N+](C)(C)C,Enzo,AC740,4.42192942,2.03526701,-34.45054896,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249905-01,Phthalofyne,170466477,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),131-67-9,,0.707945784,1,-6.15,-54.05643397,-1.4,4,,-35.01275783,-35.48940946,0.627437341,0.635862915,,,O=C(O)c1ccccc1C(=O)OC(C)(C#C)CC,GVK,FFS-11-286-NCI-120,0,-44.06280694,-15.55309843,-35.48940946,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090851-10,5-Azacitidine,170465076,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),320-67-2," ;AZACITIDINE; Azacytidine, 5-; Ladakamycin;Azacitidina; Azacytidine-5; 5-Azacitidine;5-Azacitidine; 5 Azacytidin; Azacytidine; Vidaza; ara-5-aza-Cyd;5-azacytidine;5-Azacytidine",28.18382931,0,-4.55,-26.87335835,-3,4,,-101.3060255,-89.01443741,0.029392002,0.999466819,1786,DNMT1,NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,Microsource,1502111,1.31916608,3.7775583,-3.3496483,-89.01443741,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00024309-17,(+)-Diltiazem,170464699,"Ca2+ channel blocker, similar pharmacology to verapamil",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),42399-41-7,,39.81071706,0,-4.4,-94.18799367,-3,4,,-33.47247057,-40.10037372,0.733489066,0.821052887,,,CN(C)CCN1c3ccccc3S[C@H]([C@@H](OC(C)=O)C1=O)c2ccc(OC)cc2,Enzo,CA205,-24.81343331,-24.53290671,-6.78998158,-40.10037372,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181129-14,Dasatinib,405558859,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),302962-49-8,,0.316227766,1,-6.5,-291.86063,5,4,,-68.08914913,-72.69453745,0.169351476,0.981938941,,ABL1,CC1=NC(=CC(=N1)NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)N4CCN(CCO)CC4,Adooq,A10290,-53.87569354,-73.30968762,-75.97614107,-72.69453745,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167443-02,Afloqualone,405558862,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),56287-74-2,,5.623413252,1,-5.25,-20.49466018,-3,4,,-37.00307926,-10.8554089,1,0.999996359,,,CC1=CC=CC=C1N2C(=O)C3=C(C=CC(N)=C3)N=C2CF,DC Chemicals,DC9026,-38.49747043,-2.04895603,-37.0016912,-10.8554089,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378796-01,Tacalcitol,405558914,Vitamin D receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57333-96-7,,39.81071706,0,-4.4,-56.83097707,-3,4,,-54.86595417,-49.88829514,0.327856307,0.92725837,,,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C/3C[C@@H](O)C[C@H](O)C3=C,MedChem Express,HY-32337,-13.19740113,0.49500974,0,-49.88829514,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164462-01,Pyriproxyfen,26757881,juvenile hormone metabolic process Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),95737-68-1,,1.412537545,1,-5.85,-51.63176012,-1.4,4,"pyriproxyfen;pyriproxyfen, (S)-isomer;2-(1-methyl-2-(4-phenoxyphenoxy)ethoxy)pyridine;CIPLUS_668570;Pyriproxifen;pyriproxyfen, (R)-isomer;NCGC00164462-01;S 31183;juvinal;2-[1-Methyl-2-(4-phenoxyphenoxy)ethoxy]pyridine;NCGC00163945-01;CIPLUS_760107;Pyriproxyfen;S-31183;",-37.34691596,0,1,0.999830517,,,CC(COC1=CC=C(OC2=CC=CC=C2)C=C1)OC3=NC=CC=C3,EPA,EPA-CAS-95737-68-1,-5.31876178,-31.02682693,-40.02725009,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262575-02,Cyproterone acetate,170465682,Androgen Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),427-51-0,,39.81071706,0,-4.4,-19.88651588,-3,4,,-68.2085267,-56.84043892,0.006832298,0.999971216,,AR,CC(=O)[C@@]4(OC(C)=O)CC[C@H]3[C@@H]5C=C(Cl)C2=CC(=O)[C@@H]1C[C@@H]1[C@]2(C)[C@H]5CC[C@@]34C,Prestwick,Prestw-1074,0,0,0,-56.84043892,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167488-08,Sorafenib,170465175,VEGFR-1/2/3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),475207-59-1,;Sorafenib;BAY-54-9085; Sorafenib Tosilate;BAY-43-0006; Sorafenib base;sorafenib; Sorafenib; Nexavar;Nexavar,28.18382931,0,-4.55,-212.1244912,-2.3,4,,-63.88720693,-98.06783182,0.143648989,0.987056031,2321,FLT1,O=C(NC)c3cc(Oc2ccc(NC(=O)Nc1cc(c(Cl)cc1)C(F)(F)F)cc2)ccn3.O=S(=O)(O)c1ccc(C)cc1,Sequoia,284461-73-0,-42.00010993,-33.65650992,-39.93401731,-98.06783182,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188442-01,Estradiol enanthate,144206583,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),4956-37-0,,39.81071706,0,-4.4,-26.83109181,-3,4,ESTRADIOL?ENANTHATE,-92.02764593,-76.68970494,0.006832298,0.999971211,,,CCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CCc1cc(O)ccc1[C@H]4CC[C@]23C,APAC,877917,0,0,0,-76.68970494,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346456-05,Macitentan,405558977,Endothelin ETA/ETB Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),441798-33-0,,3.981071706,1,-5.4,-47.22881903,-1.4,4,,-51.23649925,-36.65505939,0.790672741,0.87142491,,EDNRA,CCCN[S+]([O-])(=O)NC1=NC=NC(=C1C2=CC=C(Br)C=C2)OCCOC3=NC=C(Br)C=N3,Glixx,GLXC-90056,-32.24781729,1.65330527,-58.04055472,-36.65505939,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179642-03,Isoconazole nitrate,170466012,Antifungal Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),27523-40-6,;Isoconazole; Isoconazol; Travocort; Adestan-G;Isoconazole nitrate (Travogen),39.81071706,0,-4.4,-39.39151333,-3,4,,-86.24283262,-76.03569385,0.303619604,0.938456369,,,Clc3ccc(C(OCc1c(Cl)cccc1Cl)Cn2ccnc2)c(Cl)c3,"Prestwick Chemical, Inc.",Prestw-127,0,-18.30972285,0,-76.03569385,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274061-01,Trilostane,174007161,Estrogen Receptor (ER) beta Modulators,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13647-35-3,Trilostane,10,0,-5,-47.74477224,-2.4,4,,-71.685646,-65.07512807,0.70912686,0.99989005,2099,ESR1,N#CC=2C[C@]4(C)[C@H]5CC[C@]1(C)[C@@H](O)CC[C@H]1[C@@H]5CC[C@@]34O[C@@H]3C=2O,Selleck,S1404,-30.34545914,0.02590201,-35.90100898,-65.07512807,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160397-04,Irsogladine maleate,170465947,M1 Muscarinic acetylcholine receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),84504-69-8,; ;Irsogladine maleate; Irsogladine maleate;irsogladine; Gaslon N,39.81071706,0,-4.4,-107.0043605,-2.4,4,,-48.47468109,-55.46362961,0.577059596,0.714684145,1128,CHRM1,Nc1nc(nc(N)n1)c2cc(Cl)ccc2Cl.O=C(O)/C=C\C(=O)O,Enzo,PD141,-19.55734313,-31.90409725,-9.2347287,-55.46362961,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015801-12,Pentoxifylline,170465384,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6493/5/6,,31.6227766,0,-4.5,-43.29732333,-2.4,4,,-38.67594632,-35.81039397,0.768299938,0.999973039,,,CC(=O)CCCCN2C(=O)c1n(C)cnc1N(C)C2=O,Vitas,STK177321,-26.78300474,-6.32814477,-10.45445416,-35.81039397,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178529-06,Levofloxacin,405559032,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),100986-85-4,,39.81071706,0,-4.4,-12.06594267,-3,4,,-41.3848347,-34.48736225,0.744455727,0.999967645,,TOP2B,C[C@H]1COC2=C3N1\C=C(C(O)=O)/C(=O)C3=CC(=C2N4CCN(C)CC4)F,MedChem Express,HY-B0330,-24.55816548,0,0,-34.48736225,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163699-07,Fumagillin,405559052,Methionine Aminopeptidase 2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),23110-15-8,,39.81071706,0,-4.4,-118.3617876,-2.4,4,,-41.09874686,-44.65855685,0.898611785,0.776717083,,,[H][C@@]1([C@H](OC)[C@@H](CC[C@]12CO2)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)[C@@]3(C)O[C@@H]3CC=C(C)C,MedChem Express,HY-B0751,-61.26300456,-31.4090419,-5.40960113,-44.65855685,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178499-08,Cefdinir,405559056,Cephalosporin antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),91832-40-5,,39.81071706,0,-4.4,-21.57231212,-3,4,,-73.99061938,-61.65884948,0.471052509,0.999967617,,,NC1=NC(=CS1)\C(=N\O)C(=O)N[C@H]2[C@H]3SC\C(=C(/N3C2=O)C(O)=O)C=C,Adooq,A10187,-20.63343243,0,0,-61.65884948,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00165957-07,Amlodipine,225144262,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),88150-42-9,,6.309573445,1,-5.2,-10.71922222,-3,4,,-32.40613084,0,1,0.999928531,,,CCOC(=O)C/1=C(COCCN)/N\C(=C(C1C2=C(Cl)C=CC=C2)\C(=O)OC)C,Prestwick,Prestw-1219,0,0,-30.75510903,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185751-06,Cefuroxime Axetil,405558449,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),64544-07-6,,35.48133892,0,-4.45,-20.09463568,-3,4,,-65.10727193,-50.08126661,0.635609089,0.999968495,,,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N\OC)\C3=CC=CO3)C(=O)OC(C)OC(C)=O,Enzo,AC3055,-24.56317503,0,-3.68402164,-50.08126661,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179585-04,Rescinnamin,363676949,Serotonergic synapse Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,3.981071706,1,-5.4,-30.62596237,-2.4,4,,-34.56857304,-30.89047753,0.899300428,0.9991089,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([NH]C5=C4C=CC(=C5)OC)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)\C=C\C6=CC(=C(OC)C(=C6)OC)OC,Analyticon,NP-011016,-43.5071138,1.11831705,-14.82334918,-30.89047753,,,,,,,,,,,,1.51E-07,7.54E-07,0.00000377,0.0000189,,,,,,,,,,,
NCGC00167550-08,Narasin,405558485,Nf-kappa B Signaling Pathway Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55134-13-9,,1.995262315,1,-5.7,-141.4274944,-1.3,4,,-103.9342663,-97.40181901,0.070898386,0.996886969,,,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]5CC[C@](O)(CC)[C@H](C)O5)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C)C(O)=O,Enzo,NP198,0,-57.11591177,-96.58472972,-97.40181901,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390238-01,Isepamicin,405558465,30S Ribosomal Protein Inhibitors,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58152-03-7,,11.22018454,0,-4.95,-23.31474253,-3,4,,-46.35757484,-43.73471477,0.085795967,0.995434719,,,CN[C@@H]1[C@@H](O)[C@H](OC[C@]1(C)O)O[C@@H]2[C@@H](O)[C@H](OC3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CN,Adooq,A11662,0,3.71809297,0,-43.73471477,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00522551-01,Monepantel,405558479,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),887148-69-8,,12.58925412,0,-4.9,-84.69381594,-2.3,4,,-88.70801337,-90.93492443,0.112322176,0.992137522,,,C[C@](COC1=CC(=CC=C1C(F)(F)F)C#N)(NC(=O)C2=CC=C(SC(F)(F)F)C=C2)C#N,MedChem Express,HY-14774,-8.04356143,0,-41.04907987,-90.93492443,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167547-02,Agaric acid,170465652,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),666-99-9,,39.81071706,0,-4.4,-27.22619471,-3,4,,-45.71614509,-42.26345424,0.545563987,0.755366036,,,O=C(O)C(CCCCCCCCCCCCCCCC)C(O)(CC(=O)O)C(=O)O,SIGMA,A7384,0.57049879,-20.26758807,0,-42.26345424,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00484900-01,Estramustine PhosphateNa,405558512,Dna Alkylating Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52205-73-9,,39.81071706,0,-4.4,-100.2284294,-3,4,,-76.95608666,-68.29673888,0.448946432,0.850609664,,H2AFX,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=CC=C34)OC(=O)N(CCCl)CCCl)[C@@H]1CC[C@@H]2O[P](O)(O)=O,Enzo,AC1524,-23.3895663,-8.49549831,0,-68.29673888,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185754-01,Terlipressin,144206925,Vasopressin V1a Receptor Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),14636-12-5,,12.58925412,0,-4.9,-71.83634097,-2.4,4,,-35.77991851,-38.40343729,0.481055736,0.823256193,,AVPR1A,NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@@H]3CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N3,Sequoia,TERLIPRESSIN,-14.6020383,0,-20.69010519,-38.40343729,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344544-01,Cabergoline,170464667,Serotonin 2b (5-HT2b) receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),81409-90-7,,19.95262315,0,-4.7,-98.1251517,-2.3,4,,-97.92597017,-89.88180791,0.226639222,0.966920043,,,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4ncc(C[C@H]2N(C1)CC=C)c34,SIGMA,C0246,-15.05211155,0,-30.60366552,-89.88180791,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016013-06,Trimipramine maleate,170465260,Serotonin 2 (5-HT2) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),521-78-8,,39.81071706,0,-4.4,-104.8163779,-2.4,4,,-72.2974968,-75.18912697,0.369586731,0.905010356,,,O=C(O)/C=C\C(=O)O.CN(C)CC(C)CN2c3ccccc3CCc1ccccc12,Microsource,1503117,-13.70066932,-33.45538841,-19.90917512,-75.18912697,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015831-06,Pheniramine maleate,170464902,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132-20-7,,35.48133892,0,-4.45,-37.62832262,-3,4,,-67.98896429,-54.53709416,0.415663949,0.875600425,,,[O-]C(=O)/C=C\C([O-])=O.C[NH+](C)CCC(c1ccccc1)c2[nH+]cccc2,Microsource,1500478,0,-18.26309589,-8.29180478,-54.53709416,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160387-04,Clothiapine,170465938,GABA-A receptor; benzodiazepine site Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2058-52-8,,0.707945784,1,-6.15,-57.66732281,-1.4,4,,-41.71427094,-60.7142652,0.726148828,0.40525556,,,CN1CCN(CC1)C3=Nc4ccccc4Sc2ccc(Cl)cc23,Enzo,D108,0,-45.49579772,-6.65367931,-60.7142652,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166113-04,Diphenylcyclopropenone,170465593,immune system process Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),886-38-4,,1.584893193,1,-5.8,-70.67970815,-2.4,4,,-54.89244319,-56.48459929,0.38441542,0.896153779,,,O=C2C(=C2c1ccccc1)c3ccccc3,Vitas,STK289679,0,-35.08830355,-37.81313798,-56.48459929,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249902-01,Epsiprantel,170465737,calcium ion homeostasis Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),98123-83-2,,1.77827941,1,-5.75,-55.89408334,-2.4,4,,-34.97482955,-25.84930501,0.466541666,0.836090765,,,O=C2CN(CC1c3ccccc3CCCN12)C(=O)C4CCCCC4,GVK,FFS-11-286-NCI-105,0,-23.65670038,-43.42241613,-25.84930501,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389304-01,Clindamycin Phosphate,405559083,Bacterial 70S ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),24729-96-2,,0.316227766,1,-6.5,-94.48769564,-1.4,4,,-38.27430392,-43.15803329,0.369140013,0.905343333,,,CCCC1CC(N(C)C1)C(=O)NC(C(C)Cl)C2OC(SC)C(O[P](O)(O)=O)C(O)C2O,APExBIO,B1708,-6.87240836,-40.63190433,-31.33711958,-43.15803329,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00229704-01,Raltitrexed,124939249,thymidylate synthase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),112887-68-0,Raltitrexed,3.981071706,1,-5.4,-84.08411376,-1.4,4,Raltitrexed,-32.39804114,-41.41588407,0.075455375,0.998338644,7298,TYMS,O=C(N[C@@H](CCC(=O)O)C(=O)O)c1ccc(s1)N(C)Cc2ccc3N=C(C)NC(=O)c3c2,Waterstone,WS10046,-10.68005558,-16.69677189,-36.92134336,-41.41588407,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166236-02,Oteracil potassium,405559107,Orotate Phosphoribosyltransferase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2207-75-2,,0.098152065,1,-7.00810056,-81.45385119,-2.2,4,,-30.90315837,-30.33596531,0.013378199,0.999889745,,UMPS,OC1=NC(=NC(O)=N1)C([O-])=O,Bosche,O3085,0.6953861,0,-18.06989389,-30.33596531,,,,,,,,,,,,4.57E-09,2.29E-08,1.14E-07,5.71E-07,,,,,,,,,,,
NCGC00024257-08,Phenylephrine hydrochloride,170465356,alpha1-Adrenoceptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61-76-7,"; Naldecon; Neosynephrine; Metaoxedrin;Phenylephrine hydrochloride; Glauko-Biciron; ; Neo Synephrin; Neooxedrine chloride;PHENYLEPHRINE HYDROCHLORIDE; Neo-synephrine; dimotapp L.A.; Metasympatol; Fenilefrina; (-)-m-Oxedrine; Tannate, Phenylephrin; Neo-Synephrine; Phenylephrine Hcl; Mezaton; Dimetapp; Ru-Tuss; Phenylephrine hydrochloride",12.58925412,0,-4.9,-22.65280341,-2.2,4,,-35.52948657,-33.82359868,0.026546685,0.999565597,148,ADRA1A,Cl.O[C@@H](CNC)c1cc(O)ccc1,Microsource,1500483,0,0,-15.49124278,-33.82359868,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025158-02,(S)-(+)-Dimethindene maleate,170465880,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1217457-81-2,,39.81071706,0,-4.4,-35.00811474,-3,4,,-82.04030687,-65.93962642,0.532309105,0.770756288,,,C[C@@H](C=1c2ccccc2CC=1CCN(C)C)c3ccccn3.O=C(O)/C=C\C(=O)O,Tocris,1425,3.528265,-28.87377938,-3.42149679,-65.93962642,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00348215-03,Bedaquiline (TMC-207),405558612,ATP synthase subunit c Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),843663-66-1,,39.81071706,0,-4.4,-13.47477492,-3,4,,-46.21697185,-38.51414321,0.006832298,0.99997123,886937,atpE,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C3=CC=CC=C3)[C@@](O)(CCN(C)C)C4=CC=CC5=C4C=CC=C5,Adooq,A12327,0,0,0,-38.51414321,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263579-01,rac Nebivolol hydrochloride,170465208,beta1-Adrenoceptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),169293-50-9,,11.22018454,0,-4.95,-45.97372851,-2.4,4,,-72.61047558,-70.47266257,0.801548391,0.999803142,,ADRB1,Cl.Fc1cc2CC[C@@H](Oc2cc1)[C@@H](O)CNC[C@H](O)[C@@H]3CCc4cc(F)ccc4O3,Sequoia,99200-09-6,-47.6670008,1.1037538,-36.38442498,-70.47266257,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00381753-02,NCGC00381753-02,405558648,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),147526-32-7,,0.000562341,1,-9.25,-340.3827192,5,4,,-43.53570755,-82.98207904,1,0.999697603,,,OC(CC(O)\C=C\C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4)CC([O-])=O,APExBIO,A8504,-83.3950768,-84.86952968,-86.34149976,-82.98207904,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167523-03,Ormetoprim,170465718,Folate biosynthesis Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6981-18-6,,1.584893193,1,-5.8,-27.76162255,-2.4,4,,-37.06255165,-12.92881703,1,0.999981151,,,Nc2nc(N)ncc2Cc1cc(OC)c(OC)cc1C,Sequoia,SRP01245o,0,-22.83708668,-33.88485456,-12.92881703,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00165810-02,Indoramin hydrochloride,170466233,Alpha-1d adrenergic receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),38821-52-2,,39.81071706,0,-4.4,-140.028503,-2.4,4,,-27.60271006,-43.15616,0.656960125,0.912153407,,,Cl.O=C(NC3CCN(CCc1cnc2ccccc12)CC3)c4ccccc4,SigmaAldrich,I2909,-33.55381628,-15.91276028,-18.35888668,-43.15616,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094857-05,"9-Aminoacridine, monohydrochloride, monohydrate",170465046,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52417-22-8,,39.81071706,0,-4.4,-36.53085799,-3,4,,-110.0824983,-97.14991263,0.241679061,0.962150774,,,Cl.O.Nc1c3ccccc3nc2ccccc12,Vitas,STK387428,1.76514104,-16.12160886,4.87765272,-97.14991263,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015227-08,Dexchlorpheniramine hydrochloride,170466889,Histamine H1 Receptor Antagonists; SNRI,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5502-69-2, ; Clorfenamina;Chlorpheniramine; Chlor-Trimeton; Mylaramine; Polaramine; Dexclorfeniramina; Chlortrimeton;Chlorpheniramine maleate; Ru-Tuss; Teldrin; Chlorpheniramine; Chlor-trimeton;Chlorpheniramine Maleate,22.38721139,0,-4.65,-35.24092395,-2.2,4,,-56.66788929,-54.55409692,0.015470346,0.999852418,,HRH1,Cl.Clc1ccc(cc1)[C@H](CCN(C)C)c2ccccn2,Vitas,STK736174,-2.37429724,-2.36959887,-10.52810135,-54.55409692,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182710-02,Flurbiprofen axetil,144206486,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),91503-79-6,,5.623413252,1,-5.25,-12.73238657,-3,4,Flurbiprofen Axetil;CIPLUS_701423;Flurbiprofen axetil;FLURBIPROFEN AXETIL;Ropion;FP83;FP 83;FP-83;1-acetoxyethyl-2-(2-fluoro-4-biphenyl)propionate;,-43.66205575,3.90878866,1,0.99998552,,,Fc2cc(ccc2c1ccccc1)C(C)C(=O)OC(C)OC(C)=O,ACC,Flurbiprofen Axetil,0.61204855,0,-41.81671829,3.90878866,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016098-11,Xylazine,170466147,Sigma opioid receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7361-61-7,,0.794328235,1,-6.1,-63.21494435,-1.4,4,,-44.00641395,-48.96501453,0.408276448,0.880710396,,,Cc2cccc(C)c2NC1=NCCCS1,Enzo,AC809,1.23949168,-40.91059724,-30.41044571,-48.96501453,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016049-07,Tetracaine hydrochloride,170465190,Sodium channel alpha subunit Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),136-47-0,,39.81071706,0,-4.4,-29.0977964,-3,4,,-52.05262469,-46.07351166,0.435780285,0.860942346,,,Cl.CN(C)CCOC(=O)c1ccc(NCCCC)cc1,Microsource,1500564,0,-16.91510289,-1.66545587,-46.07351166,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015741-13,"4,4 -(2,3-Dimethyltetramethylene)dipyrocatechol",405558741,5-Lipoxygenase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),500-38-9,,39.81071706,0,-4.4,-44.56950088,-3,4,,-99.73330157,-84.36108464,0.075307592,0.996485981,,ALOX5,CC(CC1=CC(=C(O)C=C1)O)C(C)CC2=CC(=C(O)C=C2)O,Prestwick,Prestw-NAT-0055,-5.00168704,0,0,-84.36108464,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164604-10,Fluvastatin Na,405559141,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,1.412537545,1,-5.85,-135.4353806,-1.4,4,,-79.1644349,-68.46648906,0.267075645,0.953255167,,,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C3=CC=C(F)C=C3,Sequoia,SRP01980f,0,-70.4256147,-89.1887017,-68.46648906,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016338-10,Dibucaine,170464829,Sodium channel protein type X alpha subunit Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),85-79-0,,14.12537545,0,-4.85,-46.3599727,-2.2,4,,-71.55847168,-69.03562193,0.032719186,0.999339263,,,CCN(CC)CCNC(=O)c1cc(OCCCC)nc2ccccc12,Microsource,1500236,-1.13520898,0,-26.90425965,-69.03562193,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262945-01,Rivaroxaban,170466121,Coagulation Factor Xa Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),366789-02-8,"Bay 59-7939;Rivaroxaban (Xarelto);5-Chloro-n-(((5s)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide;Rivaroxaban;Rivaroxabanum; Rivaroxaban",39.81071706,0,-4.4,-24.97536262,-3,4,,-43.25582718,-40.21318932,0.456441998,0.844592836,83541,F10,O=C(NCC3CN(c1ccc(cc1)N2CCOCC2=O)C(=O)O3)c4ccc(Cl)s4,GVK,FFS-12-73-NCI-1931,0,-15.61379881,0,-40.21318932,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090749-12,Diethylstilbestrol,170464803,Estrogen Receptor (ER) Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6898-97-1,"; ;DIETHYLSTILBESTROL;Diethylstilbestrol; Diethylstilbesterol; pseudo-DES; (Z,E)-Diethylstilbestrol; 5   Diethylstilbestrol; Dietilestilbestrol; (E)-Diethylstilbestrol; Stilbestrol; Diethylstilbestrol [DES]",31.6227766,0,-4.5,-38.64136827,-2.4,4,,-70.03937288,-56.090434,0.308901839,0.93612939,2099,ESR1,Oc1ccc(cc1)C(CC)=C(CC)c2ccc(O)cc2,Microsource,1500244,0,-14.47737519,-12.75040796,-56.090434,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188865-03,Pazopanib,170465625,VEGFR-1/2/3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),444731-52-6,Pazopanib; Pazopanib;GSK-786034/Votrient/Armala,35.48133892,0,-4.45,-82.75734072,-2.4,4,,-73.82704564,-67.14455114,0.306576407,0.937166195,10715,FLT1,NS(=O)(=O)c1cc(ccc1C)Nc2nccc(n2)N(C)c3ccc4c(C)n(C)nc4c3,Sequoia,SRP010772p,-9.00313489,-24.49234137,-21.56312102,-67.14455114,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378937-01,Setiptiline,405559104,serotonin receptor signaling pathway Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57262-94-9,,39.81071706,0,-4.4,-18.00212462,-3,4,,-61.74527531,-51.45439609,0.006832298,0.999971219,,,CN1CC\C2=C(/C1)C3=C(CC4=CC=CC=C24)C=CC=C3,MedChem Express,HY-32329,0,0,0,-51.45439609,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016737-04,Epirizole,170465827,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),18694-40-1,,8.912509381,1,-5.05,-16.97392072,-2.4,4,,-37.96882981,-35.93757001,0.151008171,0.985677052,,,Cc1cc(nc(n1)n2nc(C)cc2OC)OC,Prestwick,Prestw-32,4.74728338,-1.09310849,-25.6669468,-35.93757001,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016692-05,Bromperidol,170465873,Dopamine D2 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),10457-90-6,,39.81071706,0,-4.4,-28.80806876,-3,4,,-64.04702412,-53.3725201,0.14356183,0.987073249,,,Fc1ccc(cc1)C(=O)CCCN2CCC(O)(CC2)c3ccc(Br)cc3,Microsource,1505972,-4.12350339,3.25897388,0,-53.3725201,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249415-01,Fabesetron,144206751,5-hydroxytryptamine receptor 4 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),129300-27-2,,39.81071706,0,-4.4,-29.10831471,-3,4,,-99.83826594,-83.19855495,0.006832298,0.99997121,3360,HTR4,Cc4ncnc4C[C@H]3CCc2c(C)c1ccccc1n2C3=O,NCGCChem,DJM10-012,0,0,0,-83.19855495,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00522453-01,MLN9708,405559125,Proteasome subunit beta type-5 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1239908-20-3,,0.01,1,-8,-454.9764702,5,4,,-92.47138255,-98.0664071,0.516825248,0.817338189,5693,PSMB5,CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(=CC=C1Cl)Cl)B2OC(=O)C(CC(O)=O)(CC(O)=O)O2,MedChem Express,HY-10452,-94.75692164,-97.40454608,-96.53963754,-98.0664071,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015851-10,Protriptyline hydrochloride,170465077,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1225-55-4,,28.18382931,0,-4.55,-79.19130687,-2.3,4,,-90.37188135,-82.85748587,0.210150377,0.971734764,,,Cl.CNCCCC2c3ccccc3C=Cc1ccccc12,Microsource,1505984,-14.19989501,0,-10.68498886,-82.85748587,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015036-11,Amantadine hydrochloride,170464860,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),768-94-5, Adamantamine fumarate;Adamantamine fumarate;AMANTADINE HYDROCHLORIDE; 1-Adamantylamine;AMANTIDINE; ; Symmetrel; Ambroxol Hydrochloride;Amantadine hydrochloride; Amantadine hydrochloride; 1-Aminoadamantane; Midantan; Amantadina;Amantadine; Adamantine hydrochloride,0.630957345,1,-6.2,-95.09832698,-1.4,4,,-30.78812893,-27.52005579,0.675646534,0.539321082,1812,DRD1,NC13CC2CC(CC(C1)C2)C3,Vitas,STK298781,-9.5669797,-53.54936483,-27.59256613,-27.52005579,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016642-04,Piperacetazine,170465363,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3819-00-9,,15.84893192,0,-4.8,-75.86998943,-2.3,4,,-108.1357578,-91.7797982,0.169030518,0.981954743,,,CC(=O)c2cc3N(CCCN1CCC(CCO)CC1)c4ccccc4Sc3cc2,Prestwick,Prestw-1048,0,-20.14262432,-42.51126942,-91.7797982,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015264-13,Clomipramine hydrochloride,170464702,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),303-49-1, 7   Clomipramine; ; Chlomipramine;; Hydiphen;CLOMIPRAMINE HYDROCHLORIDE; Anafranil;Clomipramine; Anafranil hydrochloride; Chloripramine;Clomipramine?HCl; Clomipramina; 8   Clomipramine Hcl;Clomipramine hydrochloride; Clomipramine hydrochloride,28.18382931,0,-4.55,-94.39211535,-2.2,4,,-98.19808317,-88.12546887,0.014428181,0.9998716,6532,SLC6A4,CN(C)CCCN2c3ccccc3CCc1ccc(Cl)cc12,Microsource,2300061,-11.48541832,-13.40385646,-28.10399943,-88.12546887,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091146-08,Phenothiazine,170466563,Trichostrongylus colubriformis Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),92-84-2,,25.11886432,0,-4.6,-12.52014075,-3,4,,-48.14508924,-44.16276924,0.095359443,0.994352028,,,c1ccc2Sc3ccccc3Nc2c1,SIGMA,P14831,0,4.19601729,0,-44.16276924,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164588-02,Malotilate,170465879,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),59937-28-9, Kantec; Malotilate; Malotilato;Malotilate; ,25.11886432,0,-4.6,-31.21593184,-3,4,,-40.98716522,-39.46242563,0.511022914,0.794043916,,MMP1,CC(C)OC(=O)C(/C(=O)OC(C)C)=C1/SC=CS1,Sequoia,SRP01140m,0,-15.87162179,-9.05375846,-39.46242563,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164603-04,Ebastine,170465995,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),90729-43-4,,39.81071706,0,-4.4,-56.75817496,-2.3,4,,-112.2257967,-97.34153831,0.429207891,0.865793341,3269,HRH1,CC(C)(C)c1ccc(cc1)C(=O)CCCN2CCC(CC2)OC(c3ccccc3)c4ccccc4,Sequoia,SRP00750e,0,-32.50093187,0,-97.34153831,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00023339-16,Pilocarpine,170464845,Muscarinic acetylcholine receptor M3 Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),92-13-7,,3.16227766,1,-5.5,-74.89728026,-2.4,4,,-30.88914639,-9.10009455,1,0.999968506,1131,CHRM3,Cn2cncc2C[C@H]1COC(=O)[C@H]1CC,Enzo,AC214,-14.64798789,-24.71563562,-38.8624856,-9.10009455,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090965-07,Propyl-4-hydroxybenzoate,405559148,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),94-13-3,,1.77827941,1,-5.75,-24.98513775,-2.4,4,,-31.20058568,-6.47454699,1,0.999883624,,,CCCOC(=O)C1=CC=C(O)C=C1,SigmaAldrich,P53357,0,-20.50927929,-30.5838214,-6.47454699,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167492-03,Lercanidipine hydrochloride,170465587,Voltage-gated L-type calcium channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132866-11-6,,31.6227766,0,-4.5,-24.74146555,-3,4,,-90.37107696,-78.4691087,0.050985552,0.998393381,,,Cl.CC=3NC(C)=C(C(C=3C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c2ccccc2)c4cccc(c4)[N+]([O-])=O)C(=O)OC,Sequoia,132866-11-6,0,3.88289264,0,-78.4691087,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185765-02,Encainide hydrochloride,405558508,Sodium channel protein type V alpha subunit Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),66794-74-9,,8.912509381,1,-5.05,-407.8343824,5,4,,45.97305373,-48.69250667,0.086656864,0.995341836,,,COC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2CCC3CCCCN3C,SIGMA,E9156,-93.02617291,-96.60666762,-62.03048251,-48.69250667,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249929-01,Neticonazole,170466035,ergosterol biosynthetic process Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),130726-68-0,,17.7827941,0,-4.75,-38.9514127,-2.4,4,,-82.26149984,-72.16780291,0.083628727,0.995662109,,,CS\C=C(/c1ccccc1OCCCCC)n2ccnc2,GVK,FFS-11-286-NCI-232,0,3.78851335,-23.40868662,-72.16780291,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378631-01,Boceprevir,405558552,"Hepatitis C virus serine protease, NS3/NS4A Inhibitor",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),394730-60-0,,28.18382931,0,-4.55,-15.06690773,-3,4,,-41.04624087,-35.26230369,0.853329699,0.999953158,,,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C,MedChem Express,HY-10237,-41.12640114,0,-3.90870342,-35.26230369,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167520-06,Cilomilast,405558432,Phosphodiesterase IIII (PDE4) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),153259-65-5,,10,0,-5,-72.91592431,-2.4,4,,-32.05559762,-39.52589191,0.286351391,0.945808603,,PDE4A,COC1=CC=C(C=C1OC2CCCC2)C3(CCC(CC3)C(O)=O)C#N,APExBIO,A4329,-12.25364211,-2.91993263,-28.87409298,-39.52589191,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389632-02,Tipiracil,405558450,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),183204-72-0,,39.81071706,0,-4.4,-30.79556524,-3,4,,-74.23566259,-65.19638549,0.218720496,0.969288833,,TYMP,ClC\1=C(/CN2CCCC2=N)NC(=O)NC1=O,Adooq,A13098,0,-11.432578,0,-65.19638549,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167529-02,Itopride hydrochloride,170465974,Acetylcholinesterase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),122892-31-3,,39.81071706,0,-4.4,-21.98776491,-3,4,,-38.87740083,-33.23116736,0.130461261,0.989365542,43,ACHE,Cl.COc1cc(ccc1OC)C(=O)NCc2ccc(OCCN(C)C)cc2,Sequoia,SRP02400i,-3.44244155,0,0,-33.23116736,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00229511-10,Tofacitinib,405558458,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),477600-75-2,,39.81071706,0,-4.4,-64.99800197,-3,4,,-31.94152179,-36.30378551,0.831625733,0.960775735,,JAK1,C[C@@H]1CCN(C[C@@H]1N(C)C2=C3C=C[NH]C3=NC=N2)C(=O)CC#N,XcessBio,M60033-2s,-38.48391519,-12.82745596,-6.76918402,-36.30378551,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183866-01,Oxypertine hydrochloride,144206763,Adenylate cyclase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),17506-66-0,,25.11886432,0,-4.6,-78.59779619,-2.4,4,"OXYPERTINE;LS-82918;oxypertine;CIPLUS_152240;Indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-;Oxipertina;Equipertine;Forit;CIPLUS_179718;Oxypertinum;Oxypertin;oxypertinum;1H-Indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-;Oxypertine;",-55.70084251,-52.80366857,0.41800344,0.873962258,,,Cl.COc3cc4nc(C)c(CCN1CCN(CC1)c2ccccc2)c4cc3OC,NCI,NSC_169107,-17.37634404,0,-11.20126842,-52.80366857,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167969-02,Rubitecan,124893436,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,22.38721139,0,-4.65,-484.40655,5,4,,-5.158291016,-98.9326633,0.577524359,0.726502649,,,CC[C@@]1(O)C(=O)OC/C2=C1/C=C/3N(CC4=CC5=C(C=CC=C5[N+]([O-])=O)N=C34)C2=O,SIGMA,R3655,-95.8840693,-92.55075412,-97.02776286,-98.9326633,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00166079-02,C.I. Solvent Red 24,170465710,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),85-83-6,,39.81071706,0,-4.4,-9.592107882,-3,4,,-37.44322032,-31.61935027,0.082613947,0.995771558,,,Cc4ccccc4/N=N/c3ccc(/N=N/c1c2ccccc2ccc1O)c(C)c3,SIGMA,198102,0,0,2.10540566,-31.61935027,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179364-03,Ioversol,170464725,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),87771-40-2,,5.011872336,1,-5.3,-11.67631443,-3,4,,-36.18124721,-2.07414946,1,0.999983187,,,OCC(O)CNC(=O)c1c(I)c(N(CCO)C(=O)CO)c(I)c(c1I)C(=O)NCC(O)CO,Prestwick,Prestw-878,-30.79387048,0,-33.50115482,-2.07414946,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166142-04,Diperodon hydrochloride,170465536,sodium ion transmembrane transport Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),537-12-2,,19.95262315,0,-4.7,-213.1211808,-2.3,4,,-64.009211,-93.3393113,0.129259213,0.989554808,,,Cl.O=C(Nc1ccccc1)OCC(OC(=O)Nc2ccccc2)CN3CCCCC3,Prestwick,Prestw-300,-39.67854436,-33.96606762,-53.42547202,-93.3393113,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090548-04,Deferiprone,405558541,Iron Chelating Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),30652-11-0,,35.48133892,0,-4.45,-13.6703147,-3,4,,-32.17676045,-31.81396704,0.871409032,0.999846832,,,CN/1\C=C/C(=O)/C(=C1C)O,Selleck,S4067,-47.48272812,0,-3.69658512,-31.81396704,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00016371-08,Diclofenamide,405558546,Carbonic Anhydrase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),120-97-8,,8.912509381,1,-5.05,-20.92176427,-3,4,,-39.7348212,0,1,0.973070227,,CA1,N[S+]([O-])(=O)C1=CC(=C(Cl)C(=C1)[S+](N)([O-])=O)Cl,APExBIO,A8408,-3.75833758,2.14103338,-31.862351,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179623-04,Lisinopril dihydrate,170464907,Angiotensin-converting enzyme Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),83915-83-7,,11.22018454,0,-4.95,-31.83112411,-2.4,4,,-45.76061079,-32.30050899,0.236988398,0.963738442,,,O.O.OC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)N[C@@H](CCc1ccccc1)C(=O)O,Microsource,1501217,0,-11.74639266,-17.64818455,-32.30050899,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185767-01,Spiramycin II,144207139,Bacterial 70S ribosome Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),24916-51-6,,25.11886432,0,-4.6,-50.08131056,-2.2,4,,-80.31007535,-64.49442533,0.013099724,0.999894175,,,CN(C)[C@H]1CC[C@H](O[C@@H]1C)O[C@H]4C=CC=CC[C@@H](C)OC(=O)C[C@@H](OC(C)=O)[C@H](OC)[C@@H](O[C@@H]3O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]3O)N(C)C)[C@@H](CC=O)C[C@H]4C,Toronto Research,A187800,-2.76880507,-5.31911145,-22.14746897,-64.49442533,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167477-01,Fidarestat,144206034,Aldose reductase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),136087-85-9,SNK-860; Aldos; ,39.81071706,0,-4.4,-47.74556978,-3,4,"LS-145864;fidarestatum;fidarestat;Aldos;SNK-860;Fidarestat;FIDARESTAT;(2S,4S)-6-fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide;6-FLUORO-2',5'-DIOXOSPIRO(CHROMAN-4,4'-IMIDAZOLIDINE)-2-CARBOXAMIDE, 2S,4S, D-;CIPLUS_737489;Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-;SNK 860;fedarestat;",-69.16102012,-60.5508501,0.251517462,0.958841765,,,NC(=O)[C@@H]2C[C@]1(NC(=O)NC1=O)c3cc(F)ccc3O2,Chemical Block,A4376/0186841,-9.88530597,0,4.571354,-60.5508501,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179332-03,Naftifine hydrochloride,170464903,Squalene monooxygenase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),65473-14-5,,11.22018454,0,-4.95,-57.59688126,-2.3,4,,-81.01595775,-80.10736829,0.699310498,0.999639483,3646509,,Cl.CN(C\C=C\c1ccccc1)Cc3cccc2ccccc23,Prestwick,Prestw-1063,-40.813059,0,-42.33970971,-80.10736829,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015954-04,Sobuzoxane,90341303,DNA topoisomerase II Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,12.58925412,0,-4.9,-23.79293148,-2.2,4,,-37.91649753,-36.49675697,0.027880582,0.999520733,,,CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O,SigmaAldrich,Lopac-S-4692,0,0,-15.78460156,-36.49675697,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015787-09,PINACIDIL,405558656,"Sulfonylurea receptor 2, Kir6.2 Opener",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),"85371-64-8, 60560-33-0 [anhydrous]",,35.48133892,0,-4.45,-38.27152306,-3,4,,-82.18547708,-69.07990688,0.232620892,0.965071974,,,CC(N\C(NC1=CC=NC=C1)=N\C#N)C(C)(C)C,Microsource,2300270,0,-13.45527319,-6.73597358,-69.07990688,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025085-02,NCGC00025085-02,26752140,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,3.981071706,1,-5.4,-46.25924967,-2.4,4,"NCGC00015383-01;CIPLUS_171759;1-DEOXYNOJIRIMYCIN;deoxynorjrimycin(1);DDIG;Bay n 5595;1,5-Dideoxy-1,5-imino-D-mannitol hydrochloride;LS-177035;Moranoline;1 Deoxynojirimyci;Deoxymannojirimycin;1-Deoxynojirimycin Hydrochloride;1 Deoxynojirimycin Hydrochlorid;1 Deoxymannojirimyci;1-Deoxynojirimycin  Hydrochloride;1-Deoxymannojirimycin hydrochloride;LS-116263;CIPLUS_10555535;1,5-Dideoxy-1,5-imino-D-mannitol;1,5-dideoxy-1,5-iminogalactitol;CIPLUS_214523;CIPLUS_753274;NCGC00025086-02;NCGC00162154-01;1,5-Dideoxy-1,5-imino-D-sorbitol hydrochloride;NCGC00025086-01;Deoxynojirimycin;moranoline;NCGC00093860-01;NCGC00025085-01;DEOXYMANNOJIRIMYCIN;3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-;LS-177819;deoxymannojirimycin(1);NCGC00025085-02;1-Deoxynojirimycin;1-Deoxynojirimycin hydrochloride;",-40.92565292,-28.1391651,0.457293557,0.843825726,,,OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,BIOMOL,S-110,0,0,-52.13961436,-28.1391651,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386236-02,TAK 438,405558685,Potassium-transporting ATPase Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),881681-01-2,,39.81071706,0,-4.4,-61.33000394,-3,4,,-43.34929481,-40.29107901,0.430559729,0.864905581,,,CNCC1=C[N](C(=C1)C2=CC=CC=C2F)[S+]([O-])(=O)C3=CC=CN=C3,Axon Medchem,1971,-14.76470117,-3.99949263,0,-40.29107901,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018277-06,Mebeverine hydrochloride,170466168,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2753-45-9,,11.22018454,0,-4.95,-48.60249735,-2.2,4,,-68.13966444,-67.25894856,0.026774755,0.999557667,,,Cl.COc1cc(ccc1OC)C(=O)OCCCCN(CC)C(C)Cc2ccc(OC)cc2,Microsource,1501117,0,0,-35.89761141,-67.25894856,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016283-04,Diphemanil methylsulfate,170464876,antimitotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),62-97-5, Vagophemanil; ; Diphemanil; Prantal;Diphemanil methylsulfate; Diphemanil methylsulfate,3.548133892,1,-5.45,-26.72696118,-1.4,4,,-43.13007224,-33.63829159,0.198002589,0.975023044,,,[O-]S(=O)(=O)OC.C[N+]1(C)CC\C(CC1)=C(\c2ccccc2)c3ccccc3,"Prestwick Chemical, Inc.",Prestw-79,4.84269096,0.48647899,-42.77458063,-33.63829159,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015428-15,(+/-) -Fluoxetine,170465374,Serotonin transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54910-89-3,,39.81071706,0,-4.4,-45.83870532,-2.4,4,,-47.96966157,-44.51787415,0.781880004,0.579697055,,,FC(F)(F)c2ccc(OC(CCNC)c1ccccc1)cc2,Vitas,STK734483,0,-43.32666737,0,-44.51787415,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00168085-05,Vorinostat (SAHA),170465180,HDAC Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),149647-78-9, ;MK-0683;SAHA; SAHA cpd; Vorinostat;Vorinostat; M344 compound;Zolinza,39.81071706,0,-4.4,-30.3884939,-3,4,,-104.2291374,-86.85761454,0.006832298,0.999971209,3065,HDAC1,O=C(Nc1ccccc1)CCCCCCC(=O)NO,"Prestwick Chemical, Inc.",Prestw-1362,0,0,0,-86.85761454,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159346-04,Terbinafine,170465174,Fungal Squalene Monooxygenase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),91161-71-6," ;Terbinafine; terbinafine, (Z)-isomer; Lamasil;TERBINAFINE HYDROCHLORIDE; Terbinafine; TERBINAFINE HCl;Terbinafine?HCl; Terbinafine HCl",39.81071706,0,-4.4,-88.73943,-2.4,4,,-67.88570336,-71.31399155,0.113102527,0.992028475,,,CC(C)(C)C#C\C=C\CN(C)Cc2cccc1ccccc12,Vitas,STK802069,-14.15299805,-18.09625645,-12.24257208,-71.31399155,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00388522-02,NCGC00388522-02,405558729,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),107007-99-8,,25.11886432,0,-4.6,-39.51737373,-3,4,,-44.05303008,-39.71298726,0.566050049,0.729490309,,HTR3A,CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=N[N](C)C4=C3C=CC=C4,Enzo,DL166,-12.92776973,18.23592003,0.78770103,-39.71298726,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00165774-05,Cloprostenol (sodium salt),405558813,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55028-72-3,,39.81071706,0,-4.4,-89.18399997,-3,4,,-41.77239818,-45.5594821,0.453586451,0.846944769,,,O[C@@H](COC1=CC(=CC=C1)Cl)\C=C\[C@H]2[C@H](O)C[C@H](O)[C@@H]2C\C=C/CCCC([O-])=O,Cayman,16764,-21.49006465,-5.74915028,-6.50934397,-45.5594821,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00165825-02,Milnacipran hydrochloride,225144261,Serotonin transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),101152-94-7,,39.81071706,0,-4.4,-93.17652853,-3,4,,-45.80419508,-42.54926825,0.76170735,0.837530809,,,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2,SIGMA,M1318,-27.14083157,-16.44393499,0,-42.54926825,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016634-04,Acetopromazine maleate,170465731,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3598-37-6,,31.6227766,0,-4.5,-50.11457778,-3,4,,-81.02943316,-72.24558187,0.333229982,0.924581585,,,O=C(O)/C=C\C(=O)O.CC(=O)c1cc2N(CCCN(C)C)c3ccccc3Sc2cc1,"Prestwick Chemical, Inc.",Prestw-576,-11.51345565,14.05271277,0,-72.24558187,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016504-09,Droperidol,170464722,HERG Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),548-73-2,,39.81071706,0,-4.4,-37.3581095,-2.4,4,,-44.60071435,-41.45519486,0.72870618,0.729177004,,,Fc1ccc(cc1)C(=O)CCCN2CC=C(CC2)N3c4ccccc4NC3=O,Microsource,1501002,0,-32.71946651,0,-41.45519486,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00093704-12,Cyclosporine A,170466812,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),59865-13-3, Antibiotic S 7481F1; ; 11-me-Leu-CsA;Cyclosporin A; cyclosporin A synthetase;; Cyclophilins; F-7-62 cyclosporin; CYCLOSPORIN A;CYCLOSPORINE; Cyclosporine; cyclosporin O; CYCLOSPORINE; Cyclosporin A; cyclosporin metabolite M1; H-7-94 cyclosporin; cyclosporin A-SPTP; 3-MeAla-7-Phe-8-Ser-CsA; Cs29 (cyclosporin); M1 cyclosporin metabolite; Cyclosporin SG,39.81071706,0,-4.4,-40.28919326,-3,4,,-74.1875209,-65.98960075,0.459525225,0.841936776,,PPP3CC,C[C@H](C\C=C\C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C)C(C)C,Microsource,1502202,0,-24.62682872,0,-65.98960075,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091616-03,2-Ethoxybenzamide,170465775,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),938-73-8,,39.81071706,0,-4.4,-46.61793578,-2.4,4,,-55.5416045,-53.16343212,0.770437867,0.625098631,,,CCOc1ccccc1C(N)=O,Specs,AN-153/I166787,-4.52318651,-49.43616868,4.38170832,-53.16343212,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178255-02,QUININE ETHYL CARBONATE,405558844,Ferriprotoporphyrin IX Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),83-75-0,,35.48133892,0,-4.45,-59.35134505,-3,4,,-51.18427952,-45.59415115,0.395263214,0.889329146,,,CCOC(=O)O[C@H]([C@H]1C[C@@H]2CCN1C[C@@H]2C=C)C3=C4C=C(OC)C=CC4=NC=C3,Microsource,310050,-13.84962426,3.28016179,-5.73459598,-45.59415115,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160530-13,Toremifene citrate,405558853,Selective Estrogen Receptor Modulators (SERM),SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),89778-27-8,,39.81071706,0,-4.4,-75.57210828,-3,4,,-63.87949096,-58.6495758,0.438342279,0.858937131,,ESR1,CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)C2=CC=CC=C2)C3=CC=CC=C3,MedChem Express,HY-B0005,-19.858721,3.90234163,2.85492929,-58.6495758,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166097-02,Cinnamyl alcohol,225144268,prostaglandin secretion Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),104-54-1,,35.48133892,0,-4.45,-12.35802275,-3,4,,-42.85499699,-36.96249749,0.023779282,0.999651372,,,OC\C=C\C1=CC=CC=C1,SIGMA,108197,0,0.82160247,0,-36.96249749,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00244253-12,Ruxolitinib,405558887,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),941678-49-5,,39.81071706,0,-4.4,-85.23203868,-3,4,,-75.05744101,-72.16733282,0.681947114,0.97711694,,JAK1,N#CC[C@H](C1CCCC1)[N]2C=C(C=N2)C3=NC=NC4=C3C=C[NH]4,MedChem Express,HY-50856,-45.16271936,-15.30508845,-4.61946531,-72.16733282,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016981-05,Troleandomycin,405558894,70S ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),311074,,39.81071706,0,-4.4,-18.65995521,-3,4,,-64.00156069,-53.33463391,0.006832298,0.999971218,,,CO[C@@H]1C[C@@H](O[C@H](C)[C@H]1OC(C)=O)O[C@H]2[C@H](C)[C@H](O[C@@H]3O[C@@H](C)C[C@H]([C@H]3OC(C)=O)N(C)C)[C@H](C)C[C@]4(CO4)C(=O)[C@H](C)[C@H](OC(C)=O)[C@H](C)[C@H](C)OC(=O)[C@@H]2C,Enzo,EI249,0,0,0,-53.33463391,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386364-01,Lomitapide,405558897,Microsomal triglyceride transfer protein large subunit Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),182431-12-5,,39.81071706,0,-4.4,-34.34242422,-3,4,,-117.7906765,-98.15889708,0.006832298,0.999971208,4547,MTTP,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C3=C(C=CC=C3)C4=CC=C(C=C4)C(F)(F)F)C5=C(C=CC=C5)C6=C1C=CC=C6,Selleck,S7635,0,0,0,-98.15889708,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167528-02,Alosetron hydrochloride,170465416,Serotonin 3a (5-HT3a) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),122852-69-1,,10,0,-5,-26.32788012,-2.4,4,,-35.16004761,-34.35091896,0.904310419,0.999930157,,,Cl.Cc4ncnc4CN1CCc3c(C1=O)c2ccccc2n3C,Sequoia,SRP04894a,-58.65391557,0.02776414,-20.63663735,-34.35091896,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163160-04,Talipexole,170466015,Dopamine D4 receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),101626-70-4,,0.707945784,1,-6.15,-51.79831369,-1.4,4,,-33.58240677,-31.05513604,0.307770114,0.936689616,,,C=CCN1CCc2sc(N)nc2CC1,Tocris,2759,0,-33.90432036,-24.70103935,-31.05513604,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390569-01,Netupitant,363680908,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),290297-26-6,,39.81071706,0,-4.4,-70.64843249,-3,4,,-48.04294379,-44.20245316,0.486621719,0.818007427,,,CN1CCN(CC1)C2=CC(=C(C=N2)N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=C(C)C=CC=C4,MedChem Express,HY-16346,-18.33414943,0,0,-44.20245316,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390811-01,Oxytocin,405558950,Oxytocin receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),50-56-6,,39.81071706,0,-4.4,-13.86080802,-3,4,,-40.61702508,-34.26418757,0.148700551,0.986122256,,,CC[C@H](C)C1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,MedChem Express,HY-17571,-1.4140669,0,3.41239723,-34.26418757,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386317-11,Ribociclib (LEE011),405558961,CDK4/6 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,17.7827941,0,-4.75,-44.95177076,-3,4,,-58.64257149,-54.94962411,0.104527256,0.993202326,,CDK4,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2[N]1C5CCCC5,Bio Vision,May-81,-4.57685796,0,0,-54.94962411,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00166308-02,Difloxacin hydrochloride,170465623,Bacterial DNA gyrase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),91296-86-5,,8.912509381,1,-5.05,-61.77148263,-1.4,4,,-48.00982471,-51.54253775,0.780134095,0.999839426,,,Cl.CN1CCN(CC1)c2cc3N(C=C(C(=O)O)C(=O)c3cc2F)c4ccc(F)cc4,Vitas,STK618168,-35.47101757,-4.03435049,-41.20510077,-51.54253775,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181120-02,Acetophenazine Maleate,405558986,Sigma opioid receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5714-00-1,,3.981071706,1,-5.4,-134.0304157,-1.4,4,,-62.66088309,-69.89856658,0.815886803,0.99529446,,,[CH3][C](=[O])C1=CC=C2[S]C3=C(C=CC=C3)[N]([CH2][CH2][CH2][N]4[CH2][CH2][N]([CH2][CH2][OH])[CH2][CH2]4)C2=C1,USP,1007000,-45.2444437,-17.77464068,-62.51480957,-69.89856658,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188399-06,Fingolimod hydrochloride,405558994,Sphingosine Kinase 1 (SphK1) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-115.318521,-3,4,,-92.4809888,-93.72901494,0.039809199,0.999021392,,SPHK1,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Selleck,S5002,-18.22423412,-20.69321094,-18.92780917,-93.72901494,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00014925-06,Topotecan hydrochloride,170465137,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),119413-54-6,; Hycamtamine; Topotecane; Nogitecan hydrochloride;Nogitecan hydrochloride/NSC-609699;Topotecan hydrochloride; Topotecan hydrochloride;TOPOTECAN HYDROCHLORIDE; Nogitecan Hydrochloride; Hycamtin,3.16227766,1,-5.5,-230.3356314,-1.2,4,,-64.8408484,-95.24778648,0.033644481,0.999301321,7150,TOP1,Cl.CN(C)Cc1c2cc3CN4C(=O)C=5COC(=O)[C@](O)(CC)C=5C=C4c3nc2ccc1O,Prestwick,Prestw-1196,-31.81156903,-48.66389689,-96.32208706,-95.24778648,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159376-04,Methylparaben,170465480,canonical glycolysis Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),99-76-3,,7.079457844,1,-5.15,-60.25125294,-3,4,,-48.64049876,3.78845582,1,0.900294554,,,Oc1ccc(cc1)C(=O)OC,Labotest,LTBB002210,-14.37376675,0,-48.74120256,3.78845582,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167499-02,Roxatidine acetate hydrochloride,170465941,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),93793-83-0,,0.707945784,1,-6.15,-55.25095312,-1.4,4,,-35.23390579,-31.95455898,0.106085661,0.993002193,,,Cl.CC(=O)OCC(=O)NCCCOc2cc(CN1CCCCC1)ccc2,"Prestwick Chemical, Inc.",Prestw-428,0,-33.11158816,-29.98694936,-31.95455898,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094476-03,Terguride,144204835,Serotonin 1a (5-HT1a) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),37686-84-3,R(+)-Terguride; S(+)-Terguride; Teluron; ,39.81071706,0,-4.4,-58.53950375,-3,4,"Teluron;R(+)-TERGURIDE;transdihydrolisuride;CIPLUS_3867987;S(+)-N,N-Diethyl-N'([8alpha]-6-methylergolin-8-yl)urea;TERGURIDE;NCGC00016838-01;NCGC00015990-01;Terguride;N-(D-6-methyl-8-isoergolin-1-yl)-N',N'-diethylurea;NCGC00016838-02;CIPLUS_739798;S(+)-Terguride;S(-)-terguride hydrogen maleate;terguride;VUFB 6638;dironyl maleate (1:1);NCGC00094476-01;trans-9,10-dihydrolisuride hydrogen maleate;LS-159804;NCGC00094476-03;LS-159803;NCGC00094476-02;R(+)-Terguride;R(+)-N,N-Diethyl-N'[(8alpha)-6-methylergolin-8-yl]urea;S(+)-Terguride (5R, 8S, 10R);CIPLUS_179126;1,1-DIETHYL-3-(6-METHYL-ERGOLIN-8A-YL)UREA;terguridum;dironyl;urea, N,N-diethyl-N'-((8 alpha)-6-methylergolin-8-yl)-, (Z)-2-butenedioate (1:1);",-48.60091235,-45.83495416,0.561763432,0.735171341,,,CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4ncc(C[C@H]2N(C)C1)c34,BIOMOL,AC-839,-8.75305054,-21.96500591,-1.1675272,-45.83495416,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00250399-08,Vemurafenib,405559058,Raf kinase B Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1029872-54-5,,39.81071706,0,-4.4,-27.0443677,-3,4,,-91.09995205,-77.99996004,0.010110678,0.99993695,,BRAF,CCC[S+]([O-])(=O)NC1=CC=C(F)C(=C1F)C(=O)C2=C[NH]C3=NC=C(C=C23)C4=CC=C(Cl)C=C4,Bio Vision,2235,0,0,0.35099833,-77.99996004,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00014483-16,Pamelor,405559064,Norepinephrine transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),894-71-3,,17.7827941,0,-4.75,-101.5388775,-2.4,4,,-95.60448036,-79.99355504,0.606269371,0.671152065,,,CNCCC=C1C2=C(CCC3=C1C=CC=C3)C=CC=C2,SIGMA,N7261,-8.07283249,-44.95805887,-25.55942389,-79.99355504,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095748-04,"3-(Octadecyloxy)-1,2-propanediol",170465730,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),544-62-7,,0.707945784,1,-6.15,-60.9150968,-1.4,4,,-38.68036861,-33.42047247,0.411206401,0.878742764,,,OC(CO)COCCCCCCCCCCCCCCCCCC,Microsource,1503983,0,-42.97818735,-27.4948362,-33.42047247,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025000-14,Ketoconazole,405559066,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13463-41-7,; ; Ketoconazol; Nizoral;Ketoconazole; Ketoconazole; Ketocanazole,31.6227766,0,-4.5,-47.93909137,-2.3,4,,-105.9280401,-87.66191394,0.15568731,0.984747009,1588,CYP19A1,CC(=O)N1CCN(CC1)C2=CC=C(OC[C@H]3CO[C@@](C[N]4C=CN=C4)(O3)C5=CC=C(Cl)C=C5Cl)C=C2,SIGMA,K1003,0,-11.83809065,-12.88710994,-87.66191394,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00261971-01,Mazaticol,170466055,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),42024-98-6,Mazaticol;Mazaticolum;Pentona;Mazaticol,2.818382931,1,-5.55,-73.69705845,-2.4,4,,-67.35027693,-62.82433049,0.490120136,0.814659664,,,OC(C(=O)OC1CC2CCC(C)(C)C(C1)N2C)(c3cccs3)c4cccs4,GVK,FFS-11-286-NCI-243,0,-38.72699224,-35.31842669,-62.82433049,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166257-03,NCGC00166257-03,50111747,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,25.11886432,0,-4.6,-20.95004456,-3,4,"Mn3O4;Manganese(II,III) oxide;hausmannite;manganese oxide;manganous-manganic oxide;CIPLUS_158079;manganese oxide, hydrate;",-65.06326162,-58.76004668,0.058362607,0.997893795,,,O=[Mn]O[Mn]O[Mn]=O,SigmaAldrich,377473,0,3.25291441,-3.81452601,-58.76004668,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016498-08,Dyclonine hydrochloride,170464776,Sodium channel protein type II alpha subunit Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),536-43-6,,39.81071706,0,-4.4,-19.4134487,-3,4,,-61.68136199,-51.81780166,0.046087123,0.998688169,,,Cl.CCCCOc1ccc(cc1)C(=O)CCN2CCCCC2,Microsource,1500268,0,-1.83849877,0,-51.81780166,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095045-05,Sulfanitran,170466141,Eimeria tenella Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),122-16-7,,7.079457844,1,-5.15,-38.39281203,-3,4,,-33.57568823,0,1,0.940021825,,,O=S(=O)(Nc1ccc(cc1)[N+]([O-])=O)c2ccc(NC(C)=O)cc2,Microsource,1503339,-8.72676773,0,-34.79230392,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015155-11,Bepridil,170465240,Calcium Channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),64706-54-3," ; Bepridil, (-)-Isomer; Bepridil;Bepridil; Vascor;Bepridil hydrochloride; Bepridil, (+)-Isomer",12.58925412,0,-4.9,-71.38935803,-2.4,4,,-56.45201899,-44.47444819,0.27245677,0.951287029,,KCNT1,CC(C)COCC(CN(Cc1ccccc1)c2ccccc2)N3CCCC3,BIOMOL,AC104,-7.71187718,-20.87419294,-25.82613266,-44.47444819,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091112-09,Methylrosaniline chloride,170464787,TNFR1 (p55/CD120a) Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),548-62-9,; Triple Dye; Basic Violet 3; ; Methyl violet 2B; Hexamethyl-p-rosaniline chloride (Gentian violet); Crystal Violet;GENTIAN VIOLET; Genapax; Methyl Violet 10B; Gentian violet; Crystal violet solution;Gentian violet,1,1,-6,-238.2998111,-1.1,4,,-97.38018663,-99.15060883,0.037698698,0.999122573,,TNFR1,[Cl-].C/[N+](C)=C1\C=C\C(C=C1)=C(/c2ccc(cc2)N(C)C)c3ccc(cc3)N(C)C,Microsource,1500315,-27.55302256,-75.06740781,-97.71628742,-99.15060883,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00023064-05,Medroxyprogesterone,170466063,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),520-85-4,,39.81071706,0,-4.4,-9.183939086,-2.4,4,,-31.49988455,-26.24990379,0.007297871,0.999967209,,,CC(=O)[C@@]3(O)CC[C@H]2[C@@H]4C[C@H](C)C1=CC(=O)CC[C@]1(C)[C@H]4CC[C@@]23C,SIGMA,M6013,0,0,0,-26.24990379,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095169-05,Miltefosine,170465622,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58066-85-6,,14.12537545,0,-4.85,-51.06423102,-2.2,4,,-78.25443135,-73.38373273,0.045630667,0.998713795,,,C[N+](C)(C)CCOP([O-])(=O)OCCCCCCCCCCCCCCCC,Microsource,1505329,0.39746434,-5.39588996,-32.67052523,-73.38373273,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262929-01,BIBR-1048,170466107,Thrombin Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),211915-06-9,Bibr 1048;BIBR-1048 (Dabigatran);3-((2-((4-Amino((e)-hexyloxycarbonylimino)methyl)-phenylamino)methyl-1-1h-benzoimidazole-5-carbonyl)pyridin-2-yl-amino)propionic acid ethyl ester;Dabigatranum etexilatum;Dabigatran etexilate; Dabigatran etexilate,19.95262315,0,-4.7,-26.67990976,-2.2,4,,-56.87075261,-50.65966107,0.016042621,0.999841302,,F2,O=C(OCCCCCC)\N=C(\N)c1ccc(cc1)NCc3nc2cc(ccc2n3C)C(=O)N(CCC(=O)OCC)c4ccccn4,GVK,FFS-12-73-NCI-1548,0,0,-12.82335565,-50.65966107,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160622-04,D-delta-Tocopherol,144206758,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),119-13-1,,5.623413252,1,-5.25,-14.6223483,-3,4,,-30.4808636,0,1,0.999897334,,,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1,NCGCChem,XJB03-045,-0.91807101,-1.97432109,-30.06879068,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016278-10,Mefenamic acid,170464813,Cyclooxygenase-2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61-68-7,,1.584893193,1,-5.8,-26.67253812,-2.4,4,,-36.44691806,0,1,0.999843146,,,O=C(O)c2ccccc2Nc1cccc(C)c1C,Vitas,STK666691,0.8410188,-24.71389431,-34.26168437,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016386-06,Sulfamerazine,170464738,Bacterial dihydropteroate synthase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),127-79-7,,5.011872336,1,-5.3,-7.767298708,-3,4,,-38.87486072,-1.33580792,1,0.99998366,,,O=S(=O)(Nc1nc(C)ccn1)c2ccc(N)cc2,Vitas,STK520614,1.58753771,0,-35.99524141,-1.33580792,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159325-05,Desloratadine,170464781,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),100643-71-8,,39.81071706,0,-4.4,-100.6736197,-3,4,,-93.71085504,-86.3348946,0.290878529,0.943895199,,,Clc2cc3CCc4cccnc4\C(=C1\CCNCC1)c3cc2,Vitas,STK586537,-18.23010876,-18.71670761,-3.61415865,-86.3348946,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181042-02,Menthyl salicylate,225144318,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),89-46-3,,11.22018454,0,-4.95,-25.1265706,-2.2,4,,-35.82359925,-35.48481412,0.013992104,0.999879353,,,CC(C)C1CCC(C)CC1OC(=O)C2=CC=CC=C2O,SIGMA,84320,0,0,-18.20109981,-35.48481412,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091195-08,Hexachlorophene,170464690,Glucose-6-phosphate dehydrogenase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),70-30-4,,2.818382931,1,-5.55,-129.4229264,-1.1,4,,-99.95848823,-98.08529411,0.039296646,0.999046372,,,Clc2c(Cc1c(O)c(Cl)cc(Cl)c1Cl)c(O)c(Cl)cc2Cl,Vitas,STK377478,0,-39.24514133,-96.92685345,-98.08529411,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181101-01,Isothipendyl hydrochloride,144206270,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1225-60-1,Isothipendyl hydrochloride; Andantol; Isotipendilo; Adanton hydrochloride; ,11.22018454,0,-4.95,-55.69113326,-2.4,4,"ISOTHIPENDYL HYDROCHLORIDE;isothipendylum;isothipendyl;Isotipendilo;LS-133223;N,N,alpha-trimethyl-10H-pyrido(3,2-b)(1,4)benzothiazine-10-ethanamine;LS-133221;Isothipendyl;CIPLUS_157919;CIPLUS_213648;Andantol;10H-Pyrido(3,2-b)(1,4)benzothiazine-10-ethanamine, N,N,alpha-trimethyl-;Isothipendylum;Isothipendyl hydrochloride;Adanton hydrochloride;ISOTHIPENDYL;CIPLUS_694884;10H-Pyrido(3,2-b)(1,4)benzothiazine, 10-(2-dimethylamino-2-methylethyl)-, hydrochloride;10H-Pyrido(3,2-b)(1,4)benzothiazine, 10-(2-(dimethylamino)propyl)-;Isothipendyl Hydrochloride;",-81.70196837,-78.68593717,0.066224272,0.997285517,,,Cl.CN(C)C(C)CN1c3ccccc3Sc2cccnc12,NCI,NSC-169186,0,2.40434643,-42.72771674,-78.68593717,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00013495-15,Benztropine mesylate,405558618,Dopamine transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132-17-2,,12.58925412,0,-4.9,-95.24709534,-2.4,4,,-66.17115758,-69.13996072,0.306883632,0.937020617,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,APExBIO,B1554,-16.02524025,0,-32.6795616,-69.13996072,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00271596-03,Exemestane,170464628,Aromatase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),107868-30-4,Exemestane,22.38721139,0,-4.65,-143.5102282,-2.4,4,,-31.09277959,-53.05340327,0.161402144,0.983611945,1588,CYP19A1,O=C3C=C4C(=C)C[C@@H]1[C@H](CC[C@]2(C)C(=O)CC[C@@H]12)[C@@]4(C)C=C3,Tocris,3759,-28.01828779,-24.53142727,-33.6226018,-53.05340327,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00522464-01,Lusutrombopag,405558628,Thrombopoietin receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1110766-97-6,,14.12537545,0,-4.85,-30.3765636,-2.2,4,,-51.42138293,-48.53831753,0.021169301,0.999723638,,,CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C2=CSC(=N2)NC(=O)C3=CC(=C(/C=C(C)/C(O)=O)C(=C3)Cl)Cl,MedChem Express,HY-19883,0,0,-19.17907879,-48.53831753,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182606-01,Physalien,144206657,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),144-67-2,Helenien; Palmitato de xantofila; ,39.81071706,0,-4.4,-38.40362829,-3,4,xanthophyll dipalmitate;Xantofyl palmitate;Helenien;Palmitate de xantofyle;heleniene;CIPLUS_214390;palmitate de xantofyle;xantofyle palmitate;Xantofyli palmitas;helenien;Palmitato de xantofila;xantofyli palmitas;XANTOFYL PALMITATE;HELENIEN;,-62.83099836,-56.52583197,0.551241568,0.748359625,,,O=C(O[C@@H]2CC(C)=C(/C=CC(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)CC1(C)C)C(C)(C)C2)CCCCCCCCCCCCCCC,INDOFINE,020309S,0,-26.66762189,0,-56.52583197,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00371130-03,Vilazodone Hydrochloride,405558674,Sodium-dependent serotonin transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),163521-08-2,,14.12537545,0,-4.85,-96.47492165,-2.3,4,,-93.13034693,-95.78929678,0.173677974,0.980922557,6532,SLC6A4,NC(=O)C1=CC2=CC(=CC=C2O1)N3CCN(CCCCC4=C[NH]C5=C4C=C(C=C5)C#N)CC3,APExBIO,A3919,-12.7507658,0,-35.19946474,-95.78929678,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389572-01,FIROCOXIB,405558697,Cyclooxygenase-2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),189954-96-9,,10,0,-5,-74.67843876,-2.4,4,,-45.03959794,-49.15754205,0.29568615,0.941903898,,,CC\1(C)OC(=O)\C(=C1C2=CC=C(C=C2)[S+](C)([O-])=O)OCC3CC3,Microsource,1504526,-11.76270669,0.99307306,-32.60203811,-49.15754205,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00250406-02,Tipifarnib,405558726,Farnesyltransferase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),192185-72-1,,39.81071706,0,-4.4,-34.11485448,-3,4,,-85.436823,-68.5127447,0.173610983,0.980940282,,COX10,C[N]1C=NC=C1[C@@](N)(C2=CC=C(Cl)C=C2)C3=CC=C4N(C)C(=O)\C=C(\C5=CC=CC(=C5)Cl)C4=C3,Selleck,S1453,0,-10.38796981,-4.13611217,-68.5127447,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00345789-05,Venetoclax (ABT-199),405558742,Bcl-2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),8444499-71-4,,1.584893193,1,-5.8,-24.02167373,-1.4,4,,-32.42214197,-9.18083495,1,0.999852535,,BCL2,CC1(C)CCC(=C(\C1)C2=CC=C(Cl)C=C2)/CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)N[S+]([O-])(=O)C5=CC=C(NCC6CCOCC6)C(=C5)[N+]([O-])=O)OC7=CN=C8[NH]C=CC8=C7,ChemieTek,CT-A769,1.42398776,-25.17390171,-30.76845164,-9.18083495,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179619-06,Erythromycin propionate,170465433,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),134-36-1,,39.81071706,0,-4.4,-71.40493534,-3,4,,-51.52799438,-47.10666198,0.461108996,0.840658662,,,CCC(=O)O[C@@H]3[C@H](C[C@@H](C)O[C@H]3O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)N(C)C,Microsource,1500280,-18.24790667,0,0,-47.10666198,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00387997-02,ValganciclovirHCl,405558800,Viral Dna Polymerase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),175865-59-5,,7.079457844,1,-5.15,-33.38784862,-1.4,4,,-35.23754235,-34.78128529,0.882210067,0.999960937,,,CC(C)[C@H](N)C(=O)OCC(CO)OC[N]1C=NC2=C1N\C(=N/C2=O)N,Enzo,AC3286,-37.06120436,0,-30.38239243,-34.78128529,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00142483-09,CYTIDINE,405558808,Dna Polymerase Inhibitors; Nucleoside,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),65-46-3,,39.81071706,0,-4.4,-27.2332516,-3,4,,-47.49993125,-41.24994271,0.129941607,0.989446539,,POLB,NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,Microsource,1503431,-4.25310383,0,0,-41.24994271,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163157-05,Mesoridazine,170465272,D(2) dopamine receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5588-33-0,,10,0,-5,-157.2476517,-2.3,4,,-67.18370148,-87.05291649,0.179006238,0.979704142,1813,DRD2,CS(=O)c2cc3N(CCC1CCCCN1C)c4ccccc4Sc3cc2,"Prestwick Chemical, Inc.",Prestw-529,-25.13394629,-14.16557154,-59.05810534,-87.05291649,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181016-04,Bexarotene,170465308,Retinoid RXR Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),153559-49-0, ; LG69 compound; Bexarotene;Bexarotene;Targretin; Elan brand of bexarotene; Bexarotene (Targretin); 3-methyl-TTNEB,3.16227766,1,-5.5,-82.30495861,-1.4,4,,-65.05709798,-58.90130837,0.054828789,0.998142078,6256,RXRA,O=C(O)c1ccc(cc1)C(=C)c2cc3c(cc2C)C(C)(C)CCC3(C)C,CiVentiChem,CV-1209,-3.82532797,-25.07656279,-46.77520281,-58.90130837,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167493-04,Manidipine,174006297,Calcium Channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),89226-75-5,; Manidipine 6300;Manidipine; Manidipine; Mandipine 6300; Calslot;manidipine dihydrochloride,39.81071706,0,-4.4,-28.33562939,-3,4,,-62.45215734,-52.87679778,0.078404584,0.99619066,,,Cl.Cl.[O-][N+](=O)c1cccc(c1)C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OCCN3CCN(CC3)C(c4ccccc4)c5ccccc5,Selleck,S2481,-3.26786081,0,0,-52.87679778,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00065890-14,Nevirapine,405558819,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),129618-40-2,,39.81071706,0,-4.4,-44.83584716,-3,4,,-46.06149937,-41.71791614,0.296777565,0.941450634,,TERT,CC1=CC=NC2=C1NC(=O)C3=CC=CN=C3N2C4CC4,MedChem Express,HY-10570,-10.04698659,0,0,-41.71791614,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094047-10,Ivermectin,405558905,Glutamate-gated Chloride Channel Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),70288-86-7,,39.81071706,0,-4.4,-125.7347679,-2.4,4,,-40.85812433,-50.77793826,0.526423737,0.777509859,,,[H][C@@](C)(CC)[C@@]1([H])O[C@]2(CC[C@@H]1C)C[C@@H]3C[C@@]([H])(C\C=C(C)\[C@@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C6/CO[C@]7([H])[C@H](O)C(C)=C[C@@]([H])(C(=O)O3)[C@]67O)O2,APExBIO,A2813,-29.94853429,-15.04529877,-10.47950132,-50.77793826,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015358-18,Disopyramide,174006632,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3737/9/5," Rythmodan P; ;Disopyramide; Searle 703; Disopyramide, (S)-Isomer; Norpace; Disopyramide; Disopyramide, (R)-Isomer; Disopiramida",8.912509381,1,-5.05,-44.73667277,-1.4,4,,-35.63106887,-37.19255739,0.104500947,0.993209131,,,CC(C)N(CCC(c1ccccn1)(c2ccccc2)C(N)=O)C(C)C,Microsource,1500261,-3.57919611,0,-29.99904069,-37.19255739,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015998-06,THIOTHIXENE,405558925,dopamine secretion Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),"5591-45-7, 3313-26-6 [//Z//]",,8.912509381,1,-5.05,-301.3587237,-1.3,4,,-46.71524637,-97.57152108,0.887374493,0.999937536,,,CN(C)[S+]([O-])(=O)C1=CC2=C(SC3=C(C=CC=C3)\C2=C/CCN4CCN(C)CC4)C=C1,Microsource,1500576,-94.25439551,-56.76639364,-81.20128303,-97.57152108,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263129-08,Palbociclib,405558929,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),571189-11-2,,31.6227766,0,-4.5,-198.2015609,-2.3,4,,-84.57591982,-89.71574903,0.106875649,0.992891043,,CDK4,CC(=O)C\1=C(/C)C2=CN=C(NC3=CC=C(C=N3)N4CCNCC4)N=C2N(C5CCCC5)C1=O,Axon Medchem,1505,-33.20739075,-41.66307675,-54.06864433,-89.71574903,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183872-01,Brotizolam,144207150,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57801-81-7,,39.81071706,0,-4.4,-47.11706541,-2.4,4,"We 941;CIPLUS_183076;2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine;brotizolamum;Lendormin;Europharma brand of brotizolam;Sintonal;Boehringer Ingelheim brand of brotizolam;Lindormin;Brotizolam;brotizolam;LS-152570;Lendorm;WE-941;2-BROMO-4-(2-CHLOROPHENYL)-9-METHYL-6H-THIENO(3,2-F)-S-TRIAZOLO(4,3-A)(1,4)DIAZEPINE;Brotizolamum;BROTIZOLAM;Promeco brand of brotizolam;WHO NO. 4549;WE 941;",-79.50077153,-70.41730961,0.546947154,0.753570661,,,Clc4ccccc4C2=NCc1nnc(C)n1c3sc(Br)cc23,Toronto Research,B689280,0,-32.1841829,0,-70.41730961,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346691-02,Canagliflozin,405558992,SGLT-2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),842133-18-0,,39.81071706,0,-4.4,-27.35876502,-3,4,,-39.64988372,-37.20823643,0.597439942,0.685116894,,SCL5A2,CC1=C(CC2=CC=C(S2)C3=CC=C(F)C=C3)C=C(C=C1)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O,Selleck,S2760,0,-20.531136,0,-37.20823643,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016362-05,Benzonatate,170465391,Slowly adapting pulmonary stretch receptor Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),104-31-4,,44.66835922,0,-4.35,-177.1939654,5,4,,-25.24123159,-55.37700745,0.07114978,0.996874977,,,O=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)c1ccc(NCCCC)cc1,Prestwick,Prestw-12,-35.93345876,-36.11654818,-34.9899622,-55.37700745,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182996-01,Pamicogrel,144206832,platelet aggregation Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),101001-34-7,KBT-3022; ,14.12537545,0,-4.85,-67.34125207,-2.2,4,"KB-3022;KB 3022;pamicogrel;1H-Pyrrole-1-acetic acid, 2-(4,5-bis(4-methoxyphenyl)-2-thiazolyl)-, ethyl ester;LS-136537;CIPLUS_207912;PAMICOGREL;Pamicogrel;ETHYL 2-(4,5-BIS(P-METHOXYPHENYL)-2-THIAZOLYL)PYRROLE-1-ACETATE;pamicogrelum;ethyl 2-(4,5-bis(4-methoxyphenyl)thiazol-2-yl)pyrrol-1-ylacetate;KBT-3022;",-70.11395633,-65.05732112,0.0091544,0.999948325,,,O=C(OCC)Cn1cccc1c2nc(c(s2)c3ccc(OC)cc3)c4ccc(OC)cc4,Pharmaron,PH-NIH-151650,-4.62615812,-9.88716844,-34.00576786,-65.05732112,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015718-12,Naftopidil,170466026,alpha1-Adrenoceptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57149-07-2,;Naftopidil;Naftopidil dihydrochloride; Flivas; KT-611 dihydrochloride; Naftopidil,3.548133892,1,-5.45,-100.5813654,-1.2,4,,-34.3814883,-45.1177958,0.009672782,0.99994237,148,ADRA1A,OC(CN1CCN(CC1)c2ccccc2OC)COc4cccc3ccccc34,Tocris,597,-13.37733243,-23.59945475,-40.16035503,-45.1177958,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167521-02,Tenatoprazole,170465931,Potassium-transporting ATPase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),113712-98-4,,19.95262315,0,-4.7,-35.81047763,-2.2,4,,-75.6033021,-67.50250159,0.016489448,0.999832295,,IDO1,Cc3c(OC)c(C)cnc3CS(=O)c1nc2nc(ccc2n1)OC,Sequoia,SRP011927t,0,0,-17.45943159,-67.50250159,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090793-05,"NAPHTHALENE, ZONE REFINED",225144198,Metabolism of xenobiotics by cytochrome P450 Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),91-20-3,,11.22018454,0,-4.95,-22.11410811,-2.2,4,,-32.60133931,-32.16778276,0.042901789,0.998864532,,,C1=CC=C2C=CC=CC2=C1,SIGMA,147141,0,0,-15.54940108,-32.16778276,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016374-05,Carbarsone,170466507,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),121-59-5,,7.943282347,1,-5.1,-81.52785619,-1.4,4,,-31.77576522,-36.06313768,0.528624726,0.775068276,,,O=C(N)Nc1ccc(cc1)[As](O)(O)=O,"Prestwick Chemical, Inc.",Prestw-413,-16.4837265,3.69832861,-31.3285874,-36.06313768,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00246968-04,Olmesartan,405558442,Angiotensin AT1 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),144689-24-7,,39.81071706,0,-4.4,-85.87883801,-3,4,,-44.79805219,-41.6345929,0.800939525,0.74851208,,AGT,CCCC1=NC(=C([N]1CC2=CC=C(C=C2)C3=CC=CC=C3C4=N[NH]N=N4)C(O)=O)C(C)(C)O,Microsource,1505206,-22.79431446,-24.72572928,0,-41.6345929,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386242-02,Cilengitide,405558444,Integrin alpha-V/beta-5 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),188968-51-6,,39.81071706,0,-4.4,-139.7536973,-2.3,4,,-72.1469637,-69.00880594,0.759424478,0.809965624,,,CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,MedChem Express,HY-16141,-38.76464617,-34.34903424,2.62722837,-69.00880594,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390646-02,Isavuconazole,405558433,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),241479-67-4,,39.81071706,0,-4.4,-25.60309205,-3,4,,-87.81574398,-73.17978665,0.006832298,0.999971211,,,C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](O)(C[N]3C=NC=N3)C4=CC(=CC=C4F)F,MedChem Express,HY-14273,0,0,0,-73.17978665,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181783-03,Iguratimod,405558470,NF-kappaB (NFKB) Activation Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),123663-49-0,,35.48133892,0,-4.45,-15.01832183,-3,4,,-55.88434874,-46.57029062,0.040698434,0.99897749,24835,NFKB1,C[S+]([O-])(=O)NC1=CC2=C(C=C1OC3=CC=CC=C3)C(=O)\C(=C/O2)NC=O,MedChem Express,HY-17009,0,1.82538657,0,-46.57029062,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00510749-15,Loracarbef,405558434,Bacterial penicillin-binding protein Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),121961-22-6,,3.16227766,1,-5.5,-36.99788475,-2.4,4,,-69.78865547,-24.27374213,1,0.999968206,,,N[C@@H](C(=O)N[C@H]1[C@H]2CCC(=C(N2C1=O)/C(O)=O)/Cl)C3=CC=CC=C3,USP,1370203,0,-19.35752556,-67.35846971,-24.27374213,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182049-02,Nitroscanate,225144331,ATP biosynthetic process Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,31.6227766,0,-4.5,-49.354712,-2.3,4,,-118.7616952,-97.49736456,0.080548895,0.995976967,,,[O-][N+](=O)C1=CC=C(OC2=CC=C(C=C2)N=C=S)C=C1,Oakwood,8991,0,-7.38173815,-14.44391258,-97.49736456,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00532513-01,ADRENOCHROME MONOAMINOGUANIDINE MESILATE ANHYDROUS,405558436,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,1.995262315,1,-5.7,-42.57984097,-1.2,4,,-32.5952876,-30.496073,0.00856776,0.999954791,,,CN1CC(O)C/2=C/C(=N/NC(N)=N)C(=O)/C=C12,Carbosynth,FA17227,0,-16.39968149,-29.28868785,-30.496073,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00261966-01,NCGC00261966-01,405558496,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,Selamectin,39.81071706,0,-4.4,-21.83783654,-3,4,,-40.13968925,-38.44974104,0.448433842,0.851109163,,,CO[C@H]1C[C@H](O[C@@H](C)[C@H]1O)O[C@H]\2[C@@H](C)\C=C\C=C\3CO[C@@H]4C\C(=C/[C@@H](C(=O)O[C@H]5C[C@@H](C/C=C2C)O[C@@]6(CC[C@H](C)[C@H](O6)C7CCCCC7)C5)[C@]34O)C,GVK,FFS-11-286-NCI-104,0,-14.08553329,2.08057087,-38.44974104,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163470-27,FK-506,405558441,mTOR Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),109581-93-3,,11.22018454,0,-4.95,-43.17314552,-2.4,4,,-60.76499436,-59.96758737,0.845494999,0.999576754,,MTOR,CO[C@@H]1C[C@@H](CC[C@H]1O)/C=C(C)/[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@H]([C@H](C[C@@H](C)C\C(=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC)[C@H](C[C@H]4C)OC,Microsource,1503968,-49.86059222,0,-31.77625707,-59.96758737,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179445-03,Dydrogesterone,170465104,signaling/transport,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),152-62-5,,0.707945784,1,-6.15,-50.03005857,-1.4,4,,-34.97414234,-47.08023579,0.748252111,0.331959959,,,CC(=O)[C@H]2CC[C@H]3[C@@H]4C=CC1=CC(=O)CC[C@@]1(C)[C@@H]4CC[C@]23C,"Prestwick Chemical, Inc.",Prestw-671,0,-48.04377223,0,-47.08023579,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179239-05,Clocortolone pivalate,405559113,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),34097-16-0,,39.81071706,0,-4.4,-24.4440715,-3,4,,-48.39134073,-41.15945061,0.102318699,0.993491375,,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)\C4=C\C(=O)\C=C/[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Prestwick,Prestw-1119,-3.33694643,0,0,-41.15945061,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181750-01,Cefozopran hydrochloride,144206474,Bacterial penicillin-binding protein Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),113981-44-5,Cefozopran; Firstcin; ,8.912509381,1,-5.05,-109.0771794,-2.4,4,Cefozopran Hydrochloride;CEFOZOPRAN;LS-172220;Cefozopran;CEFOZOPRAN HYDROCHLORIDE;CIPLUS_766339;SCE-2787;CZOP;Firstcin;cefozopranum;SCE 2787;cefozopran;CIPLUS_214061;Cefozopran hydrochloride;,-47.91860362,-32.82524565,1,0.90197361,,,Cl.CO\N=C(/c1nc(N)sn1)C(=O)N[C@@H]5C(=O)N4C(C([O-])=O)=C(C[n+]3ccn2ncccc23)CS[C@@H]45,ACC,CEFOZOPRAN HYDROCHLORIDE,-26.72444997,-12.8852392,-56.34915959,-32.82524565,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167422-01,Enflurane,144205979,Glycine receptor Positive Allosteric Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13838-16-9,Enflurane; Ethrane; Enflurano; Pisa Brand of Enflurane; Enlirane; Zeneca Brand of Enflurane; Etran; Abbott Brand of Enflurane; Alyrane; Enfran; ,39.81071706,0,-4.4,-83.68046462,-3,4,"enfluranum;LS-7376;Enfran;ENFLURANE;Alyrane;Etran;Zeneca Brand of Enflurane;Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-;Enflurano;Baxter Anaesthesia Brand of Enflurane;CIPLUS_169039;HS_566;Pisa Brand of Enflurane;Enlirane;Enflurane;Ethrane;AstraZeneca Brand of Enflurane;nsc-115944;Enfluranum;Abbott Brand of Enflurane;enflurane;",-58.98477852,-53.32064877,0.513657713,0.791152704,,,FC(Cl)C(F)(F)OC(F)F,Alfa Aesar,L16725,-22.65915497,4.5466952,0,-53.32064877,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166289-02,Hydroxystilbamidine bis(methanesulfonate),124893257,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,19.95262315,0,-4.7,-134.0065591,-2.4,4,,-55.06223218,-63.96545787,0.410376381,0.879273432,,,NC(=N)C1=CC=C(C=C1)/C=C/C2=CC=C(C=C2O)C(N)=N,FLUKA,39286,-27.51232373,-9.89347684,-31.36886916,-63.96545787,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378622-03,Osimertinib mesylate,405558589,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1421373-65-0,,3.548133892,1,-5.45,-152.3732324,-1.3,4,,-82.64836086,-98.32577861,0.07982525,0.996049355,,EGFR,COC1=C(NC2=NC=CC(=N2)C3=C[N](C)C4=C3C=CC=C4)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,Axon Medchem,2342,-11.60357996,-27.89760622,-91.00907638,-98.32577861,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016010-09,Terbutaline hemisulfate,170464990,cAMP biosynthetic process Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),23031-32-5,,12.58925412,0,-4.9,-43.58745937,-2.4,4,,-62.56762215,-45.12698648,0.300735685,0.939757087,,,Oc1cc(cc(O)c1)C(O)CNC(C)(C)C.O=S(=O)(O)O.CC(C)(C)NCC(O)c1cc(O)cc(O)c1,Microsource,1500558,0,-17.21156122,-22.59005293,-45.12698648,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015162-10,Buspirone,170464909,Serotonin 1a (5-HT1a) receptor Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),36505-84-7,,19.95262315,0,-4.7,-20.08474634,-3,4,,-50.86636521,-45.35330698,0.082988984,0.995730294,,,O=C4CC1(CCCC1)CC(=O)N4CCCCN2CCN(CC2)c3ncccn3,Enzo,AC526,0,3.22512713,-9.26390778,-45.35330698,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167356-07,Raltegravir,405559137,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),871038-72-1,,10,0,-5,-449.4677921,5,4,,1.33082556,-93.78474508,0.475561155,0.925985255,,,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C2=NN=C(C)O2)C(=O)NCC3=CC=C(F)C=C3,Selleck,S2005,-94.58370376,-94.89376638,-94.05461284,-93.78474508,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015767-10,Oxybutynin chloride,405559139,Muscarinic Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1508-65-2, Oxibutinina; ;; Oxytrol; Tropax;Oxybutynin Chloride; Esoxybutynin Chloride; Ditropan; Oxybutinin;OXYBUTYNIN CHLORIDE; Oxybutynin Hcl; Oxybutynin Chloride;Oxybutynin chloride,22.38721139,0,-4.65,-84.34843221,-2.4,4,,-59.26343878,-57.39654453,0.409769934,0.879675834,,CHRM1,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C2=CC=CC=C2,SIGMA,O2881,-18.16495728,0,-13.73580143,-57.39654453,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090774-05,Nitazoxanide,170465090,antiprotozoal agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55981-09-4,Nitazoxanide; ; Alinia; Nitazoxanida; Nitazoxanide,6.309573445,1,-5.2,-137.9492449,-1.3,4,,-94.54332808,-97.18276931,0.137445799,0.988164178,,,O=C(Nc1ncc(s1)[N+]([O-])=O)c2ccccc2OC(C)=O,Vitas,STK395664,-12.46127849,0,-95.13373911,-97.18276931,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179034-07,Pentamidine isethionate,170464786,PRL Phosphatase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),140-64-7," cis-Pt(II) pentamidine; Pentamidin; Pt-pentamidine complex; platinum(II) pentamidine;4,4 -(Pentane-1,5-diylbis(oxy))dibenzimidamide; Pentam 300; Pt-pent; cis-Pt pentamidine iodide;Pentamidine isethionate;",39.81071706,0,-4.4,-93.06344226,-3,4,,-49.22036379,-45.65487617,0.777139599,0.797797878,,PTP4A1,OCCS(=O)(=O)O.OCCS(=O)(=O)O.N=C(N)c1ccc(cc1)OCCCCCOc2ccc(cc2)C(=N)N,"Prestwick Chemical, Inc.",Prestw-553,-25.45062683,-23.56528151,0,-45.65487617,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015771-13,Orphenadrine dihydrogen citrate,170464910,Muscarinic Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),4682-36-4,; ; Mebedrol; Norgesic forte; Orphenadrine citrate salt; Orfenadrina; Orphenadrine Hcl;ORPHENADRINE CITRATE;Orphenadrine dihydrogen citrate; Orphenadrine hydrochloride;Orphenadrine hydrochloride,7.943282347,1,-5.1,-40.34527935,-1.2,4,,-42.45337568,-43.29447973,0.037930828,0.999112051,,CHRM1,O=C(O)C(O)(CC(=O)O)CC(=O)O.CN(C)CCOC(c1ccccc1)c2ccccc2C,Microsource,1500447,0,-1.55912706,-34.52029895,-43.29447973,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016866-11,Pipemidic acid,170465767,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),51940-44-4,,6.309573445,1,-5.2,-14.16271834,-3,4,,-50.84930155,0,1,0.996394875,,,O=C(O)C2=CN(CC)c1nc(ncc1C2=O)N3CCNCC3,Microsource,1502024,0,2.98624092,-46.61972366,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00186653-01,NCGC00186653-01,170465265,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),440-17-5,,35.48133892,0,-4.45,-57.53836996,-3,4,,-113.8471785,-91.78129168,0.387010274,0.894502366,,DRD2,Cl.Cl.FC(F)(F)c2cc3N(CCCN1CCN(C)CC1)c4ccccc4Sc3cc2,Labotest,LT00452002,0,-27.02788003,-9.37632717,-91.78129168,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091070-02,Diisopropylamine,170466002,Pyruvate dehydrogenase kinase isoform 4 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),108-18-9,,1.258925412,1,-5.9,-51.76072512,-1.4,4,,-53.20324578,-23.91179474,1,0.999923687,,,CC(C)NC(C)C,Labotest,LTBB000412,0,-47.90533794,-52.50300535,-23.91179474,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344584-01,Verapamil,170464904,Calcium Channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52-53-9,,19.95262315,0,-4.7,-72.0373319,-2.4,4,,-47.91785122,-52.63301499,0.144517891,0.986901485,,DRD2,COc1cc(ccc1OC)C(C#N)(CCCN(C)CCc2ccc(OC)c(OC)c2)C(C)C,SIGMA,V106,-11.71879373,-6.29810714,-19.9764269,-52.63301499,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346550-02,Lumacaftor,405559081,CFTR Channel Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),936727-05-8,,3.16227766,1,-5.5,-55.89001864,-2.4,4,,-43.20078275,-25.02940993,1,0.99999841,,CFTR,CC1=C(N=C(NC(=O)C2(CC2)C3=CC4=C(OC(F)(F)O4)C=C3)C=C1)C5=CC=CC(=C5)C(O)=O,Selleck,S1565,-35.67837345,-10.88612709,-44.52994321,-25.02940993,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179370-05,Methotrimeprazine maleat salt,405559100,Serotonin 2 (5-HT2) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7104-38-3,,19.95262315,0,-4.7,-49.09229923,-2.3,4,,-105.0098482,-92.75076007,0.621913801,0.999978692,,,COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1,Prestwick,Prestw-797,-39.12189549,0,-23.82873541,-92.75076007,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016710-05,Clemastine fumarate,170465318,Histamine H1 Receptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),14976-57-9, ;CLEMASTINE FUMARATE; Clemastine fumarate salt; Meclastine;Clemastine fumarate; Corto-Tavegil; Clemastine fumarate; Tavist; Tavegyl;CLEMASTINE; Clemastina,10,0,-5,-67.46410557,-2.1,4,,-86.17676711,-85.48004646,0.014918519,0.999862714,9704,HRH1,CN3CCC[C@@H]3CCO[C@](C)(c1ccccc1)c2ccc(Cl)cc2.O=C(O)/C=C/C(=O)O,Microsource,1500191,0,-2.03624649,-51.74005238,-85.48004646,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166088-02,Decitabine,170465126,DNA Methyltransferase (DNMT) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2353-33-5, ;5-Aza-2 -deoxycytidine; Dacogen; 5-Aza-2??-deoxycytidine;Decitabine; Decitabine,19.95262315,0,-4.7,-54.22586836,-2.4,4,,-77.48772182,-71.48045774,0.356669721,0.912304359,1786,DNMT1,NC1=NC(=O)N(C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2,Tocris,2624,0,-20.29368312,-21.53820711,-71.48045774,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015802-18,Pimozide,170464864,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2062-78-4,,11.22018454,0,-4.95,-57.45130313,-2.2,4,,-80.69674546,-78.68135567,0.042702903,0.99887372,,,Fc1ccc(cc1)C(CCCN2CCC(CC2)N3c4ccccc4NC3=O)c5ccc(F)cc5,NCGCChem,NCGC00015802-17pur,0,0,-42.84562968,-78.68135567,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017112-10,Ciclopirox,170464708,Antifungal Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),41621-49-2,; Dafnegin-CSC;Ciclopirox ethanolamine; Ciclopirox ethanolamine; Penlac;Ciclopirox; Batrafen; Loprox;ciclopirox; ciclopirox,39.81071706,0,-4.4,-56.95023348,-2.3,4,,-119.6694205,-94.1167584,0.604595551,0.673742925,,CAT,CC=2C=C(C1CCCCC1)N(O)C(=O)C=2.NCCO,Microsource,1500189,4.29868623,-47.81446323,-5.10079273,-94.1167584,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015735-11,Niclosamide,170465184,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),50-65-7, Yomesan;Niclosamide; Niclosamida;NICOLSAMIDE; ; Bayluscide;NICLOSAMIDE; Niclocide; Phenasal; Fenasal; Niclosamid; Radewerm; Bayer 73; Bayer 2353; Niclosamide; Clonitralide; Niclosamidel; Devermine; Niclosamide-olamine; Tr??d??mine,0.501187234,1,-6.3,-191.8696506,-1.1,4,,-98.79187314,-98.36572474,0.03034255,0.999431735,6774,STAT3,Clc2cc(ccc2NC(=O)c1cc(Cl)ccc1O)[N+]([O-])=O,Vitas,STK396676,0,-95.48091495,-95.61839161,-98.36572474,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00162179-08,cis-Flupentixol,170465964,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),53772-82-0,,2.511886432,1,-5.6,-95.02858594,-1.4,4,,-79.93330495,-77.57307452,0.209547617,0.971904677,,,FC(F)(F)c2cc3C(=C\CCN1CCN(CCO)CC1)/c4ccccc4Sc3cc2,Tocris,4057,0,-38.28295773,-58.91750615,-77.57307452,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016311-19,Phentolamine mesilate,170464866,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),50-60-2, Regitine;Phentolamine mesylate;Phentolamine;PHENTOLAMINE; ; Regitin;Phentolamine hydrochloride; Regitin mesylate; Vasomax;PHENTOLAMINE HYDROCHLORIDE; Phentolamine hydrochloride; Fentolamina;,10,0,-5,-20.96547062,-2.4,4,,-53.25889112,-34.28703873,0.334359971,0.924104905,148,ADRA1A,Cc1ccc(cc1)N(CC2=NCCN2)c3cc(O)ccc3,Vitas,STK802099,3.3445096,-12.01907825,-15.2361257,-34.28703873,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00013895-08,Benzbromarone,170465792,Xanthine dehydrogenase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3562-84-3,,3.548133892,1,-5.45,-95.64867301,-1.2,4,,-31.75862246,-37.70826943,0.037623193,0.999128602,,,Brc1cc(cc(Br)c1O)C(=O)c2c3ccccc3oc2CC,Labotest,LT00134669,-14.79483085,-22.11226564,-32.18777137,-37.70826943,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164553-02,Clofarabine,170465145,DNA Polymerase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),123318-82-1, Clofarabine; ; Clolar;Clofarabine,19.95262315,0,-4.7,-49.31931043,-2.1,4,,-105.7114862,-96.87982152,0.008291688,0.999957595,,POLA1,Nc3nc(Cl)nc2c3ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,Sequoia,SRP03671c,0,0,-22.08531483,-96.87982152,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00161621-03,Cepharanthine,170465994,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),481-49-2,,1.122018454,1,-5.95,-207.3350303,-1.3,4,,-91.45864328,-100.9460082,0.052105277,0.998321865,,,COc8ccc1cc8Oc7ccc(C[C@H]4c5c(Oc3cc2c(CCN(C)[C@@H]2C1)cc3OC)c6OCOc6cc5CCN4C)cc7,Vitas,STK801907,-14.38879395,-87.52420832,-96.75517654,-100.9460082,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159412-04,Tromethamine,170464686,calcium ion transport Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),77-86-1,,39.81071706,0,-4.4,-26.3799974,-3,4,,-44.56038105,-36.78816746,0.462948634,0.839194796,,,OCC(N)(CO)CO,Labotest,LT03329109,0,-14.62255706,-4.71836693,-36.78816746,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262941-01,Ipenoxazone hydrochloride,170465754,Glutamate [NMDA] receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),118635-68-0,"2-Oxazolidinone,",39.81071706,0,-4.4,-93.0294561,-2.4,4,,-80.02209466,-73.73228927,0.55035746,0.749432178,,,Cl.CC(C)C[C@H]3N(CCCN1CCCCCC1)C(=O)O[C@H]3c2ccccc2,GVK,FFS-11-286-NCI-165,-9.42043931,-39.81008818,-15.85278355,-73.73228927,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159491-04,Rimantadine,170465164,M2 Channel Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1501-84-4,"; Flumadine; Riamantadine;Rimantadine hydrochloride; Rimantadina; ; Hydrochloride, Rimantadin; Flumadine Oral; Roflual;RIMANTADINE HYDROCHLORIDE; Rimantadine hydrochloride; Rimantadine Hcl",35.48133892,0,-4.45,-35.52676798,-3,4,,-80.17743986,-65.28593929,0.171766783,0.981354027,,,Cl.CC(N)C12CC3CC(C1)CC(C2)C3,Vitas,STK177253,0,-9.92351832,-8.23874282,-65.28593929,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015798-11,Dexpropranolol,170464682,Adrenergic receptor beta Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5051-22-9,,4.466835922,1,-5.35,-51.92237125,-1.4,4,,-49.06628197,-37.08169481,0.356305319,0.912508126,,,CC(C)NC[C@@H](O)COc2cccc1ccccc12,Specs,AN-153/I110481,0,1.52713045,-57.29586886,-37.08169481,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390656-02,Pimavanserin,405558435,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),706779-91-1,,39.81071706,0,-4.4,-34.61128816,-3,4,,-118.7128498,-98.9273748,0.006832298,0.999971208,,,CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1,MedChem Express,HY-14557,0,0,0,-98.9273748,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167536-03,Tosufloxacin toluenesulfonic acid,170466053,Topoisomerase IV Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),115964-29-9,,39.81071706,0,-4.4,-30.22867033,-3,4,,-56.19704478,-48.49753732,0.114535459,0.991824486,,,O=S(=O)(O)c1ccc(C)cc1.O=C(O)C2=CN(c1nc(c(F)cc1C2=O)N3CCC(N)C3)c4ccc(F)cc4F,Sequoia,SRP02535t,-4.40584584,0,0,-48.49753732,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253604-01,Rescimetol,170465875,smooth muscle contraction Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),73573-42-9,,39.81071706,0,-4.4,-28.23885502,-3,4,,-96.85611638,-80.71343032,0.006832298,0.99997121,,,Oc1ccc(cc1OC)/C=C/C(=O)O[C@@H]3C[C@@H]4CN5CCc2c6ccc(OC)cc6nc2[C@H]5C[C@@H]4[C@@H]([C@H]3OC)C(=O)OC,GVK,FFS-11-286-NCI-194,0,0,0,-80.71343032,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178839-08,NAD+,405558451,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),53-84-9,,28.18382931,0,-4.55,-12.56993912,-3,4,,-41.51583553,-35.23926934,0.163836926,0.98308453,,,NC(=O)C1=C[N+](=CC=C1)[C@@H]2O[C@H](CO[P]([O-])(=O)O[P](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)[N]4C=NC5=C(N)N=CN=C45)[C@@H](O)[C@H]2O,Adooq,A11679,-1.02459932,4.76223137,-0.69216014,-35.23926934,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095191-12,Oseltamivir Phosphate,405558461,Neuraminidase (sialidase) Inhibitors,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),204255-11-8,,0.707945784,1,-6.15,-61.46831563,-1.4,4,,-31.35153658,0,1,0.79837229,,NEU1,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Enzo,DL194,-7.12966324,-43.65326299,-27.30677439,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178520-03,Bromhexine hydrochloride,170465803,Mucolytic Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),611-75-6,; Amiorel;abiadin;Bromhexine hydrochloride;Bromhexine HCl;BROMHEXINE HYDROCHLORIDE; Amyorel,35.48133892,0,-4.45,-23.12815888,-3,4,,-80.81290406,-69.42742005,0.025605346,0.999595464,,,Cl.CN(Cc1cc(Br)cc(Br)c1N)C2CCCCC2,Vitas,STK177356,0,1.66373444,0,-69.42742005,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185990-04,Ketorolac,170464659,non-steroidal antiinflammatory,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),74103-07-4,Ketorolac tromethamine;KETOROLAC TROMETHAMINE,39.81071706,0,-4.4,-29.15852793,-3,4,,-41.04550401,-36.28792001,0.268090741,0.952914438,,PTGS1,OCC(N)(CO)CO.O=C(O)[C@@H]1CCn2c(ccc12)C(=O)c3ccccc3,Vitas,STL018674,-6.20348674,0,3.16307544,-36.28792001,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016912-06,Terconazole,405558493,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),67915-31-5,,15.84893192,0,-4.8,-161.1407006,-2.3,4,,-107.9513348,-91.85994173,0.911021326,0.997451695,,,CC(C)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=NC=N4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2,Prestwick,Prestw-495,-96.24593527,-24.82682646,-52.88514495,-91.85994173,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016600-08,Clofazimine,387065713,DNA Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2030-63-9,,39.81071706,0,-4.4,-150.1644968,-2.4,4,,-36.37605587,-51.0069539,0.670259913,0.551547551,,,CC(C)\N=C\1/C=C\2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)\N=C2\C=C1NC5=CC=C(Cl)C=C5,SIGMA,C8895,-34.33865958,-28.32461317,-13.14322631,-51.0069539,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015838-06,Propionylpromazine hydrochloride,170466841,Trypanothione reductase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7681-67-6,,39.81071706,0,-4.4,-30.96772659,-3,4,,-106.2158408,-88.51320069,0.006832298,0.999971209,,,Cl.CCC(=O)c1cc2N(CCCN(C)C)c3ccccc3Sc2cc1,SIGMA,P7780,0,0,0,-88.51320069,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00023699-09,Cephalothin,170465101,Solute carrier family 22 member 7 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),153-61-7,,25.11886432,0,-4.6,-446.4070646,5,4,,13.04830486,-83.56712126,0.181780232,0.97925357,10864,SLC22A7,O=C(O)C=2N3C(=O)[C@@H](NC(=O)Cc1cccs1)[C@H]3SCC=2COC(C)=O,Microsource,1500166,-94.46399045,-96.44353388,-93.7566265,-83.56712126,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00319022-01,Octotiamine,170465976,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),137-86-0,,0.707945784,1,-6.15,-62.14261132,-1.4,4,,-34.83272269,-17.45878842,1,0.963962969,,,Nc1nc(C)ncc1CN(C=O)C(\C)=C(/CCO)SSCCC(CCCCC(=O)OC)SC(C)=O,GVK,FFS-11-286-NCI-250,-7.02244146,-41.43103181,-34.6209268,-17.45878842,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164512-02,Guaiacol carbonate,170465684,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),553-17-3,,31.6227766,0,-4.5,-12.69907091,-2.4,4,,-36.88766116,-29.07305097,0.014332794,0.999873474,,,COc2ccccc2OC(=O)Oc1ccccc1OC,Labotest,LT02084807,0,0,-3.61885528,-29.07305097,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015368-11,Dicyclomine,170464896,Muscarinic acetylcholine receptor M3 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),77-19-0,,25.11886432,0,-4.6,-32.83633139,-3,4,,-40.07742574,-34.98208392,0.644937034,0.603818871,,,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,Microsource,1500240,0,-20.86613938,-8.62316719,-34.98208392,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181775-02,Toluidine blue,170466390,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),92-31-9,,14.12537545,0,-4.85,-60.34949387,-2.1,4,,-99.55611743,-97.4086353,0.044076482,0.998799898,,,[Cl-].CN(C)c1ccc2nc3cc(C)c(N)cc3[s+]c2c1,Labotest,LT00451843,-0.25057548,-1.7210479,-34.81272379,-97.4086353,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018167-05,Cladribine,405558565,Adenosine Deaminase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),4291-63-8,,11.22018454,0,-4.95,-184.8922523,-2.2,4,,-70.25010399,-96.59761453,0.035386675,0.999227019,,ADA,NC1=NC(=NC2=C1N=C[N]2C3CC(O)C(CO)O3)Cl,APExBIO,A2187,-28.95517096,-28.91656429,-62.63820438,-96.59761453,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00379052-01,Ticagrelor,405558613,Purinergic receptor P2Y12 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),274693-27-5,,7.079457844,1,-5.15,-35.07552515,-3,4,,-30.54440874,2.37359605,1,0.9421618,,,CCCSC1=NC(=C2N=N[N]([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1)N[C@@H]4C[C@H]4C5=CC=C(F)C(=C5)F,MedChem Express,HY-10064,-7.93403902,0,-32.12034062,2.37359605,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00142611-02,D-HISTIDINE,26754413,Histidine decarboxylase Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,"Histidine; L-Histidine hydrochloride; Cu-His; Zn(His)2; Histidine, L isome; DL-Histidine; L-Histidine-ul-13C,15N; Cu(His)2; poly(L-histidine); polyhistidine, (D)-isomer; Zn-His(2); L-Histidine-2,5-3H; D-His; Histidina; D-His-OH; L-isomer Histidin; L-Histidine-15N3; Fe(II)-histidinate; Levadial; L-Histidine-13C6,15N3; Poly-L-histidine; Pt(His)(adenine); PRu-Hi; Histidine, L-isomer; poly-(alpha-L-histidine); ",17.7827941,0,-4.75,-12.72573631,-2.4,4,"CIPLUS_688453;CIPLUS_670571;L-Histidine Monohydrochloride Monohydrate;L-Histidine monohydrochloride monohydrate;DL-Histidine monohydrochloride monohydrate;L-Histidine-15N3;Poly-L-histidine;L-HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE;CIPLUS_208166;polyhistidine;HISTIDINE, DL-;CIPLUS_163873;CIPLUS_213264;DL-Histidine;L-Histidine Monohydrochloride;poly-(alpha-L-histidine);CIPLUS_207332;(+/-)-2-Amino-3-(4-imidazolyl)propionic acid;S(+)-alpha-Amino-1H-imidazole-4-propanoic acid hydrochloride;HISTIDINE;L-alpha-Amino-beta-(4-imidazolyl)propionic acid monohydrochloride;NCGC00093950-01;Histidine, L isome;L-HISTIDINE;(R)-2-Amino-3-(4-imidazolyl)propionic acid;CIPLUS_3885719;NCGC00162189-01;L-Histidine hydrochloride;D-His;L-isomer Histidin;polyhistidine, (D)-isomer;D-HISTIDINE;L-Histidine;D-Histidine;D-alpha-Amino-beta-(4-imidazolyl)propionic acid;histidinum;CIPLUS_166016;CIPLUS_742841;Histidina;DL-alpha-Amino-beta-(4-imidazolyl)propionic acid monohydrochloride;D-alpha-Amino-beta-(4-imidazolyl)propionic acid monohydrochloride;L-Histidine dihydrochloride;(S)-2-Amino-3-(4-imidazolyl)propionic acid;L-Histidine Monohydrochloride Anhydride;L-Histidine-13C6,15N3;D-His-OH;CIPLUS_215801;CIPLUS_3886763;CIPLUS_149204;L-Histidine-2,5-3H;poly(L-histidine);L-Histidine hydrochloride solution;NCGC00015518-01;Histidinum;D-Histidine monohydrochloride monohydrate;Histidine, L-isomer;CIPLUS_214867;HISTIDINE, L-;L-HISTIDINE MONOHYDROCHLORIDE;L-Histidine monohydrochloride;CIPLUS_3887315;Histidine;CIPLUS_750166;histidine;L-Histidine-ul-13C,15N;NCGC00142611-02;Poly-L-histidine hydrochloride;CIPLUS_711628;",-53.92030408,-44.25780612,0.888499252,0.999924722,3067,HDC,N[C@H](CC1=CNC=N1)C(O)=O,BIOMOL,BIOMOL_AC-1014,-63.02675736,3.089712,-12.45596086,-44.25780612,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344558-01,NCGC00344558-01,225144392,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),129497-78-5,,39.81071706,0,-4.4,-33.92064622,-3,4,,-116.3440251,-96.95335426,0.006832298,0.999971208,,YAP1,COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C\5N=C(C=C1[NH]2)\C(=C5C)CCC(O)=O)C=C)C/6=C/C=C(\[C@H](C(=O)OC)[C@@]36C)C(=O)OC,Prestwick,Prestw-1105,0,0,0,-96.95335426,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181343-03,Ivabradine hydrochloride,405558672,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),148849-67-6,,39.81071706,0,-4.4,-69.74899556,-3,4,,-60.87618742,-56.14682285,0.399709258,0.886404664,,HCN,COC1=C(OC)C=C2CC(=O)N(CCCN(C)C[C@H]3CC4=CC(=C(OC)C=C34)OC)CCC2=C1,MedChem Express,HY-B0162A,-17.45060318,0,3.46362507,-56.14682285,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182977-01,Trimethoquinol,144206771,Beta-3 adrenergic receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),18559-59-6,Tretoquinol; Tetroquinol; Trimetoquinol; Inolin; Tretoquinol-(S) HCl; Tretoquinol-(R); ,5.623413252,1,-5.25,-16.18100631,-3,4,"CIPLUS_207808;AQ11;1,2,3,4-TETRAHYDRO-1-(3,4,5-TRIMETHOXYBENZYL)-6,7-ISOQUINOLINEDIOL MONOHYDRATE HYDROCHLORIDE;TRETOQUINOL;Tretoquinol Hydrochloride, (S)-Isomer;CIPLUS_169251;Inolin;6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-, (S)-;TETRAHYDROISOQUINOLINE;tretoquinol;Trimetoquinol hydrochloride;6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-, hydrochloride, (S)-;AQ-110;Tetroquinol;Trimetoquinol Hydrochloride Anhydride;Tretoquinolum;AQL 20;Tretoquinol;Tretoquinol-(S) HCl;LS-173897;AQ 11;Trimetoquinol;LS-85640;CV 70;Tretoquinol-(R);CIPLUS_171514;CIPLUS_171515;Trimetoquinol Hydrochloride;tretoquinolum;AQL-208;CV-705;CIPLUS_171513;TRIMETOQUINOL HYDROCHLORIDE;l-trimetoquinol;AQL20;CV70;",-57.04257729,-13.04390747,1,0.999989365,,,Cl.COc1cc(cc(OC)c1OC)C[C@@H]2NCCc3cc(O)c(O)cc23,NCI,NSC_288748,-35.2942101,0.64421263,-53.28016416,-13.04390747,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00271513-02,Lofexidine,170466275,Adrenergic receptor alpha-2 Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),31036-80-3,,39.81071706,0,-4.4,-52.70939223,-3,4,,-67.35172869,-59.45977391,0.222124887,0.968286556,,,Clc2cccc(Cl)c2OC(C)C1=NCCN1,Prestwick,Prestw-1430,-10.60059044,0,0,-59.45977391,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00186632-01,Strychnine,124897819,Glycine receptor subunit alpha-1 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1421-86-9,,39.81071706,0,-4.4,-11.64609717,-3,4,STRYCHNINE HCl,-39.94481158,-33.28734298,0.70587095,0.999967648,,,O=C1C[C@@H]2OC\C=C/3C[N@]4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C7=C6C=CC=C7,BIOMOL,AC745,-20.84098476,0,0,-33.28734298,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015686-11,Gallopamil hydrochloride,170465991,Voltage-gated L-type calcium channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),16662-46-7,,28.18382931,0,-4.55,-58.24931429,-3,4,,-74.7260489,-72.49556837,0.072224012,0.996769449,,,Cl.COc1c(cc(cc1OC)C(C#N)(CCCN(C)CCc2ccc(OC)c(OC)c2)C(C)C)OC,Enzo,AC103,-7.83824684,-3.30675112,-9.9995803,-72.49556837,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00522014-01,Zolazepam Hydrochloride,405558721,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),33754-49-3,,7.943282347,1,-5.1,-148.4972362,-1.4,4,,-23.45587791,-44.69557635,0.559718806,0.921083527,,,C[N]1N=C(C)C2=C1N(C)C(=O)C\N=C2\C3=CC=CC=C3F,Toronto Research,Z613500,-31.03373929,-16.24756594,-40.23946579,-44.69557635,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389554-01,DORAMECTIN,405558736,chloride transmembrane transport Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),117704-25-3,,39.81071706,0,-4.4,-64.58167903,-3,4,,-46.42613435,-43.11466759,0.685785276,0.862374896,,,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@@H]2[C@H](C)O[C@@H](C[C@@H]2OC)O[C@H]\3[C@@H](C)\C=C\C=C\4CO[C@@H]5C(O)\C(=C/[C@@H](C(=O)O[C@H]6C[C@@H](C/C=C3C)O[C@@]\7(C6)O[C@@H]([C@@H](C)\C=C7)C8CCCCC8)[C@]45O)C,Microsource,1505902,-16.49613749,-21.37505314,0,-43.11466759,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249414-01,Fonazine,144206752,Serotonin (5-HT) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7456-24-8,,31.6227766,0,-4.5,-81.49831962,-2.3,4,,-89.45337459,-88.49751382,0.12148045,0.990786804,3269,,CN(C)S(=O)(=O)c1cc2N(CC(C)N(C)C)c3ccccc3Sc2cc1,NCGCChem,DJM10-019,-8.07754776,0,-34.23606975,-88.49751382,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00408838-01,Piroheptine Hydrochloride,405558780,Muscarinic acetylcholine receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),16378-22-6,,12.58925412,0,-4.9,-52.85272793,-2.4,4,,-78.28796995,-59.35553171,0.180713851,0.979308899,,,CCN1CCC(C1C)=C2C3=CC=CC=C3CCC4=CC=CC=C24,Glixx,GLXC-06115,0,-16.01765442,-29.92270538,-59.35553171,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00384190-03,(S)-Crizotinib,405558812,HGFR (MET; c-Met) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1374356-45-2,,39.81071706,0,-4.4,-96.32785701,-2.3,4,,-65.67327422,-65.22271046,0.68042137,0.892070379,,MET,C[C@H](OC1=CC(=CN=C1N)C2=C[N](N=C2)C3CCNCC3)C4=C(Cl)C=CC(=C4Cl)F,Axon Medchem,2296,-36.05703613,-25.62789944,-3.70155208,-65.22271046,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00348372-01,LINDANE,405558821,GABA-A receptor Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58-89-9,,39.81071706,0,-4.4,-16.46956852,-3,4,,-43.49462518,-37.91218765,0.151887182,0.985508195,,,[Cl][C@H]1[C@H]([Cl])[C@H]([Cl])[C@@H]([Cl])[C@H]([Cl])[C@@H]1[Cl],SigmaAldrich,233390,0,-4.5890096,0,-37.91218765,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015754-16,Nilutamide,170465021,Androgen Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),63612-50-0, ;Nilutamide; Nilutamide;NILUTAMIDE; Nilandron,35.48133892,0,-4.45,-58.95389067,-2.1,4,,-105.1853044,-86.05308537,0.011051748,0.999924666,374,AR,FC(F)(F)c1cc(ccc1[N+]([O-])=O)N2C(=O)C(C)(C)NC2=O,Microsource,1504152,-5.76449356,-5.25571436,-11.20471622,-86.05308537,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015725-15,Nimesulide,170465612,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),51803-78-2,; ;NIMESULIDE; Nimesulide;Nimesulide; Nimesulida,39.81071706,0,-4.4,-27.00968761,-3,4,,-39.35755422,-36.96462852,0.592281189,0.692888459,5743,PTGS2,[O-][N+](=O)c2cc(Oc1ccccc1)c(cc2)NS(C)(=O)=O,Vitas,STL018679,0,-20.15339869,0,-36.96462852,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159456-11,Imatinib,170465393,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),220127-57-1,GGP-57148B; ; Imatinib base; Imatinib base(IMA-3);STI-571; Imatinib;Imatinib;Gleevec; Glivec,12.58925412,0,-4.9,-59.19814111,-2.1,4,,-93.59884749,-90.78318381,0.026790164,0.999557097,25,ABL1,CS(=O)(=O)O.Cc3ccc(cc3Nc1nc(ccn1)c2cccnc2)NC(=O)c4ccc(cc4)CN5CCN(C)CC5,Prestwick,Prestw-1290,0,0,-39.2843831,-90.78318381,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00022680-05,Chlormadinone acetate,170465776,Androgen receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),302-22-7,,39.81071706,0,-4.4,-59.08819975,-3,4,,-33.81200865,-32.76000721,0.518636724,0.786127011,367,AR,CC(=O)[C@@]3(OC(C)=O)CC[C@H]2[C@@H]4C=C(Cl)C1=CC(=O)CC[C@]1(C)[C@H]4CC[C@@]23C,Prestwick,Prestw-1374,-14.32253308,-6.46755854,0,-32.76000721,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091886-04,Denatonium benzoate,170464678,Glycolysis / Gluconeogenesis Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3734-33-6,,39.81071706,0,-4.4,-22.32880365,-3,4,,-39.19583042,-33.49652535,0.842304536,0.968221847,,,O=C(Nc1c(C)cccc1C)C[N+](Cc2ccccc2)(CC)CC.[O-]C(=O)c1ccccc1,Vitas,STK301730,-40.15479022,-3.50417235,3.41530123,-33.49652535,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181023-03,NOLATREXED HCL,405558825,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),152946-68-4,,19.95262315,0,-4.7,-15.02938362,-2.4,4,,-30.88305492,-27.81921243,0.023203836,0.99966837,,,CC1=C(SC2=CC=NC=C2)C3=C(C=C1)N=C(N)N=C3O,Sequoia,152946-68-4,0,0,-7.58361255,-27.81921243,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274079-01,Sodium urate,170465686,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1198-77-2,,8.912509381,1,-5.05,-62.90929373,-3,4,,-33.56671971,-30.05559976,0.571651722,0.722327621,,,[Na+].O=C1NC(=O)NC=2[N-]C(=O)NC1=2,SIGMA,U0881,-12.80174529,-8.89349798,3.81082514,-30.05559976,,,,,,,,,,,,9.14E-08,4.57E-07,0.00000229,0.0000114,,,,,,,,,,,
NCGC00160567-01,Acetomenaphthone,144205458,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),573-20-6,Acetomenaphtone; Acetomenaphthone; Menadiol diacetate; Vitamin K4; ,63.09573445,0,-4.2,-33.63304839,-3,4,"Menadiol diacetate;ACETOMENAPHTONE;Acetomenaphtone;Vitamin K4;Acetomenaphthone (2-Methyl-1,4-naphthalenediol diacetate);Acetomenaphthone;CIPLUS_154611;",-101.9023376,-96.49842579,0.010823292,0.999927743,,,CC(=O)Oc1cc(C)c(OC(C)=O)c2ccccc12,SigmaAldrich,S353078,0,0,0,-96.49842579,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00017043-03,Denatonium benzoate,405558882,Taste receptor type 2 member 8 Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3734-33-6,,7.943282347,1,-5.1,-33.702779,-1.2,4,,-36.1708767,-36.39239725,0.012678282,0.999900923,50836,TAS2R8,CC[N+](CC)(CC(=O)NC1=C(C)C=CC=C1C)CC2=CC=CC=C2,Prestwick,Prestw-961,0,0,-30.02623235,-36.39239725,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389499-01,TELITHROMYCIN,405558900,Ketolide antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),191114-48-4,,11.22018454,0,-4.95,-34.39719254,-2.2,4,,-49.95865216,-49.03578904,0.026135095,0.999578685,,,CCC1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@@H](C)[C@@H]3N(CCCC[N]4C=NC(=C4)C5=CC=CN=C5)C(=O)O[C@]13C)OC,Microsource,1505265,0,-0.30005003,-24.38669031,-49.03578904,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182027-01,Amogastrin,144206458,Cholecystokinin receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),16870-37-4,Amogastrin; Amogastrina; ,10,0,-5,-103.9768144,-2.4,4,AMOGASTRIN;amogastrin;CIPLUS_214157;Amogastrina;tert-amyloxycarbonyltetragastrin;Amogastrinum;Amogastrin;Amogastrine;amogastrine;amogastrinum;,-50.53918129,-32.86990409,1,0.924688039,,,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)OC(C)(C)CC)Cc3cnc2ccccc23,ACC,AMOGASTRIN,-25.11785937,-14.15346382,-53.04798324,-32.86990409,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166298-02,Melengestrol acetate,170465702,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2919-66-6,,39.81071706,0,-4.4,-16.58360749,-3,4,,-34.75440722,-30.21200602,0.083194219,0.995712676,,,CC(=O)[C@@]3(OC(C)=O)C(=C)C[C@H]2[C@@H]4C=C(C)C1=CC(=O)CC[C@]1(C)[C@H]4CC[C@@]23C,Prestwick,Prestw-1435,-1.99791132,0,0,-30.21200602,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188962-02,Pravastatin sodium,174007284,HMG-CoA Reductase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),81131-70-6,Pravastatin,31.6227766,0,-4.5,-1.194894133,-3,4,,-54.34704238,-43.92622411,0.106378676,0.992958327,3156,HMGCR,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)\C=C2\C=C/[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12,Prestwick,Prestw-1319,4.70895898,0,0,-43.92622411,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253591-01,Nepaprazole,170465906,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),156601-79-5,,39.81071706,0,-4.4,-22.53709233,-3,4,,-41.74763656,-38.9563638,0.384119712,0.896376788,,,COc4ccnc1c4CCCCC1S(=O)c2nc3ccccc3n2,GVK,FFS-11-286-NCI-253,0,-12.53330939,-0.21929277,-38.9563638,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015095-15,Amitriptyline hydrochloride,170464758,Sodium-dependent serotonin transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),549-18-8,,35.48133892,0,-4.45,-37.9745363,-3,4,,-101.3704852,-85.6900535,0.071375447,0.996844882,6532,SLC6A4,Cl.CN(C)CC\C=C1\c3ccccc3CCc2ccccc12,Microsource,1500117,0,-5.6518628,-5.79429549,-85.6900535,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181170-02,Bendamustine,170465340,DNA Alkylating Drugs,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),16506-27-7,Bendamustine HCL;Bendamustine;Inno-P08001; Bendamustine;SyB L-0501;SDX-105,31.6227766,0,-4.5,-14.57548797,-3,4,,-38.28768732,-35.23973943,0.106366322,0.992962837,7515,XRCC1,ClCCN(CCCl)c1cc2nc(CCCC(=O)O)n(C)c2cc1,Sequoia,3543-75-7,-1.29678461,2.3720254,0,-35.23973943,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263117-05,Panobinostat,405558944,HDAC Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),404950-80-7,,4.466835922,1,-5.35,-145.0327715,-1.3,4,,-89.18384514,-97.5160506,0.495950394,0.995164521,,HDAC1,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3[NH]1,Selleck,S1030,45.59383492,-13.00146337,-89.77805004,-97.5160506,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00162222-04,Cibenzoline succinate,405558949,Voltage-sensitive sodium channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),100678-32-8,,1.584893193,1,-5.8,-45.81405852,-1.2,4,,-33.38453326,-30.73711105,0.017602951,0.999809122,,,C1C/N=C(N1)/C2CC2(C3=CC=CC=C3)C4=CC=CC=C4,SIGMA,C1618,0,-20.21393891,-29.98406191,-30.73711105,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167979-01,Methenolone enanthate,144206153,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),303-42-4,Methenolone enanthate; Metenolone enanthate; Metenolone Enanthate; Primobolan Depot; Primobolan depot; ,39.81071706,0,-4.4,-42.92155097,-3,4,"Primobolan Depot;LS-174294;Primobolan depot;Methenolone Enanthate;CIPLUS_152547;methenolone oenanthate;Schering brand of methenolone enanthate;Metenolone Enanthate;Methenolone enanthate;methenolone enanthate, (17beta)-isomer;methenolone enanthate, (17alpha)-isomer;methenolone enanthate;methenolone heptanoate;METHENOLONE ENANTHATE;Metenolone enanthate;",-49.25152221,-44.37626851,0.845865712,0.974610974,,,CCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CC[C@H]1CC(=O)C=C(C)[C@]1(C)[C@H]4CC[C@]23C,Bosche,M5729,-53.74691876,-7.38756345,0,-44.37626851,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262543-01,Midecamycin,405558985,Ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),35457-80-8,,39.81071706,0,-4.4,-50.66263142,-3,4,,-38.26514303,-36.05428586,0.409477076,0.8799501,,,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@@H](O)[C@H](C)C[C@H](CC=O)[C@H](OC2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC,"Prestwick Chemical, Inc.",Prestw-153,-12.5418383,-0.42820668,0,-36.05428586,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389730-01,NCGC00389730-01,405558988,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5133-19-7,,25.11886432,0,-4.6,-14.65030317,-3,4,,-49.69428008,-37.64718188,0.024536031,0.999628835,,,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@@H]2C3=CC=CC(=C3C(=O)C4=C2C=C(CO)C=C4O)O,Microsource,1503427,1.62378021,0,-9.11543842,-37.64718188,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00161336-01,Potassium ricinoleate,26754911,Prostanoid EP3 receptor Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,Ricinoleic acid; 12-Hydroxyoleic acid; ,22.38721139,0,-4.65,-39.10706004,-3,4,"ricinelaidic acid;ricinoleic acid, (R-(E))-isomer;LS-195;12-oxooctadecanoic acid;Ricinoleic acid;RICINOLEIC ACID, SODIUM SALT;CIPLUS_658255;CIPLUS_680366;12-hydroxy-9-octadecenic acid;CIPLUS_750550;RICINOLEIC ACID;CIPLUS_671898;CIPLUS_166631;12-hydroxy-9-octadecenoic acid;CIPLUS_151987;CIPLUS_663822;CIPLUS_3886623;Ricinelaidic acid sodium salt;(R)-12-Hydroxy-9(E)-octadecenoic acid;kyselina 12-hydroxy-9-oktadecenova (czech);12-Hydroxyoleic acid;CIPLUS_661801;CIPLUS_164143;12-ketostearate;CIPLUS_689393;(R)-12-Hydroxy-cis-9-octadecenoic acid;Potassium ricinoleate;CIPLUS_686506;ricinoleic acid;CIPLUS_689370;CIPLUS_664600;LS-143811;HSDB 4280;CIPLUS_684810;POTASSIUM RICINOLEATE;CIPLUS_666567;12-HYDROXY-9-OCTADECENOIC ACID;",-46.57540048,-42.14616707,0.705898611,0.464085604,,,CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O,BIOMOL,BIOMOL_AL-112,0,-28.345027,-6.53310745,-42.14616707,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015580-13,Ketotifen,170465378,Histamine H1 Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),34580-13-7,"Ketotifen; Zaditor;Ketotifen fumarate; Ketotifen fumarate;; ; Fumarate, Ketotife; Ketotiphen;KETOTIFEN FUMARATE; Zaditen; Ketotifen fumarate salt; Ketotifen Maleate; Ketotiphene; Ketotifeno",0.794328235,1,-6.1,-69.80271903,-1.4,4,,-45.08540612,-56.2060068,0.536330003,0.766199327,9704,HRH1,CN1CC/C(CC1)=C3\c4ccccc4CC(=O)c2sccc23,Vitas,STK048448,0,-44.27502932,-27.50902603,-56.2060068,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00023945-12,3'-Azido-3'-deoxythymidine,170464737,Reverse Transcriptase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),30516-87-1,"3'-Azido-3'-deoxythymidine; ; 3'-Azido-3'-deoxythymidine (AZT); Zidovudine, AZT;; 3'-Azido-3'-deoxythymidine; Antiviral AZ; AZT Antiviral; Retrovir; AZTMP-MAN-SA conjugate; 3' Azido 3' deoxythymidin; bis(t-butyl-SATE)-AZTMP; zidovudine (ZDV or AZT);Zidovudine; AZT, Antiviral;Zidovudine, AZT;ZIDOVUDINE [AZT]",1.77827941,1,-5.75,-136.7118347,-1.3,4,,-94.34097401,-93.56600689,0.210483837,0.971641125,7015,TERT,CC1=CN(C(=O)NC1=O)[C@H]2C[C@H](\N=[N+]=[N-])[C@@H](CO)O2,Vitas,STK801891,-3.36982387,-57.8123138,-76.53487449,-93.56600689,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015810-12,Papaverine hydrochloride,170465687,Phosphodiesterase X (PDE10) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61-25-6,"; ;Papaverine?HCl;PAPAVERINE HYDROCHLORIDE; Pavatym; Cerespan;Papaverine hydrochloride; Albatran; Omnopon-Scopolamine; Hydrochloride, Papaverin; Cepaverin; Papaverine hydrochloride; Papaverine Hcl; Pavabid",14.12537545,0,-4.85,-54.47046944,-2.1,4,,-92.34102651,-86.99145382,0.021432412,0.9997166,10846,PDE10A,Cl.COc1ccc(cc1OC)Cc3nccc2cc(OC)c(cc23)OC,Vitas,STK039035,0,0,-34.41457475,-86.99145382,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263541-01,Reboxetine mesylate,170465620,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),98769-84-7,,39.81071706,0,-4.4,-31.53883048,-3,4,,-32.42369955,-30.35308296,0.282001117,0.947577724,,,CS(=O)(=O)O.CCOc3ccccc3O[C@H](c1ccccc1)[C@H]2CNCCO2,"Prestwick Chemical, Inc.",Prestw-1328,-6.95023022,0,0,-30.35308296,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167489-03,Sarpogrelate hydrochloride,174006666,5HT(2A) and 5HT(2B) inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),135159-51-2, ; Sarpogrelate;Sarpogrelate; Anplag; Sarpogrelate HCl,39.81071706,0,-4.4,-55.2840853,-3,4,,-51.95827144,-47.88189287,0.367114608,0.906454509,,,Cl.O=C(O)CCC(=O)OC(COc2ccccc2CCc1cccc(OC)c1)CN(C)C,Tocris,3739,-13.52215831,1.44191501,1.66235809,-47.88189287,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178027-08,VALSARTAN,405559028,Neprilysin Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),137862-53-4,,7.079457844,1,-5.15,-80.71309819,-3,4,,-37.67966105,-20.1476549,1,0.694180418,,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=N[NH]N=N3)[C@@H](C(C)C)C(O)=O,Microsource,1505209,-21.45489961,-2.47363933,-41.34076689,-20.1476549,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00496851-01,NCGC00496851-01,405559033,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),207300-70-7,,7.079457844,1,-5.15,-73.82004696,-1.4,4,,-35.92299146,-39.46384018,0.276377967,0.949747868,,,OC1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O,SIGMA,G8645,-10.48360283,0,-39.51915955,-39.46384018,,,,,,,,,,,,5.49E-07,0.00000274,0.0000137,6.86E-05,,,,,,,,,,,
NCGC00159455-09,Gefitinib,170464828,EGFR Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),184475-35-2,;Iressa/ZD-1839;Gefitinib; Iressa; Gefitinib,12.58925412,0,-4.9,-62.77745603,-2.1,4,,-99.30850012,-96.38088247,0.02792838,0.999518628,1956,EGFR,Fc1ccc(cc1Cl)Nc2ncnc3cc(OC)c(cc23)OCCCN4CCOCC4,Tocris,3000,0,0,-41.60521906,-96.38088247,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263909-02,Tadalafil,170464819,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),171596-29-5,,1.412537545,1,-5.85,-64.24797389,-1.4,4,,-38.54255349,-27.23330657,0.486075088,0.818534855,,PDE5A,O=C6N(C)CC(=O)N4[C@@H]6Cc1c5ccccc5nc1[C@H]4c2ccc3OCOc3c2,Microsource,1505639,0,-30.52127801,-47.82505943,-27.23330657,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178754-06,Primaquine diphosphate,174006623,antimalarial,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),63-45-6,,0.707945784,1,-6.15,-51.62357681,-1.4,4,,-37.03247574,-39.42256105,0.666634436,0.559145313,,,O=P(O)(O)O.O=P(O)(O)O.CC(CCCN)Nc1cc(cc2cccnc12)OC,Microsource,1500500,1.46187403,-48.25294731,-12.20879629,-39.42256105,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00092386-13,Sertraline hydrochloride,170465121,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),79559-97-0,,35.48133892,0,-4.45,-154.9801837,-2.3,4,,-84.06091165,-87.97370776,0.490322166,0.814451495,,SLC6A4,Cl.Clc1ccc(cc1Cl)[C@@H]3CC[C@H](NC)c2ccccc23,Microsource,1505262,-21.1876428,-49.54880979,-36.96944291,-87.97370776,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00021394-04,Anisotropine methylbromide,144207024,Muscarinic acetylcholine receptor M3 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),80-50-2,Anisotropine methylbromide; Valpin; Lytispasm; Valpin 50; ,39.81071706,0,-4.4,-54.96372133,-3,4,"LS-157873;Octatropini methylbromidum;ANISOTROPINE;(3-ENDO)-8,8-DIMETHYL-3-((2-PROPYLPENTANOYL)OXY)-8-AZONIABICYCLO(3.2.1)OCTANE BROMIDE;METHYLOCTATROPINE BROMIDE;OCTATROPINE METHYLBROMIDE;8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide;ANISOTROPINE METHYLBROMIDE;methylbromure d'octatropine;8-AZONIABICYCLO(3.2.1)OCTANE, 8,8-DIMETHYL-3-((1-OXO-2-PROPYLPENTYL)OXY)-, BROMIDE, (3-ENDO);3.ALPHA.-HYDROXY-8-METHYL-1.ALPHA.H,5.ALPHA.H-TROPANIUM BROMIDE 2-PROPYLVALERATE;Octatropine methylbromide;Valpin;CIPLUS_750008;Lytispasm;octatropine;Anisotropine methyl bromide;Metilbromuro de octatropina;CIPLUS_149624;anisotropine methylbromide;anisotropine methylbromide, (endo)-isomer;Methyloctatropine bromide;8-Azoniabicyclo(3.2.1)octane, 8,8-dimethyl-3-((1-oxo-2-propylpentyl)oxy)-, bromide, endo-, mixt. with 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one;octotropine methylbromide;Valpin 50;valpinax;Methylbromure d'octatropine;CIPLUS_709435;octatropini methylbromidum;Methyloctatropine Bromide;Anisotropine methylbromide;",-61.03713936,-55.03094947,0.267001607,0.953295324,,,[Br-].C[N+]2(C)[C@H]1C[C@@H](C[C@@H]2CC1)OC(=O)C(CCC)CCC,SigmaAldrich,A5181,-11.86437099,0,0,-55.03094947,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386241-01,Avanafil,405558527,Phosphodiesterase 5A Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),330784-47-9,,39.81071706,0,-4.4,-10.69259437,-3,4,,-35.67440354,-30.56200295,0.003495275,0.999992475,,,COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N3CCC[C@H]3CO)C(=O)NCC4=NC=CC=N4)C=C1,Selleck,S4019,0,0,0,-30.56200295,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386206-03,Azilsartan (TAK-536),405558540,Type-1 angiotensin II receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),147403-03-0,,39.81071706,0,-4.4,-67.8827784,-3,4,,-45.10832022,-41.75693352,0.581717471,0.708234172,,,CCOC1=NC2=CC=CC(=C2[N]1CC3=CC=C(C=C3)C4=CC=CC=C4\C5=N\C(=O)ON5)C(O)=O,Adooq,A11775,-13.93822445,-16.2079163,0,-41.75693352,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00021147-11,Doxylamine succinate,170465171,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),562-10-7,,4.466835922,1,-5.35,-51.95276167,-1.4,4,,-40.97544203,-39.53652549,0.1193973,0.991107452,,,O=C(O)CCC(=O)O.CN(C)CCOC(C)(c1ccccn1)c2ccccc2,Vitas,STL018676,-2.18549916,-1.22849548,-43.93484871,-39.53652549,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182552-02,Atazanavir,170465290,HIV Protease Inhibitors,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),198904-31-3, ;ATAZANAVIR SULFATE; Atazanavir;Atazanavir sulfate; Reyataz,0.707945784,1,-6.15,-50.80405865,-1.4,4,,-34.6658148,-40.18423867,0.584842496,0.703742507,,,CC(C)(C)[C@H](NC(=O)OC)C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)Cc2ccc(cc2)c3ccccn3,Sequoia,229975-97-7,0,-35.59121617,-17.01704878,-40.18423867,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00261973-01,Butoctamide semisuccinate,170466034,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),32838-28-1,"Butoctamide hydrogen succinate, monosodium salt;Butoctamide",2.238721139,1,-5.65,-55.24623209,-2.4,4,,-45.66301644,0,1,0.999861302,,,CC(CC(=O)NCC(CC)CCCC)OC(=O)CCC(=O)O,GVK,FFS-11-286-NCI-226,-7.74239937,-24.76819761,-42.01052703,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167426-03,Caramiphen edisylate,170465518,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),125-86-0,,39.81071706,0,-4.4,-44.91945069,-3,4,,-74.39973711,-64.91644759,0.654218492,0.99234386,,,O=S(=O)(O)CCS(=O)(=O)O.CCN(CC)CCOC(=O)C1(CCCC1)c2ccccc2.CCN(CCOC(=O)C1(CCCC1)c2ccccc2)CC,ASDI,100028134,-36.12756266,-5.98845745,0,-64.91644759,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249917-01,Cloxazolam,170465787,GABA-A receptor; benzodiazepine site Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),24166-13-0,,3.981071706,1,-5.4,-36.10486377,-1.4,4,,-33.56578321,-27.16255554,0.292440617,0.943281434,,,Clc1ccccc1C34OCCN4CC(=O)Nc2ccc(Cl)cc23,GVK,FFS-11-286-NCI-177,0,0,-38.08935751,-27.16255554,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00476141-01,11?-Prostaglandin E1,405558649,Prostanoid EP1 receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),24570-01-2,,0.707945784,1,-6.15,-37.25216671,-1.4,4,,-38.27695811,0,1,0.966006015,,PTGER2,CCCCCC(O)\C=C\[C@H]1[C@@H](O)CC(=O)C1CCCCCCC(O)=O,Cayman,13450,0,-38.0166256,-30.69355771,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181165-01,Sodium decanehydroxamate,144206782,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),35440-53-0,n-decanohydroxamic acid; ,35.48133892,0,-4.45,-2.924657959,-3,4,n-decanohydroxamic acid;Decanohydroxamic acid;CIPLUS_720094;DECANOHYDROXAMIC ACID;,-57.0136361,-43.66161595,0.093795913,0.994537143,,,[Na+].[O-]NC(=O)CCCCCCCCC,NCI,NSC-111679,4.10350506,0,0,-43.66161595,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166290-03,Polyoxyethylene (9) lauryl ether,170466791,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3055-99-0,,19.95262315,0,-4.7,-44.23818808,-2.3,4,,-106.1761704,-96.38689721,0.490068484,0.999975973,,,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,SIGMA,P9641,-29.81062446,1.15373865,-21.18300268,-96.38689721,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025325-03,Vapiprost hydrochloride,174006925,Prostanoid TP Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),87248-13-3,GR 32191 hydrochloride; Vapiprost hydrochloride;GR-32191B; ,35.48133892,0,-4.45,-38.27360767,-3,4,,-56.88515377,-46.12511649,0.667177787,0.558020136,6915,TBXA2R,O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\C=C/CCC(O)=O)[C@H]1N4CCCCC4,SIGMA,G5044,0,-26.66837354,-5.02334714,-46.12511649,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025357-04,Nicorandil,170465582,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),65141-46-0,;Nicorandil; Nicorandil; ; Sigmart,7.079457844,1,-5.15,-49.29331747,-3,4,,-36.71807114,-0.35562188,1,0.881291299,,KCNJ8,O=C(NCCO[N+]([O-])=O)c1cccnc1,Prestwick,Prestw-106,-12.18806588,0.76117092,-37.70191772,-0.35562188,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00241103-06,Masitinib,405558715,FGFR 3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1048007-93-7,,22.38721139,0,-4.65,-38.85578562,-2.3,4,,-92.65641325,-85.79297523,0.541054521,0.999985867,,FGFR3,CN1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC=C(C)C(=C3)NC4=NC(=CS4)C5=CC=CN=C5,Axon Medchem,1419,-32.05323084,0,-12.65717134,-85.79297523,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00180461-02,Hydroquinidine HCl,405558746,Sodium channel alpha subunit Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1476-98-8,,39.81071706,0,-4.4,-139.7014252,-2.4,4,,-59.41281859,-71.7189856,0.378613986,0.899684647,,,CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)C3=C4C=C(OC)C=CC4=NC=C3,Prestwick,Prestw-NAT-0284,-27.05743738,-32.36476726,-15.12497011,-71.7189856,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00187598-03,Amaranth,405558767,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),915-67-3,,39.81071706,0,-4.4,-25.69630424,-3,4,,-88.1354514,-73.4462095,0.006832298,0.999971211,,,OC1=C(N=NC2=CC=C(C3=CC=CC=C23)[S]([O-])(=O)=O)C4=CC=C(C=C4C=C1[S]([O-])(=O)=O)[S]([O-])(=O)=O,SIGMA,6409,0,0,0,-73.4462095,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185766-04,Esmolol hydrochloride,170465277,sodium ion transport Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),81161-17-3,,6.309573445,1,-5.2,-18.4583765,-3,4,,-55.69673681,-10.55796019,1,0.999925145,,,Cl.CC(C)NCC(O)COc1ccc(cc1)CCC(=O)OC,Prestwick,Prestw-1137,0,0,-52.95994149,-10.55796019,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00013058-02,Malachite green oxalate,170465712,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2437-29-8,,2.238721139,1,-5.65,-167.2811508,-1.1,4,,-93.90806882,-98.03853652,0.043803206,0.998814786,,,C/[N+](C)=C1\C=C/C(C=C1)=C(/c2ccccc2)c3ccc(cc3)N(C)C.[O-]C(=O)C(=O)O.[O-]C(=O)C(=O)O.O=C(O)C(=O)O.CN(C)c1ccc(cc1)C(\c2ccccc2)=C3/C=C/C(C=C3)=[N+](/C)C,SIGMA,38800,-9.58583934,-51.86551631,-97.22344079,-98.03853652,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185745-01,Cefroxadine,144206693,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),51762-05-1,,17.7827941,0,-4.75,-25.8291045,-2.2,4,,-52.39289202,-46.50976668,0.035743946,0.999211605,,,N[C@H](C1=CCC=CC1)C(=O)N[C@@H]3C(=O)N2C(=C(OC)CS[C@@H]23)C(=O)O,Kemprotec,51762-05-1,0,0.48185583,-14.16595774,-46.50976668,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018234-07,Sulfaguanidine,170465708,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57-67-0,,1.584893193,1,-5.8,-31.36529206,-1.4,4,,-36.29296494,-7.46438324,1,0.999917682,,,Nc1ccc(cc1)S(=O)(=O)NC(=N)N,Specs,AT-084/J157969,0,-27.14977186,-35.58133818,-7.46438324,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183871-04,N-Acetyl sulfamethoxazole,170466005,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),21312-10-7,,1,1,-6,-53.49392306,-1.4,4,,-46.59747406,-52.33052673,0.483603824,0.820786323,,,Cc2cc(NS(=O)(=O)c1ccc(NC(C)=O)cc1)no2,Specs,AA-504/07985056,3.38838095,-37.0451027,-27.93252238,-52.33052673,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017063-07,Amodiaquin dihydrochloride dihydrate,405558845,Antimalarial; Histamine N-methyl Transferase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6398-98-7,,10,0,-5,-76.79889089,-2.1,4,,-97.67475505,-97.39559033,0.013210454,0.99989235,,,CCN(CC)CC1=C(O)C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl,Prestwick,Prestw-309,0,-2.60677567,-58.56627309,-97.39559033,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167984-01,Tiquizium bromide,144206157,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),71731-58-3,Tiquizium bromide; Bromuro de tiquizio; ,14.12537545,0,-4.85,-68.12748082,-2.2,4,CIPLUS_214419;tiquizium bromide;thiaton;Bromuro de tiquizio;Tiquizium Bromide;bromide (cis)-isomer;Tiquizii bromidum;LS-176911;tiquizii bromidum;TIQUIZIUM BROMIDE;bromure de tiquizium;Tiquizium bromide;3-(di-2-thienylmethylene)-5-methyl-trans-quinolizidinium bromide;3-(Di-2-thienylmethylene)-5-methyl-trans-quinolizidinium bromide;LS-142883;Thiaton;Bromure de tiquizium;HSR 902;HSR-902;,-38.01859205,-45.63775189,0.010970063,0.999925845,,,[Br-].C[N@@+]14CCCC[C@@H]4CC\C(C1)=C(/c2sccc2)c3cccs3,Bosche,T6489,-9.39181666,-10.12949552,-24.07903111,-45.63775189,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179626-05,NCGC00179626-05,405558909,Mineralocorticoid Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,28.18382931,0,-4.55,-14.52419426,-3,4,,-40.571819,-35.66046894,0.004694833,0.999986418,,,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC([O-])=O,Prestwick,CAS-102731,0,0,-2.93216061,-35.66046894,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00024623-04,NCGC00024623-04,170465413,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1229-29-4,,17.7827941,0,-4.75,-58.90640893,-2.3,4,,-85.68658862,-83.04313761,0.208709148,0.972136129,,,Cl.CN(C)CC\C=C1\c3ccccc3OCc2ccccc12,Microsource,1500264,0,-14.94513507,-27.79691961,-83.04313761,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00090705-15,"2',3'-Dideoxycytidine",170465128,Reverse Transcriptase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7481-89-2,"; ; 2',3' Dideoxycytidin; Cytidine, 2',3'-dideoxy-; 2',3'-dideoxycytidine;2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine; Hivid; 2';Zalcitabine;2',3'-dideoxycytidine; Dideoxycytidine-3H; HIVID Roche; Zalcitibine",10,0,-5,-31.09843473,-2.2,4,,-42.6199987,-41.77192868,0.036527493,0.999176726,7015,TERT,NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2,"Prestwick Chemical, Inc.",Prestw-1037,0,0,-23.60232713,-41.77192868,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00507682-01,Emodepside,405558968,synaptic transmission Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),155030-63-0,,0.794328235,1,-6.1,-158.4545438,-1.4,4,,-44.82529597,-69.2282199,0.552658011,0.746704005,174419,,CC(C)C[C@@H]1N(C)C(=O)[C@@H](C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC2=CC=C(C=C2)N3CCOCC3)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC4=CC=C(C=C4)N5CCOCC5)OC1=O,AdvChemBlocks,M15352,-21.77816261,-53.65680985,-44.68128932,-69.2282199,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00522015-01,Pirlimycin Hydrochloride,405558973,Bacterial 70S ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),78822-40-9,,39.81071706,0,-4.4,-8.778393302,-2.4,4,,-30.10890784,-25.09075653,0.007297871,0.999967215,,,CC[C@@H]1CCN[C@@H](C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,Toronto Research,P509300,0,0,0,-25.09075653,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167452-03,Pirenoxine Sodium,225144286,maintenance of lens transparency Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),51410-30-1,,12.58925412,0,-4.9,-50.03674663,-2.4,4,,-33.07214336,-36.02819593,0.275353618,0.950171729,,,OC1=C2C(=NC(=C1)C([O-])=O)C(=O)/C=C\3OC4=CC=CC=C4\N=C23,Bosche,P6175,-7.87677305,0,-19.65006323,-36.02819593,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00379082-01,Anidulafungin,405558984,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),166663-25-8,,17.7827941,0,-4.75,-59.43008531,-3,4,,-109.5376474,-100.3092009,0.006976366,0.999969981,,,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(NC(=O)C(NC(=O)C6CC(O)CN6C(=O)C(NC4=O)C(C)O)C(O)C(O)C7=CC=C(O)C=C7)C(C)O,MedChem Express,HY-13553,0,0,0,-100.3092009,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00247716-01,(+)-Pentazocine succinate,144206429,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),124819-26-7,,70.79457844,0,-4.15,-78.40329676,-3,4,,-41.76916993,-42.37886105,0.521660529,0.782688837,,,O=C(O)CCC(=O)O.C/C(C)=C\CN2CC[C@]1(C)c3cc(O)ccc3C[C@H]2[C@H]1C,RTI,9709-002,-19.20973934,0,0,-42.37886105,,,,,,,,,,,,9.14E-07,0.00000457,0.0000228,0.000114,,,,,,,,,,,
NCGC00387861-02,NCGC00387861-02,405559011,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),936563-96-1,,14.12537545,0,-4.85,-53.74687755,-2.4,4,,-79.58534321,-79.10643164,0.480983466,0.999831763,,BTK,NC1=NC=NC2=C1C(=N[N]2C3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4,APExBIO,A3001,-24.88761675,-1.33601422,-30.2345524,-79.10643164,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160515-02,Acarbose,170464784,alpha-Glucosidase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),56180-94-0,; Lasa Brand of Acarbose; Glucobay; Glumida; Bayer Brand of Acarbose; Precose;ACARBOSE; Prandase;Acarbose; Glucor; Acarbosa,6.309573445,1,-5.2,-12.58038378,-3,4,,-37.98267542,-9.81949504,1,0.99992737,2548,GAA,OCC4=C[C@H](N[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]1C)O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]3O)[C@H](O)[C@@H](O)[C@@H]4O,Vitas,STK801930,0,0,-36.09506983,-9.81949504,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159483-04,Hydroxychloroquine sulfate,170464696,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),747-36-4,; Hidroxicloroquina;Plaquenil???;Hydroxychloroquine sulfate; Oxychlorochin;Plaquenil; Plaquenil;HYDROXYCHLOROQUINE SULFATE; Hydroxychloroquine sulfate; Hydroxychloroguine,0.446683592,1,-6.35,-105.8388402,-3,4,,-59.73748472,-24.17487796,1,0.999998527,84557,MAP1LC3A,O=S(=O)(O)O.CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,Microsource,1503978,-22.75168161,1.23491657,-54.84952289,-24.17487796,,,,,,,,,,,,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,,,,
NCGC00159424-04,Tetramethylthiuram monosulfide,170465567,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),97-74-5,,1.412537545,1,-5.85,-153.7849856,-1.1,4,,-101.0752107,-97.96707898,0.013919786,0.999880477,,,CN(C)C(=S)SC(=S)N(C)C,Labotest,LT02090816,2.87594342,-86.70111199,-96.80074387,-97.96707898,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178579-04,Levobupivacaine hydrochloride,170465452,Sodium channel protein type IV alpha subunit Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),27262-48-2,,39.81071706,0,-4.4,-17.04459236,-3,4,,-58.46104668,-48.7175389,0.006832298,0.99997122,,,Cl.Cc2cccc(C)c2NC(=O)[C@@H]1CCCCN1CCCC,Specs,AN-153/I154112,0,0,0,-48.7175389,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00507845-01,Netarsudil,384569326,ROCK Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1253952-02-1,,5.011872336,1,-5.3,-140.8585164,-2.3,4,,-78.53235797,-83.12745401,0.329174443,0.926589625,,ROCK1,CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C,Selleck,S8226,-20.70995077,-1.0480376,-49.71330429,-83.12745401,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00183097-01,Beraprost sodium,144206467,Thyroid hormone receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),88475-69-8,Beraprost sodium; Procylin; ,39.81071706,0,-4.4,-71.41592484,-3,4,"TRK-100;1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt;beraprost;4-(1,2,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyloct-6-yne-1-enyl)-5-cyclopenta(b)benzofuranyl)butyrate;BERAPROST;CIPLUS_685106;beraprost sodium;Procylin;Beraprost sodium;TRK 100;Beraprost Sodium;CIPLUS_193198;Beraprostum;1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-;Beraprost;trk-100;BERAPROST SODIUM;ML-1129;2,3,3A,8B-TETRAHYDRO-2-HYDROXY-1((E)-(3S)-3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-1H-CYCLOPENTA(B)BENZOFURAN-5-BUTYRIC ACID SODIUM SALT;LS-57735;beraprostum;LS-57736;",-40.52072328,-37.93393607,0.565472406,0.730372378,19222,,[Na+].CC(CC#CC)[C@H](O)/C=C/[C@H]2[C@H](O)C[C@@H]3Oc1c(cccc1CCCC([O-])=O)[C@H]23,ACC,BERAPROST SODIUM,-19.31778835,0,0,-37.93393607,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00510003-01,Vaborbactam,405559093,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1360457-46-0,,39.81071706,0,-4.4,-19.2308909,-3,4,,-70.98860505,-59.99050421,0.052812779,0.998276151,,,OB1O[C@@H](CC[C@@H]1NC(=O)CC2=CC=CS2)CC(O)=O,MedChem Express,HY-19930,0,0,2.51678661,-59.99050421,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018254-08,Bifonazole,170465826,Cytochrome P450 51 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),60628-96-8,,31.6227766,0,-4.5,-23.28488786,-3,4,,-80.4844373,-71.81304548,0.038047594,0.999106196,,,c1cc(ccc1c2ccccc2)C(c3ccccc3)n4ccnc4,Microsource,1505309,0,2.63427827,0,-71.81304548,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00017245-10,Ellagic acid,170466649,Aldose Reductase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),476-66-4,"; Elagostasine; Acid, Ellagi; Acido elagico;ELLAGIC ACID; Acid, Benzoari;Ellagic Acid; EADME cpd;Ellagic acid; Ellagic acid hydrate",19.95262315,0,-4.7,-36.75103193,-3,4,,-37.82286688,-36.68672533,0.629807021,0.631719712,231,AKR1B1,Oc1c4OC(=O)c2cc(O)c(O)c3OC(=O)c(cc1O)c4c23,Vitas,STK801964,0,-22.05665249,0.55605131,-36.68672533,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00249926-01,Pirmenol,170466004,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),68252-19-7,,39.81071706,0,-4.4,-26.13457885,-3,4,,-64.69661622,-56.83051352,0.196730441,0.975350281,,,C[C@H]3CCC[C@@H](C)N3CCCC(O)(c1ccccc1)c2ccccn2,GVK,FFS-11-286-NCI-216,0,-8.95001619,0,-56.83051352,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179493-03,Solanine alpha,405559114,Cholinesterase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),20562-02-1,,12.58925412,0,-4.9,-107.5045762,-2.3,4,,-83.62666955,-85.90849956,0.249567939,0.959506546,,,C[C@H]1CC[C@@H]2[C@@H](C)[C@H]3[C@H](C[C@H]4[C@@H]5C\C=C6\C[C@H](CC[C@]6(C)[C@H]5CC[C@]34C)O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O)N2C1,Prestwick,Prestw-NAT-0174,-16.07327295,0,-41.62310434,-85.90849956,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159510-05,Aripiprazole,170465392,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),129722-12-9, Abilify;;Aripiprazole; ;ARIPIPRAZOLE; Aripiprazole,39.81071706,0,-4.4,-139.0366103,-2.3,4,,-74.18624269,-87.79081323,0.248350417,0.959926881,3356,HTR2A,Clc4cccc(N3CCN(CCCCOc1ccc2CCC(=O)Nc2c1)CC3)c4Cl,Microsource,1505851,-21.25188659,-36.02447631,-27.48164566,-87.79081323,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167832-06,Carvedilol tartrate,170465440,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),NOCAS_45916,"; carvedilol, 14C-labeled; 8   Carvedilol;Carvedilol; Coreg; carvedilol, (S)-isomer; Carvedilol; carvedilol, (R)-isomer",14.12537545,0,-4.85,-63.92702468,-2.3,4,,-106.0565778,-92.15489283,0.119287084,0.991120267,153,ADRB1,O=C(O)C(O)C(O)C(=O)O.COc4ccccc4OCCNCC(O)COc2cccc3nc1ccccc1c23,Microsource,1504257,2.5322341,-13.71446295,-42.56503087,-92.15489283,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00096077-06,Olanzapine,170465009,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132539-06-1,; ;OLANZAPINE; Zyprexa; OLANZAPINE;Olanzapine; Olanzapine; Lilly brand of olanzapine,17.7827941,0,-4.75,-27.84301089,-2.2,4,,-53.69437082,-48.25331123,0.015337168,0.999854965,1813,DRD2,CN1CCN(CC1)C2=Nc4ccccc4Nc3sc(C)cc23,SIGMA,O1141,0.00110939,-0.34009996,-15.35883771,-48.25331123,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00022382-06,NCGC00022382-06,405559134,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),22260-51-1,,31.6227766,0,-4.5,-10.93051803,-3,4,,-38.90243978,-35.75203315,0.02083205,0.999732484,,,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]/3CN(C)C4CC5=C(Br)[NH]C6=CC=CC(=C56)\C4=C3)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C,SIGMA,B2134,0.52423741,0,0,-35.75203315,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091902-11,Malathion,170465311,Acetylcholinesterase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),121-75-5,,28.18382931,0,-4.55,-47.94310678,-3,4,,-47.88099045,-44.22802307,0.226356145,0.967027945,,,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,Microsource,330021,-8.50690671,0,-9.82890268,-44.22802307,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016373-08,Benzethonium chloride,170465473,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),121-54-0,,25.11886432,0,-4.6,-24.31612405,-3,4,,-60.36611361,-52.17129819,0.008364113,0.999956867,,,[Cl-].CC(C)(C)CC(C)(C)c2ccc(OCCOCC[N+](C)(C)Cc1ccccc1)cc2,Microsource,1500138,0,0,-8.68152535,-52.17129819,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159450-04,Parethoxycaine,170465538,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),94-23-5,,39.81071706,0,-4.4,-11.33752229,-3,4,,-37.88643421,-32.40536184,0.744545705,0.99998839,,,CCOc1ccc(cc1)C(=O)OCCN(CC)CC,Specs,AO-365/40892107,-23.0834902,0,0,-32.40536184,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015436-11,Fluphenazine hydrochloride,170465375,Nicotinic alpha7 Receptor Ligands,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),69-23-8, Motipress; Liogen;Fluphenazine; Flumezin;; ; Fluphenazine dihydrochloride;Fluphenazine di?HCl; Flufenazine; Prolixin; Lyogen; Motival;Fluphenazine dihydrochloride; Fluphenazine Hcl; prolixin S,35.48133892,0,-4.45,-26.74129674,-3,4,,-106.619552,-88.79500992,0.120476245,0.990940031,1813,DRD2,FC(F)(F)c2cc3N(CCCN1CCN(CCO)CC1)c4ccccc4Sc3cc2,Vitas,STK050763,3.78019748,-6.37211289,-3.72567869,-88.79500992,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015007-14,R-(+)-Atenolol,170464744,Beta-2 adrenergic receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),56715-13-0,,0.707945784,1,-6.15,-35.92933945,-1.4,4,,-39.55162865,-47.50208801,0.681521371,0.525504292,,,CC(C)NC[C@@H](O)COc1ccc(cc1)CC(N)=O,Vitas,STK528649,4.58712774,-39.63758948,-7.77497534,-47.50208801,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015453-08,Fexofenadine hydrochloride,170464669,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),153439-40-8,,6.309573445,1,-5.2,-10.71723336,-3,4,,-32.39928322,0,1,0.999928558,,,Cl.O=C(O)C(C)(C)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4,Microsource,1504179,0,0,-30.74940268,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00168785-03,Diclazuril,405559143,antiprotozoal agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),101831-37-2, ; Diclazuril;Diclazuril;DICLAZURIL,11.22018454,0,-4.95,-90.51331271,-2.3,4,,-115.4770342,-84.45229865,0.451881255,0.848229572,,,ClC1=CC=C(C=C1)C(C#N)C2=C(Cl)C=C(C=C2Cl)N3\N=C/C(=O)NC3=O,FLUKA,34057,0,-44.70045356,-42.58781454,-84.45229865,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181913-02,Difeterol,144206884,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),14587-50-9,Difeterol; Difeterol Phosphate; Difeterol Hydrochloride; ,39.81071706,0,-4.4,-27.62274483,-3,4,CIPLUS_783660;DIFETEROL;Difeterol;difeterolum;difeterol;Difeterol Phosphate;Difeterol Hydrochloride;,-85.91279308,-72.42732757,0.057865791,0.997929344,,,OC(C(C)N(C)CCOC(c1ccccc1)c2ccccc2)c3ccccc3,Pharmaron,PH-NIH-2,0,-3.26833343,0,-72.42732757,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00348378-01,FOSFOMYCIN,405559146,UDP-N-acetylglucosamine 1-carboxyvinyltransferase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),26016-99-9,,3.981071706,1,-5.4,-57.41883122,-1.2,4,,-50.9274166,-49.93279315,0.027213523,0.999543118,,,C[C@@H]1O[C@@H]1[P]([O-])([O-])=O,SIGMA,P5396,0,0.11808271,-39.89774332,-49.93279315,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00015883-11,Risperidone,170464925,Dopamine D2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),106266-06-2," ; Risperdal;Risperidone; Risperidone; Risperidal; Risperdal Consta; Consta, Risperda",39.81071706,0,-4.4,-141.7924169,-2.4,4,,-24.36072574,-49.26267768,0.645824602,0.825479568,1813,DRD2,CC=5N=C1CCCCN1C(=O)C=5CCN2CCC(CC2)c4noc3cc(F)ccc34,Tocris,2865,-26.73600693,-40.36850511,-22.74893901,-49.26267768,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167420-01,Perflenapent,144205977,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),678-26-2,"QW-7437; 2H,3H-perfluoropentane; ",39.81071706,0,-4.4,-20.85809316,-3,4,"CIPLUS_156010;QW7437;perfluoropentane;DODECAFLUOROPENTANE;dodecafluoropentane;QW-7437;2H,3H-perfluoropentane;perflenapentum;QW 7437;PERFLUOROPENTANE;PERFLENAPENT;Perflenapent;",-50.03704124,-42.11420103,0.062156336,0.997611107,,,FC(F)(C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)F,Alfa Aesar,L16969,-2.03456291,0,0,-42.11420103,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167524-02,Amorolfine hydrochloride,170466078,Antifungal Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),78613-35-1, ;Amorolfine Hydrochloride;Amorolfine; Amorolfine; Amorolfine [USAN:BAN:INN];Amorolfine hcL; Loceryl; Pekiron,39.81071706,0,-4.4,-32.29002897,-3,4,,-110.7511902,-92.29265851,0.006832298,0.999971209,,,C[C@H]2CN(CC(C)Cc1ccc(cc1)C(C)(C)CC)C[C@@H](C)O2,Sequoia,SRP0563571a,0,0,0,-92.29265851,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179636-04,Clindamycin hydrochloride,405558965,Antibacterial,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),21462-39-5,,10,0,-5,-61.60614493,-2.4,4,,-51.52743864,-52.48118763,0.898641145,0.999986414,,,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)C2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,Prestwick,Prestw-137,-59.42224228,-5.66759605,-31.82592664,-52.48118763,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00162137-02,Dehydroepiandrosterone Sulfate (sodium salt),405558967,Estrogen receptor alpha Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1099-87-2,,39.81071706,0,-4.4,-18.69160675,-3,4,,-57.88326049,-48.23605041,0.655622325,0.999811431,,,C[C@]12CC[C@H]3[C@@H](C\C=C4\C[C@H](CC[C@]34C)O[S]([O-])(=O)=O)[C@@H]1CCC2=O,Cayman,15873,-25.89895551,-0.48956026,0,-48.23605041,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159411-02,Triethanolamine,144206717,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),102-71-6,trolamine salicylate; Tris(2-hydroxyethyl)amine; Solupront; Thiofaco T-35; Myoflex; texapon TH; ,39.81071706,0,-4.4,-77.15450096,-3,4,"CIPLUS_734310;CIPLUS_3747852;CIPLUS_740704;CIPLUS_752482;CIPLUS_750425;CIPLUS_737530;CIPLUS_737531;Triethanolamine aluminate barium salt;CIPLUS_749510;CIPLUS_686266;triethanolamine salicylate;TRIETHANOL AMMONIUM CHLORIDE;CIPLUS_740747;CIPLUS_3755473;CIPLUS_732537;CIPLUS_739845;CIPLUS_749773;CIPLUS_749544;CIPLUS_749685;CIPLUS_740695;CIPLUS_3889761;CIPLUS_745468;CIPLUS_691861;CIPLUS_753415;CIPLUS_740654;CIPLUS_3730238;CIPLUS_175532;CIPLUS_3749955;NCGC_FLUKA_90290;CIPLUS_739743;LS-173901;2,2',2''-Nitrilotriethanol hydrochloride;CIPLUS_749503;CIPLUS_738415;trolamine salicylate;CIPLUS_752427;CIPLUS_752428;CIPLUS_3756040;NCGC00159411-04;CIPLUS_666794;CIPLUS_3885762;Tris(2-hydroxyethyl)amine hydrochloride;CIPLUS_193084;CIPLUS_748749;CIPLUS_3755605;CIPLUS_3733577;CIPLUS_740728;Myoflex;CIPLUS_739153;CIPLUS_3745711;CIPLUS_3755043;Trolamine (Triethanolamine hydrochloride);CIPLUS_736952;CIPLUS_687637;Triethanolamine;CIPLUS_732449;CIPLUS_3749677;CIPLUS_746627;CIPLUS_3753376;CIPLUS_668732;CIPLUS_193079;CIPLUS_667351;Triethanolamine Hydrochloride;CIPLUS_193078;Tris(2-hydroxyethyl)amine;CIPLUS_3887736;CIPLUS_749757;CIPLUS_737348;CIPLUS_738912;CIPLUS_767549;Trolamine salicylate;2,2',2''-Nitrilotriethanol;CIPLUS_753583;Triethanolamine hydrochloride;CIPLUS_750558;CIPLUS_3752239;CIPLUS_3745729;",-43.41557733,-40.34631444,0.583476694,0.705658305,,,OCCN(CCO)CCO,Labotest,LT03329084,-21.31237313,1.58753573,0,-40.34631444,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167542-01,Tiamulin,144206092,Bacterial 70S ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55297-95-5,Tiamulin; Tiamulina; ,19.95262315,0,-4.7,-46.18232863,-2.1,4,"TIAMULIN FUMARATE;THIAMUTILIN FUMARATE;tiamulin hydrochloride;(3AS,4R,5S,6S,8R,9S,9AR,10R)-5-HYDROXY-4,6,9,10-TETRAMETHYL-1-OXO-6-VINYLDECAHYDRO-3A,9-PROPANOCYCLOPENTA(8)ANNULEN-8-YL ((2-(DIETHYLAMINO)ETHYL)THIO)ACETATE (2E)-BUT-2-ENEDIOATE (SALT);Tiamulina;sandoz 81723hfu;Tiamuline;Tiamulinum;ACETIC ACID, ((2-(DIETHYLAMINO)ETHYL)THIO)-, (3AS,4R,5S,6S,8R,9S,9AR,10R)-6-ETHENYLDECAHYDRO-5-HYDROXY-4,6,9,10-TETRAMETHYL-1-OXO-3A,9-PROPANO-3AH-CYCLOPENTACYCLOOCTEN-8-YL ESTER, (2E)-2-BUTENEDIOATE (1:1) (SALT);tiamulinum;Tiamulin Hydrogen Fumarate;tiamuline;(1S,2R,3S,4S,6R,7S,14R)-6-[(2-Diethylaminoethylthio)acetoxy]-3-hydroxy-2,4,7,14-tetramethyl-4-vinyltricyclo[5,4,3,01.8]tetradecan-9-one;LS-174933;Thiamutilin fumarate;2-(diethylaminoethyl)thioacetoxymutilin;14-DEOXY-14-((2-DIETHYLAMINOETHYL)THIOACETOXY)MUTILIN HYDROGEN FUMARATE;CIPLUS_182128;Tiamulin;TIAMULIN HYDROGEN FUMARATE;Tiamulin Fumarate;TIAMULIN;LS-11694;LS-11693;(3AS,4R,5S,6S,8R,9S,9AR,10R)-6-ETHENYL-5-HYDROXY-4,6,9,10-TETRAMETHYL-1-OXODECAHYDRO-3A,9-PROPANO-3AH-CYCLOPENTACYCLOOCTEN-8-YL((2-(DIETHYL-AMINO)ETHYL)SULPHANYL)ACETATE HYDROGEN (E)-BUT-2-ENEDIOATE;CIPLUS_207320;Tiamulin fumarate;",-96.15705316,-82.69473724,0.025284571,0.999605521,,,CCN(CC)CCSCC(=O)O[C@@H]3C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]21CCC(=O)[C@H]1[C@@]3(C)C(C)CC2,SigmaAldrich,34044,0,0,-24.69970602,-82.69473724,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166222-04,"N,N'-Dibenzylethane-1,2-diamine dihydrochloride",170465030,F-box only protein 3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3412-76-8,,39.81071706,0,-4.4,-89.16242657,-3,4,,-46.96775661,-43.30646384,0.62110817,0.64687845,26273,FBXO3,Cl.Cl.C(NCc1ccccc1)CNCc2ccccc2,SIGMA,D35201,-22.75364874,-7.91033733,0,-43.30646384,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378665-02,Ixabepilone,405558443,Microtubule-Stabilizing Agents,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),219989-84-1,,39.81071706,0,-4.4,-42.79598129,-2.4,4,,-50.23274921,-46.57522655,0.737845902,0.709930047,,TUBB,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)\C(C)=C\C3=CSC(=N3)C,Adooq,A11449,0,-37.94005107,0,-46.57522655,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164557-11,Eprosartan mesylate,405558474,urate transport Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),144143-96-4,,39.81071706,0,-4.4,-34.88155227,-3,4,,-51.6346311,-45.11219258,0.176026519,0.98039973,,AGTR1,CCCCC1=NC=C(\C=C(CC2=CC=CS2)\C(O)=O)[N]1CC3=CC=C(C=C3)C(O)=O,SIGMA,E2535,-6.3452274,0,0,-45.11219258,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181916-01,Sulfaethoxypyridazine,144206640,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),963-14-4,CIPLUS_157090; ,8.912509381,1,-5.05,-55.38662036,-3,4,SULFAETHOXYPYRIDAZINE;sulfaethoxypyridazine;CIPLUS_157090;N-1-(6-ethoxy-3-pyridazinyl)sulfanilamide;,-47.45368434,0,1,0.833802693,,,O=S(=O)(Nc1ccc(OCC)nn1)c2ccc(N)cc2,FLUKA,2743,-14.43289248,3.10465108,-40.49521541,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346629-02,Dolutegravir (GSK1349572),405558481,HIV Integrase Inhibitors,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1051375-16-6,,141.2537545,0,-3.85,-382.2236557,5,4,,-22.48307133,-94.48409513,1,0.874881967,,,C[C@@H]1CCO[C@H]2CN\3/C=C(/C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)\C(=C3C(=O)N12)O,Selleck,S2667,-94.21323866,-93.67221871,-95.32477815,-94.48409513,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167432-05,FosinoprilNa,405558492,Angiotensin-converting enzyme Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),98048-97-6,,6.309573445,1,-5.2,-37.93859435,-3,4,,-40.36249608,-38.29860748,0.010175546,0.999936183,,,CCC(=O)O[C@@H](O[P](=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C([O-])=O)C3CCCCC3)C(C)C,Enzo,DL155,0,0,0,-38.29860748,,,,,,,,,,,,9.14E-08,4.57E-07,0.00000229,0.0000114,,,,,,,,,,,
NCGC00522019-01,Polaprezinc,405559035,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),107667-60-7,,2.238721139,1,-5.65,-56.38176499,-2.2,4,,-43.59576591,-42.74094697,0.038086516,0.99910473,,,O=C1CCN[Zn++]2[O-]C(=O)[C@H](CC3=CN=C[NH]3)[N-]12,Toronto Research,P688000,1.68782381,0,-31.84559969,-42.74094697,,,,,,,,,,,,1.14E-07,5.71E-07,2.86E-06,0.0000143,,,,,,,,,,,
NCGC00184864-02,NCGC00184864-02,405559057,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),[6640-22-8],,39.81071706,0,-4.4,-14.85096029,-3,4,,-50.93713385,-42.44761154,0.006832298,0.999971225,,,OC1=C(CC2=C(O)C(=CC3=CC=CC=C23)C([O-])=O)C4=CC=CC=C4C=C1C([O-])=O,Tocris,4298,0,0,0,-42.44761154,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160514-02,Idebenone,170465611,Free Radical Scavenger,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58186-27-9, ;Idebenone;IDEBENONE; Idebenone,22.38721139,0,-4.65,-51.33549567,-2.4,4,,-53.0143325,-46.10820647,0.604443633,0.674242308,,,COC1=C(OC)C(=O)C(C)=C(CCCCCCCCCCO)C1=O,Vitas,STK801942,-2.56833971,-25.60011319,-13.73410265,-46.10820647,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164631-05,Sunitinib malate,170465289,VEGFR-1/2/3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),341031-54-7, Sunitinib malate;Sunitinib malate; Sunitinib base; ;Sutent,10,0,-5,-137.1528475,-2.3,4,,-72.64544969,-89.8682516,0.0817876,0.995851975,2321,FLT1,O=C(O)C(O)CC(=O)O.CCN(CC)CCNC(=O)C1C(C)=C(N=C1C)/C=C2/c3cc(F)ccc3NC2=O,Sequoia,SRP01785s,-14.9514566,-20.50721148,-66.41582985,-89.8682516,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015479-19,Genistein,170466848,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),446-72-0,"; ; Genistein;GENISTEIN;Genistein (4',5,7-Trihydroxyisoflavone); Genestein;Genistein",39.81071706,0,-4.4,-37.35181504,-3,4,,-107.7537872,-92.33985527,0.098816377,0.993928856,7153,TOP2A,Oc1ccc(cc1)C3=COc2cc(O)cc(O)c2C3=O,Vitas,STK801619,0,-7.2230702,0,-92.33985527,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160395-04,Dibenzepin hydrochloride,170466001,Monoamine transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),315-80-0,,7.079457844,1,-5.15,-51.92700913,-2.4,4,,-55.73813196,-44.06247595,0.268954556,0.952592635,,,Cl.CN(C)CCN3c1ccccc1N(C)c2ccccc2C3=O,Enzo,NS107,-1.18694691,-19.79588561,-27.36422985,-44.06247595,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159383-04,Propyl benzoate,170465563,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2315-68-6,,0.707945784,1,-6.15,-41.54832212,-1.4,4,,-41.72089084,-17.34804072,1,0.916843796,,,O=C(OCCC)c1ccccc1,Labotest,LTBB003527,0,-43.98009463,-31.06857383,-17.34804072,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091120-13,Griseofulvin,170465739,Tubulin beta chain Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),126-07-8,,8.912509381,1,-5.05,-88.46781818,-1.4,4,,-37.97935543,-41.64946286,0.473822341,0.829710481,,TUB2,O=C2c3c(O[C@]12C(=CC(=O)C[C@H]1C)OC)c(Cl)c(OC)cc3OC,Prestwick,Prestw-226,-16.65305982,0,-34.03844444,-41.64946286,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183853-01,Mosapramine,144206880,Dopamine D4 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),89419-40-9,,35.48133892,0,-4.45,-29.97758576,-3,4,"MOSAPRAMINE HYDROCHLORIDE;LS-178090;Cremin;3-chloro-5-(3-(2-oxo-1,2,3,5,6,7,8,8a-octahydroimidazo(1,2-a)pyridine-3-spiro-4'-piperidino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine;Spiro(imidazo(1,2-a)pyridine-3(2H),4'-piperidin)-2-one, 1'-(3-(3-chloro-10,11-dihydro-5H-dibenz(b,f)azepin-5-yl)propyl)hexahydro-, dihydrochloride;CIPLUS_3853867;mosapraminum;CIPLUS_703731;Mosapramine hydrochloride;Y 516;(+/-)-1'-(3-(3-CHLORO-10,11-DIHYDRO-5H-DIBENZ(B,F]AZEPIN-5-YL)PROPYL)HEXAHYDROSPIRO(IMIDAZO(1,2-A)PYRIDINE-3(2H),4'-PIPERIDIN)-2-ONE;Mosapramine Hydrochloride;Mosapramine;mosapramine;Y-516;MOSAPRAMINE;",-91.04428587,-75.82879831,0.022159919,0.999697039,,,Clc5ccc6CCc1ccccc1N(CCCN2CCC4(CC2)C(=O)NC3CCCCN34)c6c5,Pharmaron,PH-NIH-183543,0,-1.49078057,-3.44557952,-75.82879831,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274059-01,Nelarabine,170464759,Antimetabolite,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),121032-29-9,,39.81071706,0,-4.4,-39.21767474,-3,4,,-34.97911418,-33.31592848,0.543593836,0.757907282,,HPRT1,Nc3nc2c(ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O)c(OC)n3,Selleck,S1213,-5.51669607,-15.68660741,0,-33.31592848,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00168746-02,Methyldigoxin,99455400,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,0.003548134,1,-8.45,-476.2726757,5,4,,-43.44119448,-98.2844108,0.235380565,0.966435221,,,CO[C@H]1[C@@H](O)CC(O[C@@H]1C)OC2[C@@H](O)CC(O[C@@H]2C)OC3[C@@H](O)C[C@@H](O[C@@H]3C)OC4CC[C@@]5(C)C(CCC6C5CC(O)[C@]7(C)[C@@H](CCC67O)C/8=C/C(=O)OC8)C4,Chemdiv,N001-0009,-92.91674873,-95.83509697,-96.48081318,-98.2844108,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00507698-01,Talaporfin sodium,405558614,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),220201-34-3,,39.81071706,0,-4.4,-40.9672832,-3,4,,-52.79272138,-48.16060115,0.377227435,0.900532206,,,CCC1=C2[NH]C(=C1C)C=C3[NH]C(=CC4=NC(=C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)C\5=NC(=C2)\C(=C5C(O)=O)C)[C@@H](CCC(O)=O)[C@@H]4C)C(=C3C=C)C,MedChem Express,HY-16477,-4.50701901,-15.10674631,0,-48.16060115,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018163-10,Bithionol,170465515,Adenylate cyclase type 10 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),97-18-7,,39.81071706,0,-4.4,-43.35855951,-3,4,,-114.2779434,-96.06495283,0.043953663,0.998806571,,,Oc2c(Sc1cc(Cl)cc(Cl)c1O)cc(Cl)cc2Cl,Specs,AN-153/J117612,-3.2389158,0,0,-96.06495283,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016801-05,Levobunolol hydrochloride,170464743,Beta-2 adrenergic receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),27912-14-7,,39.81071706,0,-4.4,-15.24556488,-3,4,,-44.30895161,-36.59769061,0.384105062,0.896401379,,,Cl.CC(C)(C)NC[C@H](O)COc2cccc1c2CCCC1=O,"Prestwick Chemical, Inc.",Prestw-847,2.84276256,-10.6209137,-5.12457568,-36.59769061,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179625-03,Thioproperazine dimethanesulfonate,170465871,Serotonin 2a (5-HT2a) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2347-80-0,,39.81071706,0,-4.4,-21.44365836,-3,4,,-111.9711336,-93.56507146,0.052442291,0.998299941,,,CS(=O)(=O)O.CS(=O)(=O)O.CN(C)S(=O)(=O)c2cc3N(CCCN1CCN(C)CC1)c4ccccc4Sc3cc2,Prestwick,Prestw-149,2.68187473,0,4.60972618,-93.56507146,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094748-07,Oxyphenbutazone,170465310,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),129-20-4,,35.48133892,0,-4.45,-34.73282214,-3,4,,-109.8044712,-97.86494755,0.002125651,0.999997213,,,Oc1ccc(cc1)N3C(=O)C(CCCC)C(=O)N3c2ccccc2,Microsource,1500455,0,0,-0.70624362,-97.86494755,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274269-01,NCGC00274269-01,225144370,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,12.58925412,0,-4.9,-116.6053865,-2.4,4,,-66.76297086,-73.81603935,0.318074852,0.931910532,,,CCCCCCCCCCCCNCCNCCNCC(O)=O,GVK,FFS-11-286-NCI-158,-22.65445867,-4.48942833,-11.97546359,-73.81603935,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00024622-05,Dantrolene sodium,170464793,Ryanodine receptor 1 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),14663-23-1,,39.81071706,0,-4.4,-13.1681445,-3,4,,-33.09561122,-30.49634268,0.618328617,0.651745393,6261,RYR1,[Na+].[O-][N+](=O)c1ccc(cc1)c3ccc(/C=N/N2CC(=O)[N-]C2=O)o3,Enzo,AC100,3.44001803,-17.79403002,-0.6064152,-30.49634268,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00014617-01,Benzylhydrochlorothiazide,144203604,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1824-50-6,Benzylhydrochlorothiazide; Behyd; BHCTh; ,39.81071706,0,-4.4,-126.0597363,-2.4,4,"6-Chloro-3,4-dihydro-3-(phenylmethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide;Behyd;Benzylhydrochlorothiazide;LS-40438;BENZYLHYDROCHLOROTHIAZIDE;BHCTh;CIPLUS_208144;benzylhydrochlorothiazide;2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(phenylmethyl)-, 1,1-dioxide;",-33.40180417,-40.45090921,0.718252501,0.867962128,,,NS(=O)(=O)c3cc1c(NC(NS1(=O)=O)Cc2ccccc2)cc3Cl,NCI,,-32.34181993,-12.81674492,-8.03273907,-40.45090921,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091534-02,o-Cresol,26753043,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),95-48-7,2-Methylphenol-d8; o-Cresol-d8; ,63.09573445,0,-4.2,-7.344744031,-3,4,"2-methylphenol;CIPLUS_732542;CIPLUS_723417;methylphenol, polymer with formaldehyde;phenoaldehyde resinifying agent;CIPLUS_3741557;CIPLUS_3751665;CIPLUS_3881950;2-cresol, sodium salt;2-METHYLPHENOL;CIPLUS_749387;2-cresol, potassium salt;phenoaldehyde;CRESOL;CIPLUS_150287;CIPLUS_749458;O-CRESOL;ortho-cresol;Methylphenol tricresol;o-Cresol-d8;CIPLUS_3882512;o-cresol;NCGC00091534-02;Cresol mixture of isomers;CIPLUS_743211;CIPLUS_749586;AB08007336-01;2-cresol;CIPLUS_3752378;CIPLUS_671502;2-cresol, ammonium salt;CIPLUS_745732;tricresolformalin;2-Methylphenol-d8;CIPLUS_653786;CIPLUS_163487;2-Methylphenol;CIPLUS_3750176;CIPLUS_714209;CIPLUS_682977;o-Cresol;",-36.16767422,-32.22306185,0.129370483,0.989543593,,,CC1=C(O)C=CC=C1,SigmaAldrich,MFCD00002226,0,1.56263726,3.9987904,-32.22306185,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00183865-01,Flugestone,144206781,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),337-03-1,,35.48133892,0,-4.45,-4.362193396,-3,4,"CIPLUS_160491;Flugestonum;CIPLUS_679087;FLUROGESTONE ACETATE;Pregn-4-ene-3,20-dione, 17-(acetyloxy)-9-fluoro-11-hydroxy-, (11beta)-;Fluorogestone acetate;Flurogestone acetate;FLUGESTONE;Flugestona;flugestonum;flugestone;Flugestone;Flurogestone Acetate;Flugestone acetate;LS-118677;",-50.44906646,-39.73414126,0.080345821,0.995999878,,,CC(=O)[C@@]4(O)CC[C@@H]2[C@]4(C)C[C@H](O)C1(F)[C@@]3(C)CCC(=O)C=C3CC[C@H]12,NCI,NSC_79327,3.16937223,0,0,-39.73414126,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015408-05,RACEPHEDRINE HYDROCHLORIDE,405558670,Norepinephrine Transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),"134-71-4, 90-81-3 [racephedrine]",,7.079457844,1,-5.15,-26.19059627,-1.4,4,,-39.38227565,-37.13948593,0.069384741,0.997020749,,,CNC(C)C(O)C1=CC=CC=C1,Microsource,1500525,3.15080745,0,-32.47465026,-37.13948593,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386699-01,Fluphenazine decanoate dihydrochloride,405558673,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2376-65-0,,14.12537545,0,-4.85,-53.87224205,-2.3,4,,-91.7135496,-85.91766629,0.411301565,0.999959538,,,CCCCCCCCCC(=O)OCCN1CCN(CCCN2C3=C(SC4=CC=C(C=C24)C(F)(F)F)C=CC=C3)CC1,Axon Medchem,2127,-20.65347061,0,-34.09592364,-85.91766629,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00022185-14,Progesterone,405559122,Progestogen hormone,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),[57-83-0],,39.81071706,0,-4.4,-139.4830196,-2.4,4,,-67.52238276,-75.36934292,0.286041458,0.945890713,,PGR,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC/4=C/C(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Tocris,2835,-29.82349211,-14.51735729,-18.91261612,-75.36934292,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164559-03,Duloxetine hydrochloride,170465319,Serotonin Transporter (SERT) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),136434-34-9, ; Duloxetine hydrochloride;Duloxetine hydrochloride; Cymbalta;DULOXETINE HYDROCHLORIDE;Duloxetine HCl; DULOXETINE HCl; 0   Duloxetine Hcl,14.12537545,0,-4.85,-64.21750749,-2.3,4,,-113.4960796,-86.10799968,0.503227822,0.801807678,6532,SLC6A4,Cl.CNCC[C@H](Oc1cccc2ccccc12)c3cccs3,Sequoia,SRP05005d,4.78540607,-39.20824729,-30.22337984,-86.10799968,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00345882-03,Silodosin,405558750,alpha1-Adrenoceptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),160970-54-7,,39.81071706,0,-4.4,-10.39907817,-3,4,,-47.68286338,-39.31905282,0.14203569,0.987355287,,ADRA1A,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC3=CC=CC=C3OCC(F)(F)F,Prestwick,Prestw-1749,0,0,4.80713839,-39.31905282,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167537-02,Donepezil hydrochloride,170464858,Acetylcholinesterase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),120011-70-3,,39.81071706,0,-4.4,-22.0683885,-3,4,,-75.69210592,-63.07675493,0.006832298,0.999971214,,,Cl.COc1cc2C(=O)C(Cc2cc1OC)CC4CCN(Cc3ccccc3)CC4,Sequoia,SRP04573d,0,0,0,-63.07675493,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00379087-02,Tipranavir,405558770,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),174484-41-4,,2.818382931,1,-5.55,-194.9638892,5,4,,43.35555964,-52.21770284,1,0.999997862,,,CCC[C@@]1(CCC2=CC=CC=C2)CC(=C([C@H](CC)C3=CC=CC(=C3)N[S+]([O-])(=O)C4=CC=C(C=N4)C(F)(F)F)/C(=O)O1)\O,MedChem Express,HY-15148,-94.55349482,-50.72856207,-19.63535714,-52.21770284,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182708-01,Pipecuronium bromide,144206565,Muscle-type nicotinic acetylcholine receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52212-02-9,Pipecuronium bromide; Arduan; Pipecuronium; Bromuro de pipecuronio; ,31.6227766,0,-4.5,-10.07867409,-3,4,"CIPLUS_188694;Arduan;LS-113699;Bromuro de pipecuronio;pipecuronii bromidum;4,4'-(3A,17B-DIHYDROXY-5A-ANDROSTAN-2B,16B-YLENE)BIS-(1,1-DIMETHYLPIPERAZINIUM)DIBROMIDE,DIACETATE;bromure de pipecuronium;Pipecuronium Dibromide, (3 beta)-Isomer;pipecuronio bromuro (spanish);CIPLUS_207311;4,4'-(3.ALPHA.,17.BETA.-DIHYDROXY-5.ALPHA.-ANDROSTAN-2.BETA.,16.BETA.-YLENE)BIS(1,1-DIMETHYLPIPERAZINIUM)DIBROMIDE, DIACETATE (ESTER);Piperazinium, 4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl);LS-177113;Pipecuronium;PIPECURONIUM BROMIDE;LS-172842;Pipecuronium Dibromide, (16 alpha)-Isomer;Bromure de pipecuronium;Pipecuronium Dibromide, (17 alpha)-Isomer;Pipecuronii bromidum;Pipecuronium bromide;LS-176664;LS-172841;CIPLUS_188695;PIPERAZINIUM, 4,4'-((2.BETA.,3.ALPHA.,5.ALPHA.,16.BETA.,17.BETA.)-3,17-BIS(ACETYLOXY)ANDROSTANE-2,16-DIYL)BIS(1,1-DIMETHYL-, DIBROMIDE;",-78.63528745,-61.08733898,0.867784458,0.999993522,,,[Br-].[Br-].C[N+]1(C)CCN(CC1)[C@H]6C[C@@]5(C)[C@@H](CC[C@@H]3[C@@H]5CC[C@]2(C)[C@@H](OC(C)=O)[C@H](C[C@H]23)N4CC[N+](C)(C)CC4)C[C@@H]6OC(C)=O,APAC,872548,-91.49197515,3.39431892,-1.852383,-61.08733898,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249896-01,Cinnamedrine,170465535,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),90-86-8,,1.77827941,1,-5.75,-48.09054887,-1.4,4,,-35.35859639,-30.20430882,0.18856152,0.977436491,,,OC(C(C)N(C)C/C=C/c1ccccc1)c2ccccc2,GVK,FFS-11-286-NCI-72,0,-18.76100223,-34.96368104,-30.20430882,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016925-11,Omeprazole,170465443,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),73590-58-6, ; Omeprazole ER; Zegerid; Prilosec;AGI-010/DM-3458;Omepral; ESOMEPRAZOLE Mg; Losec sodium; Esomeprazole;Omeprazole; Omeprazole; Omeprazol; Nexium; Losec,39.81071706,0,-4.4,-54.82464286,-3,4,,-64.10151366,-62.94553258,0.21840631,0.969383866,8714,ABCC3,Cc3c(OC)c(C)cnc3CS(=O)c1nc2cc(ccc2n1)OC,Microsource,1505693,-5.77760453,-15.9328942,-6.13295267,-62.94553258,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262961-01,Cromoglicate lisetil,170465975,mast cell activation Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),110816-79-0,O,39.81071706,0,-4.4,-36.36073563,-3,4,,-58.48764428,-54.15637023,0.577026843,0.714625484,,,O=C(OCC)C=4Oc3cccc(OCC(OC(=O)[C@@H](N)CCCCN)COc1cccc2OC(=CC(=O)c12)C(=O)OCC)c3C(=O)C=4,GVK,FFS-11-286-NCI-234,0.18678101,-27.41281878,1.67844655,-54.15637023,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181091-01,Bunamidine hydrochloride,144206260,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1055-55-6,Bunamidine hydrochloride; Bunamidina; Scolaban; ,10,0,-5,-78.88869135,-2.3,4,"bunamidinum;bunamidine monohydrochloride;N,N-DIBUTYL-4-(HEXYLOXY)-1-NAPHTHAMIDINE MONOHYDROCHLORIDE;bunamidine;LS-174664;Scolaban;CIPLUS_738221;CIPLUS_157296;Bunamidinum;N,N-dibutyl-4-(hexyloxy)-1-naphthamidine monohydrochloride;LS-95153;NSC-106571;1-Naphthamidine, N,N-dibutyl-4-hexyloxy-, monohydrochloride;CIPLUS_3885993;1-naphthalenecarboximidamide, n,n-dibutyl-4-(hexyloxy)-, hydrochloride;BUNAMIDINE HYDROCHLORIDE;Bunamidine hydrochloride;Bunamidina;BUNAMIDINE;Bunamidine;",-95.92797357,-95.09662088,0.565026058,0.998876947,,,Cl.CCCCN(CCCC)C(=N)c1ccc(OCCCCCC)c2ccccc12,NCI,NSC-106571,-36.89530002,0,-65.31734233,-95.09662088,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182972-01,Hexocyclium,144206775,Muscarinic acetylcholine receptor M5 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),115-63-9,"4-(2-cyclohexyl-2-hydroxy-2-phenethyl)-1,1- dimethylpiperazinium; Metilsulfato de hexociclo; ",39.81071706,0,-4.4,-52.72341115,-3,4,"HEXOCYCLIUM METHYLSULFATE;Hexocyclium Methylsulfate;Metilsulfato de hexociclo;4-(.BETA.-CYCLOHEXYL-.BETA.-HYDROXYPHENETHYL)-1,1-DIMETHYLPIPERAZINUM METHYLSULFATE;LS-113656;LS-113657;4-(2-cyclohexyl-2-hydroxy-2-phenethyl)-1,1- dimethylpiperazinium;Hexocyclium metilsulfate;hexocyclii metilsulfas;Hexocyclii metilsulfas;Tral;hexocyclium;metilsulfate d'hexocyclium;Metilsulfate d'hexocyclium;hexociclium;CIPLUS_679015;CIPLUS_669959;CIPLUS_3863310;hexocyclium methylsulfate;CIPLUS_166714;TRAL;Hexocyclium;HEXOCYCLIUM METILSULFATE;",-43.41261578,-40.34384648,0.435457798,0.861240276,,,OC(CN1CC[N+](C)(C)CC1)(c2ccccc2)C3CCCCC3.[O-]S(=O)(=O)OC,NCI,NSC_30256,-9.92803445,-12.49306484,0,-40.34384648,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00014482-03,Methdilazine hydrochloride,124878446,ion channel,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,11.22018454,0,-4.95,-185.7401169,-2.3,4,Methdilazine hydrochloride,-76.73085916,-98.49900635,0.271759344,0.951494878,,,CN1CC[C@@H](C1)CN2C3=C(SC4=C2C=CC=C4)C=CC=C3,NCGC,NSC-169091,-33.06005119,-14.4784593,-59.64906984,-98.49900635,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181342-02,Imidapril hydrochloride,170466024,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),89396-94-1,,3.548133892,1,-5.45,-10.53962317,-3,4,,-33.78777384,-8.93286309,1,0.999990343,,,Cl.OC(=O)[C@@H]2CN(C)C(=O)N2C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC,SIGMA,SML0148,-24.28814118,0,-30.23981153,-8.93286309,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167457-02,Gestrinone,170466364,Progesterone receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),16320-04-0,,39.81071706,0,-4.4,-101.3360214,-3,4,,-52.753657,-48.1280475,0.637042174,0.618456554,5241,PGR,O=C3C=C4CC[C@@H]2C(C=C[C@@]1(CC)[C@H]2CC[C@@]1(O)C#C)=C4CC3,Bosche,G6427,-26.31111338,-7.59417376,0,-48.1280475,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274271-01,Dimethisteron,170465914,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),79-64-1,,19.95262315,0,-4.7,-26.91223506,-2.2,4,,-78.90846196,-71.14277421,0.006616854,0.999972999,,,C[C@H]3C[C@@H]2[C@H](CC[C@@]1(C)[C@H]2CC[C@@]1(O)C#CC)[C@@]4(C)CCC(=O)C=C34,GVK,FFS-11-286-NCI-184,2.2177551,1.76967038,-14.22263949,-71.14277421,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167480-02,N-Hydroxymethylsuccinimide,225144289,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,22.38721139,0,-4.65,-69.32691594,-2.4,4,,-33.24151705,-40.16873839,0.848385368,0.999857053,,,OCN1C(=O)CCC1=O,Innovapharm,BBS-00004790,-39.31923228,-11.48434802,-18.16299509,-40.16873839,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167544-02,"2,2'-Methylenebis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol]",225144291,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),103597-45-1,,3.981071706,1,-5.4,-63.2382078,-2.4,4,,-48.29802401,-49.50211716,0.765071899,0.8328801,,,CC(C)(C)CC(C)(C)C1=CC(=C(O)C(=C1)[N]2N=C3C=CC=CC3=N2)CC4=CC(=CC(=C4O)[N]5N=C6C=CC=CC6=N5)C(C)(C)CC(C)(C)C,SIGMA,407941,-35.24873128,-20.57341642,-3.77664079,-49.50211716,,,,,,,,,,,,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,,,,
NCGC00065934-05,Oxcarbazepine,170464811,Sodium channel inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),28721-07-5,; Oxcarbazepina; Oxcarbazepine;Oxcarbazepine;OXCARBAZEPINE; Timox; Trileptal; Oxacarbazepine,39.81071706,0,-4.4,-116.2304595,-2.4,4,,-66.16539282,-70.29738743,0.300282374,0.939931819,,,NC(=O)N3c1ccccc1C(=O)Cc2ccccc23,Vitas,STK594696,-17.18929882,-31.26231502,-25.86140737,-70.29738743,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159458-05,Atorvastatin calcium,170465113,HMG-CoA Reductase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),134523-03-8,,5.011872336,1,-5.3,-83.7337669,-1.3,4,,-85.90992908,-80.89722867,0.079348233,0.996096544,,,[Ca+2].O[C@H](CCn1c(c(c(c1C(C)C)C(=O)Nc2ccccc2)c3ccccc3)c4ccc(F)cc4)C[C@@H](O)CC([O-])=O.[O-]C(=O)C[C@H](O)C[C@H](O)CCn4c(c1ccc(F)cc1)c(c2ccccc2)c(C(=O)Nc3ccccc3)c4C(C)C,Prestwick,Prestw-1232,0,4.37885503,-83.74740311,-80.89722867,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015774-06,Oxatomide,170466059,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),60607-34-3,,1,1,-6,-74.39960549,-1.4,4,,-48.9760623,-60.52895811,0.508570648,0.796438433,3269,HRH1,O=C5Nc1ccccc1N5CCCN2CCN(CC2)C(c3ccccc3)c4ccccc4,Enzo,EI114,0,-43.93960913,-32.26091892,-60.52895811,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163169-05,Pizotifen,170466311,Antimigraine drugs,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),15574-96-6, Pizotyline;Pizotyline;PIZOTIFEN MALATE; Pizotifen malate;PIZOTYLINE MALATE; ; Pizotifeno;Pizotifen malate; Polomigran; Pizotifen hydrogen malate; Sandomigran,1.258925412,1,-5.9,-92.41245439,-1.4,4,,-57.18411584,-77.38696325,0.570051926,0.724103677,,CHRM1,CN1CC/C(CC1)=C3\c4ccccc4CCc2sccc23,BIOMOL,NS740,-1.51744441,-50.25121144,-36.75529645,-77.38696325,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016258-06,Menadione,170464997,CDC25 Phosphatase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58-27-5," ; Menadione (K3);Menadione / vitamin K3;MENADIONE; Kappaxin; Kipca, oil soluble;Menadione; Menadione; Vitamin- K3",39.81071706,0,-4.4,-42.56019394,-3,4,,-103.7172229,-90.21542954,0.219839905,0.968955451,5923,CDC25,O=C2C=C(C)C(=O)c1ccccc12,Specs,AE-562/J257372,0,-15.7437442,0,-90.21542954,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253585-01,Cyclomethycaine,170465528,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),139-62-8,,31.6227766,0,-4.5,-33.74773578,-3,4,,-89.82251189,-78.43056499,0.019050386,0.999776118,,,CC3CCCCN3CCCOC(=O)c2ccc(OC1CCCCC1)cc2,GVK,FFS-11-286-NCI-76,-1.28235449,0,-3.50493696,-78.43056499,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00319020-01,NCGC00319020-01,225144374,Prostanoid IP receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-10.90586815,-3,4,,-36.40590878,-31.17159065,0.797514696,0.999991313,,,CCCCC[C@@H](O)CC[C@@H]1[C@@H](O)C[C@H]2CC3=C(C[C@@H]12)C=CC=C3OCC(O)=O,GVK,FFS-11-286-NCI-96,-27.74119118,0,0,-31.17159065,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181320-01,Mersalyl acid,144206341,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),486-67-9,2-(3-Hydroxymercurio-2-methoxypropylcarbamoyl)phenoxyacetic acid; Salyrganic acid; Mersalyl acid; ,11.22018454,0,-4.95,-78.08439507,-3,4,Mersalyl acid;2-(3-Hydroxymercurio-2-methoxypropylcarbamoyl)phenoxyacetic acid;2-[N-(3-Hydroxymercuri-2-methoxypropyl)carbamoyl]phenoxyacetic acid;Salyrganic acid;,-113.8324074,-87.42888437,0.00266441,0.999995622,,,O[Hg]CC(OC)CNC(=O)c1ccccc1OCC(=O)O,SIGMA,M9784,0,0,0,-87.42888437,,,,,,,,,,,,1.14E-07,5.71E-07,2.86E-06,0.0000143,,,,,,,,,,,
NCGC00167798-05,Oxaliplatin,405558440,DNA Alkylating Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61825-94-3,,3.16227766,1,-5.5,-43.97394117,-1.4,4,,-36.76395873,-34.38746837,0.127676313,0.989816623,,H2AFX,O=C1O[Pt]2(NC3CCCCC3N2)OC1=O,Cayman,13106,0,-6.60312076,-39.13329512,-34.38746837,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016012-12,Triflupromazine hydrochloride,170465325,Muscarinic acetylcholine receptor M2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1098-60-8,,39.81071706,0,-4.4,-28.27815921,-3,4,,-96.99092536,-80.82577113,0.006832298,0.99997121,1129,CHRM2,Cl.FC(F)(F)c1cc2N(CCCN(C)C)c3ccccc3Sc2cc1,Microsource,1503118,0,0,0,-80.82577113,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015817-14,Promethazine,170465107,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),60-87-7,,35.48133892,0,-4.45,-71.73362675,-2.4,4,,-85.44125844,-77.14191674,0.198145915,0.974979285,,,CN(C)C(C)CN1c3ccccc3Sc2ccccc12,Enzo,AC765,-6.57172638,-18.94862858,-16.79370891,-77.14191674,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091231-04,Quinidine hydrochloride monohydrate,170465031,Antimalarial Agents; Cytochrome P450 Cyp2d6 Inhibitors,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6151-40-2,,3.981071706,1,-5.4,-46.01571083,-1.4,4,,-41.72281874,-32.0108519,0.360416941,0.910243306,,CYP2D6,[H][C@@]1(CC2CCN1C[C@@H]2C=C)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12,Prestwick,Prestw-280,0,-0.15933003,-49.69202082,-32.0108519,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016715-04,Trapidil,170465770,C-C motif chemokine 2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),15421-84-8,,39.81071706,0,-4.4,-32.68935037,-3,4,,-41.48274171,-36.65145609,0.810452269,0.999618434,100009130,CCL2,CCN(CC)c1cc(C)nc2ncnn12,"Prestwick Chemical, Inc.",Prestw-1012,-34.7189788,-4.54134119,-4.33174414,-36.65145609,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094646-04,Dibenzothiophene,170465511,Cytochrome P450 2C9 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132-65-0,,6.309573445,1,-5.2,-11.80352056,-3,4,,-41.27667862,0,1,0.997017916,,,c1cccc2sc3ccccc3c12,Vitas,STK367232,0,2.17206881,-38.21914687,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263538-01,Trovafloxacin mesylate,170465074,Streptococcus pneumoniae Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),147059-75-4,,39.81071706,0,-4.4,-87.87500178,-3,4,,-93.71555277,-82.26296064,0.286133538,0.945843034,,,CS(=O)(=O)O.O=C(O)C2=CN(c1nc(c(F)cc1C2=O)N3C[C@H]4[C@H](N)[C@H]4C3)c5ccc(F)cc5F,Tocris,3863,-17.55295507,-8.96471699,0,-82.26296064,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167563-01,Mofezolac,144206111,Cyclooxygenase-1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),78967-07-4,Mofezolac; Mofezolaco; ,39.81071706,0,-4.4,-15.0328207,-3,4,"mofezolac;n-22;(3,4-di-(4-methoxyphenyl)-5-isoxazolyl)acetic acid;mofezolacum;(3,4-bis(4-methoxyphenyl)-5-isoxazolyl)acetic acid;Mofezolac;CIPLUS_213447;Mofezolaco;LS-86501;N-22;3,4-BIS(P-METHOXYPHENYL)-5-ISOXAZOLEACETIC ACID;3,4-DMPIAA;N 22;MOFEZOLAC;Mofezolacum;",-51.56089472,-42.96741227,0.006832298,0.999971225,,,O=C(O)Cc2onc(c1ccc(OC)cc1)c2c3ccc(OC)cc3,SigmaAldrich,R678899,0,0,0,-42.96741227,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346442-02,Phenprocoumon,405558576,Cytochrome P450 3A4 Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),435-97-2,,3.16227766,1,-5.5,-69.40873426,-1.4,4,,-38.0566526,-37.37535301,0.841998872,0.990903173,,,CCC(C1=CC=CC=C1)C/2=C(\O)C3=CC=CC=C3OC2=O,Adooq,A10656,-28.88926106,-7.50660632,-40.80053721,-37.37535301,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159498-03,Metipranolol,29215466,Beta-2 adrenergic receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,Metipranolol; Disorat; ,63.09573445,0,-4.2,-13.12118482,-3,4,"Trimepranol;(+/-)-1-(4-HYDROXY-2,3,5-TRIMETHYLPHENOXY)-3-(ISOPROPYLAMINO)-2-PROPANOL 4-ACETATE HYDROCHLORIDE;LS-122351;Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate;CIPLUS_173566;TRIMEPRANOL;METIPRANOLOL HYDROCHLORIDE;1-(4-HYDROXY-2,3,5-TRIMETHYLPHENOXY)-3-(ISOPROPYLAMINO)-2-PROPANOL 4-ACETATE -DL;(+/-)-1-(4-HYDROXY-2,3,5-TRIMETHYLPHENOXY)-3-(ISOPROPYLAMINO)-2-PROPANOL 4-ACETATE;Disorat;Metipranololum;Methypranol;metipranololum;PHENOL, 4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-2,3,6-TRIMETHYL-, (+/-)-, 1-ACETATE;PHENOL, 4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-2,3,6-TRIMETHYL-, (+/-)-, 1-ACETATE, HYDROCHLORIDE;1-(4-Acetoxy-2,3,5-Trimethylphenoxy)-3-Isopropylamino-2-Propanol;metipranolol;Metipranolol;METIPRANOLOL;Metipranolol (4-(2-Hydroxy-3-(isopropylamino)propoxy)-2,3,6-trimethylphenyl acetate);METHYPRANOL;",-39.65844873,-37.64671179,0.010143222,0.99993659,,,CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C,SigmaAldrich,R736139,0,0,0,-37.64671179,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00183285-15,Nilotinib,405558616,Bcr-Abl Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),641571-10-0,,22.38721139,0,-4.65,-81.64528527,-2.2,4,,-60.71713101,-61.48103838,0.009600271,0.999943178,,ABL1,CC1=C[N](C=N1)C2=CC(=CC(=C2)NC(=O)C3=CC(=C(C)C=C3)NC4=NC(=CC=N4)C5=CC=CN=C5)C(F)(F)F,Glixx,GLXC-90226,-11.19819971,-12.34198281,-25.49997054,-61.48103838,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346533-09,Daclatasvir dihydrochloride,405558621,HCV NS5A Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1009119-65-6,,39.81071706,0,-4.4,-73.45631564,-3,4,,-84.86119452,-74.88432877,0.262687939,0.95487303,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C([NH]2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C([NH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C,Glixx,GLXC-90137,-15.70060208,0,0,-74.88432877,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166138-04,Ethynodiol diacetate,170464933,Progesterone receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),297-76-7,,39.81071706,0,-4.4,-25.91040037,-3,4,,-88.86977717,-74.05814764,0.006832298,0.999971211,5241,PGR,CC(=O)O[C@@]4(C#C)CC[C@@H]3[C@]4(C)CC[C@H]2[C@H]3CCC1=C[C@H](CC[C@@H]12)OC(C)=O,"Prestwick Chemical, Inc.",Prestw-908,0,0,0,-74.05814764,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178734-06,Sitagliptin,405558639,DPP-IV Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),654671-77-9,,3.548133892,1,-5.45,-97.1912914,-1.4,4,,-41.05997154,-41.43233718,0.936525358,0.999938824,,DPP4,N[C@@H](CC(=O)N1CC[N]2C(=NN=C2C(F)(F)F)C1)CC3=C(F)C=C(F)C(=C3)F,Adooq,A10848,-36.19474951,-15.56074404,-35.7825466,-41.43233718,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263152-12,Ponatinib,405558658,FGFR Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1114544-31-8,,3.548133892,1,-5.45,-144.9761362,-1.1,4,,-88.76464305,-99.150667,0.046054372,0.998689581,,FGFR1,CN1CCN(CC1)CC2=CC=C(NC(=O)C3=CC(=C(C)C=C3)C#CC4=CN=C5C=CC=N[N]45)C=C2C(F)(F)F,Glixx,GLXC-01988,-8.1663444,-29.46564599,-93.24946642,-99.150667,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00163732-03,Moxidectin,405558680,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),113507-06-5,,17.7827941,0,-4.75,-34.51101985,-2.2,4,,-66.62122533,-59.94032222,0.022160037,0.999697089,,,CO\N=C/1C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C\4CO[C@@H]5[C@H](O)\C(=C/[C@@H](C(=O)O3)[C@]45O)C)O2)O[C@@H]([C@H]1C)\C(C)=C\C(C)C,MedChem Express,HY-B0777,0,0,-19.38710665,-59.94032222,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167586-03,Piroctone Olamine,225144295,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),68890-66-4,,39.81071706,0,-4.4,-84.41445935,-3,4,,-125.6786195,-99.14267549,0.18334215,0.978677451,,,CC(CC/1=C/C(=C\C(=O)N1O)C)CC(C)(C)C,Bosche,P6136,-15.02765318,0,-6.4382483,-99.14267549,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185769-02,Stiripentol,405558693,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-16.71890475,-3,4,,-57.34397458,-47.78664548,0.006832298,0.999971221,,,CC(C)(C)C(O)C=CC1=CC=C2OCOC2=C1,APExBIO,A8704,0,0,0,-47.78664548,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018187-09,Cinnarizine,170465920,Voltage-gated calcium channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),298-57-7,,0.794328235,1,-6.1,-46.64364468,-1.4,4,,-37.77592173,-32.02038723,0.104847543,0.993164439,,,c1ccccc1C(c2ccccc2)N3CCN(CC3)C/C=C/c4ccccc4,Prestwick,Prestw-278,3.04769723,-33.58881642,-30.28693427,-32.02038723,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094571-08,Crotamiton,170464851,antipruritic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),483-63-6,; Eurax;CROTAMITON;Crotamiton; ; CROTAMITON; 7   Crotamiton; Veteusan,3.16227766,1,-5.5,-20.76357926,-2.4,4,,-45.06391517,-17.17203919,1,0.999858752,,,CCN(C(=O)C=CC)c1ccccc1C,Microsource,1505271,0.87964576,-13.94671042,-39.21992931,-17.17203919,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00264001-02,CALCIUM GLUCEPTATE,405558708,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),299-28-5,,39.81071706,0,-4.4,-33.88497885,-3,4,,-51.94212971,-44.95177476,0.220727388,0.968709399,,,OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)C([O-])=O,Microsource,1300012,-6.63519166,2.59587672,0,-44.95177476,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182548-02,Flutropium bromide,170465904,Muscarinic acetylcholine receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),63516-07-4,,22.38721139,0,-4.65,-92.844492,-2.4,4,,-50.10655092,-48.94435676,0.581022646,0.709096,,,[Br-].[Br-].C[N+]2(CCF)[C@H]1C[C@@H](C[C@@H]2CC1)OC(=O)C(O)(c3ccccc3)c4ccccc4,APAC,871826,-22.9795694,3.68004059,-13.06611751,-48.94435676,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166300-02,Pyridoxal phosphate hydrate,170466028,P2X purinoceptor 2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),41468-25-1,,17.7827941,0,-4.75,-17.14516604,-3,4,,-33.63116889,-30.10930741,0.025411383,0.999602122,,,O.Oc1c(C=O)c(cnc1C)COP(=O)(O)O,SIGMA,P3657,0,0,-9.46585241,-30.10930741,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181788-01,Cefetamet pivoxil HCl,144206472,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),111696-23-2,Cefetamet pivoxil hydrochloride; Ro 15-8075; Ro-15-8075; Cefyl; ,39.81071706,0,-4.4,-42.50765078,-3,4,cefetamet pivaloyloxymethyl ester;7-(2 (2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-desacetoxyceph-3-em-4-carboxylic acid pivaloyloxymethyl ester;Cefyl;CIPLUS_685427;CEFETAMET PIVOXIL HYDROCHLORIDE;cefetamet pivoxil;CIPLUS_691806;Cefetamet pivoxil hydrochloride;Cefetamet Pivoxil Hydrochloride;Ro 15-8075;Ro-15-8075;CIPLUS_741318;cefetamet pivoxyl;,-56.39591234,-49.49659362,0.211203984,0.971450041,,,Cl.CC=3CS[C@H]2N(C(=O)[C@H]2NC(=O)C(=N\OC)\c1csc(N)n1)C=3C(=O)OCOC(=O)C(C)(C)C,ACC,CEFETAMET PIVOXIL HCl,-8.36928009,0,0,-49.49659362,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167445-02,Eprazinone dihydrochloride,170465851,Neurokinin 1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),10402-53-6,,7.079457844,1,-5.15,-51.96707638,-2.4,4,,-32.26949547,-32.30791289,0.384764065,0.896041821,,,Cl.Cl.O=C(c1ccccc1)C(C)CN3CCN(CC(OCC)c2ccccc2)CC3,Bosche,E5680,-8.1093731,1.72283307,-17.24332882,-32.30791289,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00420892-01,NKH477,405558797,Adenylate cyclase Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,3.16227766,1,-5.5,-94.49853508,-1.4,4,,-83.5440156,-78.10878561,0.094498063,0.99445235,,,CN(C)CCC(=O)OC1C(OC(C)=O)C2(C)OC(C)(CC(=O)C2(O)C3(C)C(O)CCC(C)(C)C13)C=C,Bio Vision,May-27,0,-32.37444478,-63.79949853,-78.10878561,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018215-06,Acebutolol hydrochloride,170465309,Beta-1 adrenergic receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),34381-68-5,,8.912509381,1,-5.05,-57.66077173,-3,4,,-36.76574496,2.90890772,1,0.676803926,,,Cl.CC(C)NCC(O)COc1ccc(cc1C(C)=O)NC(=O)CCC,Microsource,1500665,-16.27506025,3.70006992,-32.30478747,2.90890772,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167459-02,Doxapram hydrochloride,170465313,Potassium channel subfamily K member 9 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),113-07-5,,11.22018454,0,-4.95,-66.0397199,-2.4,4,,-46.91378277,-50.36296734,0.22477311,0.967500949,,,Cl.O=C4N(CC)CC(CCN1CCOCC1)C4(c2ccccc2)c3ccccc3,Sequoia,113-07-5,-9.36372392,0,-28.97450344,-50.36296734,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249897-01,Nitromersol,170465514,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),133-58-4,,10,0,-5,-79.16892588,-2.1,4,,-99.39138684,-99.19300084,0.00360295,0.999991994,,,Cc1ccc(c2[Hg]Oc12)[N+]([O-])=O,GVK,FFS-11-286-NCI-74,0,0,-63.66650112,-99.19300084,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386347-01,Ospemifene,405558829,Selective Estrogen Receptor Modulators (SERM),SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),128607-22-7,,39.81071706,0,-4.4,-10.00869562,-2.4,4,,-33.32870727,-28.60725606,0.004614626,0.999986885,2100,ESR2,OCCOC1=CC=C(C=C1)\C(=C(\CCCl)C2=CC=CC=C2)C3=CC=CC=C3,Selleck,S4285,0,0,0,-28.60725606,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094740-05,NORETHYNODREL,405558843,Progesterone receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),68-23-5,,8.912509381,1,-5.05,-345.9601052,5,4,,47.28599616,-83.76524704,1,0.999392778,,,C[C@]12CCC\3C(CCC\4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Microsource,1500439,-86.54804522,-82.81827172,-79.22638175,-83.76524704,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181755-01,Delapril hydrochloride,144206480,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),83435-67-0,Delapril hydrochloride; Adecut; ,31.6227766,0,-4.5,-8.640056456,-3,4,"Delapril Hydrochloride;Delapril hydrochloride;RHC-6000-A;RO-16-3037;N-(2,3-DIHYDRO-1H-INDEN-2-YL)-N-(N-((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)-L-ALANYL)GLYCINE HYDROCHLORIDE;CIPLUS_192483;derapril;USV 6000-A(SS);delapril;N-(2,3-dihydro-1H-inden-2-yl)-N-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)alanyl)glycine;CV 3317;N-(1-(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-(S)-ALANYL-N-(2-INDANYL)GLYCINE HYDROCHLORIDE;N-(N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl)-N-(indan-2-yl)glycine hydrochloride;DELAPRIL;LS-72517;DELAPRIL HYDROCHLORIDE;delaprilum;CV-3317;CIPLUS_667977;Delapril;LS-177754;Adecut;",-46.07169384,-40.47641153,0.046658363,0.998655766,,,Cl.O=C(OCC)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C2Cc3ccccc3C2,ACC,DELAPRIL HYDROCHLORIDE,1.83437756,0,0,-40.47641153,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167561-03,D-alpha-Tocopherol succinate,225144294,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),4345/3/3,,39.81071706,0,-4.4,-33.46541107,-3,4,,-44.88559918,-39.90466598,0.171556978,0.981411332,,,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(=C(C)C(=C2O1)C)OC(=O)CCC(O)=O,SIGMA,T3126,-6.01037369,-2.02386964,0,-39.90466598,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183870-01,Ethoheptazine hydrochloride,144206778,Opioid receptors; mu/kappa/delta Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5982-61-6,,39.81071706,0,-4.4,-14.75614453,-3,4,"Equagesic;Azepine-4-carboxylic acid, hexahydro-1-methyl-4-phenyl-, ethyl ester;Ethoheptazinum;heptacyclazin;Azepine-4-carboxylic acid, hexahydro-1-methyl-4-phenyl-, ethyl ester, citrate;MEPROBAMATE;ERBULOZOLE ETHOHEPTAZINE;CIPLUS_213306;4-carbethoxy-1-methyl-4-phenylazacycloheptane;ethoheptazine citrate (1:1);ethylheptazine;CIPLUS_149424;LS-22816;ETHOHEPTAZINE CITRATE;ASPIRIN;ethoheptazine;LS-178547;LS-22817;1-methyl-1-carbethoxy-4-phenyl hexamethylenimine citrate;ethoheptazine HCl;ETHOHEPTAZINE;CIPLUS_165746;Etoheptazina;CIPLUS_675824;Ethoheptazine;ethoheptazinum;Ethoheptazine citrate;Ethoheptazine Citrate;",-50.61192638,-42.17660532,0.006832298,0.999971226,,,Cl.CN1CCCC(CC1)(C(=O)OCC)c2ccccc2,NCI,NSC_400484,0,0,0,-42.17660532,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179360-05,Tridihexethyl chloride,405558856,Muscarinic acetylcholine receptor M3 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),4310-35-4,,39.81071706,0,-4.4,-13.14065833,-3,4,,-45.07098929,-37.55915774,0.006832298,0.999971231,,,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C2=CC=CC=C2,Prestwick,Prestw-1042,0,0,0,-37.55915774,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179596-03,Butoconazole nitrate,170464901,Antifungal Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),64872-77-1, Butoconazol;;Butoconazole nitrate; Femstat,14.12537545,0,-4.85,-51.73474522,-2.4,4,,-35.93774577,-39.15465272,0.332974871,0.924774653,,,[O-][N+](=O)O.Clc1ccc(cc1)CCC(Sc2c(Cl)cccc2Cl)Cn3ccnc3,"Prestwick Chemical, Inc.",Prestw-408,-9.47762334,2.04625904,-15.66251997,-39.15465272,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094881-07,Glafenine hydrochloride,170465943,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),65513-72-6,,4.466835922,1,-5.35,-47.6761539,-1.4,4,,-45.50314974,-40.36805228,0.165405396,0.982743156,,,Cl.OCC(O)COC(=O)c3ccccc3Nc1ccnc2cc(Cl)ccc12,Microsource,1500996,0,0,-48.04230367,-40.36805228,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016572-12,Sulfamonomethoxine,170465768,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1220-83-3,,1.584893193,1,-5.8,-58.55426819,-1.2,4,,-38.2453266,-36.84560921,0.040329451,0.99899644,,,O=S(=O)(Nc1cc(OC)ncn1)c2ccc(N)cc2,Microsource,1501147,0,-27.39333785,-37.98561431,-36.84560921,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181784-01,Iloprost,144207135,Prostanoid IP receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),78919-13-8,Iloprost; ,12.58925412,0,-4.9,-25.98432407,-2.4,4,"LS-101845;ZK 3637;i1oprost;iloprostum;ZK 36 374;ZK-36374;ZK-00036374;Ventavis;ZK3637;CIPLUS_190653;Iloprost;(5E)-5-((3AS,4R,5R,6AS)-5-HYDROXY-4-((1E,3S)-3-HYDROXY-4-METHYLOCT-1-EN-6-YN-1-YL)HEXAHYDROPENTALEN-2(1H)-YLIDENE)PENTANOIC ACID;CIPLUS_191919;Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-;ILOPROST;VENTAVIS;5-((E)-(1S,5S,6R 7R)-7-HYDROXY-6((E)-(3S,4RS)-3-HYDROXY-4-METHYL-1-OCTEN-6-INYL)-BICYLO (3,3,0)-OCTAN-3-YLIDENE)-PENTANOIC ACID;CoTherix Brand of Iloprost;PENTANOIC ACID, 5-((3AS,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-((1E,3S)-3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-2(1H)-PENTALENYLIDENE)-, (5E)-;",-48.70220989,-45.55760175,0.115182481,0.991731194,,,O[C@@H]2C[C@@H]1C/C(C[C@@H]1C2/C=C/[C@@H](O)C(C)CC#CC)=C\CCCC(=O)O,Tocris,Tocris-2038,0,4.58277449,-18.96666831,-45.55760175,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091666-04,"1,8-Cineol",170465483,tumor necrosis factor production Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),470-82-6,,39.81071706,0,-4.4,-17.095364,-3,4,,-39.01296575,-35.01080479,0.244623479,0.9612154,,,CC2(C)OC1(C)CCC2CC1,Labotest,LT00440774,0,-6.89537709,-0.0428193,-35.01080479,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018200-12,Phenolphthalein,170465559,store-operated calcium entry Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1977/9/8,,10,0,-5,-29.58056086,-2.4,4,,-43.48909698,-40.77990963,0.113491982,0.991975262,,,Oc1ccc(cc1)C3(OC(=O)c2ccccc23)c4ccc(O)cc4,Vitas,STK029876,0,4.65104383,-26.57759387,-40.77990963,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00481544-01,Cetrorelix,405558930,Gonadotropin-releasing hormone receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,3.548133892,1,-5.45,-47.20743501,-3,4,,-44.09667038,0,1,0.999955777,,,CC(C)C[C@H](\N=C(/O)[C@@H](CCCNC(O)=N)\N=C(/O)[C@H](CC1=CC=C(O)C=C1)\N=C(/O)[C@H](CO)\N=C(/O)[C@@H](CC2=CN=CC=C2)\N=C(/O)[C@@H](CC3=CC=C(Cl)C=C3)\N=C(/O)[C@@H](CC4=CC5=CC=CC=C5C=C4)\N=C(\C)O)/C(O)=N/[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6\C(O)=N\[C@H](C)C(O)=N,APExBIO,B4975,0.69878243,0,-37.99722532,0,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00182053-03,Acrivastine,405558933,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),87848-99-5,,39.81071706,0,-4.4,-8.812273694,-2.4,4,,-30.2251138,-25.18759483,0.007297871,0.999967215,,,CC1=CC=C(C=C1)\C(=C/CN2CCCC2)C3=CC=CC(=N3)\C=C\C(O)=O,Enzo,AC3005,0,0,0,-25.18759483,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263905-04,TOLTRAZURIL,405558935,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),69004-03-1,,39.81071706,0,-4.4,-55.95395787,-3,4,,-52.27435226,-49.15589674,0.602038919,0.677926787,,,CN1C(=O)NC(=O)N(C1=O)C2=CC=C(OC3=CC=C(SC(F)(F)F)C=C3)C(=C2)C,Microsource,1505681,-6.36428332,-26.6337036,-1.42726986,-49.15589674,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00483012-01,Phytic acid,405558945,lipid oxidation Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),83-86-3,,22.38721139,0,-4.65,-17.66929436,-3,4,,-40.45557249,-36.70876704,0.013269742,0.999891484,,,O[P](O)(=O)OC1C(O[P](O)(O)=O)C(O[P](O)(O)=O)C(O[P](O)(O)=O)C(O[P](O)(O)=O)C1O[P](O)(O)=O,DC Chemicals,DCZ-023,0,0,-6.91030405,-36.70876704,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00261972-01,NCGC00261972-01,225144356,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,Cymelarsan;Rm-110;Melarsominum;Merial brand of melarsomine,5.011872336,1,-5.3,-51.68091373,-1.4,4,,-30.77411445,-30.57857359,0.228230595,0.966461686,,,NCCS[As](SCCN)C1=CC=C(NC2=NC(=NC(=N2)N)N)C=C1,GVK,FFS-11-286-NCI-125,-5.47788851,0,-35.07266123,-30.57857359,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00248146-03,4-Methylbenzenesulfonic acid,405558963,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,19.95262315,0,-4.7,-27.52140585,-3,4,,-33.96749688,-32.47291407,0.127428483,0.989863549,,,CC1=CC=C(C=C1)[S+](O)([O-])=O,Specs,AE-562/J260927,-3.34598325,0,-8.71886095,-32.47291407,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263584-01,Tirofiban hydrochloride monohydrate,170465092,Integrin alpha-IIb/beta-3 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),150915-40-5,,39.81071706,0,-4.4,-30.88070038,-3,4,,-46.37353139,-42.11887685,0.504966593,0.800185232,,,Cl.O.O=C(O)[C@@H](NS(=O)(=O)CCCC)Cc1ccc(cc1)OCCCCC2CCNCC2,Sequoia,142373-60-2,-0.5802112,-18.78407462,-1.82963815,-42.11887685,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159430-04,Hexobarbital,170465860,GABA-A receptor; benzodiazepine site Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),56-29-1,,0.707945784,1,-6.15,-88.21818832,-1.4,4,,-41.13839593,-20.46781711,1,0.782094643,,,CC1(C(=O)N=C(O)N(C)C1=O)C2=CCCCC2,Labotest,LT00244803,-11.32455671,-59.09152498,-36.89039958,-20.46781711,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00385183-01,NCGC00385183-01,405559009,Potassium-transporting ATPase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,7.943282347,1,-5.1,-102.5795452,-2.3,4,,-87.89333355,-83.69156061,0.17374958,0.980907447,,,OC[C@H]1O[C@@H](OC2=CC=CC3=C2C(=O)C4=C(C=C(C=C4O)C(O)=O)[C@@H]3[C@@H]5C6=C(C(=O)C7=C5C=C(C=C7O)C(O)=O)C(=CC=C6)O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H](O)[C@@H](O)[C@@H]1O,Analyticon,NP-010759,-10.14825798,0,-36.45639717,-83.69156061,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00274273-01,NCGC00274273-01,225144371,Mu opioid receptor Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-15.72901343,-3,4,,-53.94875797,-44.95729831,0.006832298,0.999971223,,,C[C@@]12CCCCC[C@@H](CC3=C1C=C(O)C=C3)[C@@H]2N,GVK,FFS-11-286-NCI-03,0,0,0,-44.95729831,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160606-01,Sulbentine,144205485,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),350-12-9,Dibenzthion; Sulbentina; Afungin; ,15.84893192,0,-4.8,-123.4386362,-1.3,4,"Sulbentinum;Sulbentine;D 47;Afungin;Sulbentina;dibenzthione;DIBENZTHION;CIPLUS_209804;carbothialdine;2H-1,3,5-Thiadiazine-2-thione, tetrahydro-3,5-dibenzyl-;SULBENTINE;sulbentinum;CIPLUS_3866698;LS-150185;sulbentine;Dibenzthion;3,5-dibenzylperhydro-1,3,5-thiadiazine-2-thione;",-94.5305653,-97.17018274,0.131669819,0.989152271,,,S=C3SCN(Cc1ccccc1)CN3Cc2ccccc2,SigmaAldrich,S545791,-9.89444103,1.71954459,-83.06340516,-97.17018274,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00179430-04,Iocetamic acid,405559045,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),16034-77-8,,8.912509381,1,-5.05,-82.72169873,-3,4,,-35.85454378,-17.83552297,1,0.802623877,,,CC(CN(C(C)=O)C1=C(I)C(=C(I)C=C1I)N)C(O)=O,Prestwick,Prestw-838,-21.23762286,-6.98054396,-39.94787616,-17.83552297,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389309-01,Lubiprostone,405559047,ClC-2 Channel Activators,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),136790-76-6,,0.316227766,1,-6.5,-137.3361044,-1.4,4,,-33.38099725,-27.27584695,0.72112118,0.426411447,,CLCN2,CCCCC(F)(F)C1(O)CCC2C(CC(=O)C2CCCCCCC(O)=O)O1,APExBIO,B2108,-25.78314661,-34.50772675,-37.35064432,-27.27584695,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262959-01,Difethialone,170465892,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),104653-34-1,"2H-1-benzothiopyran-2-one,",25.11886432,0,-4.6,-42.5783739,-2.1,4,,-110.01754,-99.6535688,0.004330005,0.999988436,,,Brc1ccc(cc1)c2ccc(cc2)C4Cc3ccccc3C(C4)C5=C(O)c6ccccc6SC5=O,GVK,FFS-11-286-NCI-261,0,0,-11.04383157,-99.6535688,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179265-03,Netilmicin sulfate,170465142,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),56391-57-2,,0.013864348,1,-7.85810056,-135.3203233,-2.4,4,,-37.4357024,-6.18653405,1,0.999933406,,,O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.NC3CC=C(CN)OC3O[C@@H]2[C@@H](N)C[C@@H](NCC)[C@H](O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O)[C@H]2O.NC3CC=C(CN)OC3O[C@H]2[C@H](O)[C@@H](O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O)[C@H](NCC)C[C@@H]2N,Bosche,N2413,-9.59612641,-25.44198031,-36.06579083,-6.18653405,,,,,,,,,,,,4.57E-09,2.29E-08,1.14E-07,5.71E-07,,,,,,,,,,,
NCGC00345881-04,Conivaptan hydrochloride,405559087,Vasopressin (AVP) V1a/V2 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),168626-94-6,,39.81071706,0,-4.4,-32.83575797,-3,4,,-44.8226208,-39.43551733,0.190260662,0.977005435,,AVPR1A,CC1=NC2=C([NH]1)C3=CC=CC=C3N(CC2)C(=O)C4=CC=C(NC(=O)C5=CC=CC=C5C6=CC=CC=C6)C=C4,APExBIO,A8402,-6.19572686,-0.55871223,0,-39.43551733,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00021152-06,Hydroxyzine,170464958,antiparasitic agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),68-88-2,,31.6227766,0,-4.5,-21.96728988,-3,4,,-66.55736362,-59.56933621,0.005452079,0.999981671,,,Clc1ccc(cc1)C(c2ccccc2)N3CCN(CC3)CCOCCO,Microsource,1500345,0,0,-1.61229399,-59.56933621,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00013841-09,Cyclobenzaprine hydrochloride,170464953,5-HT2A Receptor Ligands,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),6202-23-9, Lisseril; ; Flexeril; Ciclobenzaprina;CYCLOBENZAPRINE HYDROCHLORIDE; Cyclobenzaprine hydrochloride;Cyclobenzaprine hydrochloride,12.58925412,0,-4.9,-85.19725916,-2.3,4,,-96.62497235,-87.65387209,0.621448583,0.999985468,3356,HTR2A,Cl.CN(C)CC\C=C2/c3ccccc3C=Cc1ccccc12,Microsource,1503207,-34.91766054,-6.34914934,-44.36593962,-87.65387209,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178741-03,NCGC00178741-03,170464822,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),105816-04-4,,39.81071706,0,-4.4,-53.48760075,-3,4,,-37.35443906,-39.64623465,0.083213175,0.995710088,,INS,CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(=O)O,Microsource,1504258,-9.37177848,-9.06694165,-7.26753543,-39.64623465,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025262-02,Cisapride,170465200,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),81098-60-4,,39.81071706,0,-4.4,-131.4604946,-2.4,4,,-66.34930965,-63.63517825,0.587653371,0.699530065,,,Clc1cc(c(OC)cc1N)C(=O)NC3CCN(CCCOc2ccc(F)cc2)CC3OC,Tocris,1695,-31.96779137,-14.81921646,-3.76075354,-63.63517825,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091454-07,Phenol,170465486,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),108-95-2,,2.238721139,1,-5.65,-24.10968589,-2.4,4,,-39.15425416,1.98260204,1,0.999919046,,,Oc1ccccc1,Specs,AE-562/J262148,-0.46190984,-16.43058288,-32.25712164,1.98260204,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164605-02,Ampiroxicam,170466020,Cyclooxygenase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),99464-64-9,,3.16227766,1,-5.5,-27.51354407,-2.4,4,,-67.64814428,-24.70770765,1,0.999987024,,,O=C(OCC)OC(C)OC=2c1ccccc1S(=O)(=O)N(C)C=2C(=O)Nc3ccccn3,Sequoia,SRP05637a,1.76887262,-20.5460645,-53.04012023,-24.70770765,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016522-10,Bisacodyl,170464843,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),603-50-9,,1.412537545,1,-5.85,-156.7429385,-1.1,4,,-98.88840527,-96.7755073,0.014179689,0.999875973,,,CC(=O)Oc1ccc(cc1)C(c2ccc(OC(C)=O)cc2)c3ccccn3,Labotest,LT00134695,0,-80.04723308,-95.89339444,-96.7755073,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015251-13,Clotrimazole,170464807,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),23593-75-1," ; Bay b 5097; Clotrimazole;Clotrimazole; b 5097, F; Clotrimazol; Kanesten; Baycuten; Canesten; Canesten HC; FB b 5097; b 5097, Ba; Baycuten SD; Lotrimin; Mycelex; Klotrimazole;CLOTRIMAZOLE; 5097, Bay",10,0,-5,-84.16325164,-2.4,4,,-50.43032545,-55.20203987,0.310816893,0.935266297,1595,CYP51A1,Clc1ccccc1C(c2ccccc2)(c3ccccc3)n4ccnc4,Vitas,STK700023,-13.65104931,0,-34.02345518,-55.20203987,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018250-06,Sulconazole nitrate,170465344,Lanosterol 14-alpha demethylase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61318-91-0,,39.81071706,0,-4.4,-34.53763632,-3,4,,-103.4148796,-90.13305807,0.064300077,0.997441361,,,[O-][N+](=O)O.Clc3ccc(C(SCc1ccc(Cl)cc1)Cn2ccnc2)c(Cl)c3,Microsource,1501148,0,-4.52371041,0.22423922,-90.13305807,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181337-03,"2,4-Dichlorobenzyl alcohol",170465574,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1777-82-8,,3.16227766,1,-5.5,-21.43645761,-3,4,,-45.98279683,0,1,0.99998498,,,OCc1ccc(Cl)cc1Cl,Bosche,D0540,0,-7.71771159,-46.03754108,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178238-05,Midodrine hydrochloride,170464672,Alpha-1b adrenergic receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3092-17-9,,3.16227766,1,-5.5,-22.72445046,-2.4,4,,-43.85687812,0,1,0.999822246,,,Cl.COc1ccc(cc1C(O)CNC(=O)CN)OC,Microsource,1503257,0,-10.92988771,-43.29550712,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015243-10,Clemizole hydrochloride,170465924,Histamine H1 Receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1163-36-6,,11.22018454,0,-4.95,-146.2972299,-2.4,4,,-54.99246153,-73.79260311,0.281883971,0.94756483,,HRH1,Cl.Clc1ccc(cc1)Cn3c4ccccc4nc3CN2CCCC2,Microsource,1505990,-26.61962179,-12.25295819,-45.53170377,-73.79260311,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015096-17,Amiodarone hydrochloride,170464920,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1951-25-3,; Ancaron; Kordaron; Amiodarone;Amiodarone; Amiodarona;Amiodarone hydrochloride;Amiodarone?HCl,12.58925412,0,-4.9,-66.37705505,-2.4,4,,-94.74788816,-72.02213346,0.392868285,0.890826055,,CHRM3,CCN(CC)CCOc1c(I)cc(cc1I)C(=O)c2c3ccccc3oc2CCCC,Microsource,2300165,0,-28.49112611,-30.46690523,-72.02213346,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183876-03,Tenofovir disoproxil fumarate,170465338,Reverse Transcriptase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),202138-50-9,Tenfovir disoproxil fumarate;TENOFOVIR DISOPROXIL FUMARATE,0.316227766,1,-6.5,-436.4053342,5,4,,-23.46656253,-95.71043938,0.099051492,0.994091561,7015,TERT,O=C(O)C=CC(=O)O.CC(C)OC(=O)OCOP(=O)(OCOC(=O)OC(C)C)CO[C@H](C)Cn2cnc1c(N)ncnc12,Sequoia,202138-50-9,-89.39877109,-96.0375732,-95.58792951,-95.71043938,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386213-04,Rupatadine (Fumarate),405558713,Platelet activating factor receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),182349-12-8,,39.81071706,0,-4.4,-149.5656681,-2.4,4,,-72.04521554,-77.77843068,0.230020063,0.965893186,,,CC1=CN=CC(=C1)CN2CCC(CC2)=C3C4=CC=C(Cl)C=C4CCC5=CC=CN=C35,MedChem Express,HY-13511A,-24.26859413,-35.24716428,-35.34973955,-77.77843068,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181140-02,Carboquone,124893654,cell growth Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-89.21309316,-3,4,,-61.6035756,-63.91844899,0.455200599,0.845553775,,,CO[C@@H](COC(N)=O)\C1=C(/N2CC2)C(=O)\C(=C(\N3CC3)C1=O)C,NCI,NSC-134679,-13.85591075,-28.83529193,-7.16546932,-63.91844899,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181912-01,Iomazenil,144206800,GABAergic synapse Modulator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),127985-21-1,,14.12537545,0,-4.85,-22.06334953,-2.4,4,"IOMAZENIL (123I);iomazenilum (123I);iomazenil (123 I);Ro 16-0154;Iomazenil(123I);Ro-16-0154;IOMAZENIL (123 I);CIPLUS_208012;Iomazenil (123I);Benzodine;ethyl 7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate;iomazenil;Iomazenil ((sup 123)I);(123I)iomazenil;",-44.52257461,-40.76164316,0.105256479,0.99310874,,,O=C(OCC)c3ncn2c3CN(C)C(=O)c1c(I)cccc12,Pharmaron,PH-NIH-10,0,3.53562479,-14.70770458,-40.76164316,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390625-02,Maropitant,405558794,Substance-P receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),147116-67-4,,8.912509381,1,-5.05,-87.41926435,-1.4,4,,-50.92592986,-54.52160822,0.261428623,0.955341306,403815,TACR1,COC1=CC=C(C=C1CN[C@H]2C3CCN(CC3)[C@H]2C(C4=CC=CC=C4)C5=CC=CC=C5)C(C)(C)C,MedChem Express,HY-10053,-12.45864056,0,-44.16531009,-54.52160822,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263546-01,Moexipril hydrochloride,170465131,Angiotensin-converting enzyme Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),82586-52-5,,39.81071706,0,-4.4,-19.05303128,-3,4,,-51.22406255,-43.10338546,0.040855258,0.998969722,,,Cl.O=C(OCC)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3cc(OC)c(OC)cc3C[C@H]2C(=O)O,Tocris,2691,-1.31986781,0,0,-43.10338546,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160570-01,Butonate,144205461,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),126-22-7,Butonate; Butonato; Pedix PE 50; ,63.09573445,0,-4.2,-21.68751374,-3,4,"Pedix PE 50;Tribufon;butonatum;0,0,dimethyl-2,2,2-trichloro-1-n-butyryloxyethyl phosphonate;CIPLUS_173408;LS-47987;Butonate;BUTONATE;butonate;tribuphon;tribufon;Butonatum;Butonato;",-65.70282336,-62.22483644,0.010772433,0.999928435,,,O=P(OC)(OC)C(OC(=O)CCC)C(Cl)(Cl)Cl,SigmaAldrich,S360910,0,0,0,-62.22483644,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00378598-01,PSI-7976,405558839,RNA-Directed RNA Polymerase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1190308-01-0,,39.81071706,0,-4.4,-123.6690173,-2.4,4,,-40.79971907,-50.72975416,0.508914055,0.796192092,,,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](N2\C=C/C(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3,MedChem Express,HY-15005A,-29.13109439,-15.63393614,-10.47998827,-50.72975416,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00510188-01,NCGC00510188-01,405558893,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1221573-85-8,,39.81071706,0,-4.4,-25.51631804,-3,4,,-54.91891966,-50.34909972,0.381378882,0.898009879,,,CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC\C=C/[C@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=C6C=CC=CC6=C7C=CC=CC7=N5)C(=O)N[S+]([O-])(=O)C8CC8,Glixx,GLXC-90367,0,-14.6442925,3.33341287,-50.34909972,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00345792-04,AN-2728,405558907,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),906673-24-3,,39.81071706,0,-4.4,-46.43783529,-3,4,,-51.52886052,-47.9407171,0.52160153,0.782727399,,PDE4A,OB1OCC2=CC(=CC=C12)OC3=CC=C(C=C3)C#N,MedChem Express,HY-10978,-5.18733489,-20.84448088,0.72731841,-47.9407171,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015267-11,Citalopram hydrobromide,405558908,5-HT Reuptake Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),[59729-32-7],,10,0,-5,-35.61168852,-2.2,4,,-43.4273842,-42.91875807,0.036988427,0.999155712,,HTR1A,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3,Tocris,1427,0,0,-29.49009311,-42.91875807,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025346-08,Mirtazapine,405558918,5-HT2A/3 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),85650-52-8 ,,39.81071706,0,-4.4,-19.84613901,-3,4,,-68.07003853,-56.72503211,0.006832298,0.999971216,,HTR2A,CN1CCN2C(C1)C3=C(CC4=C2N=CC=C4)C=CC=C3,APExBIO,B2113,0,0,0,-56.72503211,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00242513-02,NCGC00242513-02,405558854,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),[376348-65-1],,39.81071706,0,-4.4,-10.15239091,-3,4,,-37.15679519,-31.38066266,0.839019434,0.998786433,,CCR5,CC(C)C1=NN=C(C)[N]1C2CC3CCC(C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5,Tocris,3756,-36.86455516,0,1.18359677,-31.38066266,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015572-06,MIBG,405558858,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),103346-16-3,,39.81071706,0,-4.4,-23.50683084,-3,4,,-38.97337887,-36.64448239,0.482524967,0.821871495,,,NC(=N)NCC1=CC=CC(=C1)I,Axon Medchem,1750,0,-15.29888732,0,-36.64448239,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183110-02,Imidafenacin,405558861,potassium ion transport Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),170105-16-5,,39.81071706,0,-4.4,-13.57189323,-3,4,,-46.5500768,-38.79173067,0.650402424,0.999967637,,,CC1=NC=C[N]1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3,MedChem Express,HY-B0662,-20.66398083,0,0,-38.79173067,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00388369-01,Prednisolone Phosphate (sodium salt),405558865,Glucocorticoid receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),125-02-0,,6.309573445,1,-5.2,-31.22666091,-3,4,,-33.32757847,-31.52298206,0.011547094,0.999917853,,,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC\4=C\C(=O)\C=C/[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO[P]([O-])([O-])=O,Cayman,15933,0,0,0,-31.52298206,,,,,,,,,,,,9.14E-08,4.57E-07,0.00000229,0.0000114,,,,,,,,,,,
NCGC00095303-04,Cloxyquin,170465523,Mycobacterium tuberculosis Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),130-16-5,,5.623413252,1,-5.25,-129.8119294,-1.4,4,,-32.90861288,-46.2507769,0.410138753,0.87946953,,,Oc1ccc(Cl)c2cccnc12,Vitas,STK015543,-24.22253162,-9.23885628,-49.06966705,-46.2507769,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00161602-06,Doxycycline,170465097,Matrix Metalloproteinase (MMP) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),10592-13-9,; ; Monodox;DOXYCYCLINE HYDROCHLORIDE; Doryx; 1   Doxycycline Mono; Doxycycline hydrochloride; Doxycycline SSa; Atridox;Doxycycline; Doxiciclina; Vibramycin; Vibra-Tabs;Doxycycline hydrochloride; 0   Doxycycline Hyclate; Periostat,10,0,-5,-39.2195978,-2.2,4,,-48.21576845,-47.55769162,0.02855513,0.999496979,4312,MMP1,Cl.NC(=O)C=3C(=O)[C@@]4(O)C(O)=C2C(=O)c1c(O)cccc1[C@H](C)[C@H]2[C@H](O)[C@H]4[C@@H](C=3O)N(C)C,Prestwick,Prestw-1399,0,0,-32.33216784,-47.55769162,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00347131-03,D(-)-Tartaric acid,405558948,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),526-83-0,,3.981071706,1,-5.4,-80.23361098,-1.4,4,,-45.72177634,-48.90721974,0.117440785,0.99139885,,,OC(C(O)C(O)=O)C(O)=O,DC Chemicals,DCJ-065,-6.33432427,-8.61604448,-54.46570876,-48.90721974,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389841-01,LINACLOTIDE (1 mg/ml),405558997,Heat-stable enterotoxin receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),851199-59-2,,19.95262315,0,-4.7,-38.82057202,-3,4,,-30.7758017,-30.64650142,0.616163998,0.655481083,,,C[C@@H](O)[C@@H]1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(O)=O)NC(=O)[C@H](CC5=CC=C(O)C=C5)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CC(N)=O)C(=O)N6CCC[C@H]6C(=O)N[C@@H](C)C(=O)N2,Microsource,1504425,-3.03951696,-17.79972706,0,-30.64650142,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00181767-03,Tolcapone,170465081,catechol-O-methyltransferase (COMT),SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),134308-13-7, ; Roche brand of tolcapone; Tasmar;TOLCAPONE; Tolcapone;Tolcapone,25.11886432,0,-4.6,-10.46067002,-3,4,,-59.17926074,-46.72671268,0.007174646,0.999968265,1312,COMT,Oc1cc(cc([N+]([O-])=O)c1O)C(=O)c2ccc(C)cc2,Sequoia,134308-13-7,3.02615817,2.55603917,-7.16829367,-46.72671268,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016403-06,Mafenide hydrochloride,170465055,Carbonic anhydrase II Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),138-37-4,,39.81071706,0,-4.4,-23.20259067,-3,4,,-48.28485364,-41.9040447,0.119682881,0.991065726,,,Cl.O=S(N)(=O)c1ccc(CN)cc1,Vitas,STK083032,-3.17235238,0,1.44126661,-41.9040447,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159380-05,Benzoyl peroxide,170464986,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),94-36-0,,25.11886432,0,-4.6,-46.55508058,-2.4,4,,-52.64294667,-43.14995629,0.722915518,0.687371703,,,O=C(OOC(=O)c1ccccc1)c2ccccc2,Labotest,LTBB002750,0,-32.39645317,-12.64268519,-43.14995629,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015360-08,Pentetic acid,170465150,Radioactive metals Chelating Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),67-43-6,,19.95262315,0,-4.7,-27.64608601,-3,4,,-40.76167245,-37.94883548,0.438408515,0.858959844,,,O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O,Vitas,STK373226,0,-12.19495074,4.79381284,-37.94883548,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00178060-03,Tolperisone hydrochloride,170465769,Voltage-gated calcium channel Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3644-61-9,,5.623413252,1,-5.25,-111.804117,-1.4,4,,-33.69971509,-39.66301222,0.496679305,0.808432342,,,Cl.CC(CN1CCCCC1)C(=O)c2ccc(C)cc2,Microsource,1501194,-21.22858939,-4.05529753,-44.67261973,-39.66301222,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183837-01,Monatepil,124894552,Calcium Channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),103377-41-9,Monatepil; Monatepil,39.81071706,0,-4.4,-16.88978693,-3,4,"CIPLUS_696267;AJ 2615;MONATEPIL;monatepil, (S)-isomer;monatepil, (+-) monatepil;LS-172819;LS-172817;Monatepil Maleate;monatepil maleate;LS-173001;maleate;LS-171860;11-((4-(4-(4-fluorophenyl)-1-piperazinyl)butyryl)amino)-6,11-dihydrodibenzo(b,e)thiepin maleate;1-Piperazinebutanamide, N-(6,11-dihydrodibenzo(b,e)thiepin-11-yl)-4-(4-fluorophenyl)-, (Z)-2-butenedioate (1:1);CIPLUS_3853864;MONATEPIL MALEATE;monatepil;Monatepil maleate;CIPLUS_197056;monatepil x maleate;monatepil, (R)-isomer;monatepilum;LS-173055;AJ-2615;N-(6,11-DIHYDRODIBENZO(B.E)THIEPIN-11-YL)-4-(4-FLUOROPHENYL)-1-PIPERAZINEBUTYRAMIDE MALEATE, DL-;LS-173056;",-57.93008134,-48.27506778,0.613526453,0.999967625,,,Fc1ccc(cc1)N2CCN(CC2)CCCC(=O)NC3c5ccccc5SCc4ccccc34,Pharmaron,PH-NIH-152406,-23.29281332,0,0,-48.27506778,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179520-04,Metrizamide,405559101,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),31112-62-6,,22.38721139,0,-4.65,-66.5662262,-2.4,4,,-54.70095181,-50.5310241,0.313131378,0.934221861,,,CN(C(C)=O)C1=C(I)C(=C(I)C(=C1I)NC(C)=O)C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O,Prestwick,Prestw-463,-12.35147558,0,-16.76796176,-50.5310241,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263883-04,NCGC00263883-04,405559105,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),147098-20-2,,1.584893193,1,-5.8,-107.6721534,-1.4,4,,-74.17908341,-71.35889755,0.073696083,0.996635547,,,CC(C)C1=C(/C=C/[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)[S+](C)([O-])=O)C2=CC=C(F)C=C2,Adooq,A10810,0,-17.45518863,-76.03428369,-71.35889755,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00093926-05,Doxifluridine,170465861,thymidylate synthase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3094/9/5, ;5'dFUrd; Ro 21-9738; Furtulon; 5'dFUrd;Doxifluridine; Doxifluridine; Doxifluridina; 5-Fluro-5??-Deoxyuridine;5-fluoro-5'-deoxyuridine; 5-fluoro-5'-deoxyuridine,0.794328235,1,-6.1,-28.44655931,-1.4,4,,-34.4936823,0,1,0.998788332,7298,TYMS,FC1=CN(C(=O)NC1=O)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O,Bosche,D1649,1.44240927,-31.66140192,-30.62169425,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025060-15,Methotrexate,170464688,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1959/5/2," Methylaminopterin; Antifolan; Amethopterin (R,S); Mtx-1 protein, rat; Dl-Amethopterin; Methotrexate Hydrate;Abitrexate (Methotrexate); (+/-)Amethopterin; ; D-Methotrexate; (-)Amethopterin; Mexate; methotrexate; Methotrexate hydrate; Metotrexato; Slc19a1 protein, rat; L-Amethopterin hydrate; (+)-Amethopterin hydrate; Methotrexate; 8   D-(-)-Amethopterin;Methotrexate hydrate; DL-Amethopterin; MTXGlu3; Methotrexate Pres-Fre; (+)-Amethopterin;Methotrexate",5.011872336,1,-5.3,-221.7391051,-1.4,4,,-37.19033577,-63.86103921,0.426687899,0.867714923,1719,DHFR,O=C(O)[C@H](CCC(=O)O)NC(=O)c1ccc(cc1)N(C)Cc2nc3c(nc2)nc(N)nc3N,Prestwick,Prestw-135,-40.01843605,-31.80364533,-81.23010801,-63.86103921,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018186-07,Procyclidine hydrochloride,170464805,Muscarinic acetylcholine receptor M4 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1508-76-5,,10,0,-5,-37.56787322,-2.4,4,,-30.44674494,-33.07191592,0.811545292,0.999888379,,,Cl.OC(CCN1CCCC1)(c2ccccc2)C3CCCCC3,Microsource,1500507,-24.02808573,-3.11629514,-20.67692464,-33.07191592,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094779-05,Salicyl alcohol,170465547,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1990/1/7,,3.981071706,1,-5.4,-4.282117585,-3,4,,-52.94893611,0,1,0.999971179,,,OCc1ccccc1O,Microsource,1500531,4.20085816,0,-48.56382973,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094652-06,DIGITOXIN,405559111,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),71-63-6,,0.316227766,1,-6.5,-456.7239443,5,4,,-36.55735456,-99.54868016,0.158226939,0.984823373,,,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C,Sequoia,71-63-6,-93.87813144,-100.1759269,-99.31474133,-99.54868016,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263198-04,Lenvatinib,405559112,VEGFR-1/2/3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),417716-92-8,,3.548133892,1,-5.45,-88.18411053,-1.2,4,,-81.32162773,-76.22372938,0.0278113,0.999522713,,FLT1,COC1=C(C=C2C(=CC=NC2=C1)OC3=CC(=C(NC(=O)NC4CC4)C=C3)Cl)C(N)=O,APExBIO,A2174,0,-25.08342161,-62.99455923,-76.22372938,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00238451-11,Olaparib,405559119,PARP Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),763113-22-0,,22.38721139,0,-4.65,-28.63247747,-2.4,4,,-66.96635986,-51.11087868,0.829391364,0.999926516,,PARP1,FC1=C(C=C(C/C2=N/NC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5,Adooq,A10111,-38.98801294,0,-15.39308843,-51.11087868,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159441-03,Deslanoside,170465236,Sodium/potassium-transporting ATPase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),17598-65-1,"Deslanoside; Cedilanid; Cedilanid-D; Cedilanid-d; C, Desacetyllanatosid; Lanatoside, Desacety; Deslanatoside C; C, Deslanatosid; C, Desacetyldigilanid; Desacetyl Lanatoside; Deslanosido; ",0.891250938,1,-6.05,-260.8150047,-1.2,4,"Cedilanid-d;Cedilanid-D;C, Desacetyllanatosid;deslanoside;Cedilanid;LS-87553;C, Deslanatosid;Lanatoside, Desacety;CIPLUS_171064;Deslanatoside C;deslanosidum;Deslanosido;C, Desacetyldigilanid;CARD-20(22)-ENOLIDE, 3-((O-.BETA.-D-GLUCOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-12,14-DIHYDROXY-, (3B,5B,12B)-;Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-;DEACETYLANATOSIDE C;Desacetyl Lanatoside;deacetyllanatoside c;DESLANOSIDE;Deslanosidum;Deslanoside;",-74.18869794,-97.77143238,0.014478982,0.999870701,,,O=C1C=C(CO1)[C@H]2CC[C@@]9(O)[C@]2(C)[C@H](O)C[C@H]4[C@H]9CC[C@@H]3C[C@H](CC[C@@]34C)O[C@@H]8O[C@H](C)[C@@H](O[C@@H]7O[C@H](C)[C@@H](O[C@@H]6O[C@H](C)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)C6)[C@@H](O)C7)[C@@H](O)C8,ChemDiv,N045-0007,-30.99304059,-94.01973668,-96.86519765,-97.77143238,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00091835-10,Chlormethine,170465017,DNA Alkylating Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55-86-7, Nitrogen mustard HCl;Nitrogen mustard HCl;Nitrogen mustard hydrochloride; Nitrogen mustard hydrochloride;MECHLORETHAMINE,39.81071706,0,-4.4,-93.48581365,-3,4,,-95.57614279,-90.89071477,0.310625882,0.935330078,,H2AFX,Cl.ClCCN(C)CCCl,Microsource,1500375,-12.7235989,-27.39409967,-6.09278148,-90.89071477,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249914-01,Bencyclane,170465760,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2179-37-5,,35.48133892,0,-4.45,-14.77140548,-3,4,,-55.5714426,-46.08844651,0.043278139,0.998843563,,,CN(C)CCCOC1(CCCCCC1)Cc2ccccc2,GVK,FFS-11-286-NCI-166,0,1.93753588,0,-46.08844651,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095125-05,Losartan,170465135,Angiotensin II receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),114798-26-4,,14.12537545,0,-4.85,-74.69417139,-2.4,4,,-47.4189606,-49.46200056,0.363977912,0.908258828,,,OCc4c(Cl)nc(CCCC)n4Cc1ccc(cc1)c2ccccc2c3nnnn3,Microsource,1504268,-13.91932008,0,-22.18454368,-49.46200056,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262960-01,Resocortol butyrate,170466824,Glucocorticoid receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),76738-96-0,Resocortol,39.81071706,0,-4.4,-16.55652498,-3,4,,-56.78703011,-47.32252509,0.006832298,0.999971221,,,CCC(=O)[C@@]4(OC(=O)CCC)CC[C@@H]2[C@]4(C)C[C@H](O)[C@@H]1[C@@]3(C)CCC(=O)C=C3CC[C@H]12,GVK,FFS-11-286-NCI-149,0,0,0,-47.32252509,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253595-01,Clocapramine,170465785,Serotonin 2a (5-HT2a) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),47739-98-0,,25.11886432,0,-4.6,-38.75749173,-3,4,,-100.829691,-93.36082496,0.008288945,0.999957623,,,Clc4ccc5CCc1ccccc1N(CCCN2CCC(CC2)(C(N)=O)N3CCCCC3)c5c4,GVK,FFS-11-286-NCI-179,0,0,-8.72529396,-93.36082496,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00538142-01,NCGC00538142-01,405558454,vasoconstriction Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-76.74236407,-3,4,,-33.01818597,-32.09848831,0.668244553,0.556004498,,,CCCCCCC(COC(=O)C1=CN=CC=C1)(COC(=O)C2=CN=CC=C2)COC(=O)C3=CN=CC=C3,Pharmaron,PH-NIH-2017-009-L1-20-0,-21.09421235,-2.89371877,0,-32.09848831,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00168778-06,Solifenacin (hydrochloride),405558475,Muscarinic acetylcholine receptor M5 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),180468-39-7,,11.22018454,0,-4.95,-50.61660141,-2.4,4,,-71.18193378,-70.53882757,0.630722529,0.999686229,,,O=C(O[C@H]1CN2CCC1CC2)N3CCC4=C(C=CC=C4)[C@@H]3C5=CC=CC=C5,MedChem Express,HY-I0230,-30.49035098,0,-37.13842862,-70.53882757,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344566-01,NCGC00344566-01,170464796,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),170729-80-3,,39.81071706,0,-4.4,-67.88455068,-3,4,,-39.42057438,-37.01714532,0.580212519,0.710308844,,,C[C@@H](O[C@H]2OCCN(CC1=NC(=O)N=N1)[C@H]2C3CCC(F)CC3)c4cc(cc(c4)C(F)(F)F)C(F)(F)F,Prestwick,Prestw-1600,-19.1689754,3.95523913,0,-37.01714532,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181080-01,Phenacaine hydrochloride,144206789,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Inhibitor",SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),620-99-5,phenacaine hydrochloride; Fenacaina; ,28.18382931,0,-4.55,-118.5421351,-2.4,4,"Phenacainum;phenacaine hydrochloride;Phenacaine (N,N'-bis-(4-ethoxy-phenyl)-acetamidine);phenacainum;CIPLUS_150668;PHENACAINE;Phenacaine hydrochloride;Acetamidine, N,N'-bis(p-ethoxyphenyl)-, hydrochloride;phenacaine;LS-10332;CIPLUS_155428;PHENACAINE HYDROCHLORIDE;Phenacaine;LS-176183;Phenacaine Hydrochloride;CIPLUS_743918;Fenacaina;",-66.30555425,-68.72181671,0.349048618,0.916441353,5136,PDE1A,Cl.CCOc1ccc(cc1)NC(\C)=N\c2ccc(OCC)cc2,NCI,NSC-9293,-24.98888814,-7.42270317,-20.18980595,-68.72181671,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390584-01,Exatecan,384569198,DNA Topoisomerase I Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),169869-90-3,,5.623413252,1,-5.25,-458.6619035,5,4,,-0.972932452,-97.08897489,0.300103183,0.968645693,,TOP1,CC[C@@]1(O)C(=O)OC/C2=C1/C=C3\N(CC4=C5[C@@H](N)CCC6=C5C(=CC(=C6C)F)N=C34)C2=O,MedChem Express,HY-13631A,-96.27717126,-95.9658844,-97.19332811,-97.08897489,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346455-05,Cobimetinib,405558491,Mek Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1453848-26-4,,22.38721139,0,-4.65,-78.78208721,-2.4,4,,-61.81222595,-59.3274439,0.342316484,0.919982955,,MAP2K1,OC1(CN(C1)C(=O)C2=C(NC3=C(F)C=C(I)C=C3)C(=C(F)C=C2)F)[C@@H]4CCCCN4,ActiveBioChem,A-1318,-15.7554124,0,-15.18272317,-59.3274439,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167552-01,Piperocaine hydrochloride,144206100,Nicotinic acetylcholine receptor  Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),533-28-8,piperocaine; Piperocainio; Neothesin; ,39.81071706,0,-4.4,-17.84529607,-3,4,"Piperocaine;2-methylpiperidinepropanol benzoate;piperocaine hydrochloride;Neothesin;Piperocainio;CIPLUS_667885;piperocaine;Piperocainum;LS-172947;Methycaine hydrochoride;LS-116051;piperocaine, (+-)-isomer;(+/-)-2-methyl-1-piperidinepropanol benzoate (ester);PIPEROCAINE;piperocainum;CIPLUS_699088;piperocaine monohydrochloride, (+-)-isomer;CIPLUS_154086;CIPLUS_660991;PIPEROCAINE HYDROCHLORIDE;1-Piperidinepropanol, 2-methyl-, benzoate (ester), hydrochloride;METHYCAINE HYDROCHORIDE;metycaine hydrochloride;",-37.60249935,-34.25208279,0.301840689,0.939295731,,,Cl.CC2CCCCN2CCCOC(=O)c1ccccc1,SigmaAldrich,S403253,0,-8.39186431,0,-34.25208279,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181002-04,Cinacalcet hydrochloride,170465336,Calcium-Sensing Receptor (CaSR) Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),364782-34-3, Cinacalcet;Cinacalcet;Cinacalcet hydrochloride; Sensipar; ,39.81071706,0,-4.4,-108.1840362,-3,4,,-86.80972535,-76.50810446,0.539473741,0.762481531,846,CASR,Cl.FC(F)(F)c3cccc(CCCN[C@H](C)c2cccc1ccccc12)c3,Selleck,S1260,-21.28637855,-24.83502431,0,-76.50810446,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164547-06,Zafirlukast,174007053,Leukotriene CysLT1 (LTD4) Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),107753-78-6, ; Zafirlukast;Zafirlukast,12.58925412,0,-4.9,-20.91858888,-2.2,4,,-32.12971956,-31.7747663,0.018049956,0.99979927,10800,CYSLTR1,Cc1ccccc1S(=O)(=O)NC(=O)c5ccc(Cc3cn(C)c2ccc(cc23)NC(=O)OC4CCCC4)c(OC)c5,Sequoia,SRP00200z,0,0,-14.03448727,-31.7747663,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015385-18,Dipyridamole,170464694,Phosphodiesterase PDE3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),58-32-2,; ; Prandiol; Dipyridamole;DIPYRIDAMOLE; Asasantin; Dipiridamol;Dipyridamole; Persantine,31.6227766,0,-4.5,-122.2927681,-2.4,4,,-24.0229251,-43.8747563,0.073634012,0.99929096,8654,PDE5A,OCCN(CCO)c2nc1c(nc(nc1c(n2)N3CCCCC3)N(CCO)CCO)N4CCCCC4,Enzo,EI127,-24.40527848,-23.02231872,-24.9207818,-43.8747563,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164574-06,Erlotinib,170465434,EGFR Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),183321-74-6, ;CP-358774; Erlotinib hydrochlorid;Erlotinib hydrochlorid;OSI-774; erlotinib HCl; Erlotinib HCL;RG-1415;Tarceva;Ro-50-8231;NSC-718781,19.95262315,0,-4.7,-54.20501964,-2.4,4,,-70.76965284,-62.30804403,0.575183019,0.717170987,1956,EGFR,C#Cc1cc(ccc1)Nc3ncnc2cc(OCCOC)c(cc23)OCCOC,Sequoia,SRP01330e,0,-30.03425487,-16.36141886,-62.30804403,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015073-05,Amifostine,170465179,Alkaline phosphatase placental-like Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),20537-88-6,,7.079457844,1,-5.15,-66.13700428,-3,4,,-33.92396704,-37.28699163,0.813010785,0.978010897,,,OP(=O)(O)SCCNCCCN,Prestwick,Prestw-1489,-36.46475593,-8.86110045,-3.62165327,-37.28699163,,,,,,,,,,,,9.14E-08,4.57E-07,0.00000229,0.0000114,,,,,,,,,,,
NCGC00181088-01,Melitracen hydrochloride,144206258,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),10563-70-9,Melitracen hydrochloride; Melitraceno; Trausabun; Deanxit; Metrisil; ,10,0,-5,-116.5555892,-2.3,4,"Melitracen Hydrochloride;LS-20367;n,n,10,10-tetramethyl-delta(sup 9(10h)),gamma-anthracenepropylamine hydrochloride;melitracenum;Melitracene;Melitracen hydrochloride;Metrisil;Trausabun;9-(3-Dimetilaminopropyliden)-10,10-dimetil-9,10-diidroanthracene (Italian);melitracene hydrochloride;N,N-dimethyl-3-(9,10-dihydro-10,10-dimethylanthracen-9-yliden)propylamine;CIPLUS_670601;melitracene;CIPLUS_168125;Melitracen;LS-20365;Melitracenum;MELITRACEN;MELITRACEN HYDROCHLORIDE;Melitraceno;",-74.47153098,-86.14307389,0.581697193,0.99985314,,,Cl.CN(C)CC\C=C2/c1ccccc1C(C)(C)c3ccccc23,NCI,NSC-78229,-41.12915148,-11.95319088,-60.26662823,-86.14307389,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344565-01,Mizolastine,170465604,Histamine H1 Receptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),108612-45-9,,7.943282347,1,-5.1,-41.68755476,-2.2,4,,-57.10356351,-52.16963626,0.016705211,0.999827911,,HRH1,O=C1C=CN=C(N1)N(C)C2CCN(CC2)c4nc5ccccc5n4Cc3ccc(F)cc3,Prestwick,Prestw-1506,1.52908999,-5.7175809,-34.42705414,-52.16963626,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00160485-01,Diamthazole,144205400,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),95-27-2,Diamthazole; Asterol; ,15.84893192,0,-4.8,-53.7339903,-3,4,"DIAMTHAZOLE HYDROCHLORIDE;diamthazole dihydrochloride;CIPLUS_151863;Benzothiazole, 6-(2-diethylaminoethoxy)-2-dimethylamino-, dihydrochloride;amikazol;DIMAZOLE DIHYDROCHLORIDE;DIAMTHAZOLE;Dimazole Dihydrochloride;diamthazole;dimazole;dimazol;Dimazole dihydrochloride;Dimazol;6-(2-diethylaminoethylaminoethoxy)-2- dimethylaminobenzothiazole;Dimazole;Asterol;Diamthazole;CIPLUS_207319;LS-40729;dimazolum;DIMAZOLE-DIHYDROCHLORIDE;CIPLUS_166123;dimazole hydrochloride;Dimazolum;DIMAZOLE;",-32.99061683,-12.05260764,1,0.824979231,,,CCN(CC)CCOc1ccc2nc(sc2c1)N(C)C,InterBioScreen,STOCK1S-45555,-12.79683397,0,-32.49218069,-12.05260764,,,,,,,,,,,,9.14E-07,0.00000457,2.29E-05,0.000114,,,,,,,,,,,
NCGC00182705-02,Azatadine,170464865,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3964-81-6,,31.6227766,0,-4.5,-11.33268969,-3,4,,-41.51574738,-36.26312282,0.054619491,0.99815703,,,CN1CC\C(CC1)=C2\c4ncccc4CCc3ccccc23,APAC,555789,0,1.93921485,0,-36.26312282,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346565-04,Elvitegravir,405558598,HIV Integrase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),697761-98-1,,0.158489319,1,-6.8,-385.3473585,5,4,,-94.78496431,-97.95887428,0.0603776,0.997750456,,,COC1=CC2=C(C=C1CC3=C(F)C(=CC=C3)Cl)C(=O)\C(=C/N2[C@H](CO)C(C)C)C(O)=O,MedChem Express,HY-14740,-73.18395394,-91.62979266,-95.64344257,-97.95887428,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183104-02,Nizofenone,170466022,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54533-86-7,,39.81071706,0,-4.4,-12.58451004,-3,4,,-43.16346282,-35.96955235,0.006832298,0.999971234,,,Clc1ccccc1C(=O)c2cc(ccc2n3ccnc3CN(CC)CC)[N+]([O-])=O,APAC,556416,0,0,0,-35.96955235,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00379014-01,Cariprazine,405558596,Serotonin 1a (5-HT1a) receptor Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),839712-12-8,,17.7827941,0,-4.75,-89.66299129,-3,4,,-68.86217994,-66.98436837,0.352997588,0.914306893,,,CN(C)C(=O)N[C@H]1CC[C@@H](CC1)CCN2CCN(CC2)C3=CC=CC(=C3Cl)Cl,MedChem Express,HY-14763,-18.73913678,1.1106596,0,-66.98436837,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00181094-01,Sodium tyropanoate,144206263,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),7246-21-1,"TYROPANOATE SODIUM; Bilopaque; Tyropanoate; Tyropanoic acid; Sodium, Tyropanoat; Tiropanoato sodico; Tyropanoate, Sodiu; ",3.16227766,1,-5.5,-10.09230469,-3,4,"Benzenepropanoic acid, alpha-ethyl-2,4,6-triiodo-3-((1-oxobutyl)amino)-;Bilopaque;BENZENEPROPANOIC ACID, .ALPHA.-ETHYL-2,4,6-TRIIODO-3-((1-OXOBUTYL)AMINO)-;natrii tyropanoas;Tyropanoate de sodium;Sodium, Tyropanoat;Sodium tyropanoate;Natrii tyropanoas;WIN 8851;BENZENEPROPANOIC ACID, .ALPHA.-ETHYL-2,4,6-TRIIODO-3-((1-OXOBUTYL)AMINO)-, MONOSODIUM SALT;Tyropanoate sodium;TYROPANOATE SODIUM;Tyropanoic acid;WIN8851;Tyropanoate;WIN-88512;Tiropanoato sodico;CIPLUS_166239;SODIUM TYROPANOATE;2-(3-(BUTYRYLAMINO)-2,4,6-TRIIODOBENZYL)BUTANOIC ACID;Tyropanoate Sodium;CIPLUS_175604;Tyropanoate, Sodiu;TYROPANIC ACID;Sodium Tyropanoate;tyropanoate de sodium;",-42.40001978,-5.80242401,1,0.999946862,,,[Na+].O=C(Nc1c(I)c(CC(CC)C([O-])=O)c(I)cc1I)CCC,NCI,NSC-107434,2.30252447,-4.49877739,-39.82457875,-5.80242401,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262603-04,Idelalisib,405558681,PI3Kdelta Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),870281-82-6,,1.412537545,1,-5.85,-65.8087909,-1.4,4,,-45.00171994,-50.5574666,0.352619586,0.914546249,,PIK3CD,CC[C@H](NC1=C2N=C[NH]C2=NC=N1)C/3=N/C4=C(C(=CC=C4)F)C(=O)N3C5=CC=CC=C5,Axon Medchem,2170,0,-33.76086665,-35.13557603,-50.5574666,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166061-02,L-Cysteine ethyl ester hydrochloride,225144266,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),868-59-7,,39.81071706,0,-4.4,-43.87134197,-3,4,,-76.74845546,-66.45704622,0.221485735,0.968472805,,,CCOC(=O)[C@@H](N)CS,SIGMA,C121908,-8.62054316,2.84796197,4.77831056,-66.45704622,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00168777-04,Etonogestrel,405558738,contraceptive,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54048-10-1,,39.81071706,0,-4.4,-13.97541528,-3,4,,-47.93411234,-39.94509362,0.006832298,0.999971228,,,CC[C@]12CC(=C)[C@H]3[C@@H](CCC/4=C/C(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,MedChem Express,HY-B0652,0,0,0,-39.94509362,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00241107-02,Bosutinib,170466788,Bcr-Abl Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),918639-10-8, Bosutinib;Bosutinib;PF-5208763/SKI-606,39.81071706,0,-4.4,-40.46881111,-3,4,,-117.2371448,-97.27924334,0.072429723,0.996750422,25,ABL1,CO.COc4cc(Nc3c(C#N)cnc2cc(OCCCN1CCN(C)CC1)c(OC)cc23)c(Cl)cc4Cl,Sequoia,380843-75-4,0,-6.40637589,-2.8054545,-97.27924334,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263180-14,Trametinib,405558802,Mek 1/2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1204531-25-8,,1.584893193,1,-5.8,-60.59483412,-1.4,4,,-36.86875107,-29.87931644,0.360517579,0.910228184,,MAP2K1,CN1C(=O)C(=C/2N(C(=O)N(C3CC3)C(=O)C2=C1/NC4=CC=C(I)C=C4F)C5=CC=CC(=C5)NC(C)=O)\C,ActiveBioChem,A-1258,0,-28.60284359,-43.18750119,-29.87931644,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016872-12,Ticlopidine hydrochloride,170464698,P2Y12 (P2T) Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55142-85-3," Ticlid; Ticlopidina;Ticlopidine; ;; Ticlodone; Ticlopidine Hcl;TICLOPIDINE HYDROCHLORIDE; Ticlopidine hydrochloride; Hydrochloride, Ticlopidin;Ticlopidine hydrochloride",19.95262315,0,-4.7,-19.25542964,-3,4,,-40.07697769,-35.66437704,0.023177938,0.99966886,64805,P2RY12,Clc3ccccc3CN1CCc2sccc2C1,Vitas,STK589340,0,0,-9.70459181,-35.66437704,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00021146-09,Ketanserin,170466645,5-HT2A Antagonists?,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),74050-98-9,Ketanserin tartrate;Ketanserin;KETANSERIN TARTRATE,11.22018454,0,-4.95,-24.16298722,-2.2,4,,-35.81390252,-35.0128727,0.039344199,0.999045058,3356,HTR2A,Fc1ccc(cc1)C(=O)C4CCN(CCN2C(=O)c3ccccc3NC2=O)CC4,Enzo,NS515,0,0,-17.05781954,-35.0128727,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016602-04,Benperidol,170466409,Dopamine D2 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2062-84-2,,0.630957345,1,-6.2,-132.899361,-1.4,4,,-36.66710186,-43.5133328,0.266851694,0.9535279,,,Fc1ccc(cc1)C(=O)CCCN2CCC(CC2)N3c4ccccc4NC3=O,"Prestwick Chemical, Inc.",Prestw-484,-22.44841461,-34.73079047,-37.01221224,-43.5133328,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263575-01,Ezetimibe,170465013,NPC1L1 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),163222-33-1,,12.58925412,0,-4.9,-29.31761286,-2.2,4,,-43.49682404,-42.12668893,0.027505859,0.999533422,,NPC1L1,Fc1ccc(cc1)[C@@H](O)CC[C@H]3C(=O)N(c2ccc(F)cc2)[C@@H]3c4ccc(O)cc4,Sequoia,163222-33-1,0,-1.69952032,-19.17500152,-42.12668893,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00164619-02,Anastrozole,170464923,Aromatase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),120511-73-1,Anastrozole; Anastrozole; ; Arimidex; Zeneca ZD 1033; 4   Anastrazole,39.81071706,0,-4.4,-10.6301518,-3,4,,-35.4602325,-30.38352708,0.00351773,0.999992378,1588,CYP19A1,N#CC(C)(C)c1cc(cc(c1)C(C)(C)C#N)Cn2cncn2,Sequoia,SRP05647a,0,0,0,-30.38352708,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181159-03,Trabectedin,384568393,DNA-Damaging Drug,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),114899-77-3,,0.354813389,1,-6.45,-447.8699311,5,4,,3.854712764,-93.8505329,0.356884672,0.919030933,,H2AFX,COC1=CC2=C(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=C6C(=C(OC)C(=C7)C)O)[C@H](O)N5[C@@H](COC3=O)C8=C4C(=C(C)C9=C8OCO9)OC(C)=O)C=C1O,MedChem Express,HY-50936,-97.1607175,-94.12931701,-92.45631147,-93.8505329,,,,,,,,,,,,9.14E-08,4.57E-07,0.00000229,0.0000114,,,,,,,,,,,
NCGC00183366-07,NORETHINDRONE ACETATE,405558906,Progesterone Receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),51-98-9,,39.81071706,0,-4.4,-26.07830202,-3,4,,-50.56808708,-42.9734059,0.108016907,0.992738536,,,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C,Microsource,1500438,-3.6690498,0,0,-42.9734059,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00182979-02,Perlapine,405558916,Histamine H1 receptor Inverse Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),[1977-11-3],,39.81071706,0,-4.4,-69.41776856,-3,4,,-65.74432691,-58.95360576,0.749647478,0.946790388,,,CN1CCN(CC1)C/2=N/C3=C(CC4=C2C=CC=C4)C=CC=C3,Tocris,5549,-40.36377156,-13.15724322,0,-58.95360576,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015321-11,Dobutamine,170465050,beta1-Adrenoceptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),34368-04-2," ; Dobutamine, (-)-Isomer;Dobutamine hydrochloride; Dobutamine hydrochloride;Dobutamine; Dobutamina; Dobutaminum; Dobutamine HCl; Dobutamine (+)-Isomer",28.18382931,0,-4.55,-13.32481359,-3,4,,-38.07149085,-34.97737369,0.006605881,0.999973111,153,ADRB1,Oc2ccc(CCNC(C)CCc1ccc(O)cc1)cc2O,Tocris,515,0,0,-1.55703361,-34.97737369,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015656-12,Mianserin,170465596,5-HT2A Antagonists?,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),24219-97-4,"; ; Org GB 94;Mianserin; Mianserin Hcl;Mianserin hydrochloride; Mianserin hydrochloride; Mianserina;MIANSERIN HYDROCHLORIDE; Mianserine hydrochloride; Mianserine Hcl;Mianserin..HCl;Mianserine hydrochloride; Lerivon; Bolvidon; Tetramide; Hydrochloride, Mianseri; Tolvon",39.81071706,0,-4.4,-74.53604595,-3,4,,-72.90968567,-71.64221371,0.063247891,0.997525173,3356,HTR2A,CN1CC2N(CC1)c4ccccc4Cc3ccccc23,Enzo,AC554,-11.178924,-13.02120319,-9.63414232,-71.64221371,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00188430-01,Moperone,144207164,Serotonin 2a (5-HT2a) receptor Inverse Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1050-79-9,,12.58925412,0,-4.9,-41.25259363,-2.4,4,Moperone,-65.80664718,-62.32096961,0.623028701,0.999979196,,,O=S(=O)(O)O.Fc1ccc(cc1)C(=O)CCCN2CCC(O)(CC2)c3ccc(C)cc3,Toronto Research,M610500,-25.03525099,0,-27.84739364,-62.32096961,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166000-04,Iohexol,170464962,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),66108-95-0,,12.58925412,0,-4.9,-4.360091871,-2.4,4,,-35.10786012,-25.5065501,0.032473994,0.999350143,,,OCC(O)CNC(=O)c1c(I)c(N(CC(O)CO)C(C)=O)c(I)c(c1I)C(=O)NCC(O)CO,Prestwick,Prestw-512,4.2652839,0,-11.84736247,-25.5065501,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167430-04,Tioconazole,170465343,Antifungal Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),65899-73-2, ; Vagistat-1;Tioconazole; Tioconazol;TIOCONAZOLE; Tioconazole,39.81071706,0,-4.4,-33.92578584,-3,4,,-116.3616534,-96.96804454,0.006832298,0.999971208,,,Clc3sccc3COC(Cn1ccnc1)c2ccc(Cl)cc2Cl,Microsource,1505581,0,0,0,-96.96804454,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346470-02,ZilpaterolHCl,405558976,beta1-Adrenoceptor Antagonists,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),119520-06-8,,19.95262315,0,-4.7,-24.12320325,-2.4,4,,-52.63065062,-47.82625047,0.817610485,0.999949015,,ADRB1,CC(C)N[C@@H]1CCN2C(=O)NC3=CC=CC(=C23)[C@H]1O,Enzo,AR113,-38.63321928,0,-10.58195699,-47.82625047,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00185757-01,Diethylmethyl(2-3-methyl-2-phenylvaleryloxy)-ethyl)ammonium bromide,144207102,Muscarinic acetylcholine receptor M3 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),90-22-2,,31.6227766,0,-4.5,-8.199895228,-2.4,4,,-31.1441639,-28.03680325,0.026325972,0.999572959,,,[Br-].CC[N+](C)(CC)CCOC(=O)C(C(C)CC)c1ccccc1,SigmaAldrich,S422649,0.53464616,0,0,-28.03680325,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179506-05,Kanamycin (sulfate),405558981,30S Ribosomal Protein Inhibitors,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),25389-94-0,,3.981071706,1,-5.4,-63.11292137,-3,4,,-37.12188052,-33.8515671,0.346327553,0.917952108,,,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,MedChem Express,HY-16566A,-9.6373826,0,0,-33.8515671,,,,,,,,,,,,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,,,,
NCGC00025155-07,Omacetaxine mepesuccinate,405558996,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),26833-87-4,,3.16227766,1,-5.5,-124.3794346,-1.1,4,,-99.78635261,-98.40863177,0.032751016,0.999337857,,RPL3,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]\1[C@H]2C3=CC4=C(OCO4)C=C3CCN5CCC[C@]25\C=C1OC,MedChem Express,HY-14944,0,-32.35490183,-96.4345523,-98.40863177,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025341-06,Isradipine,170465070,Calcium Channel Blocker,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),75695-93-1,";Isradipine; Isradipine; DynaCirc; Lomir; Isradipine, (S)-Isomer; Dynacirc; Isaradipine; Isradipine, (R)-Isomer; Isradipine, (+-)-Isomer",3.548133892,1,-5.45,-24.55931138,-3,4,,-31.62895698,-15.89051372,1,0.999928501,,,O=C(OC)C3=C(C)NC(C)=C(C(=O)OC(C)C)C3c1cccc2nonc12,Tocris,2004,-2.79657158,-6.04594342,-34.19723059,-15.89051372,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00246113-02,NCGC00246113-02,405558428,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-151.5015142,-2.4,4,,-79.93654389,-70.78045324,0.706951904,0.460948921,,,C(CC1=CC=CC=C1)NCC2=CC=CC=C2,Specs,AN-465/J120002,-37.01248408,-21.95420091,0,-70.78045324,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016271-05,Tolazoline hydrochloride,170465219,Adrenergic receptor alpha-1 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),59-97-2,,6.309573445,1,-5.2,-33.94169067,-1.2,4,,-33.37309968,-33.22758307,0.014715336,0.999866528,,,Cl.c2cc(CC1=NCCN1)ccc2,Specs,AT-139/J221336,0,0,-31.95373917,-33.22758307,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183008-01,Israpafant,144206851,Interleukin-5 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),117279-73-9,ISRAPAFANT; ,39.81071706,0,-4.4,-68.2452065,-2.4,4,"6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-(2-(4-(2-methylpropyl)phenyl)ethyl)-;4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine;Y 24180;CIPLUS_695838;(+/-)-4-(O-CHLOROPHENYL)-2-(P-ISOBUTYLPHENETHYL)-6,9-DIMETHYL-6H-THIENO(3,2-F)-S-TRIAZOLO(4,3-A)(1,4)DIAZEPINE;israpafant;ISRAPAFANT;Israpafant;Y-24180;israpafantum;",-59.39539413,-57.13644828,0.786489519,0.606341949,,,CC(C)Cc1ccc(cc1)CCc2cc5c(s2)n3c(C)nnc3C(C)N=C5c4ccccc4Cl,Pharmaron,PH-NIH-155125,-10.91690615,-52.93021965,4.54698981,-57.13644828,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00021268-04,Hydroxyprogesterone caproate,170465210,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),630-56-8,,0.707945784,1,-6.15,-53.42600257,-1.4,4,,-37.85241376,-49.81078687,0.73924218,0.363160864,,,CC(=O)[C@@]3(OC(=O)CCCCC)CC[C@H]2[C@@H]4CCC1=CC(=O)CC[C@]1(C)[C@H]4CC[C@@]23C,Bosche,H1727,0,-49.30393781,-2.23424804,-49.81078687,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344524-01,Benzylhexadecyldimethylammonium chloride,170465465,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),122-18-9,,7.943282347,1,-5.1,-93.45066722,-1.1,4,,-97.38336026,-98.77847416,0.018240242,0.999794739,,,[Cl-].C[N+](C)(Cc1ccccc1)CCCCCCCCCCCCCCCC,SIGMA,13400,0,-2.05694233,-82.26615978,-98.77847416,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179499-05,Dipivefrin hydrochloride,405559013,Beta-2 adrenergic receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),64019-93-8,,25.11886432,0,-4.6,-233.7363062,5,4,,-10.90067931,-55.85525025,0.676292003,0.540607769,,,CNCC(O)C1=CC(=C(OC(=O)C(C)(C)C)C=C1)OC(=O)C(C)(C)C,Prestwick,Prestw-632,-51.14637547,-39.68801749,-46.57555059,-55.85525025,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00509861-02,Auristatin PE,405559023,microtubule polymerization Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),149606-27-9,,10,0,-5,-38.25707219,-2.4,4,,-49.94514533,-49.07468889,0.896236453,0.999900682,,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC2=CC=CC=C2)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,MedChem Express,HY-14672,-61.05456819,0,-30.19403761,-49.07468889,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00509905-01,Eliglustat (Tartrate),405558462,Ceramide glucosyltransferase Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),491833-29-5,,39.81071706,0,-4.4,-53.07222155,-3,4,,-97.47504874,-84.98747801,0.28689746,0.94553079,7357,UGCG,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC=C3OCCOC3=C2,Selleck,S7852,-3.25227529,-19.39755102,0,-84.98747801,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167557-01,DL-Methionine methylsulfonium chloride,144206105,ERK1 and ERK2 cascade Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),3493/12/7,"Sulfonium, (3-amino-3-carboxypropyl)dimethyl-, chloride, (S)-; Vitamin U; S-Methylmethionine; Vitamin U Chloride; S Methylmethionin; ",39.81071706,0,-4.4,-13.41161924,-3,4,"Methylsulfonium Chloride, Methionin;Vitamin U Chloride;CIPLUS_203938;LS-148013;Sulfonium, (3-amino-3-carboxypropyl)dimethyl-, chloride, (S)-;Vitamin U;S Methylmethionin;S-Methylmethionine;CIPLUS_723454;methionylmethylsulfonium chloride;Sulfonium, (3-amino-3-carboxypropyl)dimethyl-, chloride, L-;DL-Met-S-methylsulfonium chloride;CIPLUS_3886671;Methylmethionine sulfonium chloride;CIPLUS_8144825;DL-methionine-S-methylsulfonium chloride;CIPLUS_742496;Methylmethionine Sulfonium Chloride;Chloride, Methionine Methylsulfoniu;DL-Methionine Methylsulfonium Chloride;(3-Amino-3-carboxypropyl)dimethyl sulfonium chloride;CIPLUS_157505;CIPLUS_777498;Methyl-methionine sulphonium chloride;MMSC;Chloride, Methylmethioninesulfoniu;DL-Methionine methylsulfonium chloride;CIPLUS_775683;METHYLMETHIONINE SULFONIUM CHLORIDE;",-46.00035492,-38.3336291,0.683909535,0.999967638,,,[Cl-].C[S+](C)CCC(N)C(=O)O,SigmaAldrich,64382,-22.45798735,0,0,-38.3336291,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00166124-03,Benzyl cinnamate,170465584,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),103-41-3,,5.011872336,1,-5.3,-12.82980808,-3,4,,-38.75556335,-7.08952724,1,0.999983445,,,O=C(OCc1ccccc1)C=Cc2ccccc2,SIGMA,234214,-25.60673204,0,-36.81070681,-7.08952724,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183845-01,Pibutidine,144206830,Histamine H2 receptor Binding Agent,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),103922-33-4,,17.7827941,0,-4.75,-28.26517344,-3,4,"LS-55930;Pibutidine hydrochloride;IT-066;pibutidine hydrochloride;pibutidinum;PIBUTIDINE;PIBUTIDINE HYDROCHLORIDE;3-amino-4-(4-(4-(1-piperidinomethyl)-2-pyridyloxy)-2-butenylamino)-3-cyclobutene-1,2-dione;3-Cyclobutene-1,2-dione, 3-amino-4-((4-((4-(1-piperidinylmethyl)-2-pyridinyl)oxy)-2-butenyl)amino)-, monohydrochloride, (Z)-;IT 066;Pibutidine Hydrochloride;CIPLUS_3889336;pibutidine;CIPLUS_696295;",-52.38647648,-47.70743551,0.695646334,0.999964568,,,NC=3C(=O)C(=O)C=3NC\C=C/COc2cc(CN1CCCCC1)ccn2,Pharmaron,PH-NIH-151621,-28.94554477,0,0,-47.70743551,,,,,,,,,,,,2.29E-07,1.14E-06,5.71E-06,0.0000286,,,,,,,,,,,
NCGC00091865-02,Benzyl alcohol,124891475,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),,,39.81071706,0,-4.4,-16.39535238,-3,4,,-65.29562124,-54.4130177,0.08447192,0.995574362,,,OCC1=CC=CC=C1,SigmaAldrich,108006,0,0,3.78277644,-54.4130177,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00508820-02,Dalfopristin,405559042,Bacterial 70S ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),112362-50-2,,1.584893193,1,-5.8,-38.81776097,-1.4,4,,-44.94401216,-9.03440228,1,0.999877343,,,CCN(CC)CC[S+]([O-])(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(=C\[C@@H](O)CC(=O)CC3=NC(=CO3)C2=O)C,MedChem Express,HY-A0241_cm1,0,-33.58704716,-44.06275702,-9.03440228,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00346457-02,Copanlisib,405559053,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1032568-63-0,,3.16227766,1,-5.5,-276.3565679,-2.3,4,,-45.07017357,-90.89073608,0.269328095,0.952435349,,PIK3CA,COC1=C(OCCCN2CCOCC2)C=CC\3=C1/N=C(/NC(=O)C4=CN=C(N)N=C4)N5CC/N=C35,Selleck,S2802,-51.76225485,-40.08122538,-55.39414026,-90.89073608,,,,,,,,,,,,9.14E-08,4.57E-07,0.00000229,0.0000114,,,,,,,,,,,
NCGC00016624-05,Diphenidol,170465280,Muscarinic acetylcholine receptor M5 Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),972-02-1,,8.912509381,1,-5.05,-64.93031042,-2.2,4,,-35.46849819,-40.15678152,0.008616928,0.999954263,,,OC(CCCN1CCCCC1)(c2ccccc2)c3ccccc3,Prestwick,Prestw-252,-7.68303303,-11.89196249,-27.84848264,-40.15678152,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00025297-04,Gabexate mesilate,170465830,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),56974-61-9,"; ;Gabexate mesylate; Gabexate mesylate;Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester;Gabexate mesilate; Gabexate Methanesulfonate; Arodate; Gabexato",1.412537545,1,-5.85,-26.36188414,-2.4,4,,-32.44217096,0,1,0.999911633,4790,NFKB1,O=C(Oc1ccc(cc1)C(=O)OCC)CCCCCNC(=N)N.CS(=O)(=O)O,Prestwick,Prestw-1008,0,-22.58775259,-30.3684758,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389735-01,NCGC00389735-01,405558544,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55721-31-8; 53003-10-4 (acid),,3.981071706,1,-5.4,-106.3812242,-1.1,4,,-97.12949795,-97.51957626,0.006344535,0.999975172,,WNT1,CCC([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2OC\3(O[C@@]4(CC[C@](C)(O4)[C@H]5CC[C@](O)(CC)[C@H](C)O5)[C@H](O)\C=C3)[C@H](C)C[C@@H]2C)C([O-])=O,Microsource,1503602,0,-7.43153508,-96.036027,-97.51957626,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179401-03,Ethotoin,225144304,Sodium channel protein type V alpha subunit Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),86-35-1,,31.6227766,0,-4.5,-74.6068517,-2.4,4,,-32.25677594,-37.9621414,0.875765769,0.999907244,,,CCN1C(=O)NC(C1=O)C2=CC=CC=C2,Prestwick,Prestw-696,-50.65642231,-13.39626852,-16.67651131,-37.9621414,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00013289-09,Pridinol,170465865,Muscarinic acetylcholine receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),511-45-5,,28.18382931,0,-4.55,-17.59929893,-3,4,,-71.44125777,-56.01610437,0.044828287,0.99875889,,,OC(CCN1CCCCC1)(c2ccccc2)c3ccccc3,Specs,AG-680/20240026,2.66455412,0,-8.62136848,-56.01610437,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178737-05,Trimeprazine tartrate,170465278,Histamine H1 receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),4330-99-8,,19.95262315,0,-4.7,-138.6257635,-2.3,4,,-77.0281926,-85.87547547,0.185457919,0.978171754,,,O=C(O)[C@H](O)[C@H](O)C(=O)O.CN(C)C[C@H](C)CN1c3ccccc3Sc2ccccc12.CN(C)C[C@H](C)CN1c3ccccc3Sc2ccccc12,Microsource,1500593,-23.70817787,-13.57798764,-39.71657322,-85.87547547,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00162150-04,Cilnidipine,170465867,Voltage-gated N-type calcium channel alpha-1B subunit Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),132203-70-4,,1.122018454,1,-5.95,-53.31166854,-2.4,4,,-40.06532518,-10.51729743,1,0.999929363,,,CC=1NC(C)=C(C(C=1C(=O)OCCOC)c2cccc(c2)[N+]([O-])=O)C(=O)OC/C=C/c3ccccc3,Prestwick,Prestw-1376,-8.69247748,-22.8596149,-32.08024846,-10.51729743,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167427-02,Epoprostenol sodium,124893308,Prostanoid IP receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),61849-14-7,,28.18382931,0,-4.55,-44.85700638,-3,4,PROSTAGLANDIN I2 Na,-55.33701844,-50.255317,0.158442737,0.984197705,64805,,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC([O-])=O,BIOMOL,PG011,-6.85276308,0,-9.51951503,-50.255317,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00386518-01,Cannabidiol,377020361,Cannabinoid Receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),13956-29-1,,39.81071706,0,-4.4,-43.11758449,-3,4,,-55.38054044,-49.4837837,0.804730721,0.982068466,,CNR1,CCCCCC1=CC(=C([C@@H]2\C=C(C)/CC[C@H]2C(C)=C)C(=C1)O)O,Axon Medchem,1234,-45.95579911,-6.95855814,0,-49.4837837,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00262907-01,Bilastine,170466329,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),202189-78-4,Bilastine;Bilastinum,22.38721139,0,-4.65,-87.54319109,-2.4,4,,-50.86101765,-48.00077095,0.547843205,0.752597249,,,O=C(O)C(C)(C)c4ccc(CCN1CCC(CC1)c3nc2ccccc2n3CCOCC)cc4,GVK,FFS-12-73-NCI-1870,-20.63510228,2.51479227,-14.88665354,-48.00077095,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00014602-05,L-Penicillamine,405558637,Copper Chelator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1113-41-3,,3.981071706,1,-5.4,-78.37831342,-3,4,,-51.56212283,-47.13510236,0.592209404,0.692873036,,CAT,CC(C)(S)[C@H](N)C(O)=O,Enzo,NP226,0,-25.01145095,0,-47.13510236,,,,,,,,,,,,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,,,,
NCGC00024846-08,Guanabenz,170465364,Adrenergic receptor alpha-2 Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5051-62-7,,25.11886432,0,-4.6,-153.5561748,-2.4,4,,-41.59735812,-41.34157508,0.946992192,0.999956724,,,Clc1cccc(Cl)c1/C=N/NC(=N)N,Enzo,AC153,-31.5899935,-51.36423618,-11.64460082,-41.34157508,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015562-25,Indomethacin,170464705,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),53-86-1, Indocin;; Cu salt; Indocid; Al salt; Indocin I.V.; ; Li salt; Cu(2+) salt; Metindol; Mg salt; Indomethacin; Ca salt; Osmosin; Cu-IMCC; Zn salt; Combiflex;Indomethacin; Indomet 140; Amuno; NH4 salt;INDOMETHACIN; Indometacina,3.981071706,1,-5.4,-20.74194784,-1.4,4,,-31.68955606,-28.90796338,0.013326906,0.999890549,,PTGS2,Clc1ccc(cc1)C(=O)n3c2ccc(cc2c(CC(=O)O)c3C)OC,Microsource,1500350,2.97629283,0,-28.04454206,-28.90796338,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167436-02,Azelnidipine,174006618,Ca channel blocker - DHP class,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),123524-52-7, ; Calblock;Azelnidipine; Azelnidipine,39.81071706,0,-4.4,-46.20203808,-3,4,,-116.5562211,-97.96351759,0.052328139,0.998307348,,,[O-][N+](=O)c1cccc(c1)C2C(C(=O)OC(C)C)=C(C)NC(N)=C2C(=O)OC3CN(C3)C(c4ccccc4)c5ccccc5,Bosche,A2998,-3.96294434,0,0,-97.96351759,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00014670-17,Domperidone,170465594,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),57808-66-9, ; Motilium; 5   Domperidone; Prestwick-06G02;Domperidone; Domperidona; Domperidone; TFMP domperidone;DOMPERIDONE; Domperidone Maleate (1:1),11.22018454,0,-4.95,-39.77118128,-2.2,4,,-59.49624676,-58.32985811,0.037663592,0.99912431,1812,DRD1,Clc4cc5NC(=O)N(C3CCN(CCCN1c2ccccc2NC1=O)CC3)c5cc4,Microsource,2300212,0,1.56173903,-29.28755083,-58.32985811,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018193-11,Fluvoxamine,170464809,5-HT Reuptake Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54739-18-3,";FLUVOXAMINE MALEATE;Fluvoxamine; Fluvoxamina;Fluvoxamine maleate; Fluvoxamine, (Z)-Isomer",35.48133892,0,-4.45,-38.91008734,-3,4,,-81.7915795,-68.78149962,0.244634106,0.96117846,3350,HTR1A,FC(F)(F)c1ccc(cc1)C(\CCCCOC)=N\OCCN,Tocris,1033,0,-13.97076229,-7.28422721,-68.78149962,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00018098-07,Iodoquinol,170465640,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),83-73-8,,25.11886432,0,-4.6,-36.88723459,-2.2,4,,-62.49490981,-50.28502597,0.042228816,0.998899109,,,Oc1c(I)cc(I)c2cccnc12,Vitas,STK070581,-1.56777039,-4.68587007,-16.18324661,-50.28502597,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016819-05,Gliquidone,170465581,Cytochrome P450 3A4 Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),33342-05-1,,0.707945784,1,-6.15,-58.48251332,-2.4,4,,-52.28865931,-0.63111252,1,0.708822271,,,O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(cc2)CCN4C(=O)c3cc(ccc3C(C)(C)C4=O)OC,"Prestwick Chemical, Inc.",Prestw-991,-0.30699859,-66.85364002,-31.16360569,-0.63111252,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00249899-01,Cinoxate,170465555,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),104-28-9,,0.707945784,1,-6.15,-37.26854206,-2.4,4,,-36.28714504,0,1,0.82030465,,,COc1ccc(C=CC(=O)OCCOCC)cc1,GVK,FFS-11-286-NCI-86,0,-41.43016115,-23.89951405,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00183005-01,Zanapezil fumerate,144206802,Acetylcholinesterase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),263248-42-6,CIPLUS_775863; Zanapezil Fumarate; ,31.6227766,0,-4.5,-52.90701651,-2.3,4,CIPLUS_775863;ZANAPEZIL;Zanapezil Fumarate;CIPLUS_3882440;CIPLUS_3882439;zanapezilum;,-104.4418351,-82.15290535,0.22777905,0.966572785,,,O=C(O)/C=C/C(=O)O.O=C(CCC2CCN(Cc1ccccc1)CC2)c3ccc4CCCCNc4c3,Pharmaron,PH-NIH-100582,0,-15.75647754,-18.84124083,-82.15290535,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016246-09,Chlorhexidine,170464748,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),55-56-1," Corsodyl ICI; Chlorhexidine base; Anticataracticum; Arlacide H; Lisium; 8   Chlorhexidine Base; Hibiclens; Tubilicid blue label; Hexidine; Curasept ADS 220; Clorhexidina;Chlorhexidine; Eludril; Instillagel; Hibisol; Trisdine; A, Sebidi; Sebidin A; Chlorhexidine; Gibitan; Hibident; Progaron; ; Anticataracticum tablet; Perio Chip; Chlorhexamed; Tubilicid red label;CHLORHEXIDINE; Tubilicid; Acetate, Chlorhexidin;Chlorhexidine diacetate; Novalsan; Hibiscrub; Dyna-Hex; Peridex; Dantroche hibitane",39.81071706,0,-4.4,-10.54323778,-3,4,,-38.54428414,-32.53690345,0.046982118,0.99863761,4312,MMP1,Clc2ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)cc2,Vitas,STK089248,0,0,1.20318731,-32.53690345,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274060-01,Posaconazole,170464963,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),171228-49-2,,14.12537545,0,-4.85,-56.33964619,-2.2,4,,-81.89736308,-79.53459544,0.04562035,0.998714312,,CYP51A1,C[C@H](O)[C@H](CC)N1N=CN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OCC6C[C@@](Cn5cncn5)(OC6)c7ccc(F)cc7F,Selleck,S1257,-2.24742331,0,-31.14082203,-79.53459544,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253592-01,Menadiol,170465455,regulation of blood coagulation Activator,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),481-85-6,,39.81071706,0,-4.4,-37.68642839,-3,4,,-116.1859476,-98.07162297,0.06295021,0.997547945,,,Oc1cc(C)c(O)c2ccccc12,GVK,FFS-11-286-NCI-27,0,-4.83116077,0,-98.07162297,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00178874-03,DL-Carnitine HCl,405558577,Mitochondrial carnitine/acylcarnitine carrier protein Substrate,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),461-05-2,,28.18382931,0,-4.55,-88.65900883,-2.4,4,,-66.29037656,-64.487374,0.322136434,0.930001765,788,SLC25A20,C[N+](C)(C)CC(O)CC(O)=O,Selleck,S2293,-18.62077399,-2.3607976,-12.03016599,-64.487374,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181136-01,Pyrrolnitrin,144206296,respiratory electron transport chain Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1018-71-9,Pyrrolnitrin; Pyrrolnitrin Microbial; Pirrolnitrina; ,39.81071706,0,-4.4,-13.78697616,-3,4,"3-Chloro-4-(3-chloro-2-nitrophenyl)pyrrole;Pirrolnitrina;pyrrolnitrine;LS-136879;Pyrrolnitrine;Pyrrolnitrinum;Pyrrolnitrin Microbial;PYRROLNITRIN;CIPLUS_157237;Pyrrolnitrin;pyrrolnitrinum;1H-Pyrrole, 3-chloro-4-(3-chloro-2-nitrophenyl)-;",-47.28778721,-39.40648934,0.006832298,0.999971229,,,Clc2cncc2c1cccc(Cl)c1[N+]([O-])=O,NCI,NSC-107654,0,0,0,-39.40648934,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181085-01,Miripirium chloride,144206257,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),2748-88-1,CIPLUS_160809; Cloruro de miripirio; ,5.623413252,1,-5.25,-278.7566999,-1.3,4,Miripirii chloridum;Miripirium chloride;1-TETRADECYL-4-PICOLINIUM CHLORIDE;MIRIPIRIUM CHLORIDE;Cloruro de miripirio;Chlorure de miripirium;CIPLUS_160809;MYRISTYL-GAMMA-PICOLINIUM CHLORIDE;miripirii chloridum;chlorure de miripirium;myristyl-gamma-picolinium chloride;1-myristylpicolinium;,-52.17662932,-96.4000597,0.155984904,0.984690084,,,[Cl-].Cc1cc[n+](CCCCCCCCCCCCCC)cc1,NCI,NSC-36338,-49.48733199,-41.2233604,-96.34105663,-96.4000597,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378841-01,Levomefolate calcium,405558655,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),151533-22-1,,2.511886432,1,-5.6,-70.23879036,-3,4,,-57.88373057,-49.9119171,0.009802801,0.999940754,,,CN\1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC\3=C1C(=O)NC(=N3)\N,MedChem Express,HY-17383,0,0,-8.22255476,-49.9119171,,,,,,,,,,,,4.57E-08,2.29E-07,1.14E-06,5.71E-06,,,,,,,,,,,
NCGC00183848-01,Troxacitabine,124894563,DNA Polymerase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),145918-75-8,Troxacitabine,7.079457844,1,-5.15,-49.11325215,-3,4,"2R(-)-cis-HMD-cytosine;Troxacitabine;LS-173247;LS-173246;LS-173400;TROXACITABINE;BCH-4556;BCH 4556, trans-(+-)-isomer;LS-173262;2'-DEOXY-3'-OXACYTIDINE,1'S,4'S,L-;BCH 4556, cis-(+-)-isomer;BCH 4556, (2S-trans)-isomer;BCH 4556, 2R(-)-cis-isomer;LS-173106;troxacitabine;CIPLUS_728716;troxacitabinum;CIPLUS_703293;",-41.28680235,0,1,0.922404907,,POLB,OC[C@H]1OCC(O1)[N@@]2C=CC(N)=NC2=O,Pharmaron,PH-NIH-148677,-11.46174107,0,-41.9322244,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179344-04,Pivmecillinam,405558689,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),32886-97-8,,15.84893192,0,-4.8,-106.7850972,-2.4,4,,-71.35593522,-65.59443321,0.834363453,0.994206414,,,CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N3CCCCCC3)C2=O,SIGMA,SML0817,-46.62393492,-16.13115386,-34.38653935,-65.59443321,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00263565-01,Gestodene,170466131,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),60282-87-3,Gestodene,39.81071706,0,-4.4,-28.06182893,-3,4,,-81.70776222,-68.50646852,0.027739198,0.999525193,5241,PGR,O=C4CC[C@H]3C(CC[C@@H]2[C@@H]3CC[C@@]1(CC)[C@H]2C=C[C@@]1(O)C#C)=C4,Bosche,G2883,-1.36011267,0,0,-68.50646852,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00159337-04,Efavirenz,170464810,Reverse Transcriptase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),154598-52-4," Sustiva;0   Efavirenz;DMP-266;L-743726; ;Stocrin;Sustiva; efavirenz (EFV or EFZ); Efavirenz;Efavirenz; efavirenz, (R)-isomer",28.18382931,0,-4.55,-40.33440459,-2.4,4,,-85.65463779,-71.32927105,0.091570623,0.994793292,7015,TERT,FC(F)(F)[C@@]3(C#CC1CC1)OC(=O)Nc2ccc(Cl)cc23,Vitas,STK582240,0,-6.3959471,-15.6231482,-71.32927105,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00250382-07,Sonidegib,405558711,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1218778-77-8,,39.81071706,0,-4.4,-17.21419344,-3,4,,-60.69718522,-51.41432102,0.028951615,0.999482859,,SMO,C[C@H]1CN(C[C@@H](C)O1)C2=NC=C(NC(=O)C3=C(C)C(=CC=C3)C4=CC=C(OC(F)(F)F)C=C4)C=C2,Aobious,AOB87343,0,0,1.10811849,-51.41432102,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00270540-02,Miglitol,170465326,alpha-Glucosidase Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),72432-03-2,Miglitol;Miglitol (Glyset),8.912509381,1,-5.05,-53.34986164,-3,4,,-35.92544052,0,1,0.948716802,2548,GAA,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,Prestwick,Prestw-1169,-12.36267339,-4.99308245,-36.30086323,0,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00167543-05,CEFTIOFUR HYDROCHLORIDE,405558783,Cephalosporin antibiotic,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),80370-57-6,,39.81071706,0,-4.4,-10.925851,-3,4,,-36.47444773,-31.22870644,0.736249206,0.999991248,,,CO\N=C(\C(=O)N[C@H]1[C@H]2SC\C(=C(/N2C1=O)C(O)=O)CSC(=O)C3=CC=CO3)C4=CSC(=N4)N,Microsource,1504832,-21.60253385,0,0,-31.22870644,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378574-01,Brexpiprazole,405558789,Dopamine D3 receptor Partial Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),913611-97-9,,35.48133892,0,-4.45,-4.289273701,-3,4,,-50.39926995,-39.69641663,0.080937968,0.995940383,,,O=C\1NC2=C(\C=C1)C=CC(=C2)OCCCCN3CCN(CC3)C4=C5C=CSC5=CC=C4,MedChem Express,HY-15780,3.18921396,0,0,-39.69641663,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016241-10,Furosemide,170464879,Loop Diuretics,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54-31-9, ; Diumide-K; Frusemid;FUROSEMIDE; Errolon; Lasix; Furosemide;Furosemide; Furosemide and potassium; Furosemida; Furantral; Furosemide solution; Fusid; Diumide-K continus; Furanthril,25.11886432,0,-4.6,-9.642446071,-3,4,,-48.09909564,-36.05992094,0.059273831,0.997828773,,,NS(=O)(=O)c2cc(c(NCc1ccco1)cc2Cl)C(=O)O,Vitas,STK177334,2.94573417,0,-8.43730046,-36.05992094,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00015819-15,Propafenone hydrochloride,170464755,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),54063-53-5,"Propafenona; ;Propafenone; Propafenone Hcl; Propafenone;Propafenone hydrochloride; Rythmol;Propafenone?HCl; Propafenone, (S)-Isomer; Rhythmol; Propafenone, (R)-Isomer",39.81071706,0,-4.4,-26.7248686,-3,4,,-58.60352784,-53.00293987,0.273415451,0.950876192,,KCNK3,CCCNCC(O)COc2ccccc2C(=O)CCc1ccccc1,SigmaAldrich,P-4670,0,-11.71228087,0,-53.00293987,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00181300-01,Riboflavin tetrabutyrate,144206329,platelet aggregation Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),752-56-7,CIPLUS_668986; Hibon; vitamin B2 tetrabutyrate; ,4.466835922,1,-5.35,-52.29523025,-2.4,4,"Hibon;Riboflavin butyrate;Riboflavin Butyrate;riboflavin tetrabutyrate, riboflavin-2-14C-labeled;vitamin B2 tetrabutyrate;RIBOFLAVIN BUTYRATE;riboflavin tetrabutyrate;CIPLUS_668986;",-41.79025536,-27.55578485,0.486752688,0.817835949,,,CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN2C3=NC(=O)NC(=O)C3=Nc1cc(C)c(C)cc12,ACC,riboflavin butyrate,-3.02694399,4.69655579,-52.72649448,-27.55578485,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00095118-17,Rofecoxib,405558837,Cyclooxygenase-2 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),162011-90-7,,39.81071706,0,-4.4,-47.75398444,-3,4,,-67.24473001,-58.12060834,0.249300609,0.959604868,,PTGS2,C[S+]([O-])(=O)C1=CC=C(C=C1)C/2=C(/C(=O)OC2)C3=CC=CC=C3,SIGMA,SML0613,-9.9356961,3.55855486,0,-58.12060834,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00484056-01,Testosterone (undecanoate),405558851,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),5949-44-0,,10,0,-5,-39.29303362,-2.4,4,,-46.42919658,-47.014172,0.755441243,0.999940557,,,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC/4=C/C(=O)CC[C@]4(C)[C@H]3CC[C@]12C,MedChem Express,HY-B0626,-28.41217555,-0.55579958,-29.75840621,-47.014172,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00379007-02,Retapamulin,405558888,70S ribosome Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),224452-66-8,,10,0,-5,-72.78446829,-2.4,4,,-66.04973716,-68.02608523,0.162240863,0.983408424,,,C[C@@H]1CCC23CCC(=O)[C@H]2C1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CSC4C[C@@H]5CC[C@H](C4)N5C,MedChem Express,HY-17010,-6.99165518,3.2024128,-43.20921945,-68.02608523,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00024595-08,Carbetapentane,170465562,Sigma-1 receptor Agonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),77-23-6,,12.58925412,0,-4.9,-58.8387077,-2.2,4,,-31.34191659,-37.553866,0.039420603,0.999041825,,,CCN(CC)CCOCCOC(=O)C1(CCCC1)c2ccccc2,Enzo,NO103,-8.19889959,-8.09688224,-22.00257415,-37.553866,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00179676-03,Lynestrenol,170465984,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52-76-6,,39.81071706,0,-4.4,-25.09846933,-3,4,,-52.34646682,-47.78872235,0.308271391,0.936417987,,,C[C@]32CC[C@@H]1[C@H]4CCCC=C4CC[C@H]1[C@@H]3CC[C@]2(O)C#C,"Prestwick Chemical, Inc.",Prestw-95,0,-11.99557054,0,-47.78872235,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00389219-01,Oxeladin Citrate,405558942,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52432-72-1,,10,0,-5,-45.29533354,-2.4,4,,-60.49744741,-57.89249773,0.074941813,0.996520794,,,CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1,APExBIO,A8493,0,3.59500997,-39.44991432,-57.89249773,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00378944-02,NCGC00378944-02,405558979,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),226700-81-8,,28.18382931,0,-4.55,-52.28974664,-2.4,4,,-85.57638459,-67.11611077,0.653834984,0.999978918,,,CC(C)CN(C[C@@H](O[P]([O-])([O-])=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)[S+]([O-])(=O)C3=CC=C(N)C=C3,MedChem Express,HY-17431,-32.61272827,-4.18073469,-19.0498405,-67.11611077,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00344326-02,"9(E),12(E)-Octadecadienoic acid",405558983,Streptococcus mutans Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),n/a,,39.81071706,0,-4.4,-15.64184542,-3,4,,-53.64978146,-44.70815122,0.664520866,0.999967629,,,CCCCC/C=C/C/C=C/CCCCCCCC(O)=O,Enzo,BL118,-24.77092381,0,0,-44.70815122,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016549-05,Dosulepin hydrochloride,405558989,Serotonin transporter Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),897-15-4,,19.95262315,0,-4.7,-36.68563695,-2.1,4,,-104.8129528,-91.72338093,0.00249642,0.999996156,,,CN(C)CC\C=C1/C2=C(CSC3=C1C=CC=C3)C=CC=C2,Prestwick,Prestw-488,2.97999178,1.95359019,-21.37564272,-91.72338093,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00521081-01,Cycrimine Hydrochloride,405558993,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),126-02-3,,39.81071706,0,-4.4,-96.28981615,-3,4,,-70.43956714,-64.53297262,0.479299192,0.824691127,,,OC(CCN1CCCCC1)(C2CCCC2)C3=CC=CC=C3,Toronto Research,C991450,-23.40547897,-8.74889895,4.07602172,-64.53297262,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00013683-06,Chlorprothixene,170465069,Serotonin (5-HT) receptor Antagonist,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),113-59-7,,10,0,-5,-69.08576881,-2.1,4,,-94.87902078,-93.19263551,0.039339045,0.999044326,3269,,CN(C)CC\C=C1/c3ccccc3Sc2ccc(Cl)cc12,Microsource,1503203,0,0,-52.23489758,-93.19263551,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00390707-01,Oclacitinib,405559019,Tyrosine-protein kinase JAK3 Inhibitor,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),1208319-26-9,,35.48133892,0,-4.45,-20.35219361,-3,4,,-73.69391869,-65.16159891,0.013503013,0.999887547,,,CN[S+]([O-])(=O)C[C@H]1CC[C@@H](CC1)N(C)C2=C3C=C[NH]C3=NC=N2,MedChem Express,HY-13577,0.81252858,0,0,-65.16159891,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00094207-05,Pentolinium bitartrate,405559046,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),52-62-0,,19.95262315,0,-4.7,-24.88139893,-2.2,4,,-52.25420642,-46.40470183,0.019109022,0.999774843,,,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,Prestwick,Prestw-188,0,0,-12.37970345,-46.40470183,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00274068-01,NCGC00274068-01,170464949,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),84625-61-6,Itraconazole;Itraconazole (Sporanox),39.81071706,0,-4.4,-130.8770737,-2.4,4,,-66.20358309,-78.58175167,0.116578179,0.991525348,,CYP3A4,CC(CC)N1N=CN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OC[C@H]6CO[C@@](Cn5ncnc5)(O6)c7ccc(Cl)cc7Cl,Selleck,S2476,-24.9325415,-21.92605411,-18.64967818,-78.58175167,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00253576-01,Amelometasone,170465753,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),123013-22-9,,3.16227766,1,-5.5,-333.6319121,5,4,,57.64078251,-76.69226271,1,0.999964,,,COCC(=O)[C@]3(OC(=O)CC)[C@@]4(C)C[C@H](O)C2(F)[C@@H](CCC1=CC(=O)C=C[C@@]12C)[C@@H]4C[C@@H]3C,GVK,FFS-11-286-NCI-162,-90.03964054,-71.37615328,-36.63318401,-76.69226271,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00016382-07,Oxethazaine,170465643,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),126-27-2,,35.48133892,0,-4.45,-26.76201556,-3,4,,-70.00151819,-60.22842287,0.177980014,0.979944687,,,CC(C)(Cc1ccccc1)N(C)C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc2ccccc2,Microsource,1503279,1.35829731,-8.47790303,-5.52219059,-60.22842287,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
NCGC00165976-02,Squalane,170465658,,SARS-CoV Pseudotyped particle entry,Approved Drugs Collection (NPC),111-01-3,,3.16227766,1,-5.5,-100.1510514,-2.4,4,,-31.25243328,-28.11718845,1,0.999905042,,,CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C,SIGMA,234311,-21.04500094,-30.71507931,-44.05272572,-28.11718845,,,,,,,,,,,,4.57E-07,0.00000229,0.0000114,0.0000571,,,,,,,,,,,
